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PORTFOLIO ABSTRACT 
The current portfolio is presented in support of the post-chartered “Top-up” Doctorate 
in Psychology degree. This portfolio comprises of 3 parts; Part 1 - a research project 
looking at the efficacy of a combination treatment regimen for smokers (which will be 
referred to throughout the portfolio as the thesis), Part 2 - a systematic review looking 
at the effectiveness of smoking cessation interventions in acute care and Part 3 - two 
case studies reflecting my professional practice which looks at the current clinician and 
patient perspective of using a combination of treatments in smoking cessation and a 
reflection on conducting research in an academic setting.  
 
Part 1 describes a randomised placebo controlled trial; designed to answer the principal 
question of whether using a combination of varenicline and nicotine patches reduces 
post-quitting urges to smoke more than varenicline alone. The study found no difference 
in post quitting urges between the active and placebo patch groups.  
 
Part 2 is a systematic review that was commissioned by the National Institute of 
Clinical Excellence (NICE) to review the available evidence concerning the efficacy of 
different types of smoking cessation interventions in acute care settings. Results from a 
meta-analysis showed that for interventions with hospital patients to be effective, an 
extended period of support and stop smoking medication provided for over 4 weeks 
after discharge is recommended. 
 
Finally, part 3 is a series of case studies looking at current clinician practice in 
prescribing combination nicotine replacement therapy (NRT) in UK stop smoking 
services (UK-SSS); a patient perspective of using combination NRT and varenicline and 
a reflection on my current clinical practice which gives some insight into my day-to-day 
role as a practicing health psychologist. 
 
These parts are independent of one another but all reflect practice in the field of 
smoking cessation.   
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GLOSSARY OF TERMS AND ABBREVIATIONS 
AD Alzheimer’s disease 
AE Adverse event 
ALA American Lung Association  
BCT Behaviour change techniques  
BID (bis in die) Twice daily  
BPS British Psychological Society 
CI Confidence interval 
CO Carbon Monoxide 
COPD Chronic Obstructive Disease 
CPsychol Chartered Health Psychologist 
CQC Care quality commission 
CR Conditioned response  
CRF Client record forms 
CVD Cardiovascular disease 
CWS Cigarette Withdrawal Scale  
DNCs De-nicotinised cigarettes 
DoH Department of Health 
DPsych Professional Doctorate in Psychology 
DSM Diagnostic and Statistical Manual  
E-C Electronic cigarette 
FTND  Fagerström Test for Nicotine Dependence  
GABA Gamma aminobutyric acid  
GCP Good clinical practice 
GRAND Global research awards for nicotine dependence 
GSK Glaxo Smith Kline  
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HAD Health Development Agency  
HCPs Healthcare professionals  
HIS Heaviness of Smoking Index 
HTA Health Technology Assessment 
IMP Investigational Medicinal Product  
ITT Intention to treat  
JRO Joint Research Office  
KG Kilograms  
MHRA Medicines and healthcare products regulatory agency 
MNWS Minnesota Nicotine Withdrawal Scale  
MPSS Mood and Physical Symptoms Scale  
NA Nucleus accumbens  
nAChRs Nicotinic acetylcholine receptors  
NCSCT UK National Centre for Smoking Cessation and 
Training 
NHS National Health Service 
NHS-SSS National Health Service Stop Smoking Services 
NICE National institute of Clinical Excellence 
NIHR National Institute for Health Research 
NRES National research ethics service 
NRT Nicotine Replacement Therapy 
OR Odds ratio 
PBC Perceived behavioural control  
PCT Primary Care Trust 
PD Parkinson’s disease 
PDG Programme development group 
PRIME Theory Plans, responses, impulses, motives and evaluations 
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QMUL Queen Mary University of London 
R&D Research & Development 
RCT Randomised control trial 
RCT Randomised controlled trial 
REC Research Ethics Committee  
RPS Relapse prevention service  
SAE Serious adverse event 
SOP Standard operating procedure  
SPC Summary of Product Characteristics  
SS Shiffman Scale  
SUSAR Serious unexpected serious adverse reaction 
SUTS Strength of urge to smoke  
SWAP/WAP Peer support weight action programme 
SWQ Smoking Withdrawal Questionnaire  
TDRU Tobacco Dependence Research and Treatment Unit 
TMF Trial master file 
TPB Theory of Planned Behaviour  
TQD Target quit date 
TTFC Time to first cigarette  
TWS Tobacco withdrawal syndrome  
UC Ulcerative colitis 
UK United Kingdom 
USDHHS United States Department of Health and Human 
Services   
VBA Very brief advice  
VTA Ventral tegmental area  
WSWS Wisconsin Smoking Withdrawal Scale  
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PREFACE  
The preface provides an overview of the portfolio of evidence presented in support of 
the Professional Doctorate in Psychology (DPsych) (Post-chartered) degree. It begins by 
outlining my previous training as a trainee health psychologist and introduces the 
structure of the portfolio, which comprises of three independent parts (a research project 
(thesis), a systematic review and two case studies). My work experience as a health 
psychologist has been discussed alongside a summary of the clinical studies and the 
grant applications I have been involved in. Finally, an overview of how this portfolio 
has allowed me to use all the skills I have been developing over the last few years, 
which illustrates my skills as a practicing health psychologist.  
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Background to undertaking the Doctorate in Psychology Degree 
Since completing my stage 2 training I have continued to work as a health psychologist 
at the Tobacco Dependence Research and Treatment Unit (TDRU); the unit is part of 
the Wolfson Institute of Preventive Medicine at Queen Mary University of London 
(QMUL) (further details of the unit can be found in Chapter 5).  
 
Stage 2 training is a vocational degree for trainee psychologists who wish to conduct 
applied research and further their teaching, supervisory and consultancy skills. The 
training is supported by the British Psychological Society (BPS). The qualification is 
undertaken via two routes, university or independent. The university route is a full time 
lecture-based degree, which leads to the award of Doctorate in Psychology (DPsych). 
The independent route is the appointment of an external supervisor (a chartered health 
psychologist) who supervises the work of the trainee. The trainee will usually remain in 
their place of work (a health care setting) in order to complete the training. The award 
granted is chartered status as a health psychologist (CPsychol). Both routes involve the 
submission of a portfolio of evidence that reflects the trainees experience in 5 core 
areas; teaching, ethics, research (thesis project and systematic review), expert opinion 
and consultancy. The difference between the two routes is that the independent route 
trainees are not awarded the doctorate degree, as it is not undertaken with the support of 
a university. 
 
In 2009 I submitted my portfolio of evidence and after a viva voce I was awarded the 
title of chartered health psychologist (CPsychol). 
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Professional Doctorate in Psychology (DPsych) (“Top-up” post-
chartered degree) 
The current portfolio is presented in support of the post-chartered “Top-up” post-
chartered DPsych degree, which includes evidence of undertaking a research project, a 
systematic review and two case studies reflecting my current practice as a chartered 
health psychologist. The portfolio comprises of 3 parts; Part 1 - a research project 
looking at the efficacy of a combination treatment regimen for smokers (which will be 
referred to throughout the portfolio as the thesis), Part 2 - a systematic review looking 
at the effectiveness of smoking cessation interventions in acute care settings and Part 3 
- two case studies reflecting my professional practice which look at the current clinician 
and patient perspective of using a combination of treatments in smoking cessation and a 
reflection on conducting research in an academic setting. These parts are independent of 
one another but all reflect practice in the field of smoking cessation. A bibliography is 
included at the end of each part. Appendices for all parts are contained at the end of the 
portfolio. 
 
Research experience 
I have now been involved in eleven clinical trials which have given me the opportunity 
to develop my skills, not only collecting data but with data analysis and writing for 
publication. During my time on the DPsych course I have published twelve papers (see 
Table 1) and been involved in a number of projects, which are detailed below. 
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Table 1 – K, Myers publications (current-2009) 
Author/Title Journal Impact 
factor 
Citations 
Myers, K., McRobbie, H. West, O. & 
Hajek, P. (2013) Smoking cessation 
interventions in acute and maternity 
services: Review of barriers and 
facilitators. 
National 
Institute for 
Health and 
Clinical 
Excellence 
(NICE) 
NA NA (due to 
be released 
November 
2013) 
Myers, K., McRobbie, H. & Hajek, P. 
(2013) Smoking cessation interventions 
in acute and maternity services: Review 
of effectiveness.  
NICE NA NA (due to 
be released 
November 
2013) 
McRobbie, H., Hajek, P. & Myers, K. 
(2013) Review of effects of nicotine in 
secondary care. 
NICE NA NA (due to 
be released 
November 
2013) 
Hajek, P., McRobbie, H. & Myers, K. 
(2013) Efficacy of cytisine in helping 
smokers quit: systematic review and 
meta-analysis.  
Thorax 6.84 NA 
(published 
Feb 2013) 
Snuggs, S., McRobbie, H., Myers, K., 
Schmocker, F., Goddard, J., Hajek, P. 
(2012) Using text messaging to prevent 
relapse to smoking: intervention 
development, practicability and client 
reactions.  
Addiction 
 
3.84 1 
Myers, K., Hajek, P., Hinds. C. & 
McRobbie, H (2011) Stopping smoking 
shortly before surgery and postoperative 
complications: a systematic review and 
meta-analysis 
Archives of 
Internal 
Medicine 
10.64 32 
Myers, K., Hajek, P., & McRobbie, H 
(2011) What is a reasonable threshold for 
worries about health risks? 
Archives of 
Internal 
Medicine 
10.64 0 
Hajek, P., McRobbie, H. & Myers, K., 
Stapleton, J., & Dhanji Al-Rehan (2011) 
Use of varenicline for four weeks prior to 
quitting smoking: Effects on ad-lib 
smoking, post-cessation withdrawal 
discomfort, and short-term smoking 
cessation rates. 
 
Archives of 
Internal 
Medicine 
10.64 15 
Hajek, P., McRobbie, H. & Myers, K., 
Stapleton, J., & Dhanji Al-Rehan (2011) 
Is Varenicline effectiveness declining in 
randomized trials? 
 
 !
Archives of 
Internal 
Medicine 
10.64 0 
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McRobbie, H. & Myers, K. (2011) 
Continuing Professional Development: 
Understanding why people smoke and 
helping them to stop 
British Journal 
of Wellbeing. 
1.52 0 
Hajek, P., Myers, K., Rehan-Dhanji, A., 
West, O., & McRobbie H. (2011) Weight 
change during and after Ramadan fasting.  
Journal of 
Public Health 
1.88 7 
Myers, K., West, O. & Hajek, P (2009). 
Relapse prevention for pregnant women 
– Review. 
NICE NA NA 
 
1. National Institute for Health and Clinical Excellence (NICE) 
In September 2011, NICE announced a tender for systematic reviews in the field of 
smoking (six in total). The reviews were to be part of a new smoking guideline for acute 
and maternity services across the UK. My clinical background has been primarily 
working with inpatient smokers in acute care settings and I have experience of working 
with pregnant women, which made my expertise very relevant to the tender call and 
application. Applications to write three of the six reviews were submitted by Professor 
Hajek, Dr McRobbie and myself. We were successful in our application for all three of 
the reviews (one of the two papers I led on, which looks at the effectiveness of smoking 
cessation interventions in acute care settings is presented in Part 2 of the portfolio). My 
role in the project was to write the proposal, conduct the literature search, systematically 
screen abstracts for relevant papers, extract data from included papers, data analysis and 
write up. Each of the three systematic reviews has been presented to the programme 
development group (PDG) for review who will use the reviews to inform the 
development of the new guidelines for acute and maternity services. The guidelines are 
due to be released in November 2013. 
 
2. An open label pragmatic randomised controlled trial of nicotine preloading for 
smoking cessation (2012) 
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This randomised control trial (RCT) will examine the relative efficacy, safety and cost 
effectiveness of standard NHS stop-smoking treatment versus standard treatment plus 
the use of a nicotine patch worn for 4 weeks prior to quitting. The study has been 
funded by the National Institute for Health Research (NIHR) Health Technology 
Assessment (HTA) programme. This multisite study is being led by Birmingham 
University; the TDRU is one of four research sites. For this project I have been involved 
in the Research & Development (R&D) approval at QMUL, planning the logistics of 
the recruitment and will be involved in data collection. My role on this study is as the 
research manager, supporting two psychologists who have been recruited to co-ordinate 
the project. Ethical approval has been granted and recruitment started in September 
2012. The outcomes of this trial will indicate whether pre-loading with a nicotine patch 
before stopping smoking increases abstinence rates. The findings of this trial will have 
important implications for guidelines and clinical practice. The project is expected to be 
completed in 2015. 
 
3. Peer support weight action programme (SWAP) (2012) 
The proposed study will determine whether a promising group-based weight 
management program (Weight Action Programme; WAP), targeting underprivileged 
groups has a long-term effect that is over and above the effect of a ‘best practice’ weight 
management intervention that is provided in primary care by practice nurses. The 
SWAP study is funded by the NIHR HTA programme. I was a co-applicant on the grant 
application for this project, and I have also had involvement in the protocol 
development and led on the application to gain ethical approval to conduct the study. I 
will have the role of research manager for the duration of the trial. Ethical approval has 
been granted and recruitment started in September 2012, with completion of data 
collection expected in 2015. The outcomes of this study will provide further insight into 
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the best methods to approach weight management in the community. 
 
4. Comparison of the effects of the electronic cigarette and nicotine inhalator on 
tobacco withdrawal symptoms over 24 hours of abstinence (2012) 
A randomised cross over study was recently conducted at the TDRU looking at whether 
the electronic cigarette (E-C) is more effective in alleviating withdrawal symptoms 
during 24hr abstinence than the nicotine inhalator. My role in this project is to provide 
guidance with regards to protocol development, ethics, medicines and healthcare 
products regulatory agency (MHRA) approval processes and R&D requirements for 
setting up this study. My role in this study will primarily be to support the lead clinician 
throughout the project. This study began recruitment in January 2013 and data 
collection is now completed. The data analysis is now being conducted. Results from 
this study will be important; the study has been designed to further understanding on the 
role E-Cs may have as a smoking cessation aid. 
 
5. Effects of a combination of varenicline and transdermal nicotine patch on post-
quitting urges to smoke (CONVICT) (2011) 
CONVICT is an RCT looking at whether combining NRT and varenicline provides 
better withdrawal and craving relief in the first week of abstinence than varenicline 
alone. In 2010 an application was made for 2 investigator-initiated grants; TVIN 
(discussed below) and CONVICT. My role in this project has been to write and review 
the grant application, protocol development, ethics and MHRA approval and 
recruitment. I was the research manager on this trial and ran the study on a day-to-day 
basis. I was the lead in data entry, analysis and write up. The paper will be submitted to 
a high impact journal, as the results of this study will be of great interest to many in the 
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smoking cessation field. CONVICT will be presented as the thesis for this portfolio 
(part 1). 
 
6. Effects of a tailored dose of varenicline on post-quitting urges to smoke (TVIN) 
(2011) 
This RCT is investigating whether a tailored dose of varenicline provides better 
withdrawal and craving relief in the first week of abstinence than a standard varenicline 
dose. My role in this project has been to write and review the investigator-initiated grant 
application, protocol development, MHRA and ethics approval and the recruitment of 
participants. I am the research manager on this trial and oversee two psychologists who 
run this project on a day-to-day basis. This study is currently recruiting participants. 
Data collection was completed in February 2013. The results will have important 
implications on whether the current use of varenicline can be tailored to individual 
smokers.  
 
7. Complementing current NHS Stop Smoking Service treatment for smokers with 
behavioural replacement: The role of de-nicotinised cigarettes (2011) 
The aim of this study was to see if using a behavioural replacement for smoking (de-
nicotinised cigarettes; DNCs), in addition to standard treatment during the first two 
weeks after the target quit date (TQD), reduces urges to smoke over the first 4-weeks of 
abstinence. I was a co-applicant on the grant submission and acted as the research 
manager on this project. The role has involved protocol development, ethics approval 
and supervision of two psychologists who run the project on a day-to-day basis. The 
study will provide useful information regarding the use of DNCs as an aid to stopping 
smoking. 
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8. Tobacco control health inequalities pilot (2011) 
The aim of the project was to present the outcomes of an SMS text-based relapse 
prevention service enhancement provided to smokers who had successfully stopped 
smoking. The relapse prevention study was a health inequalities pilot sponsored by the 
Department of Health (DoH). My role in this project was to develop the protocol and to 
oversee the psychologist running the project on a day-to-day basis. The findings from 
the service enhancement were published in Addiction in 2012. The service enhancement 
proved acceptable to clients and was easily implemented. The outcomes suggest that it 
may be a useful, simple and easily implemented addition to the NHS-SSS. The next step 
will be to evaluate its efficacy in a randomised trial.  
 
9. Stopping smoking shortly before surgery and postoperative complications (2011) 
In June 2011, the systematic review I wrote for my stage 2 Health Psychology 
qualification was published in Archives of Internal Medicine (impact factor 10.64). 
The paper has been cited by 32 papers (Myers et al. 2011). The systematic review and 
meta-analysis examined the existing literature examining postoperative complications in 
people stopping smoking prior to surgery. The idea for this systematic review came 
about after witnessing some confusion between different health care professionals 
(HCPs) over the right advice to give about stopping smoking shortly before an 
operation. The results indicated that the concern that stopping smoking only a few 
weeks prior to surgery might worsen clinical outcomes is unfounded. I was the lead 
author on this review; my role included the development of the search terms, systematic 
search of the literature for relevant papers, data extraction, data analysis and write up. 
The conclusions have had an impact on the guidelines that are provided by NICE with 
regards to provision of smoking cessation advice to postoperative patients. Patients 
should be advised to stop smoking as early as possible, as there is no current evidence 
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available to suggest that health professionals should advise smokers not to quit shortly 
before surgery. 
 
10. Varenicline treatment for four weeks prior to quitting smoking reduces ad-lib 
smoking and increases smoking cessation rates (2010) 
This RCT investigated whether increasing the usual 1-week of pre-quit medication 
period of varenicline, to 4 weeks, would help alleviate tobacco withdrawal symptoms 
and facilitate quitting.  The study was published in a high impact journal, Archives of 
Internal Medicine (impact factor 10.64) and has been cited by 15 other papers (Hajek 
2011). Increasing the duration of varenicline use pre-quit, reduced the enjoyment of 
smoking and generated a substantial reduction on ad-lib smoking prior to quitting. Post 
quit withdrawal ratings were not reduced as a result of the extra pre-loading of 
varenicline, however, it did significantly increase 12-week abstinence rates. During this 
study I was involved in the submission of the grant application, development of the 
protocol, gaining ethical and MHRA approval, day-to-day management and running of 
the study including recruitment, data input, analysis and write up. The implications of 
these findings are that varenicline may be suitable for use in harm reduction, and longer 
periods of pre-loading are likely to increase the drug’s efficacy. We concluded that 
larger studies with longer follow up periods are needed to further investigate these 
findings. 
 
11. Acceptability and effects of using protein and completing hunger ratings prior 
to the evening meal (Protein Pre-load study) (2010) 
The protein pre-load study was undertaken to explore whether eating 20g of protein, 30 
minutes before eating the evening meal for two weeks would lead to weight loss, 
compared to not eating protein before the evening meal. My role in this project was to 
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develop the protocol, gain ethical approval, run the study on a day-to-day basis, data 
entry, analysis and write up. The results from this study are being analysed. The results 
will be published to inform future practice in weight management. 
 
12. Weight change during and after Ramadan fasting (2010) 
During Ramadan, observant Muslims fast from sunrise to sunset for a month. The study 
examined whether Ramadan fasting affects body weight. This has implications for 
health advice give to the Muslim community on the effects of skipping meals on body 
weight, and for general weight management advice. During Ramadan 2010, the study 
compared body weight before and after the Ramadan fast and one month later in 
observant Muslims attending a Mosque in East London, UK. The study was published 
in The Journal of Public Health (impact factor – 1.88) and has been cited by 7 other 
papers (Hajek et al. 2011). My role in this project was to write the protocol, gain ethical 
approval, the day-to-day running of the project, data collection, data entry, analysis and 
write up for publication. We found that observers of Ramadan lost on average about a 
kilogram of weight over 4 weeks, and that the lost weight is quickly regained (within 
the first month post-Ramadan).  Current weight management treatments generally 
assume that skipping meals leads to weight gain and advise against it. The finding 
suggests that further research is needed on the justification of the ‘do not skip meals’ 
advice.  
 
13. Pilot study on usage patterns of a novel nicotine replacement therapy – A 
multi-centre, open, 3-week randomized low intervention study of two different 
directions for use in smokers motivated to quit (2008) 
In 2009 the TDRU conducted a commercially funded study looking at a new nicotine 
delivery system, a nicotine mouth spray, to help people to stop smoking. The study was 
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a pilot to see if different methods of how to administer the spray would affect its use. 
My role in this study was to manage and co-ordinate the day-to-day running of this trial. 
The results indicated that there was no benefit seen between the two directions of use. 
Nicotine mouth spray is now on the market and is regularly used by smokers during 
treatment. The study informed our practice for advising people on how to use the 
product.  
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Grant applications 
As part of the process of conducting studies, I have also been involved in developing 
and writing protocols for grant applications. I have been a co-applicant for 10 funding 
applications since 2010, 9 of which were successfully funded.  
 
1. National Institute for Health and Clinical Excellence (NICE) (2011) 
As detailed in the previous section, in September 2011, NICE invited tenders for 
systematic reviews in the field of smoking (6 in total). I was the co-applicant on 3 grant 
proposals for the tender. I was the lead author on 2 of the protocols submitted; one 
review looking at the effectiveness of smoking interventions in acute and maternity 
service users and one on the barriers and facilitators for the same population. The team 
was successful in the application for all three of the reviews. The project was completed 
in 4 months and the grant awarded was £100,130. 
 
2. Evaluation of a pilot Tier 3 multidisciplinary weight management service (2011) 
I was invited to write a protocol for an evaluation of a pilot weight management 
programme for City and Hackney Primary Care Trust (PCT). I was the lead author on 
the protocol. The time frame of the project is 1 year and the project grant was £21,486. 
 
3. A peer-support weight management programme to supplement brief advice in 
general practice for obese adults from deprived communities (2011) 
As detailed in the previous section a grant application was submitted to the NIHR HTA 
programme for funding for a weight management study (SWAP). I was a co-applicant 
on this project. The project time frame is 3 years and the grant awarded was £886,741. 
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4. Tobacco control health inequalities pilot (2011) 
Further details for this study are outlined in the previous section. I was a co-applicant for a 
health inequalities pilot sponsored by the DoH. The service enhancement was an SMS 
text-based relapse prevention service for smokers who had successfully stopped 
smoking. The project was completed in 18 months and the grant awarded was £197,850. 
 
5. Effects of a combination of varenicline and transdermal nicotine patch on post-
quitting urges to smoke (CONVICT) and 6. Effects of a tailored dose of varenicline 
on post-quitting urges to smoke (TVIN) (2011) 
As detailed in the previous section, an investigator-initiated grant was submitted for 
funding for 2 trials using varenicline. I was a co-applicant for both grant applications. 
The CONVICT trial was completed within 1 year and the grant awarded was £148,933. 
The TVIN trial was completed on 18 months and the grant awarded was £196,429. 
 
7. Complementing current pharmacological treatments for smokers with “sensory 
replacement”: The role of low nicotine cigarettes (2011) 
Further details for this study are outlined in the previous section. A grant application was 
submitted to the Global Research Awards for Nicotine Dependence (GRAND). The 
study was looking at DNCs as a behavioural replacement for smoking. I was a co-
applicant on the grant proposal. The study was completed in 1 year and the grant 
awarded was £123,463. 
 
Writing and submitting grant applications involves liaising with the funding bodies 
concerned and also the gaining approvals from my academic institution, QMUL. The 
processes involved include costing, peer review, protocol design and submitting a clear 
outline of the proposals aims and applicability (both in terms of the research setting but 
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also for future impact on services and research). Having the opportunity to be involved 
in several applications has helped to further develop my skills with regard to writing 
and submitting grant applications.  
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OVERVIEW OF PORTFOLIO OF EVIDENCE 
Overview of thesis (Part 1) 
 
Background to research project and aims 
Varenicline is a popular and widely used non-nicotine treatment option for smoking 
cessation. Unlike NRT, which are often used and recommended in combination (e.g. 
using a nicotine patch alongside nicotine chewing gum), varenicline is currently not 
recommended in combination with any other licensed smoking cessation medications.  
Combining varenicline and NRT may in theory improve withdrawal relief; help to 
extinguish smoking rewards and lower the risk of lapses translating into relapse. The 
research conducted for this doctorate portfolio will look at the efficacy of using 
varenicline in combination with a nicotine patch and whether this combination regimen 
reduces urges to smoke 24 hours and 1 week post-quitting.  
 
Methods 
A randomised double blind placebo-controlled trial was conducted using a sample of 
117 participants. Participants were randomised to use varenicline plus active nicotine 
15mg/16hr transdermal patch or varenicline plus placebo 0mg/16hr patch.  
 
Results 
Adding nicotine patch to varenicline had no effect on post-quit urges to smoke or on 
other cigarette withdrawal symptoms at any time point. There was no effect on 
abstinence rates at any time point (79% vs 80%, 69% vs 59%, 50% vs 41% and 14% vs 
12% at 24 hours, 1, 4 and 12 weeks in the nicotine and placebo patch group, 
respectively).  
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Conclusion 
The efficacy of varenicline is not enhanced by the addition of nicotine patches.  
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Overview of systematic review (Part 2) 
 
The guideline developed from this review will not be released until November 
2013; the contents of the review remain confidential until its publication. 
 
Background to systematic review 
In 2010/11, of the 10 million National Health Service (NHS) secondary care admissions 
in the United Kingdom (UK), it was estimated that 460,000 were attributed to smoking 
tobacco (Office of National Statistics 2012). Hospitalisation provides a good 
opportunity to stop smoking.  Such patients are often highly motivated to quit, and 
hospital admission brings people into direct contact with healthcare professionals who 
can advise on giving up smoking and offer evidence-based treatment.  
 
Objective 
This piece of work was commissioned by the National Institute of Clinical Excellence 
(NICE) to review the available evidence concerning the efficacy of different types of 
smoking cessation interventions for hospital patients and their relatives to help guide 
clinical recommendations for smoking cessation – acute and maternity services 
guidelines are due to be published in November 2013. 
 
Methods 
A systematic search for reviews and randomised controlled trials published between 
1990 and December 2011 in the English language was undertaken. Electronic databases 
were searched including ASSIA, MEDLINE, Cochrane Central Register of Controlled 
Trials, CINAHL and PsychINFO. A total of 29,083 records were found of which 141 
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papers were identified for full text retrieval. Seventy-five trials evaluating smoking 
cessation interventions delivered in acute care settings were found.  
 
Results 
Hospitalised smokers – For interventions with hospital patients to be effective, an 
extended period of support and stop smoking medication provided for over 4 weeks 
after discharge is recommended. Interventions that are provided face-to-face after 
discharge may provide better results than support provided over the telephone.  
Relatives – There is limited research for this population, however, brief stop smoking 
interventions with parents of hospitalised children did not show any efficacy in long 
term abstinence rates. 
Hospital staff – There is evidence that providing the stop smoking medication 
bupropion (Zyban) with regular face-to-face support is an effective treatment for 
hospital staff.  
 
Conclusion 
The NHS practice currently involves interventions at bedside accompanied by 
medications and/or referrals to specialist stop-smoking service for treatment after 
discharge, which combines extended face-to-face support with smoking cessation 
medications. The reviewed evidence confirms that this is likely to be the optimal 
approach. 
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Overview of professional practice (Part 3) 
The first case study also follows the theme of treatments for smoking cessation and 
provides a clinician and patient perspective on current practices. 
 
There are two parts to the first case study. The first part of the professional practice 
chapter highlights the clinician view of current practices in combining smoking 
cessation medications; the section reviews the experience of combination NRT in 
current practice, which is a licensed and evidence-based combination medication option. 
The clinician views were taken after a presentation I gave at the “Stop Smoking Live” 
conference in London in December 2010. The case study is a reflection of my 
experience of presenting at an educational symposium. The case study also highlights 
the extent to which combination NRT is recommended in UK clinical practice, barriers 
to its use for the clinician and client and a discussion on how lessons learnt from current 
practice could impact on the potential combination of varenicline and NRT in the 
future. 
 
For the second, patient perspective case studies for this chapter, clients at the smokers’ 
clinic (TDRU) who were using combination treatment (varenicline and NRT) were 
asked to discuss why they had chosen to do this and what benefit (if any) it gave them. 
As previously noted, guidelines do not currently advocate the combination of 
varenicline and NRT due to the lack of evidence on its efficacy. However, anecdotally 
we know that clients will take it upon themselves to use the medications in combination 
and report that this is useful in helping them to stop. This piece of work gives some 
background into how clients attending an NHS stop smoking cessation clinic find the 
experience of using a combination treatment and discusses some of the potential 
guidelines for clinicians. 
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The second case study is a reflection on my current clinical practice, which discusses 
my day-to-day role at the TDRU. I reflect on some of the key issues when conducting 
research and some of the things I have learnt over last few years of my involvement in 
research. An example of a trial I have been involved in is also discussed. 
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Summary of preface 
This portfolio highlights my professional growth as a psychologist and my ability to 
review emerging data in the field. As a practicing research health psychologist I am now 
able to use my training and research experience to conduct new and important pieces of 
research within my areas of expertise in order to help inform and try to improve 
smoking cessation services and treatment outcome. 
 
As a result of undertaking the stage 2 training and completing my thesis project I have 
now completed a course with the BPS allowing me to supervise other trainee 
psychologists. The department I work in has helped me to learn on the job and develop 
as a psychologist and the potential to supervise and guide other trainees is a great 
opportunity for me. I hope to use this as part of my continued professional development 
over the next few years. I hope to continue to promote Health Psychology through the 
transferring of skills to other psychologists through supervision but also among the 
community of health professionals, highlighting the importance of psychology in the 
smoking cessation field. 
 
After completing the DPsych training programme, I will continue in my role as a 
research fellow and smoking cessation clinician at the TDRU. I am in the privileged 
position that we are currently able to implement the results we find from our research 
projects straight into practice.  This makes for an extremely interesting standpoint for 
viewing the effects of new strategies for helping smokers to quit. 
 
In summary, undertaking the doctoral programme has allowed me to use all the skills I 
have been developing over the last few years allowing me to produce one concise piece 
of work, which I hope illustrates my skills as a health psychologist. I have had major 
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involvement in the conduct of eleven clinical studies at the TDRU. My level of skill and 
expertise is reflected in the 12 papers I have had published and the grant applications I 
have been awarded. Since qualifying as a Health Psychologist my confidence and 
ability to operate as a researcher has improved and my level of independence has 
increased. My continued interest in smoking cessation and behaviour change 
interventions has led me to continue my career in the field of Health Psychology. I hope 
to continue to further develop my skills in both research and clinical practice.
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PART 1 – EFFECTS OF A COMBINATION OF A 
VARENICLINE AND TRANSDERMAL NICOTINE 
PATCH ON POST-QUITTING URGES TO SMOKE 
 
Short title/Acronym: Combination of NRT and varenicline to increase cessation 
of tobacco (CONVICT study) 
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CHAPTER 1: GENERAL INTRODUCTION AND 
BACKGROUND 
 
The strong link between smoking and mortality has now long been established. 
Almost 6 million deaths are attributed to tobacco, over 5 million of those are current 
and ex-smokers with around 600,000 deaths attributed to exposure to second-hand 
smoke (World Health Organization 2011). The importance of tackling smoking 
prevalence is realised as tobacco use has been highlighted as a risk factor for six of 
the eight leading causes of death in the world (World Health Organization 2011).  
 
In 2011, over 450,000 hospital admissions were attributed to smoking (Office of 
National Statistics 2012), this accounts for 5% of all hospital admissions in adults 
over the age of 35. Smokers typically spend longer in hospital, and are more likely to 
experience complications (Health Development Agency 2004).  
 
With such high rates of disease and hospital admissions attributed to smoking, the UK 
DoH continues to view the provision of smoking cessation as a top priority in public 
health (Department of Health 2011a).  
 
Smoking cessation in the UK 
The release of the UK government’s white paper on tobacco control (Department of 
Health 1998); was viewed as a milestone for public health interventions in the UK. 
Since its release in 1998, smoking cessation and tobacco control in the UK has been a 
key priority for the National Health Service (NHS). The white paper outlined a 
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tobacco control strategy including advertising bans and smoke-free legislation. 
England was one of the first countries to establish a nationwide network of stop 
smoking services funded by the NHS shortly after the release of the white paper in 
1998. The NHS-Stop smoking services (NHS-SSS) aim to provide the most effective 
interventions for successful smoking cessation which include both pharmaceutical, as 
well as intensive behavioural support provided by smoking cessation specialists. It is 
estimated that there are approximately 150 NHS-SSS currently providing stop 
smoking interventions within the UK (Brose, West, McDermott, Fidler, Croghan & 
McEwen 2011).  
 
Pharmaceutical treatments in the UK 
Currently there are 3 pharmaceutical treatment options available to UK smokers; 
NRT, bupropion (Zyban) and varenicline (Champix). 
 
NRT 
The use of NRT to help smokers trying to stop smoking has been widely available 
since the early 1990s (Stead, Perera, Bullen, Mant & Lancaster 2008). There are 
currently seven different NRT delivery systems available on the worldwide market 
(gum, patch, lozenge, sublingual tablet, nasal spray, inhalator, and mouth spray) and 
in the UK are available on prescription and over-the-counter (West & Zhou 2007). All 
of these products work by replacing some of the nicotine that smokers would have 
otherwise received from their tobacco smoke, thereby reducing tobacco withdrawal 
symptoms which are commonly seen when stopping smoking (e.g. irritability, 
depression, restlessness) (Molyneux 2004). There is an abundance of research 
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showing that the use of NRT increases quitting by up to 50-70%, compared with 
stopping without any medications (Stead et al. 2008).  
 
Bupropion (Zyban) 
Bupropion is an atypical antidepressant that is effective in aiding smoking cessation 
(Hughes, Stead & Lancaster 2007a). Data from 40 studies of bupropion show that this 
drug roughly doubles the chances of quitting smoking compared to placebo (Hughes 
et al. 2007a). Bupropion has over the last few years been used less since the 
introduction of varenicline to the market.  
 
Varenicline (Champix) 
In the last few years a new pharmacological product has been available for smokers; 
varenicline.  Varenicline is a partial nicotinic agonist which acts on !4"2 nicotinic 
receptors (Cahill, Stead & Lancaster 2012). It is presumed to alleviate withdrawal 
discomfort, but also to diminish rewarding effects of cigarettes. Varenicline has been 
shown to increase the success of quitting and some evidence shows a slightly higher 
success rate when compared to bupropion but the results are slightly less clear for its 
increased efficacy compared to NRT (Cahill et al. 2012). 
 
It is reported that up to 70% of smokers report wanting to, and many attempt to, stop 
smoking every year in the UK (Kava 2000). In the year April 2010- March 2011, 
smoking cessation interventions in England resulted in 780,000 smokers attempting to 
stop smoking and setting a quit date with 380,000 of those reporting successfully 
quitting (The NHS Information Centre 2011).   
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NHS-SSS use the best available evidence-based treatment, but with long-term success 
rates of about 15% (Ferguson, Bauld, Chesterman & Judge 2005), there remains 
considerable scope for improvement. 
 
Possible solutions for improving outcomes 
It has been suggested that for some smokers the standard doses of stop smoking 
medication offered may not be adequate to aid a successful quit attempt (Stead et al. 
2008). For many illnesses, medications are tailored to the individual (e.g. diabetes, 
heart disease). However, this is not the standard approach when treating smokers in 
the UK. 
 
The nicotine dependence centre at the Mayo Clinic, USA, is one of only a few clinics 
that routinely tailor smoking cessation medications to the individual smoker. The 
Mayo Clinic approaches patients with severe tobacco dependence on an individual 
basis, commonly using 3 or more smoking cessation products simultaneously (Hurt, 
Ebbert, Hays & McFadden 2009). Mayo Clinic patients who manage to reduce 
cigarettes but who do not stop smoking completely are asked to continue to take their 
chosen medication but at higher doses and in combination with other products until 
they completely stop smoking.  The current approach, recommended by NICE (NICE 
2008), within the UK NHS-SSS is to request the individual takes a break of at least 6 
months before resuming treatment in cases where they have been unable to achieve 
abstinence. 
 
The most common use of “high-dose” medications in the UK services is to use a 
combination of NRT products, for example, use of a nicotine patch in combination 
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with an oral product such as nicotine gum. The effectiveness of using combination 
NRT is well documented and research shows clear benefit for the smoker if they 
combine NRT products rather than using a single nicotine product to quit (Stead et al. 
2008). NRT is currently the only medication option that is recommended in 
combination by current guidelines (NICE 2008). However, as NRT is freely available 
in most pharmacies and over-the-counter in the UK, this has enabled many smokers to 
try different treatment options, not all of which are within current clinical guidelines.  
 
Unlike NRT, varenicline is currently not recommended as a product to be used in 
combination with other stop smoking medications (i.e. varenicline combined with a 
nicotine patch), as there is currently no research looking at the efficacy of using such 
a combination. However, despite no recommendation to use a combination of NRT 
and varenicline, many smokers who attend the East London Smokers’ Clinic choose 
to use it and anecdotally report benefits from doing so.  
 
For patients who have tried and failed to quit using combination NRT and/or 
varenicline, there is much discussion among smoking cessation specialists about the 
possibility that using a combination of varenicline alongside NRT may hold some 
promise. However, until data is available on the effectiveness of this treatment 
method then the efficacy of its use can only be speculated. 
 
This proof of principle study is the first randomised control trial to look at whether 
using a combination of varenicline alongside a nicotine patch reduces withdrawal 
symptoms post quitting. A positive finding would ultimately lead to a larger 
randomised trial being conducted before any recommendations would be made to 
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change standard medication protocols within the NHS-SSS. A negative result would 
indicate that combination therapy using both varenicline and NRT does not reduce 
withdrawal discomfort above the use of the medications on their own. 
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Overview of the thesis 
The thesis presented is made up of six chapters. The first theoretical part discusses the 
health effects of smoking and discusses the health benefits associated with stopping 
smoking (Chapter 2). A chapter outlining the role of nicotine in tobacco dependence 
follows this; which includes current definitions and measurements of dependency 
(Chapter 3). Chapter 4 covers the withdrawal symptoms that are associated with 
stopping smoking and the measures currently used to measure withdrawal will be 
discussed. 
 
The current structure of the NHS stop smoking service in the UK will then be 
presented alongside a detailed description of the most commonly used pharmaceutical 
treatments that are used by smokers as part of a stop smoking quit attempt (Chapter 
5).  
 
Chapter 6 of the thesis presents a double blind randomised trial which aimed to 
investigate the efficacy of using a combination of NRT (15mg/16hr nicotine patch) 
and varenicline in a sample of smokers wanting to stop smoking who attended a stop 
smoking clinic in London, UK. A discussion of the results and conclusions are 
detailed in this chapter. 
 
Primary Objective 
The principal question this study plans to answer is whether the combination of 
varenicline and NRT reduce post-quitting urges to smoke more than varenicline alone. 
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CHAPTER  2 - HEALTH RISKS OF SMOKING AND 
BENEFITS OF QUITTING 
 
This chapter provides background on the prevalence and socio-economic background 
of smokers in the UK. The negative health consequences associated with smoking 
tobacco will be discussed alongside the health benefits of smoking cessation.  
 
Who smokes in the UK? 
In the UK, smoking initially became popular among young men in the early half of 
the 20th Century (Wald 1991). It was not until after the Second World War that 
smoking among women became widespread (Wald 1991). It is now estimated that 
around 21% of adults in the UK smoke, which equates to around a fifth of the total 
population (Office of National Statistics 2012). Slightly more men smoke (22%) in 
the UK compared to women (21%) (Office of National Statistics 2012).   
 
The highest prevalence of smoking is seen in 16-19 and 20-24 year olds (27%), those 
over 60 years have the lowest prevalence (14%) (Office of National Statistics 2012). 
Differences in smoking prevalence can be seen among social classes with 
approximately 33% of those unemployed and very low paid versus only 15% who 
smoke in professional and managerial occupations (West 2006a). Marital status has an 
effect on smoking consumption; with those divorced or separated twice as likely to be 
heavy smokers (20 or more cigarettes) compared with both single and 
married/cohabiting smokers (12% compared to 6% and 5%, respectively) and three 
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times more likely than those who are widowed (4%) (Office of National Statistics 
2012). 
 
In recent years the UK has made substantial progress in tackling tobacco smoking 
prevalence; in 2007 it was estimated that over 24% of the population was smoking, 
compared to just under 21% in 2011 (West & Brown 2012). Since 2008, the decline 
in cigarette smoking prevalence has averaged 0.5% per year (West & Brown 2012). 
However, despite this overall reduction in prevalence, the long-term effects of 
smoking remain. 
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The effects of smoking on health 
The strong link between smoking and mortality has now long been established. 
Almost 6 million deaths are attributed to tobacco, over 5 million of those are current 
and ex-smokers with around 600,000 deaths attributed to exposure to second-hand 
smoke (World Health Organization 2011). The importance of tackling smoking 
prevalence is realised as tobacco use has been highlighted as a risk factor for six of 
the eight leading causes of death in the world (World Health Organization 2011).  
 
Approximately 18% of all deaths in adults aged over 35 in the UK are estimated to be 
caused as a result of smoking (Office of National Statistics 2012). In 2009 over 
81,000 deaths in the UK were attributed to smoking (HM Government 2011).  It has 
been estimated that significantly more men in the UK die from smoking related 
diseases compared to women (23% vs. 14%) (Office of National Statistics 2012). 
However, this is likely as a result of the male population starting smoking over a 
decade earlier than the women in the UK (Peto, Darby, Deo, Silcocks, Whitley & Doll 
2000). It was estimated to cost the UK NHS £2.7 billion to treat smoking related 
illnesses in 2006/07 (HM Government 2011).  
 
With such high rates of disease attributed to smoking and the cost implication of 
treating smokers, the UK DoH views smoking cessation as a priority in public health 
(Department of Health 2012). The establishment and continued investment into 
specialist services to help smokers quit is in order to reduce the prevalence of tobacco 
related illnesses. Smoking cessation has adverse effects on most areas of the body but 
the most common smoking related diseases are cardiovascular disease (CVD), chronic 
obstructive pulmonary disease (COPD) and cancers of the respiratory system. 
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Cardiovascular disease (CVD) 
Cardiovascular disease (CVD) is a global problem, as it is the leading cause of death 
and preventable illnesses worldwide (World Health Organisation 2007). It is 
estimated that 2.8 million men and women in the UK have CVD (NICE 2010a). The 
prevalence of CVD is estimated to cost the NHS approximately £30 billion annually 
(Luengo-Fernandez, Leal, Gray, Petersen & Rayner 2006).  
 
CVD is a disease of the blood vessels.  Gradual build up of fatty deposits on the walls 
of the blood vessels cause the artery to narrow (World Health Organisation 2011). 
This can lead to serious heart problems including stroke, angina and heart attacks. 
CVD is typically more common in people over the age of 60, and rare below the age 
of 30 (NICE 2010a). There are several modifiable lifestyle choices that are related to 
an increased risk of CVD; these include obesity, lack of physical activity and 
smoking.  
 
Smokers are at an increased risk of suffering from heart disease compared to non-
smokers; this is as a result of the effects of smoking which leads to damage to the 
arteries along with the increased blood pressure and heart needing to “work” harder as 
a result of smoking (World Health Organisation 2011). Most illnesses caused by 
smoking are often dependent on how long the smoker has smoked; however, in the 
case of CVD there is a significant risk of illness even with low levels of smoke 
exposure (Prescott 2002).  
 
Giving up smoking significantly reduces the risks of CVD (Jha & Landsman 2013). 
Stopping smoking will halve the risk of CVD after 1 year of abstinence and after 15 
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years as a non-smoker the risk of having a stroke will be that of a non-smoker (United 
States Department of Health and Human Services (USDHHS) 1990). There has been 
some debate raised over whether the associated increase in weight post smoking 
cessation may negate any positive health gains associated with stopping smoking. A 
recent cohort study was conducted which tested the hypothesis that weight gain does 
not attenuate the benefits of smoking cessation in a population of over 3000 patients 
(Clair, Rigotti, Porneala, Fox, D’Agostino, Pencina & Meigs 2013). Their findings 
showed a decreased incidence of CVD in those who stopped smoking. Weight gain 
post cessation was not shown to negate this effect. This supports that the benefit of 
smoking cessation on CVD risk outweighs any negative effect of possible weight gain 
post cessation.  
 
In the UK interventions to reduce the prevalence of CVD have been aimed at both the 
population as well as the individual level (NICE 2010a). Government implementation 
such as the smoke free law has been shown to reduce the number of hospital 
admissions for both cardiovascular as well as respiratory conditions, specifically in 
the UK but also globally (Bauld 2011; Gaudreau, Sanford, Cheverie & McClure 
2013). 
 
Chronic obstructive pulmonary disease (COPD)  
The World Health Organization (WHO) definition of COPD is a lung disease 
characterised by chronic obstruction of lung airflow that interferes with normal 
breathing and is not fully reversible (World Health Organisation 2011). COPD is 
estimated to kill approximately 25,000 people per year in England and Wales 
(National Statistics 2008). It is ranked as the 5th biggest killer in the UK (Department 
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of Health 2011b). As people get older they are more likely to die as a result of COPD, 
as the lungs get more obstructed over time (Department of Health 2011b).  Diagnosis 
of COPD is much higher in those over 75 year olds. 
 
COPD is common, with an estimated 3 million sufferers in the UK (Lopez, Shibuya, 
Rao, Mathers, Hansell, Held, Schmid & Buist 2006). It is estimated that almost 2 
million people have COPD, which is yet to be diagnosed (Healthcare Commission 
2006).  
 
Smoking is the main modifiable risk factor for COPD. A great majority of the people 
diagnosed with COPD are either ex or current smokers and would be clinically 
described as being or having been highly dependent smokers (Menezes, Perez- 
Padilla, Jardim, Mulno, Lopez, Valdiva, Montes de Oca, Talamo, Hallal & Vicotra 
2005). It is usually as a result of smoking that long-term damage to the lungs has been 
caused, which impairs the flow of air in and out of the lungs and causes 
breathlessness. Smoking is the main cause of COPD but there is also a link to other 
harmful fumes found in the work or home environment or exposure to airborne 
pollution (Menezes et al. 2005). 
 
One of the most important pieces of advice given by health professionals when a 
smoker is diagnosed with COPD is to stop as soon as possible; this is regardless of the 
age at which they are diagnosed (NICE 2010b). It is both the most effective treatment 
as well as the most cost effective (Laniado-Laborin 2009). Although COPD is not 
fully reversible the damage can be limited and a delay in deterioration of quality of 
life can be seen, by stopping smoking immediately (NICE 2010). Stopping smoking 
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reduces respiratory symptoms such as cough, wheeze, and sputum production 
(Anthonisen, Connett & Kiley 1994). Lung function in those patients who continue to 
smoke after diagnosis have a much steeper decline than those who stop smoking 
immediately (Laniado-Laborin 2009). 
 
Current NICE guidelines (NICE 2010b) specify that smoking status and an 
assessment of desire to quit should be done at least twice per year in those with severe 
COPD and at least annually with this diagnosed with mild/moderate COPD. With 
such strong links between COPD and smoking, there is often some stigma associated 
with its diagnosis. Many people view lung disease as ‘self-inflicted’; this is a barrier 
that needs to be tackled amongst the public as well as some healthcare professionals 
(DoH 2011b). The current guidance on COPD management highlights this as a major 
challenge in the treatment of this illness.  
 
Cancers of the respiratory system  
It is estimated that 90% of cancers of the respiratory system are caused by smoking 
(NICE 2010b). Lung cancer is currently the leading cause of cancer death in women 
in the UK (NICE 2010b). A reduction in the prevalence of men who smoke in the UK 
has seen their rates of the disease decrease by more than a quarter (NICE 2010b). As 
the uptake of smoking in women was later in UK women, only now is an increase in 
lung cancer among women being seen (NICE 2010b). 
 
For a smoker, the risk of developing lung cancer is approximately 15 times that in a 
non-smoker (Boffetta, Pershagen, Jockel, Forastiere, Gabourieau, Heinrich, Jahn, 
Kreuzer, Merletti, Nyberg & Rosch 1999). A recent longitudinal study followed 1.2 
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million UK women over an 8-year period (Pirie, Peto, Reeves, Green & Beral 2013). 
All participants were asked at follow up to report on their current smoking status and 
health. The mean age of the participants was 55 years. Results showed that two thirds 
of all deaths among the women in their 50s-70s were as a result of smoking, mainly 
from diseases such as lung cancer. Among those who stopped smoking before the age 
of 40, the risk associated with smoking related mortality was reduced by more than 
90% compared with continued smokers.  
 
UK treatment guidelines for lung cancer strongly recommend that the patient be told 
immediately the effects of continued smoking and that they should be referred for 
specialist treatment (NICE 2010b). Many smokers are aware of the risk of lung 
cancer, but are less knowledgeable about cancer of the stomach, pancreas, cervix, 
kidney, bladder, mouth, lips, nose and oesophagus (US Department of Health and 
Human Services 2004). Cancer of the bowel and ovarian cancer are now also 
understood to be caused primarily by smoking (US Department of Health and Human 
Services 2004). 
 
Smoking to protect health 
Research has suggested that there is a protective association between smoking and the 
onset of Parkinson’s (PD) and Alzheimer’s disease (AD) (Morens, Grandinetti, Reed, 
White & Ross 1995).  Non-smokers are estimated to be two times more likely to 
suffer from PD or AD compared to smokers (Fratiglioni 2000). The suggestion is that 
cigarette smoking has a “neuroprotective” effect (Miller 2007), however the long and 
short-term health benefits of stopping smoking far outweigh the possibility that the 
individual may not suffer from PD or AD.  
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Smoking seems to also be beneficial for ulcerative colitis (UC) (Silverstein, Lashner 
& Hanauer 1994). UC is an inflammatory disease of the bowel, which is more 
commonly seen in never smokers and ex-smokers. Smokers who have UC who quit 
smoking tend to see ‘flare ups’ in their condition once they stop. Again, the health 
benefits of stopping smoking for the individual’s general health far outweigh 
continued smoking for prevention of worsening UC symptoms. 
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Health benefits of stopping smoking 
The health benefits of stopping smoking are seen across all age groups, ethnicities and 
both sexes (USDHHS 1990). Individual risk for developing smoking related illnesses 
often depends on duration and intensity of smoking and between those with or 
without pre-existing evidence of disease. The earlier in life cessation occurs the 
greater the health gains. Those who stop smoking before the age of 35 are expected to 
have the life expectancy of a non-smoker (Doll, Peto, Boreham & Sutherland 2004). 
Among UK women it has been shown that the risk of smoking related mortality is 
reduced by more than 90% if smoking cessation occurs before the age of 40 and more 
than 97% if stopped before the age of 30 (Pirie et al. 2013). However, stopping in 
later life is still associated with a reduced risk of premature death.  
 
In a longitudinal study looking at UK smokers since 1950, which found that for men 
who stopped smoking at ages 60, 50, 40 and 30, the cumulative risks of lung cancer 
by age 75 were 10%, 6%, 3% and 2% (Peto et al. 2000). Their conclusions were that 
even stopping smoking into middle age resulted in a significant reduction in their risk 
for developing lung cancer. Stopping smoking before middle age avoided more than 
90% of the risk attributable to smoking tobacco (Peto et al. 2000). 
 
In a similar longitudinal study that started in the 1950s, British doctors who smoked 
were the population of interest (Doll et al. 2004). Over 34,000 doctors were followed 
up until 2001. The main outcome was overall mortality by individual smoking habit. 
The main reasons associated with mortality among the population were vascular, 
neoplastic and respiratory diseases. Smoking cessation at age 60, 50, 40 or 30 years 
resulted in an increase in life expectancy by approximately 3, 6, 9 or 10 years. Among 
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the men born in the early half of the 20th Century, continued cigarette smoking from 
an early age tripled the specific mortality rates. Smoking cessation at 50 years of age 
halved this risk and cessation at 30 years avoided almost all of the associated risk 
(Doll et al. 2004). 
 
Smoking cessation at any age has clear benefits on overall mortality, but for smokers 
with smoking related illnesses the benefits of cessation are more immediate. 
Regarding CVD risk, the smoking associated risk of coronary heart disease is 
approximately halved within the first year of abstinence and the excess risk of 
suffering a stroke returns to that of a non-smoker after 15 years of abstinence 
(USDHHS 1990).  
 
The reduction in risk of cancers is generally related to the length of abstinence; e.g. 
there is a 30-50% reduction in risk of developing lung cancer after 10 years of 
abstinence, and the risks of oral cancers are halved after five years of cessation 
(USDHHS 1990). 
 
There are also many immediate effects from stopping smoking; within 20 minutes 
blood pressure will decrease and pulse rates slow. Carbon monoxide (CO) and oxygen 
levels in the blood will return to normal after 8 hours without a cigarette. 
 
Along with these physiological benefits there are several other benefits related to 
health and general well being that are commonly discussed among patients; more 
energy, better skin complexion, and cigarette staining on fingers and teeth are 
reduced. 
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CHAPTER 3 – TOBACCO DEPENDENCE  
This chapter outlines the role of nicotine in dependence and how dependence is 
currently defined and measured. Two theories will be described which will aim to 
help the reader to understand the nature of tobacco dependence and its complexities 
when approaching any treatment options. 
 
Tobacco dependence 
Before the 1970’s smoking was viewed by most as habit and more a lifestyle choice 
rather than an addiction (USDHHS 1964). This was despite a 1964 surgeon general 
report that was released which described the harmful effects of smoking (USDHHS 
1964). It was not until the late 1970’s that nicotine in tobacco was widely accepted as 
being responsible for dependence on tobacco.  
 
The role of nicotine in dependence 
It is now agreed that the primary reason for being a regular smoker is a dependence on 
nicotine (Balfour 1994, Di Chiara 2000). Most people start smoking in adolescence 
usually due to social factors (Biglan, McConnell, Severson, Bavry & Ary 1983), such 
as peer pressure but it has also been suggested that parental attitude rather than 
behaviour to smoking is also an influence on early uptake (Newman & Ward 1989). 
Experimentation is common and although many young people do not progress past a 
few puffs, regular smoking can quickly follow (Balfour, Benowitz, Fagestrom, Kunze 
& Keil 2000). 
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Nicotine is synthesised in the roots of the tobacco plant and stored in the leaves 
(Haustein 2002). Nicotine remains in the tobacco leaf during the curing process and is 
vaporised when tobacco is burnt. Tobacco smoke is highly effective in transporting 
nicotine to the lungs where it is rapidly absorbed into the blood, from which it goes to 
several other organs including the brain (Benowitz 2001). Nicotine reaches the brain 
within seconds of being inhaled and it is here that it has its main effect (Rose, Behm, 
Westman & Coleman 1999).  
 
The neural pathway that is involved in ‘reward’ or the feeling of pleasure is the 
mesolimbic dopamine pathway, which comprises of the ventral tegmental area 
(VTA), nucleus accumbens (NA) and prefrontal cortex (Balfour 1994). Nicotine acts 
on this pathway by binding to, and activating, nicotinic acetylcholine receptors 
(nAChRs) on dopamine neurons in the VTA (Balfour 1994). It is believed that there 
are a variety of nAChRs, which are involved in the mediation of nicotine across the 
brain (Picciotto, Caldarone, King & Zachariou 2000). Several neurotransmitters are 
released which nicotine receptors activate, these include dopamine, norepinephrine, 
acetylcholine and gamma aminobutyric acid (GABA) (Benowitz 2001). Direct action 
on the nervous system receptors are believed to be the reason for the reinforced 
behavioural effects that are seen in smokers (Benowitz 2001). As a result of this 
stimulation, behaviours become associated with nicotine delivery, e.g. drinking coffee 
or alcohol, socialising, dealing with stress, boredom, and these become secondary 
reinforcers. When people quit smoking these behaviours act as smoking cues and 
produce urges to smoke, this typically reflects a smokers’ dependence to nicotine. 
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Defining nicotine dependence 
Nicotine dependence is a hypothetical construct that is designed to explain and predict 
societally important outcomes, such as an inability to quit smoking, heavy use, and 
other problems associated by smoking or tobacco use (Piper, McCarthy, Bolt, Smith, 
Lerman, Benowitz, Fiore & Baker 2008).  
 
There is now a wealth of research that has now been undertaken with people 
dependent on nicotine, primarily to characterise the symptoms associated with and 
define the nature of nicotine dependence (Giovino, Henningfield, Tomar, Escobedo & 
Siade 1995). The key attributes of a nicotine dependent person are the experience of 
withdrawal on cessation of smoking and the difficulty they find when attempting to 
quit smoking as a result of these symptoms, for those who do stop smoking there is a 
high rate of relapse that is reported (Ferguson et al. 2005).  
 
Early researchers defined nicotine dependence as only a term relevant to those who 
were heavy daily smokers, which led to some mistaken assumptions that those who 
did not smoke daily or were regarded as lighter smokers were not addicted (Difranza, 
Wellman, Mermelstein, Pbert, Klein, Sargent, Ahluwalia, Lando, Ossip, Wilson, 
Balk, Hipple, Tanski, Prokhorov, Best & Winickoff 2011).  
 
This difficulty in defining who is diagnosed as nicotine dependent can still be seen 
with the current and most commonly used definitions. The current American 
Psychiatric Association (2000) Diagnostic and Statistical Manual (DSM-IV) (Table 1) 
definition of substance dependence includes only 3 of a total of 7 criteria under this 
definition that are particularly relevant to smokers; these are (1) the occurrence of a 
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tobacco withdrawal syndrome; (2) a persistent desire or unsuccessful efforts to cut 
down or stop smoking; and (3) continued smoking despite knowledge of the health 
risks. 
 
Table 1: DSM-IV-TR criteria for substance dependence 
 A maladaptive pattern of substance use, leading to clinically significant 
impairment or distress, as manifest by three (or more) of the following, 
occurring at any time in the same 12-month period 
1. Tolerance, as defined by either of the following: 
• A need for markedly increased amounts of the substance to achieve 
intoxication or desired effect 
• Markedly diminished effect with continued use of the same amount of the 
substance 
2. Withdrawal, as manifest by either of the following: 
• The characteristic withdrawal syndrome for the substance (see later) 
• The same (or closely related) substance is taken to relieve or avoid 
withdrawal symptoms 
3. The substance is often taken in larger amounts and over a longer period than 
was intended 
4. There is a persistent desire or unsuccessful efforts to cut down or control 
substance use 
5. A great deal of time is spent in activities necessary to obtain the substance, use 
the substance or recovering from its effects 
6. Important social, occupational or recreational activities are given up or reduced 
because of substance use 
7. The substance use is continued despite knowledge of having a persistent or 
recurrent physical or psychological problem that is likely to have been caused or 
exacerbated by the substance (e.g. current cocaine use despite recognition of 
cocaine induces depression) 
Adapted from: American Psychiatric Association (2000) 
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A recent review was undertaken to look across studies to see how many smokers 
would be classed as nicotine dependent using the DSM-IV criteria for nicotine 
dependence (Hughes, Heizer & Lindberg 2006). The review found that only about 
half of the current smokers surveyed fulfilled the DSM-IV criteria for nicotine 
dependence. It is argued by the authors that the definition may be too stringent, which 
would explain the lower than expected numbers. It is also possible that the items 
included in the definition are not valid measures when applied to nicotine (Hughes et 
al. 2006). Another explanation may be that those smokers surveyed had not ever tried 
to stop and therefore had not experienced any negative withdrawal and perhaps are 
not then aware of their dependence. 
 
The current usefulness and applicability of all the criteria included in DSM-IV to 
nicotine dependence has been highlighted in several studies. The item in the DSM-IV 
“important social, occupational or recreational activities are given up because of 
substance use” has been highlighted as an item that may not be relevant as an 
indicator for nicotine dependence (Lessov, Martin, Statham. Todorov, Slutske, 
Bucholz, Heath & Madden 2004). This item was also seen as less relevant to nicotine 
dependence in the review by Hughes (2006). 
 
Currently there is no definitive definition that applies to the majority of smokers’ 
which is accepted in the field of tobacco research, however, elements of these 
definitions are able to guide clinicians and researchers in highlighting and targeting 
intervention to the smokers who could most benefit from help.  
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The most striking criteria from most definitions of nicotine dependence, which is 
relevant to practice, is the high rate of failed stop smoking attempts. It is reported that 
as many as 60-70% of smokers report wanting to stop (Kava 2000), and many of these 
smokers attempt to quit smoking each year. However, the high number of those who 
want to stop smoking is not reflected in the relatively low numbers who go on to 
successfully quit (Ferguson et al. 2005). It is estimated that the chances of success at 
any given quit attempt are less than 5% (Hughes, Keely & Naud 2004a). It is these 
smokers that benefit the most from the structure and support that current smoking 
cessation behavioural and pharmaceutical treatments provide. 
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Methods for determining degree of dependence 
Measuring dependence has been described as a construct, it is not in theory equivalent 
to any one criteria or measure and is more a means of testing where that individual 
stands on that construct (Piper et al. 2008). Establishing a smokers’ dependence to 
tobacco is an important measure to help tailor the level of behavioural support the 
smoker needs. It is also a useful tool for guiding health professionals as to which type 
and strength of pharmaceutical treatment should be provided (West 2004a).  
 
The more dependent the smoker is then it is assumed the harder it will be for the 
smoker to successfully stop, therefore, the assumption is that different treatment 
approaches may be more suitable for highly dependent smokers compared with less 
dependent smokers. There are several methods that are commonly used to establish 
how dependent smokers are.  
 
Cigarette consumption  
Dependence is often estimated by cigarette consumption (measured by number of 
cigarettes smoked per day). This measure is easy to ascertain from smokers and so is 
commonly used in practice. Using cigarette consumption does not always correlate 
well with blood nicotine levels (Benowitz 2001). Smokers can reduce their cigarette 
consumption but maintain their usual blood nicotine levels due to compensatory 
smoking (i.e. taking bigger puffs, longer duration of inhalation, smoking more of each 
cigarette) (Benowitz 2001).  
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Biological measures 
Another measure of consumption is cotinine, a metabolite of nicotine, which can be 
quantified in blood, urine and saliva. Cotinine has a longer half-life than nicotine, 
which means that cotinine levels vary only slightly throughout the day (Benowitz 
2001). The measure of cotinine can then be taken at any time point throughout the day 
and is not vastly influenced by the time of the last cigarette smoked. For the purposes 
of research this is a good measure of the amount of nicotine that has been consumed 
(Hughes 2004b). 
 
Measuring expired carbon monoxide (CO) is commonly used to measure dependence.  
CO is a gas inhaled from cigarettes, which has been linked to heart disease (Glantz & 
Parmley 1991). CO is measured in parts per million, a CO reading of <10ppm is the 
recognised acceptable reading for a non-smoker (West, Hajek, Stead & Stapleton 
2005).  
 
Typically CO is eliminated from the body approximately 24-hours after smoking 
cessation (American Lung Association (ALA) 1990). One of the limitations of using 
this measure is that due to COs short half-life, the measurement is limited to being an 
indication of only the last few hours of smoking (Benowitz 2001). One of the other 
limitations of CO monitors is that they are expensive pieces of equipment, costing 
approximately £300 per machine, which does not include the on-going cost of the 
disposable tubes that are needed for each use (Bedfont Scientific Ltd 2007). 
 
In practice, CO readings are the most common way of tracking progress by the NHS-
SSS and is expected that all smoking cessation advisors will verify smoking status 
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four weeks after the quit day (May & McEwen 2008). CO monitors provide an instant 
reading and so for many smokers attempting to quit, the reading acts as a useful 
motivation tool. 
 
Fagerström Test for Nicotine Dependence (FTND) 
The FTND (Heatherton, Kozlowski, Frecker & Fagestrom 1991) is the most widely 
used measure of nicotine dependence (Colby, Tiffany, Shiffman & Niaura 2000a). 
The measure is based on physical constructs of dependence and is made up of six 
questions that are scored and summed (see Table 2). Items include; how soon after 
you wake up do you have your first cigarette? Do you find it difficult not to smoke in 
places where smoking is not allowed? Do you smoke if you were so ill you were in 
bed all day? 
 
Scores of six to ten on the FTND indicate high levels of nicotine dependence; a score 
of 4 or more is typically seen in a typical smoking population. In a recent study the 
relationship between the FTND and abstinence rates was looked at across 10 RCTs 
(Fagerström, Russ, Yu, Yunis & Foulds 2012). The results found that those with an 
increasing dependence score had lower abstinence rates. This is also reflected in 
several other studies looking at smoking outcome (Colby, Tiffany, Shiffman & Niaura 
2000b, Heatherton, Kozlowski, Frecker, Rickert & Robinson 1989, Heatherton et al. 
1991, Kozlowski, Porter, Orleans, Pope & Heatherton 1994, Hughes 2007b).   
 
The FTND is not without its limitations; they include lack of internal consistency 
(Heatherton et al. 1991), its relationship with outcome is not strong (Kozlowski  et al. 
1994) and scores do not consistently correlate with objective measures (e.g. blood 
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nicotine levels) or other subjective measures such as withdrawal symptoms (Hughes 
2007b). 
 
Table 2: Fagerström Test for Nicotine Dependence 
How soon after you wake up do you smoke your first 
cigarette? 
Within 5 minutes = 3 
6-30 minutes = 2 
31-60 minutes = 1 
After 60 minutes = 0 
Do you find it difficult to refrain from smoking in places 
where it is forbidden? 
Yes = 1 
No = 0 
Which cigarette would you hate most to give up? The first one in the 
morning = 1 
Any other = 0 
How many cigarettes per day do you smoke? Up to 10 = 0 
11 – 20 = 1 
21 – 30 = 2 
Over 30 = 3 
Do you smoke more frequently during the first hours after 
waking than during the rest of the day? 
Yes = 1 
No = 0 
Do you smoke if you are so ill that you are in bed most of 
the day? 
Yes = 1 
No = 0 
Source: Heatherton et al. 1991 
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Other scales 
There are several other measures that have been developed and used to assess 
smokers’ dependence to nicotine. 
 
There are two items in the FTND that are the strongest predictors of outcome; time to 
first cigarette and cigarettes smoked per day (Colby et al. 2000a). These questions 
have been combined and used as a brief measure of dependence, the Heaviness of 
Smoking Index (HSI) (Kozlowski et al. 1994, Fagerström et al. 2012). These two 
items have been found to be fairly reliable over time as well as important predictors of 
quitting (Borland, Yong, O’Connor, Hyland & Thompson 2010). 
 
The time to first cigarette (TTFC) item has been used as a measurement of 
dependence on its own (Shiffman, Gwaltney, Balabanis, Liu, Paty & Kassel 2002a). 
The item appears to indicate a pattern of heavy, uninterrupted, and automatic smoking 
and may be a good single-item measure of nicotine dependence (Baker, Piper, 
McCarthy, Bolt, Smith, Kim, Colby, Contil, Giovino, Hatsukami, Hyland, Krishnan-
Sarin, Niaura, Perkins & Toll 2007). 
 
A more recently developed scale to measure dependence is the Nicotine Dependence 
Syndrome Scale (Shiffman, Waters & Hickcox 2004). This multidimensional tool was 
developed from theoretical concepts and incorporates five factors; drive, priority, 
tolerance, continuity and stereotypy. Smokers self-complete a 23-item questionnaire, 
rating their answers on a 5-point scale. Validation of this tool shows that it predicts 
urges to smoke, abstinence effects and smoking cessation outcome (Shiffman et al. 
2004). It also correlates with other markers of dependence (Shiffman et al. 2004). The 
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authors concluded that this scale might expand the scope of the Fagerström measures 
particularly as it has stronger associations with withdrawal and craving. However, it 
has not yet gained widespread use. 
 
It is typical to only ask about the strength and frequency of urges and cravings to 
smoke post quit day, however, in a recent study a measure of strength of urge to 
smoke (SUTS) was examined prior to quitting to see if this could predict relapse 
(Fidler, Shahab & West 2011). All smokers at baseline were asked ‘How much of the 
time have you felt the urge to smoke in the past 24 hours?’ And were asked to report 
their response on a 6 point scale from 1, ‘not at all’ to 6, ‘all of the time’ (Fidler et al. 
2011).  FTND, HSI and SUTS were all found to predict successful quitting, with 
SUTS showing the strongest association.  
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Theories used to explain dependence to nicotine 
 
Conditioning Theory  
The theory of conditioning is important to consider particularly when used in the field 
of addiction related research. Conditioning theory is typically the main model used in 
addiction. According to learning-based theories, cue-induced craving might partly 
reflect a conditioned response (CR) established by a learned association between that 
cue and nicotine intake (Field & Duka 2004, Niaura, Rohsenow, Binkoff, Monti, 
Pedraza & Abrams 1988). 
 
Cue exposure effect (i.e. an increase in urges to use the drug in the presence of stimuli 
which habitually accompany its use), has been reported in numerous laboratory 
studies (Carter & Tiffany 1999). The effect seems to be largely due to classical 
conditioning (Conklin 2006). 
 
Over the course of drug use, a range of stimuli becomes associated with drug 
administration (e.g. smoking paraphernalia, others smoking). After time, those stimuli 
become cues or conditioned stimuli, which can then elicit conditioned responses. 
When an individual is re-exposed to those cues in the laboratory (Conklin & Tiffany 
2001) or in the real world (Shiffman et al. 2002a), he or she experiences subjective 
effects (e.g. craving to smoke), physiological effects (e.g. increase in heart rate) and 
behavioural effects (e.g. quickening of drug seeking or use). This may be one of the 
factors, which contribute to relapse in drug users who try to abstain.  
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Conditioning models are useful in helping to explain the observable features of 
addiction, however, they do not specify the precise role of neurobiological 
reinforcement mechanisms necessary in establishing reinforcement of drug seeking 
behaviour (Shadel, Shiffman, Niaura, Nichter & Abrams 2000). This theory also is 
criticised for not taking into account the role of cognition in addiction, such as 
thought and affect (Shadel et al. 2000), which have established roles in regulating and 
establishing drug behaviour (Marlatt & Gordon 1985). 
 
PRIME theory of addiction 
One of the most recent theories to emerge in the field of addiction is the PRIME 
theory of addiction (West 2006b), which aims to bring together many of the concepts 
that are in existing behaviour theories into a single simple model (e.g. intention, 
emotion, instincts, habituation). The theories main aim is to explain how, when and 
why motivation “goes wrong’ in addiction. It is thought that there are 5 levels within 
our motivation system and that any one of these levels can function abnormally in 
addiction (West 2006b). The system is described in this theory by the acronym 
PRIME – plans, responses, impulses, motives and evaluations.  
 
The model is seen as fluid matrix of interacting forces that can influence behaviour 
when all elements of the system are in place (West 2006b). The “chaotic” system can 
change due to any trigger whether small or large and as the result of no event or 
reason (West 2006b). 
 
Ultimately the approach of the model with regards to smoking is to minimize the 
impulses, wants and needs to smoke of the individual and to maximise the wants and 
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needs to remain abstinent. In terms of PRIME Theory, the process of smoking 
cessation involves forming a personal rule not to smoke followed by self-conscious 
implementation of that rule in the face of impulses, wants and needs to smoke (West 
2009).  
 
The importance of the not-smoking rule is predicted by PRIME theory, in that those 
smokers who say they will “attempt to not smoke” rather than saying “I will not 
smoke” will have insufficient motivation to deal with all vulnerable situations they 
find themselves in and will ultimately fail in their attempt.  
 
Medication can reduce the drive for smoking as well as the cue-induced reaction to 
smoking in the short term thus increasing the chances of successfully stopping. The 
model is recognised as a useful tool in the provision of effective cessation 
interventions, assessing clients motivation during a quit attempt and adjusting 
treatment to levels of motivation throughout any treatment programme in order to 
overcome addiction (West 2009).  
 
The theory has been criticized for being too over inclusive with its varying constructs, 
which limits the rigorous testing that needs to be done with such a model (Redvers 
2007). There are plenty of real-life applications for this model as it is soundly based 
on common sense, however, more research is needed to test the relevance of all 
PRIME constructs in its scientific applicability to treating smokers. 
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CHAPTER 4 - TOBACCO WITHDRAWAL SYNDROME  
This chapter discusses the symptoms that are experienced by smokers on withdrawal 
of tobacco and the ways in which these symptoms are measured. Their time course 
and relationship with relapse are also discussed.  
 
Tobacco withdrawal syndrome 
When smokers attempt to abstain from cigarettes they typically experience a variety 
of uncomfortable reactions. These signs and symptoms have been termed the tobacco 
withdrawal syndrome (TWS) (Shiffman 1978). The experience of withdrawal 
symptoms after stopping drug use is one of the most utilised indicators of addiction 
and it has been proposed that the onset of these symptoms maintains smoking 
(Hughes, Hatsukami, Pickens, Krahn, Malin & Luknic 1984).  
 
There are several TWS that have been observed in smokers who abstain from tobacco. 
These include; irritability (Hughes & Hatsukami 1986), poor concentration 
(Leventhal, Water, Boyd, Moolchan, Lerman & Pickworth 2007), depression (Hughes 
1992), and hunger (West & Hajek 2004b) (see Table 3). One of the most common 
symptom after withdrawal from tobacco is an increase in craving to smoke (Shiffman 
2000). The experience of increased craving for cigarettes, weight gain and post-
cessation depression has been highlighted as predictors for relapse back to smoking 
(Hughes 1992).  
 
A mediating factor on experience of strong craving after a period of smoking 
abstinence has been found to be related to those who have a high nicotine dependence 
(Van Den Eijnden 2003). One study showed that after a period of smoking abstinence, 
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craving was stronger in those with high tobacco dependence than in those with low 
tobacco dependence (Van Den Eijnden, Splikerman & Fekkes 2003). Experiencing 
strong craving when abstaining from cigarettes has been described as “potentially the 
most important feature of cigarette withdrawal” (West, Hajek & Belcher 1989). 
 
For all smokers the experience of withdrawal is a daily occurrence. The craving to 
smoke is alleviated only by lighting and smoking the next cigarette. This cycle of 
smoking to alleviate discomfort of craving is one of the key mechanisms to continued 
use and ultimately a dependence to tobacco.  
 
Table 3: Tobacco withdrawal – mood and physical symptoms 
Symptom/Physical sign Average duration 
Depressed mood <4 weeks 
Sleep disturbance <2 weeks 
Irritability <4 weeks 
Difficulty concentrating <2 weeks 
Restlessness <4 weeks 
Increased appetite and increased weight >10 weeks 
Constipation >4 weeks 
Mouth ulcers >4 weeks 
Light-headedness <2 days 
Urges to smoke >10 weeks 
Sources: (West et al.1989; Hughes 1992; Hajek, Gillson & McRobbie 2003; Ussher, 
West, Steptoe & McEwen 2003; McRobbie, Hajek & Gillison 2004) 
 
From a treatment perspective individual variation in withdrawal symptoms is 
important. The onset of withdrawal symptoms has been found to occur within 2-12 
hours of the last cigarette (Shiffman et al. 2002a). Many smokers suffer with 
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withdrawal symptoms and some find these distressing (Hughes, Higgins & Bickel 
1994). Some smokers report that withdrawal symptoms cause significant impairment 
in social, occupational, or other important activities of daily living (Pergadia, Heath, 
Martin & Madden 2006). However, tobacco withdrawal symptoms are mostly short-
lived and people withdrawing from tobacco can be reassured that these should 
disappear within 4-6 weeks (Cummings, Giovano, Jaen & Emrich 1985). Urges to 
smoke usually last longer, but do decrease in frequency and people can learn to 
manage these (Gritz, Carr & Marcus 1991).  
 
Most people who stop smoking will gain weight, with most of the weight gain 
occurring in the first 3 months after cessation (Aubin, Farley, Lycett, Lahmek & 
Aveyard 2012). Typically smokers gain around 5kg on average in the first year of 
abstinence (Aubin et al. 2012; Farley, Hayek, Lycett & Aveyard 2012). A Cochrane 
review (Farley et al. 2012) that examined interventions to prevent post-cessation 
weight gain showed clear evidence that NRT, varenicline, and bupropion (all licensed 
medications for cessation) all reduce weight gain by about 0.5 to 1kg during the 
period of use of medication. 
 
It is common for smokers to use weight gain as a reason for not wanting to stop 
smoking so being able to reassure those who are concerned about their weight that the 
use of smoking cessation medications can help delay weight gain can be useful. It also 
helps the smoker to give their full attention to stopping smoking and deal with any 
weight concerns at a later date, after tobacco withdrawal symptoms will have 
subsided. Smokers can also be advised to eat a healthy high fibre diet, and where 
possible increase their levels of physical activity. Small bouts of exercise have also 
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been shown to reduce the desire to smoke and the intensity of withdrawal symptoms 
in abstaining smokers (Ussher, Nunziata, Cropley & West 2001). 
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Measuring withdrawal 
There are several measures, which have been developed to measure tobacco 
withdrawal symptoms, which include the Wisconsin Smoking Withdrawal Scale 
(WSWS) (Shiffman et al. 2004), the Mood and Physical Symptoms Scale (MPSS) 
(West & Hajek 2004b), Shiffamn-Jarvik Smoking Withdrawal Questionnaire (SWQ) 
(Shiffman & Jarvik 1976), Minnesota Nicotine Withdrawal Scale (MNWS) (Hughes 
& Hatsukami 1986), Shiffman Scale (SS) (Shiffman, Balabanis, Paty, Engberg, 
Gwaltney, Liu, Gnys, Hickox & Paton 2000) and the Cigarette Withdrawal Scale 
(CWS) (Etter 2005).  
 
All scales rely on self-reported measures of withdrawal recorded on a scale, with a 
higher score typically indicating higher levels of withdrawal. All scales use valid 
withdrawal symptoms but have different labels for these symptoms. For example, the 
MPSS uses the term depressed only whereas the MNWS uses depressed mood/sad. 
This may have implications for how some people rate these items. For example, on 
seeing the word depressed some people may only use that term if they were clinically 
diagnosed rather than how they would describe a slight low mood. It is important to 
consider that single label items may underestimate the prevalence of the symptoms 
but equally using multiple labels may overestimate prevalence. 
 
The MPSS and WSWS measures are most commonly used and after much testing are 
seen as the most reliable and valid measures of nicotine withdrawal. The MPSS is 
most commonly used in clinical practice. 
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The Mood and Physical Symptoms Scale (MPSS) 
The MPSS is used to track the time course of tobacco withdrawal symptoms 
throughout the initial period of quitting smoking. There are five core withdrawal 
symptoms that are included in the MPSS (irritability, poor concentration, restlessness, 
depression, and hunger) and urges to smoke (West & Hajek 2004b). All of the 
withdrawal symptoms are measured with a single item, rated on five-point scales, 
with the exception of urges to smoke.  
 
Urges to smoke are measured with two questions related to frequency and strength of 
urges on a 6-point scale. The six-point scale is used to rate ‘How much of the time 
have you felt the urge to smoke in the past week?’ (from ‘not at all’ to ‘all of the 
time’) and ‘How strong have the urges been?’ (from ‘no urges’ to ‘extremely strong’). 
The five-point scale used for the other measures asks how they have been feeling 
during the past week with regard to depression, irritability, restlessness, hunger, poor 
concentration, poor sleep at night, and anxiety on a scale ranging from 1=not at all to 
5=extremely.   
 
The MPSS has been extensively tested for its reliability in assessing nicotine 
withdrawal symptoms. The MPSS is commonly used as a composite score, taking an 
average score across the five measures and comparing it pre and post quitting to 
establish the occurrence and severity of withdrawal symptoms. The urge question on 
the MPSS consists of two items; the severity of urges experienced over the previous 
week and the frequency of the urges. In one study that examined the internal structure 
and responsiveness of the MPSS measures (West & Hajek 2004b), 96 smokers were 
recruited who had been able to maintain 24 hours of validated abstinence. The results 
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of the pre and post quitting MPSS measures demonstrated a significant increase from 
baseline in all 5-core nicotine withdrawal measures. A high correlation was seen 
between the two urge questions and so these have since been combined to represent 
an overall urge to smoke rating (West & Hajek 2004b).  
 
It is common practice to ask all patients to record baseline readings (before they stop 
smoking) on all the core withdrawal symptoms.  The only exception is that the two 
ratings on urges to smoke are only asked post quitting. The reasoning is that when the 
scale was developed rating craving at baseline, whilst the person is still smoking, was 
not viewed as being clinically meaningful. However, in a recent study a measure of 
SUTS was examined prior to quitting and was seen as a strong predictor of successful 
quitting (Fidler et al. 2011). This research seems to indicate that the addition of the 
SUTS measure before a person quits may add more strength to the MPSS.  
 
It is common for participants to question why we ask them to rate their concentration, 
irritability, depression, hunger, restlessness over the last week before they have 
stopped smoking. The reasoning behind this is to get a clean baseline score, which is 
not influenced by any of the mood and physical changes that occur when stopping 
smoking. At baseline the MPSS rating is asked to establish how depressed that person 
is at and to then compare the rating post-quitting. For example, if the depression score 
is rated as moderate at baseline and is rated again as moderate at a post quit time point 
then we are able to distinguish that this depression rating is not as a result of smoking 
whereas someone who reports no depression at baseline but post quitting reports 
being very depressed we can assume some influence of stopping smoking has had an 
effect on their mood. 
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When looking at withdrawal symptoms it is important to distinguish between those 
who have stopped smoking and those who have not as this may have major 
implications on the findings. Asking those who have relapsed back to smoking to 
gauge their frequency and intensity of urge to smoke will give distorted results as the 
participant may overcompensate with their marking of these symptoms to justify their 
relapse or continued smoking. Ultimately those who have relapsed or continued to 
smoke are not experiencing true withdrawal symptoms as they are still having a high 
intake of nicotine from cigarettes. 
 
Treatments that help smokers’ progress through the most difficult time period, for 
example, withdrawal oriented treatment (Hajek 1989), use knowledge of withdrawal 
symptom time course to help smokers understand the transition from being a smoker 
to an ex-smoker. 
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The role of environmental cues 
Although the role of nicotine deprivation plays a major part in people’s success when 
stopping smoking there are other factors which have been found to influence craving 
and urges to smoke which include expectations, habits and environmental cues. 
Higher cravings have been demonstrated in a sample of smokers who were exposed to 
smoking cues who were expecting to be able to smoke after the experiment when 
compared with a control who were instructed they could not smoke (Juliano & 
Brandon 1998). Smokers’ perceptions of cigarette availability have been found to 
mediate responses to smoking cues, such as pictures of cigarettes and lighters (Dols, 
Willems, Van Den Hout & Bittoun 2000).  
 
An earlier review undertaken by (Wertz & Sayette 2001) found that those addicted to 
substances (which included tobacco) found the urge to smoke higher when they 
perceived their drug of choice was available compared with when they were not. The 
urges to smoke were self-reported. Cue reactivity in addiction appears to depend on 
the availability which is signalled by other environmental cues e.g. a patient may have 
cigarettes on them in hospital but feel no urges to smoke as they know they cannot 
smoke but once the smoker leaves hospital (and therefore able to smoke) and the 
smoking cue (cigarettes) are still available then the urge to smoke will be increased. 
Anecdotally dependent smokers who have been unsuccessful at stopping smoking in 
the past, report that when they are hospitalised they do not think about cigarettes 
during their stay and feel comfortable without smoking (Myers, Rudell & Hajek 
2009).  
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It is assumed that this is reinforced particularly after discharge by having a smoking 
partner or living with people who smoke as the opportunity to smoke will be 
increased and they are more likely to be surrounded by smoking cues e.g. others 
smoking, cigarettes in the house. 
 
One study (Dar, Stronguin, Marouani, Krupsky & Frenk 2005) looked at the role 
smoking related habits, cues and expectations had on cravings to smoke. They used a 
unique group of participants to study this – Orthodox Jews. The reasoning for this was 
due to the fact that Orthodox Jews abstain from smoking on the Sabbath, the authors 
hypothesised that as they have no smoking cues or expectations of smoking during the 
Sabbath that craving to smoke would be lower than usual. Twenty participants were 
asked to rate craving scores and withdrawal ratings including irritability during three 
different conditions; smoke as usual during a workday, forced abstinence during a 
workday and during the Sabbath (no smoking). The results found that craving during 
the Sabbath was significantly lower than on the abstinence workday and non-
abstinence workday. The conclusion of this study was that the results show that 
craving to smoke is determined to a large extent by smoking-related habits, cues and 
expectations. 
 
Another study (Thwissen, Van Der Meijden, Havermans, Van Den Hout & Jansen 
2008) also showed patients cues predicting either smoking or no smoking and the 
effect of this was measured in two separate rooms – one a low-smoking relevant room 
and the other a high-smoking relevant room. They found that a cue predicting 
smoking availability increased participant reports of urges to smoke than a cue 
predicting no availability to smoke.  
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Relapse 
The previous sections discuss the role that dependence, the tobacco withdrawal 
syndrome and environmental cues have on an individual when attempting to stop 
smoking. Due to the complexities of overcoming tobacco dependence, many smokers 
who try to quit will relapse back to smoking.  
 
For most smokers who attempt to quit without support they will relapse within the 
first week of abstinence, with over 60% relapsing back to smoking within the first 3 
days (Hughes et al. 2004a). Approximately 60-98% of smokers who use treatment 
will relapse back to smoking within the first year (Garvey, Bliss, Hitchcock, Heinold 
& Rosner 1992), with the majority doing so within the first 6 months (Ferguson et al. 
2005, Logan, Levy, Ferguson, Pomrehn & Muldoon 1992). After several months of 
abstinence the risk of relapse reduces, however, this does not guarantee long-term 
abstinence.  
 
There is no clear definition of relapse as technically resumption of smoking anytime 
after the quit day can be viewed as a relapse (Hajek, Stead, West, Jarvis & Lancaster 
2009). Defining what relapse is in smoking cessation is often discussed, whether it is 
return to daily smoking or simply having a puff of a cigarette. In clinical practice it is 
typical to call it a lapse if less than 5 cigarettes have been smoked with continued 
efforts towards remaining abstinence after the lapse. Whereas relapse is followed by a 
return to regular smoking. 
 
There is a large amount of research that has focused on predictors for relapse among 
the smoking population. One longitudinal study looked at smokers who had 
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previously quit for more than a year and divided participants into 2 groups; those who 
were currently smoking and those who were long term abstainers (Macy, Seo, 
Chassin, Presson, Sherman & Macy 2007). The results from the study showed that the 
strongest predictor for avoiding relapse was marrying a non-smoker (OR=0.07; 95% 
CI =0.03-0.21). Other factors included working in a smoke-free building (OR=0.13; 
95% CI=0.03-0.58). The study concluded that factors related to smoking in their 
social environment played the largest role in predicting long-term abstinence versus 
relapse.  
 
Relapse is most commonly associated with situations that lead back to smoking; most 
typically associated with major life events such as bereavement, divorce, holiday and 
being under the influence of alcohol (Hymowitz, Sexton, Ockene & Grandits 1991). 
 
As the health benefits of stopping smoking are only realised with long-term abstinence, 
relapse reduces the public health benefit of investment in smoking cessation. 
 
The Cochrane Review (Hajek, Stead, West, Jarvis & Lancaster 2009) of relapse 
prevention literature identified 47 randomised trials of behavioural treatments, with 
no single trial or group of trials showing an effect. Most trials evaluated Marlatt and 
Gordon’s (Marlatt & Gordon 1985) ‘skills-based’ approach, which includes 
identifying relapse situations and coping strategies. The interventions were often brief 
and one-off, many trials mixed smoking cessation and relapse prevention 
interventions, with only 36 randomising abstaining smokers, and most trials posed 
significant methodological problems. The Cochrane review identified the need for 
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good quality research in this key area as the number one priority in the field of 
smoking cessation.  
 
The lack of proven relapse prevention interventions has not stopped NHS-SSS 
attempting to provide some relapse prevention help for their clients. A survey of 
current practice reported that most (58%) services were providing some kind of RPS 
(Coleman, Agboola, Leonardi-Bee, Taylor, McEwen & McNeill 2010). ‘Common 
sense’ approaches are usually used, such as an offer of regular drop-in sessions. 
Anecdotally some clients find these helpful but the sessions are usually poorly 
attended, and their efficacy is unknown. It has been suggested that extended use of 
varenicline may prevent relapse, however, research using extended use of NRT as a 
relapse prevention strategy are still needed (Hajek et al. 2009). 
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CHAPTER 5 – SMOKING CESSATION TREATMENT 
AND INTERVENTIONS 
This chapter provides a comprehensive overview of evidence-based smoking 
cessation interventions. Relevant theories that have been used in the development of 
these interventions will be discussed. Detailed descriptions of current pharmaceutical 
treatments for smoking cessation are also presented. 
 
Brief advice 
Brief advice to quit smoking is one of the most important interventions a healthcare 
worker can deliver. The Cochrane review looking at the effectiveness of doctor advice 
to quit in promoting cessation (Stead, Bergson & Lancaster 2008) identified 17 
studies comparing brief versus no advice. The results from 17 studies showed an 
increase rate of quitting in those who received brief advice from their doctor (RR 
1.66; CI 95% 1.42-1.94). When looking at more intensive versus minimal advice, a 
small but significant effect was seen (RR 1.37; CI 95% 1.20-1.56). 
 
Overall brief advice from a doctor in promoting cessation showed an increase in quit 
attempts by up to 3% (Stead et al. 2008); this is a small but important effect.  
 
Asking patients about their smoking status should of course not be an end in itself. A 
recent systematic review by Aveyard, Parson & West (2011) untangled the literature 
on brief interventions to look at the effect of brief advice and offering assistance to 
quit. Advice to quit on medical grounds increased the frequency of quit attempts by 
24%. However, making an offer of treatment (e.g. offering a prescription for smoking 
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cessation medications or referral to a stop-smoking programme), regardless of 
assessing readiness to quit, motivated an additional 40-60% of people. 
 
Self-help materials 
The Cochrane review, self-help interventions for smoking cessation (Lancaster 2005a) 
looked at the effectiveness of different forms of self-help materials compared with 
minimal or no treatment. When compared with no advice there was a small but 
significant increase in abstinence rates in those who received the self-help materials 
(RR 1.21; CI 95% 1.05-1.39). The significant result may be in part attributed to the 
additional contact or assessment required to obtain individual data. Tailoring self-help 
materials to individual smokers compared to no intervention showed a small benefit 
(RR 1.31; CI 95% 1.20-1.42). There was no evidence of added benefit using self-help 
materials alongside other interventions for cessation. Their conclusion was that self-
help materials may increase quit rates compared to no intervention but that the effect 
is likely to be small. There is evidence that tailored materials are more effective than 
untailored materials but again the effect is likely to be small. 
 
Group based treatment (GBT) 
The structured group orientated model (Hajek, 1989) views smokers as “addicted to 
nicotine and that nicotine dependence is the main remediable source of difficulties 
smokers encounter when stopping smoking”.  
 
The model which is widely used for smoking cessation uses withdrawal-oriented 
therapy that focuses on helping people maintain abstinence over the first 4-weeks of a 
quit attempt; a period when withdrawal symptoms are most frequently experienced 
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and relapse is most likely. Treatment is provided over 7 weekly sessions and on-going 
sessions can be offered if needed. 
 
There has been extensive research done using this model to help treat smokers, which 
show its effectiveness. The Cochrane review, Group behaviour therapy programmes 
for smoking cessation (Stead 2005), has looked at the evidence for the efficacy of 
GBTs for smoking cessation. The review includes data from 53 studies that met the 
inclusion criteria (that is they were randomised controlled trials investigating the 
efficacy of group based treatments on at least 6-month smoking cessation outcome). 
The meta-analysis showed the superiority of group-based interventions over self-help 
in achieving at least 6 months of abstinence (RR=1.98; 95% CI: 1.60-2.46).   
 
When researchers compared the effect of GBT with individual treatment, pooling data 
from five studies, long-term abstinence rates were similar between the two methods 
(RR=1.01; 95%CI: 0.77-1.32). There was limited evidence that the addition of group 
therapy to other forms of treatment, such as advice from a health professional or NRT, 
produced extra benefit. 
 
Data from NHS-SSS report GBT as having higher 4-week success rates than one-to–
one and pharmacist led sessions (Brose et al. 2011, Judge, Bauld, Chesterman & 
Ferguson 2005, McEwen, West & McRobbie 2006). However, this data are not from 
RCTs and could be explained as a result of the differences in the clinician involved in 
the treatment or in the population being treated. 
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Individual treatment 
Individual treatment follows a very similar structure to the GBT (preparation, 
medication options, quit day session and repeated contacts post quit day). Individual 
treatment is usually offered to people who are not able to commit to weekly sessions 
and need a more a more flexible option, do not feel the need or are inappropriate for 
intense group treatment. The Cochrane review on individual counselling (Lancaster 
2005b), found smokers who received individual counselling compared to minimal 
behavioural intervention had higher cessation rates at long term follow up (RR 1.39, 
95% CI; 1.24-1.57). Individual counselling was defined as a face-to-face encounter 
between a smoking patient and a counsellor trained in assisting smoking cessation. 
The intensity of the individual counselling had no effect on outcome (RR 0.96, 95% 
CI 0.74 to 1.25).  
 
Other routes to quit 
Telephone counselling (Quitlines) 
Telephone counselling (often referred to as Quitlines) typically provides proactive 
behavioural support (or counselling), via the telephone, to people who want help in 
quitting. In the Cochrane review, Telephone counselling for smoking cessation (Stead 
& Lancaster 2006), those receiving multiple (at least 2) pro-active phone calls were 
significantly more likely to report abstinence at long term follow up (RR 1.37; CI 
95% 1.26-1.50). There appears to be a dose-response effect, in that the more calls 
someone receives the greater the chances of quitting. There were 3 studies looking at 
providing smokers with the option for contacting a quitline. These results were not 
pooled; one found no effect and the other 2 showing a significant benefit of offering 
the option of a quitline to smokers.  
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In a recent UK study participants were randomised to receive NRT (6 weeks) or 
proactive telephone counselling in addition to standard smoking cessation support 
offered through a telephone quitline (Ferguson, Docherty, Bauld, Lewis, Lorgelly, 
Boyd, McEwen & Coleman 2012). At 6 month follow up no effect on smoking 
outcome was seen in either the NRT or proactive phone call condition (6.6% versus 
9.4%, NRT and proactive phone call group, respectively). 
 
Multimedia interventions 
There is growing interest in using other technologies in order to provide behavioural 
support; such as web-based interventions and mobile phone technology. Typically 
multimedia is used to provide motivational messages and to provide behavioural 
change support throughout the course of treatment. The messages are usually tailored 
to the individual and are often able to provide the smoker with extra help if needed 
without the need to attend a clinic, which for some people can be more convenient if 
they have limited availability.  
 
The Cochrane review looking at interventions delivered using mobile phones 
(Whittaker, McRobbie, Bullen, Borland, Rogers & Gu 2012), found 5 studies that 
included long term follow up of at least 6 months. Three studies looked a text 
messaging only, one study using an internet QuitCoach both with mobile phone 
intervention and without and one using video messaging delivered via mobile phones. 
When the text messaging interventions were pooled, mobile phone interventions 
showed an increase in abstinence at 6 months compared to control (RR 1.71; 95% CI; 
1.47-1.99).  
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A recent RCT was conducted in the UK, which looked at the effectiveness of text 
messaging on 6-month continuous abstinence rates (Free, Knight, Robertson, 
Whittaker, Edwards, Zhou, Rodgers, Cairns, Kenward & Roberts 2011). They found a 
significantly increased validated continuous abstinence rate at 6 months in the text 
messaging condition compared to the control group (10.7% versus 4.9%, RR, 2.20, 
95% CI 1.80-2.68, p <0.0001).  
 
A recent service enhancement conducted at the TDRU looked at the use of text 
messages to help prevent relapse after quitting smoking. The service enhancement 
focused on documenting the development, implementation and evaluation of a text-
based relapse prevention service (RPS). Clients were offered the RPS if they had 
successfully quit smoking for 4 weeks at routine community services (pharmacists, 
level 2 trained advisors) and through the NHS-SSS (Snuggs, McRobbie, Myers, 
Schmocker, Goddard & Hajek 2012). Text messages aimed at motivation to remain 
abstinent, preventing absent-minded lapses, and continuing the full course of 
medicine for smoking cessation were developed.  
 
RPS was well received by both NHS-SSS clients and staff, with 70% of clients 
considering the intervention helpful. 85% of clients responded to at least one of the 
nine interactive text messages. Seventy-seven clients (38% of the total, 56% of those 
we managed to contact) reported abstinence at 6-months. Eighteen clients who 
relapsed back to smoking used RPS to re-engage with the NHS-SSS and 10 
successfully re-established abstinence. A controlled trial is needed to establish 
whether text messaging has a significant impact on relapse.   
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Alternative smoking cessation treatments 
There are several alternative treatment methods commonly used by people who want 
to stop smoking. The most commonly reported treatments reported by clients 
attending the NHS-SSS are hypnotherapy, acupuncture and reading the Allen Carr 
“easy way to stop smoking” or attending the Allen Carr smoking clinic. The efficacy 
of these methods are summarised below. 
 
Hypnotherapy 
There are several different ways in which hypnotherapy has been used to help treat 
smokers. Whether it is in order to help smokers to focus and concentrate on the task 
of stopping smoking or to strengthen will power and determination to quit and resist 
the temptation of cigarettes, smokers are attracted to hypnotherapy as a treatment 
option.  
 
A Cochrane review on the effectiveness of hypnotherapy for smokers found 11 
studies, which compared hypnotherapy to 18 different control interventions (Barnes, 
Dong, McRobbie, Walker, Mehta & Stead 2010). Control interventions ranged from 
no treatment, brief advice to psychological treatments including NRT. When looking 
at smokers six months after the intervention was delivered, those using hypnotherapy 
did not have higher rates of abstinence compared to other smoking cessation 
interventions or no treatment (RR 9.00; 95% CI; 0.55-147.95). There is a possibility 
that hypnotherapy may be a useful counselling approach but there is currently not 
enough evidence to support this and as such is not an NHS recommended treatment 
option for smoking cessation.  
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Acupuncture 
Acupuncture is often used as a smoking cessation intervention in order to help reduce 
tobacco withdrawal symptoms.  A recent Cochrane review looked at studies 
comparing acupuncture to no intervention, sham treatment or other interventions used 
for smoking cessation (White, Rampes, Liu, Stead & Campbell 2011). Two sham 
treatments are commonly used for research in this field; 1) using a needle in an area 
not recognized as a usual acupuncture ‘point’ or 2) using a needle in a place known to 
be ineffective for the condition being studied. There was a marginally significant 
result favouring acupuncture at short term follow up compared to sham intervention 
(1.18; 95% CI 1.03-1.34). However, there were high levels of bias associated with the 
studies included in the analysis (e.g. no validation of smoking status). There was no 
evidence that acupuncture reduced withdrawal symptoms at long-term follow up. 
Acupuncture was seen as less effective than NRT. 
 
Allen Carr 
‘The easy way to quit smoking’ was first published in 1985 by Allen Carr, a self titled 
100 a day chain smoker. Smokers are typically seen once for a session that lasts 
between 4-5 hours, with shorter ‘booster’ sessions available if required by patients. 
The programme also offers a ‘money back’ guarantee. A review for NICE 
(McRobbie, Hajek, Bullen & Feigin 2007), found four cohort studies evaluating the 
Allen Carr method. Two small studies reported 26%, one-month, and between 4 and 
20% long-term abstinence rates (Foulds 1996). Higher abstinence rates were seen in 
two larger studies (40-52%) using more lax outcome criteria (Csillag & Feuerstein 
2005; Hutter & Moshammer 2006). Currently no adequate controlled data are 
available which make it difficult to ascertain the efficacy of the Allen Carr method. 
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Models of relevance to the treatment of smokers 
Helping smokers to change their behaviour is often seen as the role of HCPs. The 
development of models to predict who is ready to receive health behaviour advice and 
to highlight who is more likely to act on that advice would in practice be a useful tool 
for guiding intervention and HCP advice.  There are several models that are widely 
cited in relation to treating smokers. 
 
Theory of planned behaviour 
The Theory of Planned Behaviour (TPB) (Ajzen 1988) suggests that any behaviour 
can be placed on a continuum of the amount of control that person has over their 
respective actions (see Figure 1). There are 2 groups of factors that encourage or 
reduce behavioural control; 
 
Internal factors – information, ability, skills of the individual alongside emotions and 
compulsions 
External factors – opportunity to engage and change behaviour as well as the support 
from others that may be needed for such change 
 
Combining both internal and external behaviours is the individuals control over a 
given behaviour (i.e. practicing safe sex, smoking, drinking) (Kaptein 2004). If 
control is high and the person intends to change their behaviour (e.g. stop smoking) 
then according to this model they will have a better chance of success. However, that 
behaviour is dependent on the individual’s intention to change that behaviour. 
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Figure 1 – Theory of planned behaviour 
 
Source – Ajzen 1988 
 
The TPB has been seen to predict intent (Kaptein 2004). However, there are several 
criticisms of the TPB. Firstly, intention often does not lead to behaviour change, 
particularly in smoking cessation. A person can be intent on quitting smoking but that 
does not necessarily translate into making an actual quit attempt. Smoking cessation 
has not been found to be predicted by this model, however, measuring intention has 
been found to predict quit attempts (Norman, Connor & Bell 1999). 
 
There has also been criticism over the concept of perceived behavioural control (PBC) 
(Armitage & Conner 1999). Increased research using the model has identified a 
distinction between PBC and self-efficacy whereas the model views them as 
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intertwining concepts (Armitage & Conner 1999). PBC has been defined as the ease 
or difficulty of undertaking a specific health behaviour (Armitage & Arden 2002). 
However, it is likely that this is ambiguous in the fact that a behaviour may be viewed 
as “easy” while simultaneously being “difficult” due to lack of opportunity or 
resources. PBC may be better viewed as an external control concept over resource and 
opportunity to change behaviour whereas self-efficacy is the internal control an 
individual has i.e. the confidence that you can change a certain behaviour (Armitage 
& Arden 2002). Both are believed to be crucial elements but currently the TPB lacks 
the distinction between these 2 concepts. 
 
Stages of change model  
Prochaska and Diclementes’s (1992) stages of change model, also known as the 
transtheoretical model of behaviour, is one of the most frequently cited models for 
guiding HCPs with regard to changing health behaviour (see Figure 2). The model 
sees patients go through several concrete stages with the ultimate goal of changing 
behaviour. The model allows movement between the stages both forwards and 
backwards before reaching a change in behaviour. The model is used by some NHS-
SSS to assess motivation and to guide treatment. 
 
There are five concrete stages leading ultimately to behaviour change; the first sees 
the person happy with their negative health behaviour (e.g. smoking), this is called the 
pre-contemplation stage. The second contemplation stage is when the person is 
thinking about stopping smoking and is ready to consider change of behaviour. The 
third stage is preparation where the smoker prepares to take action (contacting the 
NHS-SSS, reducing smoking) to stop smoking. The fourth stage is action to stop 
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smoking (using NHS-SSS alongside stop smoking medication). The fifth stage is 
relapse; this is common and expected among smokers. The model sees the smoker 
move through these stages gradually. 
 
The model has time frames with regards to timing of each stage depending on which 
behaviour is changed. In the case of smoking cessation the ‘precontemplation stage’ 
sees the individual as not thinking about stopping smoking for at least 6 months; 
‘contemplation’ involves an individual planning to stop between 31 days and 6 
months, or less than 31 days if they have not tried to quit for 24hours in the past year; 
‘preparation’ involves the individual having tried to stop for 24 hours in the past year 
and planning to stop within 30 days; ‘action’ involves the individual having stopped 
for between 0 and 6months; ‘maintenance’ involves the individual having stopped for 
more than 6 months (West 2005).  
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Figure 2 – Stages of change model 
 
Source – Prochaska, Diclemente & Norcross 1992 
 
There are several limitations with this model as it assumes that the person wants to 
change their behaviour and that ultimately a person will pass through each of the 
stages to reach the goal of behaviour change. However, applying stages of change to 
complex health behaviours such as smoking is beset by difficulties. Smoking is not a 
single behaviour, but a complex category of different specific actions, such as 
biochemical, environmental and the emotional aspects of smoking. The stages are 
arbitrary; in real life people skip several stages to reach maintenance and can be seen 
to be in 2 categories at once (i.e. thinking about stopping smoking and also planning 
to stop). They also do not necessarily do this gradually; smokers often act as soon as 
they think they should stop smoking and so the diving lines of the model are arbitrary. 
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“I had to have a cigarette” 
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The implication of the stage of change model is that interventions based on the model 
need to be directed at the stage the person is at, however, the content of this targeted 
information is difficult to assess. The model also assumes conscious decision making 
and planning and does not take into account the other aspects of addiction that need to 
be addressed in order to successfully change behaviour (i.e. habits, reward of 
smoking). As a result of these flaws most researchers in the field of smoking cessation 
do not believe the stages of change model is of benefit and some have argued that the 
model has held back the advances of health promotion (West 2005). 
 
The interventions based on these models have not been found to be indicative of 
increasing abstinence rates in smokers above a common sense approach as used by 
most smoking cessation clinicians (West 2004a). Clinicians tend to use this approach 
to assess motivation in order to predict success, however, motivation appears to play a 
very small part in successful quitting (West 2004a). 
 
In a recent study looking at the efficacy of an internet programme, during and after 
treatment, for an inpatient population; participants were asked to provide answers to 
several questions based on the stages of change model (Haug, Meyerr & John 2011). 
The answers to these questions then generated a tailored programme for each 
participant. No specific details are provided in the paper regarding the success of the 
intervention based on the tailoring of the participants. Similarly, establishing 
motivation by using the definitions of the stage of change was used in a randomised 
controlled trial looking at smoking interventions provided to hospital patients 
(Lacasse, Lamontagne, Martin, Simard & Arsenault 2007). 
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It is clear that despite the limitations of these models and the limited evidence 
associated with their helpfulness at targeting successful interventions with smokers, 
the TBM and stages of change model are still commonly used in the field of smoking 
cessation. However, it should be noted that some of the concepts detailed in the model 
are of use when providing a smoker with an intervention, such as establishing 
motivation to quit and perceived control over stop smoking but it should be used only 
to provide constructive behavioural support rather than the tailoring of interventions. 
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Pharmaceutical treatments for smoking cessation 
Pharmaceutical treatments for nicotine dependence are commonly used in 
combination with the behavioural elements discussed above. Patients have access to 
NRT, bupropion (Zyban) and varenicline (Champix). All are proven to aid smoking 
cessation (Cahill et al. 2012, Hughes et al. 2007a, Stead et al. 2008).  
 
Pharmaceutical treatments are offered to help smokers alleviate tobacco withdrawal 
symptoms particularly in the first few weeks of quitting when withdrawal is most 
acute. The medications available are not a ‘magic cure’; rather they help the smoker 
remain abstinent through the initial stages of quitting, which most smokers find the 
hardest. 
 
Nicotine Replacement Therapy (NRT)  
NRT is the most widely used medicine for smoking cessation. There are extensive 
data showing the efficacy of NRT (Stead et al. 2008), which primarily reduces the 
severity of withdrawal symptoms associated with smoking cessation. The use of NRT 
products during a quit attempt approximately double the chances of long-term 
abstinence compared with placebo (Stead et al. 2008). 
 
There are currently seven different NRT delivery systems available on the worldwide 
market (gum, patch, lozenge, sublingual tablet, nasal spray, inhalator, and mouth 
spray). In the UK these products are available on prescription as well as over-the-
counter (West & Zhou 2007). All of these products work by replacing some of the 
nicotine that smokers would have otherwise received from their tobacco smoke and 
thereby reducing tobacco withdrawal symptoms (e.g. irritability, depression, 
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restlessness). However, although NRT replaces some of the nicotine, the amount of 
nicotine delivered from NRT is lower and the delivery is much slower.  
 
Abstinence rates are improved if NRT products are combined (Stead et al. 2008). 
Typical combinations include a nicotine patch with a fast-acting nicotine product (e.g. 
gum, lozenge, nasal spray).  
 
Directions for use 
Some NRT products (patch, gum, and lozenge) come in different strengths (See Table 
4). Smokers frequently start on a high-strength patch (e.g. 25mg/16 hour or 21mg/24 
hour patch) (McNeil Limited 2012a). There are medium and low strength patches but 
these are mainly marketed for ‘weaning’.  A typical weaning schedule would be to 
use a high strength patch (e.g.25mg/16hour) for up to 6 weeks to then reduce to the 
15/10/5mg patches over the remaining 6 weeks of treatment (McNeil Limited 2012a).  
The gum and lozenges come in high (4mg) and low (2mg) strengths. The higher dose 
products are usually recommended to more highly dependent smokers (e.g. people 
who smoke within 30 minutes of waking) (GlaxoSmithKline 2011; McNeil Limited 
2010a). 
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Table 4 – Nicotine replacement therapy dosing, frequency of use  
Formulation  Quantity Licensed dose 
16-hour Patch  7 patches per week 25mg/16 hours patch 
15 mg/16 hours patch  
10mg/16 hours patch  
5 mg/16 hours patch  
24-hour Patch  7 patches per week 21 mg/24 hours patch  
14 mg/24 hours patch  
7 mg/24 hours patch  
Nasal spray 1 bottle per week Use one spray in each nostril as 
required  
Inhalator 42 cartridges per 
week 
Use 6–12 cartridges daily  
Gum 105 pieces per 
week 
4 mg gum  
2mg gum 
Sublingual tablets 105 pieces 2mg 
Lozenge 72 pieces per week 1mg Lozenge 
2mg Lozenge 
4mg Lozenge 
Mini lozenge 60 pieces 
 
1.5mg 
4mg 
Nicotine mouth 
spray 
2 bottles per week 1mg 
 
NRT should be used for at least 8 weeks. Some people may need to use NRT for 
considerably longer than this (Hajek 2007).  
 
Adherence to medication 
There are several issues that are frequently reported by users of NRT, which reduce 
adherence to medications ultimately leading to a failed quit attempt.   
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NRT is not a magic cure. Many smokers think that by using NRT their urges to smoke 
will be eliminated, so it is important to outline realistic expectations as to what benefit 
will be expected from using NRT (McEwen 2012).  
 
The oral NRT products rely on the user to administer nicotine on a frequent basis; 
typically the compliance with a nicotine patch is higher than an oral product, for 
example, the nicotine nasal spray (Hajek, West, Foulds, Nilsson, Burrows & Meadow 
1999). Another barrier to using NRT is the taste (Foulds, Hughes, Hyland, Le 
Houezec, McNeill, Melvin, Okuyemi, Shiffman, Wassum, Williams & Zeller 2009 
2009). NRT can taste unpleasant but for most smokers’ regular use of the product will 
reduce the unpleasant taste.  
 
Smokers often worry about becoming addicted to NRT products. Helping clients to 
understand that the use of NRT is not giving them a new addiction but simply 
weaning them off their tobacco dependence is important in clinical practice (McEwen 
2012). 
 
Another common misconception is that nicotine is the dangerous substance in tobacco 
that causes smoking related illnesses (Bansal, Cummings, Hyland & Giovinno 2004), 
which again is important to address when discussing NRT in clinical practice. 
 
Currently it is recommended that NRT is used for at least 8 weeks, however many 
smokers stop using NRT earlier, which has implications on relapse (McRobbie 2005).  
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NRT safety 
There are no risks in using NRT in people who smoke as it provides only the nicotine 
that smokers would have otherwise received from tobacco (Stead et al. 2008). The 
risk of overdose is small and there is no evidence that NRT increases the risk of heart 
attacks (GlaxoSmithKline 2010, 2011b; McNeil Limited 2010a, 2010b, 2012a, 2012b, 
2012c). There are no safety concerns with long-term use (GlaxoSmithKline 2010, 
2011b; McNeil Limited 2009; McNeil Limited 2010a, 2010b, 2012a, 2012b, 2012c). 
 
Side effects 
NRT may cause adverse reactions similar to those associated with nicotine given by 
other means, including smoking, and these are mainly dose-dependent. 
(GlaxoSmithKline 2010, 2011b; McNeil Limited 2010a, 2010b, 2012a, 2012b, 
2012c). At recommended doses NRT has not been found to cause any serious adverse 
effects (GlaxoSmithKline 2010, 2011b; McNeil Limited 2010a, 2010b, 2012a, 2012b, 
2012c). The most common side effects seen when using NRT are outlined in table 5. 
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Table 5 – NRT side effects 
Formulation  Side effects 
16-hour Patch  Skin irritation 
24-hour Patch  
Nasal spray Sneezing, eyes watering, burning sensation in the nostrils 
Inhalator  
Hiccups, indigestion, heartburn, burning sensation in the 
mouth 
Gum 
Sublingual tablets 
Lozenge 
Mini lozenge 
Nicotine mouth 
spray 
 
Excessive use of NRT by those who have not been in the habit of inhaling tobacco 
smoke could possibly lead to nausea, faintness or headaches (GlaxoSmithKline 2010, 
2011b; McNeil Limited 2010a, 2010b, 2012a, 2012b, 2012c).  
 
When looking at nicotine patch users specifically, about 20% of users experience mild 
local skin reactions during the first weeks of treatment (McNeil Limited 2012a). In 
some patients the skin reactions may become more severe e.g. skin blistering or a 
burning sensation or may be more generalised. 
 
Contraindications 
There are no true contraindications with NRT (GlaxoSmithKline 2010, 2011b; 
McNeil Limited 2010a, 2010b, 2012a, 2012b, 2012c). NRT can be recommended and 
used in pregnant and breast-feeding women who smoke (oral products or a day-time 
only patch are generally seen as the products of choice) (GlaxoSmithKline 2010, 
2011b; McNeil Limited 2010a, 2010b, 2012a, 2012b, 2012c).  
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Combination treatment 
A Cochrane review looking at the effectiveness of NRT highlighted six trials that 
compared the use of two types of NRT with using a single type only, and one 
compared two types to no NRT (Stead et al. 2008). They found a significant effect of 
using combination NRT versus single product use (RR 1.35, 95% CI: 1.11 to 1.63). A 
similar result was found after removal of the no NRT control study. Only one of the 
trials, comparing nasal spray and patch with patch alone, showed a significantly 
higher rate of sustained abstinence at one year with combined NRT. 
 
Since the release of the Cochrane review, 2 further studies have been published. Piper, 
Schlam, Fiore, Jorenby, Fraser & Baker (2009) conducted a study using monotherapy 
(single product), combination NRT (patch and lozenge) and bupropion versus 
placebo. The results found that all treatments showed a significant effect compared to 
placebo. Only patch and lozenge combination was found to be better than 
monotherapy (OR, 1.35, 95% CI: 1.01-1.79).  
 
Another study used combination nicotine patch plus either active or placebo nicotine 
gum in alcohol dependent smokers in an outpatient setting (Cooney, Cooney, Perry, 
Carbone, Cohen, Steinberg, Pilkey, Sevarino, Oncken & Litt 2009). At 1 year follow 
up the patch plus active gum group had higher rates of validated prolonged smoking 
cessation rates compared to the placebo gum group (13% versus 0%).  
 
Use of NRT in the UK 
Over 60% of NHS-SSS patients used NRT in 2011 (April – December 2011) (The 
NHS Information Centre for Health and Social Care 2012).  
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Bupropion (Zyban) 
Bupropion is an atypical antidepressant that is effective in aiding smoking cessation. 
Data from 40 studies of bupropion show that this drug roughly doubles the chances of 
quitting smoking compared to placebo (Hughes 2007a).  
 
Bupropion should be started at least 1 week prior to the TQD. People take one tablet 
(150mg) daily for the first 6 days, and thereafter one tablet twice daily, keeping at 
least 8 hours between each dose. A course of treatment is 120 tablets (approximately 
9 weeks).  
 
Contraindications  
There are a number of people who are unable to use bupropion, including anyone with 
a current seizure disorder or any history of seizures, a known central nervous system 
tumour, abruptly withdrawing from alcohol or sedatives, use of monoamine oxidase 
inhibitors within 14 days, hypersensitivity to any ingredients in bupropion or a history 
of bulimia or anorexia nervosa (GlaxoSmithKline 2011a). In addition the use of 
bupropion is not usually recommended in patients with predisposing risk factors for 
seizures unless there is a compelling clinical justification for which the potential 
medical benefit of smoking cessation outweighs the potential increased risk of 
seizure. Prescribers also need to be aware of possible interactions with other 
medicines (GlaxoSmithKline 2011a). 
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Side effects 
The most common side effects of bupropion are dry mouth, insomnia, headache, and 
rash (GlaxoSmithKline 2011a). There is also a risk of seizure, although this is rare 
and similar to the seizure risk associated with other antidepressants (Oke, Adhiyaman, 
Aziz & Ross 2001). 
 
Combination treatment 
A 2007 Cochrane review identified 6 trials that used combination treatment with 
bupropion and NRT (Hughes 2007a). The six studies allowed analysis of 1,106 
participants. Their conclusion was that there was insufficient evidence that adding 
bupropion to NRT increases any long-term benefit (RR 1.23; 95% CI 0.67 to 2.26). 
The study by Piper et al. (2009) found a significant effect of using combination 
bupropion and NRT versus placebo (OR 1.74; 95% CI: 1.13-2.67).  
 
Use of bupropion in the UK 
Despite its efficacy, bupropion is rarely used by NHS-SSS. Only 1% of smokers 
accessing the NHS-SSS (April-December 2011) used bupropion (The NHS 
Information Centre for Health and Social Care 2012). 
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Varenicline (Champix) 
The efficacy of varenicline in smoking cessation is a result of varenicline's partial 
agonist activity at the !4"2 nicotinic receptors where its binding produces an effect 
sufficient to alleviate symptoms of craving and withdrawal (agonist activity), while 
simultaneously resulting in a reduction of the rewarding and reinforcing effects of 
smoking by preventing nicotine binding to !4"2 receptors (antagonist activity) (Cahill 
& Lancaster 2012).  
 
Varenicline at standard dose increases the chances of successful long-term smoking 
cessation between two- and threefold compared with placebo (Cahill et al. 2012).  
 
Varenicline has been found to significantly increase long-term success rates compared 
to bupropion and has a marginally significant beneficial effect compared to NRT 
(Cahill et al. 2012). Varenicline may also have a role to play in relapse prevention 
interventions but further study into this is needed (Tonstad, Holme & Tonnesen 
2006). 
 
In a recent double blind randomised control study, the pre-quit period of varenicline 
use was extended from 1 week to 4 weeks (varenicline preloading) to determine if 
increasing the pre-quit medication period makes cigarettes less satisfying and 
facilitates quitting (Hajek, McRobbie, Myers, Stapleton & Dhanji 2011). Varenicline 
preloading reduced pre-quit enjoyment of smoking (p=0.002) and smoke intake 
(p<0.001), with 37% of participants reducing their cotinine levels and CO levels by 
over 50% (‘reducers’). As would be expected the 3 measures (cigarette consumption, 
CO and cotinine levels) were moderately correlated (range, r=0.60-0.65, p<.001). 
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Preloading did not affect post-quit withdrawal symptoms, but it increased 12-week 
abstinence rates (47% vs 21%, p=0.005). The effect was particularly strong in 
participants who saw an immediate effect on their smoking intake after starting to 
take varenicline. These “reducers” substantially reduced their smoke intake during the 
ad-lib smoking preloading period by over 50%.  
 
The finding that the first ‘up-titration’ week on varenicline had limited impact, and 
that these effects needed time to emerge, is of clinical relevance. The 1-2 week period 
of pre-quit dosing recommended by the current drug labelling is likely to be too short 
to make use of this potentially important effect.  
 
Directions for use 
Varenicline should be started at least a week prior to the target quit date and is taken 
for a total of 12 weeks after the quit day. One tablet is taken daily for the first 3 days 
(0.5mg), then twice daily from days 4-7. From day seven, 2 x 1mg (BID) tablets are 
taken for duration of the treatment course (taken 8 hours apart) (Pfizer Limited 2011). 
 
Contraindications  
Varenicline has few contraindications. It should be avoided in people with 
hypersensitivity to varenicline and it is not recommended in pregnant or breastfeeding 
women or in people under the age of 18 (Pfizer Limited 2011). There are no known 
drug interactions associated with using varenicline. Varenicline does not undergo 
hepatic metabolisation and is generally excreted almost completely unchanged (Pfizer 
Limited 2011).  
 
 118 
Having a history of mental health illness is not a contraindication for the use of 
varenicline, however, it should be used with caution (Pfizer Limited 2011). Mental 
health patients should been seen regularly for follow-up during their quit attempt. 
People with mental health illness are more likely to smoke and often suffer with 
smoking related disease (Pfizer Limited 2011). Whilst it is important to discuss the 
possibility of psychiatric adverse events these need to be balanced with the potential 
benefits of smoking cessation. 
 
Side effects 
In patients treated with the recommended dose of 1mg BID following an initial 
titration period the adverse event most commonly reported is nausea (28.6%) (Pfizer 
Limited 2011). In the majority of cases nausea occurs early in the treatment period, is 
mild to moderate in severity and seldom resulted in discontinuation. 
 
Encouraging people to take varenicline with food can mitigate this (Pfizer Limited 
2011). Other side effects include sleep disturbance and vivid dreams (Pfizer Limited 
2011). Advice to avoid taking the drug too close to bedtime can help reduce these side 
effects. 
 
There have been post-marketing reports of depression and suicidal ideation in people 
using varenicline (Pfizer Limited 2011). Although there is no firm evidence of 
causality, caution is warranted. The datasheet advises, “Clinicians should be aware of 
the possible emergence of significant depressive symptomatology in patients 
undergoing a smoking cessation attempt, and should advise patients accordingly. 
Varenicline should be discontinued immediately if agitation, depressed mood or 
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changes in behaviour or thinking that are of concern for the doctor, the patient, family 
or caregivers are observed, or if the patient develops suicidal ideation or suicidal 
behaviour" (Pfizer Limited 2011). 
 
Combination treatment 
Combination varenicline and NRT treatment has not yet been experimentally 
evaluated. One cohort report from an in-patient smoking cessation facility found no 
difference between NRT plus varenicline combination and NRT plus bupropion 
(Ebbert, Burke, Hays & Hurt 2009). As there was no ‘NRT only’ or ‘varenicline only’ 
group, the results are difficult to interpret, but the report reinforces the need to 
conduct a randomised ‘proof-of- concept’ study before launching into a large outcome 
trial. 
 
Use of varenicline in the UK 
In the last quarter of 2011, varenicline was used by 26% of people accessing NHS-
SSS. 
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Helping smokers in the UK to quit 
In 1998 the release of the UK government’s white paper on tobacco control 
(Department of Health 1998), was viewed as a milestone for public health 
interventions in the UK. As a result England was one of the first countries to establish 
a nationwide network of stop smoking services. NHS-SSS aim to provide the most 
effective interventions for successful smoking cessation which include both 
pharmaceutical as well as intensive behavioural support provided by smoking 
cessation specialists.  
 
Over the last 14 years, millions of pounds have been invested by the DoH to 
implement and maintain this specialist service. In 2009 total spending on NHS-SSS 
was almost £84 million, up £10 million from 2008/09 (The NHS Information Centre 
2012). Tackling smoking cessation treatment is one of the most effective interventions 
currently available with the latest figure indicating that it costs the NHS £220 for each 
successful quitter (The NHS Information Centre 2012).   
 
Smoking cessation programmes are viewed as one of the most cost-effective health 
behaviour change programmes available on the NHS (Coleman et al. 2010). 
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National Health Service – Stop Smoking Service (NHS-SSS) 
When the DoH first set up smoking cessation services they approached it as a service 
with different levels of intensity. At the first level all healthcare professionals were 
encouraged to provide brief opportunistic advice to stop smoking to all people who 
smoke. The second level involved the provision of a structured smoking cessation 
treatment that could be accessed by any smoker that wanted help in stopping smoking. 
This was to consist of behavioural support and NRT and be provided by a group of 
specially trained healthcare professionals who became known as smoking cessation 
specialists or advisors. Further evolution gave rise to three levels of service. Level 1 
was designated to be the provision of brief advice, level 2 was provision of low to 
moderate intensity smoking cessation treatment (behavioural support and NRT) from 
a trained healthcare professional (many of these were practice nurses and pharmacists 
and became known as Level 2 advisors) and Level 3 was a high intensity smoking 
cessation service delivering multi-session behavioural support combined with 
pharmacotherapy. 
 
150 NHS-SSS are currently providing a range of stop smoking interventions within 
the UK (Brose 2011). In 2011-12 over 800,000 people set a quit date through the 
NHS-SSS (The NHS Information Centre for Health and Social Care 2012). Of these 
400,955 (50%) were self-reported as quitting at 4 weeks and nearly 300,000 (38%) of 
those were confirmed by CO validation (The NHS Information Centre for Health and 
Social Care 2012). 
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Level 1 (Brief advice and referral) 
Since the establishment of the NHS-SSS, the task of front line staff in the UK has 
been to motivate smokers to quit and refer them to a level 2 or 3 service rather than to 
take on the role of stop-smoking advisors.  
 
There is no ideal way to give smoking cessation advice, but the message should be 
clear that stopping completely is best; be linked to a current illness if appropriate; and 
given to all smokers, not just those who desire to quit. Acknowledgement of the fact 
that stopping may be difficult and many people need to try several times before finally 
succeeding can be made. However, a positive message should be conveyed (i.e. there 
are treatments to make quitting easier and improve a smokers chances of stopping).  
Currently GPs are expected as part of their duties to record smoking status. GPs are 
currently paid to do this therefore acting as an incentive to address smoking and 
cessation.  
 
Level 2 services (Pharmacy, clinic nurse, other Health Care Professionals) 
There are several level 2 routes to quit within the UK. Many pharmacists, nurses and 
other health care professionals (HCPs) such as midwives, social workers and 
physiotherapists are now trained to provide a level 2 smoking cessation service. This 
also includes GPs who offer advice and intervention. A level 2 trained advisor 
combines brief advice alongside medication. There may be follow up visits but these 
are less intensive and frequent than level 3 services. The level of training is also more 
basic. Level 3 advisors such as those at the East London specialist smokers’ clinic are 
intensively trained and are typically more knowledgeable as smoking cessation is 
their primary role. Whereas many level 2 advisors provide smoking cessation advice 
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alongside their specialist role. Despite their lack of time and knowledge they are more 
likely to come in contact with people who would not want or are unable to attend 
level 3 services which make their role in providing smoking cessation to hard to reach 
groups important.  
 
Level 3 – specialist service 
Level 3 services provide intense withdrawal-oriented therapy over several weeks to 
patients that indicate they would like to stop smoking. In order to successfully help 
people to stop smoking, the aim of the sessions are to enhance motivation to quit, 
increasing self-efficacy, to understand the role of habits, to discuss coping skills, cue 
sensitivity, patterns of smoking and to ultimately endorse behaviour change. The 
National UK smoking cessation guidelines recommend the use of “the withdrawal 
oriented treatment model as a practical and proven system for specialist services” 
(West, McNeill & Raw 2000). 
 
The structured group orientated model (Hajek 1989) is widely used by level 3 
specialist services in the UK. There is a wealth of evidence as well as real life 
experience showing the effectiveness of the treatment model in many different 
settings and using different populations (e.g. mental health patients, pregnant women, 
routine and manual populations) (Stead 2005).  
 
There are some advantages of group-based counselling over individual treatment 
(which is the other treatment format utilised by level 3 services). For example, groups 
offer smokers the opportunity to learn behavioural techniques for smoking cessation 
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and to provide each other with mutual support. Groups are also more time and cost 
efficient and they involve less clinician input.  
 
Individual appointments and flexible drop-in clinics are also common options 
available to smokers seeking level 3 smoking cessation support.  
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An example of the group oriented model – The East London Specialist Smokers’ 
Clinic (level 3 specialist service) 
 
The East London specialist smokers’ clinic is a level 3 service providing an NHS-SSS 
in the east end of London. The service provides a service to two boroughs; Tower 
Hamlets and City & Hackney. The unit has over the last 10 years utilised their 
position as an NHS-SSS level 3 service to undertake pivotal research in the field of 
smoking cessation. 
 
The service provides intense withdrawal-oriented therapy over several weeks.  The 
structure of the clinic follows GBT established at the Institute of Psychiatry by 
Professor Peter Hajek (Hajek 1989). The main aims of the clinic sessions are to 
increase motivation to quit, enhance self-efficacy, to discuss coping skills, cue 
sensitivity (identifying situations where they may be more vulnerable to relapse, i.e. 
socialising, stress at work), patterns of smoking, dealing with the habits associated 
with smoking with the ultimate aim of the programme being to help the patient to 
achieve abstinence from smoking.  
 
Accessing the service 
The most common route of accessing the service is for patients to be referred to the 
clinic via their GP or other HCPs. Patients are also able to self refer to the service. 
Clients interested in attending the clinic will be given several different locations to 
meet with a smoking cessation specialist, either at the Royal London Hospital site or 
at other venues within the local community (e.g. GP surgeries, community halls, 
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hospital venues). All locations are usually central and provide good accessibility for 
patients.  
 
Screening clients 
Patients are booked an appointment to meet with an advisor to discuss the options that 
are available to them. This session is to discuss the client’s expectations and to assess 
suitability for the NHS-SSS level 3 programme. In some cases other services may be 
more appropriate, for example, people who chew tobacco would be referred to the 
local Bangladeshi stop smoking service or the client may present with other issues 
that are more suited to individual (one-to-one) support.  
 
Structure of the clinic 
The programme takes place over 7 weeks, with clients attending the clinic every week 
for a meeting with a smoking cessation advisor. The aim of the programme is to 
provide intensive support, both behavioural and pharmacological, to help people to 
remain abstinent during the first few crucial weeks of stopping, when withdrawal 
symptoms are at their worst. It is the advisors role in the first 3 sessions to prepare 
smokers to be ready to quit in the 3rd week (TQD) (full details of each session are 
outlined in Table 6). These sessions attempt to get clients to maximise their 
commitment to the quit attempt and to prepare them for stopping.  
 
These preparatory sessions involve discussion about previous quit attempts, 
discussion of the different medications to use whilst quitting and how to use them, 
common pitfalls smokers succumb to when stopping smoking and highlighting the 
importance of complete abstinence from smoking.  
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The four post-quit day sessions monitor progress, check on medication use and 
adverse events and provide on-going motivational support.  
 
A limited relapse prevention service is offered at the end of treatment where clients 
are free to return to, or contact, the clinic as required.  The only formal contact after 
the end of treatment is that clients are contacted 1 year after the quit day to see how 
they are doing. This is also an important outcome to assess how successful the clinic 
is in the longer term. 
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Table 6 - Outline of sessions at the East London specialist stop smoking clinic  
 
SESSION 1:  Information session 
- Welcome and introductions 
- Explanation of treatment and 7-session programme, provision of both positive and 
realistic expectations 
- Explanation of group support 
- Provision of rationale for setting a quit date (session 3) and then maintaining 
complete abstinence 
- Provision of information on tobacco and withdrawal 
- Discussion of smoking cessation medications and how to access and use them 
- Elicit commitment to group programme and quitting completely 
 
SESSION 2: Preparation session 
- Facilitate group discussion on strategies for remaining abstinent 
- Ensure that each client has medication to use in the quit attempt and address and 
concerns or issues with medication 
- Elicit commitment to group programme and quitting completely 
 
SESSION 3: Quit day 
- Facilitate group discussion on how people are feeling about quitting 
- Discuss medication issues and ensure people know how to use the products correctly 
- Enhance social support by ‘buddy’ task 
- Facilitate group discussion on coping strategies 
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- Elicit commitment to a good start (e.g. facilitate a round of promises not to smoker a 
single puff in the next week) 
 
SESSIONS 4-6: First 3 weeks after quitting 
- Each member reports to the group on how the week went and reports on contact with 
their buddy 
- Facilitate group discussion on strategies to maintain abstinence 
- Provide advice and reassurance on withdrawal symptoms as required 
- Check on medication use and provide advice as required 
- Elicit commitment to maintaining abstinence 
 
SESSION 7: End of treatment 
- Celebrate success of group 
- Each member reports to the group on how the week went and reports on buddy’s 
progress as well 
- Facilitate group discussion on strategies to maintain abstinence – basic strategies can 
be communicated e.g. continuing to use medications, get in touch with stop smoking 
service whenever needed, keep in regular contact with buddy, avoid risky situations 
until confident about not smoking. 
- Reinforce key messages – not a single puff, will get easier over time 
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Role of the clinician 
One of the key roles for a smoking cessation advisor is to ensure accurate information 
is given to clients particularly on the use of NRT. NRT is typically used only 
occasionally and not for not for the recommended period of time. This is often the 
cause for relapse back to smoking (McEwen 2012). The important message here is 
frequent use of medication and for use of at least 8 weeks. 
 
As well as dealing with common misconceptions it is also important to set realistic 
and positive expectations for the group (Hajek 1989). Discussion of success rates and 
relapse rates associated with using the group-oriented treatment programme can help 
to encourage participants to attend the group on a weekly basis (Hajek 1989). 
 
Medication use 
Clients are advised to use medication for a minimum of 8-12 weeks. The quit day is 
generally set on the third visit and clients are instructed to have their last cigarette 
immediately before this session. The correct use of medication is discussed, strategies 
to boost motivation and support are provided, and the importance of complete 
abstinence is reinforced. All the medication (NRT or varenicline), support and 
guidance offered to smokers through the NHS are free of charge. The Medication is 
provided on NHS prescription on a weekly (for NRT) or fortnightly (for varenicline) 
basis. A prescription charge (£7.85) applies to each prescription, but this fee is waived 
in those people entitled to free prescriptions (e.g. those people on low income, under 
the age of 16 or over the age of 60, receiving income support) (Department of Health 
2004).  
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Measuring success 
Smoking status at 4 weeks after the TQD is used as a standard outcome measure for 
success for the NHS-SSS. It is estimated that approximately 60% of smokers per year 
successfully quit smoking through the stop smoking service (Judge et al. 2005), using 
the standard 4-week marker. One in seven clients who set a quit date are expected to 
be abstinent at 1-year follow up (Ferguson et al. 2005). 
 
Monitoring guidance  
In line with NICE best practice recommendations, service providers should aim to 
treat a minimum of 5% of their local population of smokers in the course of a year 
(NICE 2008). The DoH guidance (2011/12) specifies that NHS-SSS performance in 
treating smokers should reflect local smoking prevalence rates and in order to 
maintain standards and ensure best practice, the DoH monitors each NHS-SSS 
performance quarterly.  
 
The DoH guideline outlines the good clinical practice that should be followed by the 
NHS-SSS. Services are responsible for delivering treatment that conforms to the 
current NICE recommendations. Services should be evidence-based, effective, 
accessible and appropriate to the needs of the local population (Department of Health 
2011). 
 
Each NHS-SSS is responsible for collecting data from service users and to ensure that 
the data collected is verified. Confidentiality and data protection should be inline with 
local protocols. Data collection for the NHS-SSS involves reporting of quit days set 
and validated success rate at 4 weeks (self reported abstinence rates are also reported).  
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Validating abstinence 
For the majority of NHS-SSS objective measures of smoking status are routinely 
measured by CO readings.  CO in expired breath can be measured as an 
approximation of how much someone has smoked, however, the reading that is given 
is dependent on time since last cigarette and also time that the reading is taken. For 
example, a CO reading in the morning will only reflect the first few cigarettes of the 
morning compared to a reading at the end of a day of smoking; the reading is likely to 
be significantly higher. At each session members have their CO levels measured. This 
acts as a motivator for abstinence (people like to see their CO reading decrease when 
they stop smoking) and also validates self-reported smoking status for the purposes of 
monitoring which are sent quarterly to the DoH. 
 
Clinic Questionnaires 
There are 2 standard questionnaires used by the East London Specialist Smokers’ 
Clinic. Once a client books on to the clinic a questionnaire will be sent to them by 
post alongside an invitation letter with the time and date for their appointment at the 
clinic. This questionnaire collects personal information required by the clinic for 
contact and reporting to the PCTs in the first instance. This information will then be 
collated alongside the figures from the other smoking cessation services (e.g. 
pharmacists, GPs) within the borough and sent to the DoH. The demographics 
recorded include; date of birth, occupation, educational background. The 
questionnaire also includes questions, which are used to guide the treatment of the 
smoker which include smoking history, FTND, reasons for wanting to stop smoking, 
and questions pertaining to the state of their current health. Clients are asked to 
complete this at home and bring it with them to the first clinic visit. The other 
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questionnaire records clinic attendance, smoking status, medication use, adverse 
events and occurrence and severity of withdrawal symptoms over the past week.  
 
To summarise, the aim of the East London Specialist Smokers’ Clinic is to prevent 
relapse during the early phase of the quit attempt by providing intensive support (both 
behavioural and pharmacological) during the time that withdrawal symptoms are 
typically at their worst (i.e. in the first 2-4 weeks of abstinence). Treatment is 
delivered by specialist advisors, trained in providing smoking cessation treatment, in 
an individual or group setting over seven 1-hour sessions on a weekly basis.  
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CHAPTER 6 – STUDY – EFFECTS OF A COMBINATION 
OF VARENICLINE AND TRANSDERMAL NICOTINE 
PATCH ON POST-QUITTING URGES TO SMOKE 
 
Abstract 
Background to research project and aims 
Most smokers in the UK want to stop smoking, but many find this a difficult task. The 
NHS-SSS uses the best available evidence-based treatments and achieves long-term 
abstinence rates of about 15% (Ferguson et al. 2005). This still leaves a large number 
of smokers in need of more effective help.  
 
Nicotine replacement therapy (NRT) and varenicline are both effective in helping 
smokers quit (Cahill et al. 2012; Stead et al. 2008). There is growing interest in 
combining the two treatments to improve treatment outcomes, but no experimental 
data exist on whether this is efficacious. In theory a combination could improve 
withdrawal relief; help to extinguish smoking rewards and lower the risk of lapses 
translating into relapse. The research conducted for this doctorate portfolio will look 
at the efficacy of using varenicline in combination with a nicotine patch and whether 
this combination regimen reduces urges to smoke 24 hours and 1 week post-quitting.  
 
Methods 
A randomised double blind placebo-controlled trial was conducted using a sample of 
117 participants. Participants were randomised to use varenicline plus active nicotine 
15mg/16hr transdermal patch or varenicline plus placebo 0mg/16hr patch.  
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Results 
Adding a nicotine patch to varenicline had no effect on post-quit urges to smoke or on 
other cigarette withdrawal symptoms at any time point. There was no effect on 
abstinence rates at any time point (79% vs 80%, 69% vs 59%, 50% vs 41% and 14% 
vs 12% at 24 hours, 1, 4 and 12 weeks in the nicotine and placebo patch group, 
respectively).  
 
Conclusion 
The efficacy of varenicline is not enhanced by the addition of nicotine patches.  
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Study rationale 
NRT is the most widely used medicine for smoking cessation (Stead et al. 2008). 
There are extensive data showing the efficacy of NRT (Stead et al. 2008), however, 
despite its good track record people who use it still have a less than 20% chance of 
quitting for a year or more (Ferguson et al. 2005). It is currently recommended, and 
there is evidence to support that an increase in successful quitting can be seen if NRT 
products are used in combination when attempting to quit smoking (Stead et al. 2008).  
 
Varenicline is a partial nicotinic agonist which acts on !4"2 nicotinic receptors. It is 
presumed to alleviate withdrawal discomort, but also to diminish the rewarding 
effects of cigarettes. In studies evaluating its efficacy, patients who lapsed and 
smoked after the target quit date (TQD) were asked to rate their experience. 
Compared to patients on placebo, bupropion and nicotine patch, those on varenicline 
derived less satisfaction from their cigarettes (Aubin, Bobak, Britton, Oncken, Billing, 
Gong, Williams & Reeves 2008; Gonzales, Rennard, Nides, Oncken, Azoulay, 
Billing, Watsky, Gong, Williams & Reeves 2006; Jorenby, Hays, Rigotti, Azoulay, 
Watsky, Williams, Billing, Gong & Reeves 2006; West, Baker, Cappelleri & 
Bushmakin 2008). This is presumed to be caused by the drug blocking the nAChRs, 
which would otherwise facilitate the reward associated with smoking. 
 
There is currently no evidence available to show if using a combination of varenicline 
and NRT is effective. Anecdotal experience from the East London Specialist 
Smokers’ Clinic indicates that it is common for people stopping smoking to use 
varenicline in combination with NRT and that they report it to be beneficial. 
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Combining varenicline and NRT may in theory improve withdrawal relief; help to 
extinguish smoking rewards and lower the risk of lapses translating into relapse, 
and/or NRT may reduce some withdrawal symptoms, which are less sensitive to 
varenicline and vice versa. There are smokers who report no reaction to one of the 
treatments who may be sensitive to the other and the combination may be of particular 
benefit to this group. 
 
Based on observable effects on smokers, the two medications appear alike, although 
varenicline has antagonist as well as agonist effects. They both seem to achieve their 
effect on abstinence by alleviating the discomfort of nicotine withdrawal (Cahill et al. 
2012, Stead et al. 2008). They also make cigarettes smoked while on the medications 
less rewarding and thus may facilitate extinction. The latter effect has been 
demonstrated for both varenicline (Gonzales et al. 2006; Hajek et al. 2011; Jorenby, et 
al. 2006; Shiffman & Ferguson 2008; West et al. 2008) and NRT (Lindson & Aveyard 
2011; Shiffman & Ferguson 2008), although the evidence for the NRT seems weak 
(Lindson & Aveyard 2011). 
 
In terms of neuro-physiological targets, varenicline is known to affect primarily !4"2 
nAChRs where it has higher affinity than nicotine and so essentially blocks nicotine 
effects, as well as acting as a partial agonist (Prochaska & Hilton 2012).  Nicotine 
from NRT acts on all nAChRs in a similar manner to nicotine from tobacco smoke, 
but delivery from NRT is much slower (Le Houezec 2003).  
 
It is not clear if the central effects of the two medications are sufficiently different to 
allow synergy, but if they do differ, their combination could have several beneficial 
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effects. It could in theory improve withdrawal relief and/or assist smokers who may 
not react much or at all to one of them, but who may be sensitive to the effects of the 
other one. If their effects are due to impact on different target mechanisms, this would 
raise a possibility that their combination may achieve better results than using each of 
the medications on their own. 
 
Another putative mechanism by which a combination could be more effective than 
single administration concerns the timing of the two medications. Varenicline is used 
for 1-2 weeks prior to quitting, concurrently with smoking. It is possible that from the 
TQD on, when nicotine intake from cigarettes ceases, replacing the nicotine lost from 
cigarettes with that from NRT could reduce post-quitting urges to smoke and 
withdrawal discomfort. It is of course also possible that the targets of the two 
medications overlap too much for their combination to provide any additional benefit, 
and/or that the receptor occupancy provided by varenicline blocks any additional 
effects of NRT.  
 
Regarding the safety of combination use of NRT and varenicline, a single pre-
marketing study showed that smokers using varenicline and a transdermal patch for 
12 days reported a higher incidence of nausea, headache, vomiting, dizziness, 
dyspepsia, and fatigue than smokers who used NRT alone (Pfizer Limited 2011). 
However, these symptoms may have been due to varenicline use, as opposed to 
combined use of varenicline and NRT. Post-marketing data suggests that combined 
use of varenicline and NRT is well tolerated (Ebbert et al. 2009). 
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One cohort report from an in-patient smoking cessation facility found no difference 
between NRT plus varenicline combination and NRT plus bupropion (Ebbert et al. 
2009). As there was no ‘NRT only’ or ‘varenicline only’ group, and the various 
medication combinations were not systematic, the results need to be interpreted with 
caution. The study, however, provides a useful reassurance that a combination of 
NRT and varenicline is safe and well tolerated, but the report reinforces the need to 
conduct a randomised ‘proof-of-concept’ study before launching into a large outcome 
trial. 
 
This is a proposal to examine whether combining nicotine patches and varenicline in 
the first 4 weeks after quitting, provides better withdrawal and craving relief than 
varenicline alone, in a sample of 120 smokers who want to quit. Nicotine patches 
were used in this study due to the high level of adherance associated with the product 
and that they provide a standard dose of nicotine unlike oral products where daily 
dose is determined by how often and how well they are used.  
 
Funding 
The study was supported by an investigator-initiated grant from Pfizer, who also 
supplied varenicline. Nicotine and placebo patches were supplied by McNeil. The two 
pharmaceutical companies had no involvement in the design and conduct of the study, 
analysis and interpretation of the data, or preparation of the manuscript. 
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Study objectives and endpoints 
 
Primary Objective 
The principal question this study plans to answer is whether the combination of 
varenicline and NRT reduce post-quitting urges to smoke more than varenicline alone. 
 
Secondary Objectives 
In addition to change in urges to smoke this study will determine if combined use of 
varenicline and NRT compared to varenicline alone: 
• Affects severity of withdrawal symptoms over 4-weeks after quitting 
• Affects 4-week and 12-week abstinence rates 
• Is associated with an increase in adverse effects 
 
Trial Endpoints 
 
Primary Endpoint 
Ratings of urges to smoke one week after the target quit date assessed by the Mood 
and Physical Symptoms Scale [MPSS] (West & Hajek 2004). 
 
Secondary Endpoints 
Ratings of urges to smoke 24 hours after target quit date, change in MPSS scores of 
urges to smoke and tobacco withdrawal symptoms throughout the first four weeks of 
abstinence; adverse events profile; abstinence rates at 4-weeks and 3-months. 
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Study design 
A randomised double blind placebo-controlled trial was undertaken. Participants were 
randomised on their target quit date (TQD) to use varenicline plus nicotine 15mg/16hr 
transdermal patch or varenicline plus placebo 0mg/16hr patch. All participants in the 
study were advised to use varenicline in the standard way (commenced 1-week prior 
to the TQD and then continued use for upto 12 weeks). Participants were asked to 
smoke ad-libitum rather than try to limit their smoking up until the TQD. Participants 
attended standard weekly support sessions following a withdrawal-oriented treatment 
protocol as provided by the NHS Stop-Smoking Service. Nicotine patches were used 
for the first 4 weeks after TQD.   
 
Inclusion Criteria  
Smokers seeking treatment, aged 18 and over, consenting to take part in the trial. 
 
Exclusion Criteria  
Participants were exluded if they met any of the following criteria: 
• Current psychiatric illness  
• Pregnant/breastfeeding/planning to conceive during the study period  
• End-stage renal disease  
• Previous allergic reaction to varenicline or nicotine patches  
• Unable to fill in the questionnaire in English 
• Currently involved or intending to be involved in another research project 
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Figure 3 - Study Scheme Diagram  
Telephone screening 
! 
  Study information provided and eligible smokers invited to attend a 
baseline session 
  ! 
Day 0  Session 1: Baseline Visit 
(consent and baseline data collected) 
  ! 
Day 7  Session 2: Preparation Session 
(commence varenicline) 
  ! 
Day 14  Session 3: Target Quit Day 
(randomisation) 
  !  ! 
  Varenicline + 15mg patch  Varenicline + 0mg patch 
  !  ! 
Day 15  Session 4: 24 hour telephone 
call 
 Session 4: 24 hour telephone 
call 
  !  ! 
Days 21-
35 
 Sessions 5-7: Treatment 
sessions 
 Sessions 5-7: Treatment 
sessions 
  !  ! 
Day 42  Session 8: Last treatment 
session (patches discontinued, 
varenicline continued) 
 Session 8: Last treatment 
session (patches discontinued, 
varenicline continued) 
  !  ! 
Day 98  Session 9: 12-week follow-up 
(varenicline discontinued) 
 Session 9: 12-week follow-up 
(varenicline discontinued) 
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Study procedures 
Number of Subjects and Subject Selection  
The study aimed to recruit upto 120 participants who wanted to quit smoking. 
Participants were recruited by adverts in London newspapers including the free 
Evening Standard, Metro, and local papers (see Appendix 1). Those contacting the 
clinic who were interested were screened over the phone for initial eligibility for 
inclusion using a questionnaire.  
 
Telephone screening  
A questionnaire was developed to screen people who contacted the clinic interested in 
taking part in the study (see Appendix 2).  The telephone questionnaire covered the 
inclusion and exclusion criteria for the study. Ineligible callers were offered standard 
specialist treatment for smoking cessation at the East London Clinic or if they lived 
out of the area were referred to their local services for treatment. If eligible, they were 
invited to attend a screening visit at the clinic where they were given the opportunity 
to speak to the study doctor before consenting to take part.  
 
Piloting the telephone screening procedure 
The questionnaire and script were developed in ‘role-play’ practice sessions among 
the researchers involved in the study. The script (Appendix 3) took approximately 5 
minutes to read with a further 5 minutes to complete the screening questions. After 
booking an appointment slot and taking contact details for the invitation letter, the 
completion of the telephone sessions lasted approximately 12 minutes. No major 
issues arose from the role-play. Several changes were made to the wording of the 
questions to make them more understandable; these included examples of what fell 
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under the umbrella heading of psychiatric illnesses. The examples included were 
schizophrenia, depression and anxiety disorders. 
 
If eligible, callers were mailed a patient information sheet (PIS) (Appendix 4) 
describing the study. The PIS was drafted in simple language and given to each 
participant, at least 24 hours before consent in order for them to have sufficient time 
to consider if they wish to take part. They were also sent an appointment invitation 
(Appendix 5) and a standard clinic questionnaire to complete before attending the 
baseline session (Appendix 6). 
 
Baseline visit procedures  
At the baseline session, study details were discussed and informed consent collected. 
Participants were screened for inclusion and exclusion criteria. 
 
Informed Consent Procedures 
The formal consent of a participant, using the approved consent form (see Appendix 
7), was obtained before the participant underwent any study procedure.  The consent 
form was signed and dated by the participant and the investigator-designated research 
professional (in this case the study doctor) obtaining the consent. A copy of the 
consent form was provided to the participant and a copy was retained for the trial 
master file. 
 
Before obtaining consent, the investigator informed each participant of the objectives, 
benefits, risks and requirements of the study, as well as the nature of the test 
medication.   
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GP letter 
All participants were asked to consent to their GP being informed of their decision to 
take part in the study (see Appendix 8). The letter was sent to update the GP of their 
patient’s inclusion in the study and included a brief summary of the project. The letter 
was sent after the participant consented. 
 
Randomisation Procedures  
At the TQD session, participants were randomised to one of two conditions. The 
study treatment group received a standard dose of varenicline (Champix™), 1 mg 
twice daily (BID) combined with Nicorette® 15mg patch/16 hour and the standard 
treatment group received a standard dose of varenicline (Champix™), 1 mg bid 
combined with Nicorette® 0mg/16hour (placebo) patch. The placebo patch was 
identical to the standard patch except that it contained no nicotine. 
 
Randomisation codes were sequentially allocated to 120 participant numbers (001-
120), which were prepared by a computer in advance. The randomisation list was 
generated by an independent statistician not involved in the study. Once the 
participant was assigned a participant number, the study staff retrieved the box of 
patches corresponding to the relevant randomisation code. As the study was double 
blind both the participants and the study staff were not aware of the condition 
assigned to them. The allocated randomisation code and IMP label was updated on the 
drug accountability form for each participant. 
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Schedule of Treatment for each visit  
 
Session 1: Screening and baseline Session 
The majority of participants attended a weekend screening session that was held in 
May 2011. For those who could not make the weekend screening, weekday 
appointments were made available at the main offices of the East London Specialist 
Smokers’ Clinic.  
 
On arrival, participants were invited to ask questions about the study and were given 
further details by the research team about what to expect throughout the course of the 
study. The study doctor made the final checks for each participants eligibility to be 
involved in the trial before consenting. 
 
Participants were asked at each session to complete a questionnaire asking about their 
smoking consumption in the previous week, MPSS ratings and a CO breath test was 
also taken (full details for the schedule of assessment can be viewed in Table 7). 
Participants were asked specifically not to cut down or to stop smoking until the 
TQD. Medications were not given to the participant at this session. 
 
Session 2: Preparation session 
The preparation session (session 2) was held as a group clinic following the standard 
NHS-SSS withrawal oriented protocol. Five groups were held in total on weekday 
evenings between 5-7pm.  The groups only included people involved in the study.  
The study lead and one of the co-investigators ran all the clinics. 
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The preparation session was held one week prior to the participant’s TQD. The aim of 
the session was to provide standard NHS stop smoking advice and support on how 
best to prepare for the TQD. Participants were given a varenicline starter pack (1st 2-
week supply) to start taking the following day. Participants were told how to use the 
medication and provided information on how the medication worked. Participants 
were again asked to smoke ad-libitum untill the TQD (next session). 
 
Session 3: TQD Session 
On arrival, participants were sequentially allocated to a randomisation code and given 
the appropriately coded box of 28 patches. The possible side effects that may be 
expected from patch use were also discussed. Each participant was told how to use the 
patches and instructed to start using them the following morning.  
 
Session 4: 24-hour telephone call 
Participants were called 24 hours after their TQD and were asked to report on their 
smoking status and to rate the occurrence and severity of their urges to smoke in the 
last 24 hours. All participants were provided with brief behavioural support and 
advice. The content of the brief support covered several behaviour change techniques 
(BCTs) for smoking cessation (Michie, Churchill & West 2011). The protocol for this 
advice was based on the very brief advice (VBA) included in the UK National Centre 
for Smoking Cessation and Training (NCSCT) guidelines. Clinicians asked 
participants their smoking status (if any lapses, how many cigarettes smoked), 
completed the MPSS, provided information on later appointments and further advice 
on varenicline and the nicotine patch. Participants were then informed of the date and 
time of their next appointment. The call lasted approximately 10 minutes. 
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Sessions 5-8: Weekly treatment sessions 
Participants attended the clinic weekly, for four weeks after the TQD session. 
Participants were asked each week about their smoking status, withdrawal symptoms 
and urges to smoke and were asked to report any adverse events. CO readings were 
taken at each face to face visit. Behavioural support and advice was provided by the 
clinicians running the group and participants were encouraged to discuss the weeks 
progress.  
 
Varenicline continuation packs were provided at session 5 (2-week pack) and sessions 
6 and 7 (4-week pack).  
 
Session 9: 12-week follow-up 
A 12 week follow-up took place to check on particpants’ progress at  the end of 
medication treatment. Smoking status since the last visit, occurrence and severity of 
tobacco withdrawal symptoms and adverse events were recorded. Participants who 
had not stopped smoking were advised and referred as appropriate. 
 
Management of participants who did not attend sessions 
For participants who did not attend the sessions when expected, every effort was 
made to contact them so they could either re-schedule the appointment or fill in the 
questionnaire on the phone. Data was only collected at + or - 2 days of the scheduled 
appointment date. If someone missed a session and no data was collected but they 
reported abstinence since their last visit and were validated as being abstinent then 
they were documented as self-reported abstainers for the missing session. 
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Participant incentives 
The expected duration of participation in the study was 14 weeks (2 weeks prior to 
and 12 weeks after the target quit date). Participants in the study were required to 
attend the clinic on one extra session compared with usual practice at the NHS-SSS (8 
instead of 7 sessions) and to receive an extra phone call, 24 hours after quitting. In 
order to cover travel expenses, participants were paid £30. Participants were paid £15 
at session 4 (quit + 1 weeks) and £15 at session 7 (quit + 4 weeks). All participants 
were required to sign a participant expense form to declare they had received 
payment. All records for this were stored in the trial master file. 
 
Procedures for unblinding  
A standard operating procedure (SOP) was developed to be followed in case there 
was a need to unblind a participant’s medication allocation. If required the chief 
investigator would be contacted to agree to unblinding of the medication and to 
determine if it was necessary. Where the chief investigator needed to remain blinded, 
another member of staff not involved in the study was responsible for following these 
procedures. Any unblinding that occurred before the official close out of the study 
was recorded as a protocol violation in the trial master file.  
 
The independent study statistician held a copy of the randomisation codes. A second 
responsible person, who was not a member of the study team, but located at the study 
site held a second copy of the randomisation codes in sealed envelopes. 
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Investigational medicinal products (IMPs) and placebo descriptions 
 
Varenicline (Champix™) 
Commercial supplies were used as per standard labelling (0.5mg/d for the first 3 days, 
1mg/d on days 4-7, followed by 2mg/d for the rest of the 12-weeks course). The 
varenicline used in the study was provided by Pfizer Ltd. 
 
Formulation of varenicline 
0.5mg film-coated tablets (commercial supply) 
0.5 mg film-coated tablets (commercial supply): White, capsular-shaped, biconvex 
tablets debossed with “Pfizer” on one side and “CHX 0.5” on the other side. Each 
film-coated tablet contains 0.5 mg of varenicline (as tartrate). 
 
1 mg film-coated tablets (commercial supply)  
Light blue, capsular-shaped, biconvex tablets debossed with “Pfizer” on one side and 
“CHX 1.0” on the other side. Each film-coated tablet contains 1 mg of varenicline (as 
tartrate). 
 
Nicorette® 15mg/16 hour transdermal patch 
Nicotine (15mg/16 hours) and placebo patches (0mg/16 hours) were identically 
packaged. The patches used in the sudy (both placebo and active) were provided by 
McNeil Ltd.  
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Formulation of nicotine patch 
Nicorette® 15mg/16 hour transdermal patch 
Nicotine, 15mg released over 16 hours use. Each patch is 30 sq.cm, containing 
nicotine 0.83mg/sq.cm. 
 
Placebo 0mg/16 hour transdermal patch 
The placebo patch is identical to the standard patch except that it contained no 
nicotine. 
 
Preparation and Administration of IMP  
The table below shows the study treatment regimen. 
 
Table 7 – Study treatment regimen 
Day(s) 7-13 14-42 43-98 
Session(s) 2 3 - 8 9 
Varenicline dose Days 1-3: 0.5mg o.d. 
Days 4-7: 0.5mg b.d. 
1mg b.d 1mg b.d 
Patch dose Nil 15mg/16hr or 
0mg/16hr o.d. 
Nil 
 
Varenicline was used for a total of 12 weeks. Nicotine patches were used for 4 weeks, 
starting from the TQD. It is usual to recommend 12 weeks use of nicotine patches but 
for the purpose of the study, patches were only used during the time when withdrawal 
symptoms are most acute (the first 4 weeks post quit). 
 
 
 152 
Label design 
Bilcare UK, was contracted to label and package the IMPs. The labels were designed 
by the study team in accordance with labelling guidance as recommended by the 
MHRA (see Figures 4-6). Computer generated randomisation codes were added to 
each label and affixed to each box. A 4-week supply of patches (active or placebo) 
was packaged into a single box. 
 
Figure 4 – Nicotine/Placebo box label 
 
 
  
Protocol version 1.1 (14 Dec 2010)                 Protocol Code: qmul250510 
 
13 
4.4 Prescription of IMP  
IMP will be supplied by study staff under the supervision of the study physician.  
 
4.5 Preparation and Administration of IMP  
The table below shows the study treatment regimen. 
 
Day(s) 7-13 14-42 43-98 
Session(s) 2 3 - 8 9 
Varenicline dose Days 1-3: 0.5mg o.d. 
Days 4-7: 0.5mg b.d. 
1mg b.d 1mg b.d 
Patch dose Nil 15mg/16hr or 
0mg/16hr o.d. 
Nil 
 
4.6 Packaging and Labelling of IMPs  
A 4-week supply of patches (active or placebo) will be packaged into a single box. 
Computer generated randomisation codes will be affixed to each box. The 
medication boxes will be sorted in numerical order and will be dispensed sequentially 
at the study site. 
 
15mg/16hr or 0mg/16hr transdermal 
nicotine patches 
Pack ID No: x-xxxxxx 
Exp. Date: yyyy-mm-dd 
Protocol No: qmul250510 
For Clinical trial use only 
Transdermal administration 
Subject No: _____________ 
Dosage: Apply one patch to a dry area of 
skin each morning and remove each evening 
before bed. 
Store at room temperature (15-25 °C) 
Keep out of reach and sight of children 
Responsible investigator:  Dr. Al-Rehan 
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Standard commercial supplies of varenicline will be used according to the current 
licensing and labelled as indicated below. 
 
 153 
Figure 5 – Varenicline starter pack (commercial supply) label 
 
 
 
Figure 6 – Varenicline continuation pack (commercial supply) label 
 
 
 
Handling of IMP  
All packaged and labelled IMPs were shipped to the pharmacy outpatient department 
at The Royal London hospital where they were securely stored until required for 
dispensing in the study.  Medications were not dispensed to participants by the 
pharmacy, as study visits were out of hours. After pharmacy approval was granted the 
study manager was responsible for collecting study medications from the pharmacy 
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Varenicline starter pack (0.5mg and 1.0mg 
tablets) 
ID No: x-xxxxxx 
Exp. Date: yyyy-mm-dd 
Protocol No: qmul250510 
For Clinical trial use only 
Oral administration 
Dosage:  
Use as directed 
 
Store at room temperature (15-25 °C) 
Keep out of reach and sight of children 
Responsible investigator: Dr. Al-Rehan Dhanji 
Sponsor: Queen Mary University of London 
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Varenicline continuation pack (1.0mg tablets) 
ID No: x-xxxxxx 
Exp. Date: yyyy-mm-dd 
Protocol No: qmul250510 
For Clinical trial use only 
Oral administration 
Dosage:  
Take one tablet twice daily 
 
Store at room temperature (15-25 °C) 
Keep out of reach and sight of children 
Responsible investigator: Dr. Al-Rehan Dhanji 
Sponsor: Queen Mary University of London 
Contact: Katie Myers, Study Manager E
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4.7 Accountability/Receipt /Storage and Handling of IMP  
All packaged medications will be shipped to the Pharmacy (The Royal London) 
where they will be securely stored until required for dispensing in the study.  
Medications will not be dispensed to participants by the pharmacy, as study visits will 
be after hours. Instead, the study manager will be responsible for collecting study 
medications from the pharmacy when required and transferred to storage on the 
study site (Tobacco Dependence Research and Treatment Unit) in a locked cabinet 
in a locked room. Room temperature will be monitored on a daily basis. Only the 
study manager will have access to study medicines. 
 
4.8 Dispensing of IMP  
 
All participants will receive a commercial starter pack of varenicline at session 2. 
They will receive a commercial continuation pack (56 1mg tablets) at session 4, and 
a further two continuation packs at session 8. 
 
Participants will be randomised to either active patch or placebo by randomisation 
codes that will be prepared by computer in advance. On arrival on session 3 
participants will be sequentially allocated to a randomisation code. The study staff will 
retrieve the product corre ponding t  the relevant randomisation c de.  
 
IMP will be dispensed by the study manager at the clinic site under supervision of the 
study doctor. A dispensing log will be kept. 
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Varenicline starter pack (0.5mg and 1.0mg 
tablets) 
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Varenicline continuation pack (1.0mg tablets) 
ID No: x-xxxxxx 
Exp. Date: yyyy-mm-dd 
Protocol No: qmul250510 
For Clinical trial use only 
Oral administration 
Dosage:  
Take one tablet twice daily 
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Keep out of reach and sight of children 
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4.7 Accountability/Receipt /Storage and Handling of IMP  
All pack ged medications will be shipped to the Pharmacy (The Royal London) 
where they will be securely stored until required for dispensing in the study.  
Medications will not be dispensed to participants by the pharmacy, as study visits will 
be after hours. Instead, the study manager will be responsible for collecting study 
medications from the pharmacy when required and transferred to storage on the 
study site (Tobacco Dependen e Research and Tre tment Unit) in a locked cabinet 
in a locked room. Ro  t mperature will be monitored on a daily basis. Only the 
st dy manager w ll have acces  to tudy medicines. 
 
4.8 Dispensing of IMP  
 
All participants will rec ive a commercial starter pack of varenicline at session 2. 
They will receive a commercial continuation pack (56 1mg tablets) at session 4, and 
a further two continuation packs at session 8. 
 
Participants will be randomised to either active patch or placebo by randomisation 
codes that will be prepared by computer in advance. On arrival on session 3 
participants will be sequentially allocated to a randomisation code. The study staff will 
retrieve the product corresponding to the relevant randomisation code.  
 
IMP will be dispensed by the study manager at the clinic site under supervision of the 
study doctor. A dispensing log will be kept. 
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when required and transferring to storage at the study site (TDRU). The medications 
were kept in a locked cabinet in a locked room.  
 
IMP logs 
Logs were put in place to receive, store and dispense the IMPs in accordance with 
Good Clinical Practice Guidelines (GCP). Copies of these logs were stored in the 
TMF. 
 
IMP Stability  
The IMPs are stable at room temperature. Room temperature was monitored and 
recorded on a daily basis.  
 
Dispensing of IMP  
IMPs were dispensed by the study manager at the clinic site under supervision of the 
study doctor. A log was kept in the trial master file, which documented all medication 
dispensing activities. 
 
Return and destruction of IMP 
Participants were asked to return any unused medication each week. Quantities of 
returned medication were counted to assess compliance with treatment. Unused study 
medications were returned to the hospital pharmacy for destruction. Return of study 
drugs were documented in the drug accountability log. 
 
 
 
 155 
Measures 
All proposed questionnaire measures were included in the Baseline Smokers Clinic 
Questionnaire (Appendix 6) and Clinical Record Forms (Appendix 9). These include 
the following: 
 
Standard smokers’ clinic baseline questionnaire  
A standard baseline questionnaire from the East London Specialist Smokers’ Clinic 
was used. Participants were asked to complete the questionnaire prior to attending the 
screening session.  
 
This questionnaire collects information on demographics including; gender, age, 
ethnicity, qualifications, entitlement to free prescriptions, marital status and GP 
details. Details of cigarette consumption, previous quit attempts and the use of stop 
smoking medications were recorded. All participants were asked about their current 
and past medical history. All medical questions were asked for the purpose of 
eligibility screening by the study doctor and to identify medications which may need 
the dose altering as a result of stopping smoking e.g. warfarin. 
 
Client Record Forms (CRF) 
A CRF was designed specifically for the study by the researcher in order to collect 
study measures. Items included; attendance at the clinic, smoking status, CO reading, 
MPSS ratings. 
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Table 8: Study sessions 
DAY 0 7 14 15 21 28 35 42 98 
Session 
number 
1 2 3 Phone 
call 1 
5 6 7 8 9 
Measures/ 
procedures 
Base-
line 
visit 
Wk 1 
visit 
Wk 0 
TQD 
24h 
call 
Wk 1 
visit 
Wk 2 
visit 
Wk 3 
visit 
Wk 4 
visit 
Wk 12 
visit 
Informed 
consent 
X         
Baseline 
questionnaire* 
X         
FTND X         
CO X X X  X X X X X 
MPSS X X X X X X X X X 
Medication 
dispensed 
 X X  X   X  
Weight X X X  X X X X X 
Smoking 
status/rate 
X X X X X X X X X 
Adverse 
events 
  X X X X X X X 
* Demographic details, health status, and smoking history 
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The participant completed these at each visit and at every phone contact.  
 
Participants were also asked from session 3 onwards to report any adverse events they 
attributed to the medications. The CRF included a section for monitoring all adverse 
events that occurred during the study. Adverse events were rated by the researcher 
after discussion with the participants to be severe, moderate or mild. The appropriate 
advice was given on review of any adverse events. Details on the definition of AEs 
are outlined in the next section. 
 
The CRF was anonoymised and contained no identifiable participant data other than 
the participant number for use by the study staff. 
 
FTND 
The FTND is a measure of dependence (Heatherton et al. 1991) that consists of six 
questions that are scored and summed. A score of four or above is seen in smokers in 
the general population, and scores of six to ten indicate high levels of dependence.  
 
MPSS 
A measure of severity of tobacco withdrawal symptoms and urges to smoke was 
collected using the MPSS (West & Hajek 2004). The MPSS was completed at all 
contacts (both face to face and by telephone). A six-point scale is used to rate ‘How 
much of the time have you felt the urge to smoke in the past week?’ (from ‘not at all’ 
to ‘all of the time’) and ‘How strong have the urges been?’ (from ‘no urges’ to 
‘extremely strong’). Clients also rated how they have been feeling during the past 
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week with regard to depression, irritability, restlessness, hunger, poor concentration, 
poor sleep at night, and anxiety on a scale ranging from 1=not at all to 5=extremely.   
 
Smoking rate 
In the sessions before stopping smoking, participants were asked to estimate the 
average number of cigarettes smoked per day since the last visit. Where a range was 
entered (e.g. 10-15), the highest number was recorded on the database for consistency. 
 
Smoking status 
At each of the sessions following the quit day, participants were asked if they had 
smoked at all over the past week. If participants reported smoking they were given an 
option of four answers (1) No, not a single puff, (2) yes, just a few puffs, (3) yes, 
between 1 and 5 cigarettes, and (4) yes, more than 5 cigarettes.  
 
Carbon monoxide reading 
End-expired CO readings were recorded at all face-to-face visits using a Bedfont 
piCO smokerlyzer monitor. Clients were instructed to hold their breath for 15 seconds 
before exhaling through the CO monitor. All monitors were calibrated before being 
used in the study. Carbon monoxide readings were entered into the CRF at each visit.  
 
Smoking cessation outcomes 
Smoking cessation outcomes were measured in the following way; Continuous 
abstinence at 4 weeks and 12 weeks after TQD was defined as a self-report of no 
smoking (not a puff) since TQD validated by CO readings at all time points or if the 
session was missed, validated by CO reading (where scheduled) at the next 
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attendance. Participants who self reported abstinence but were not CO validated at 
week 4 were considered smokers unless they were validated as abstainers at week 12. 
We also calculated 4 and 12 weeks sustained abstinence in accordance with the 
Russell Standard (West et al. 2005) as a self-report of smoking no more than 5 
cigarettes since TQD validated by CO reading <10 ppm during weeks 1-4 as above. In 
the analyses of changes in smoking behaviour prior to quitting, only participants who 
provided data were included, i.e. no imputations were used.  In the analysis of 
cessation rates, participants lost to follow-up were considered to be smoking.  
 
Weight 
Participants had their weight taken in kilograms (kg) at baseline and session 7. The 
same scales were used with each participant on all occasions. The scales used were 
Omron Body Fat Scale BF400. 
 
Height 
Height was self-reported by the participants on the baseline questionnaire. The study 
staff did not verify height so in cases where the participant did not know their height 
then this field remained blank and no BMI was calculated. 
  
End of Study Definition  
The definition of the end of the study was when the last participant completed the 3-
month (post TQD) follow-up. The study was closed on 17 October 2011. The sponsor 
(QMUL), MHRA and ethics were informed as soon as the study data collection was 
complete. 
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Ethical considerations and patient safety 
The CI alongside support from the study team was responsible for ensuring that the 
trial was conducted in compliance with the principles of the Declaration of Helsinki 
(1996), the principles of good clinical practice (GCP) and in accordance with all 
applicable regulatory requirements including but not limited to the Research 
Governance Framework and the Medicines for Human Use (Clinical Trial) 
Regulations 2004, as amended in 2006 and 2008, Trust and Research Office policies 
and procedures and any subsequent amendments. 
 
Throughout the design of the study, participant’s welfare and safety was the main 
consideration for the research team. For many people stopping smoking can be a 
difficult and stressful time and maintaining regular contact with smokers ensures 
careful monitoring of their wellbeing. Participants were made aware that at any point 
they could withdraw from the study if they wished without any affect to their 
treatment. 
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Other procedural considerations 
 
Criteria for Premature Withdrawal  
There were 2 main routes that participant’s could withdraw before the end of the 
study. These were: 
 
(1) The participant withdraws his/her consent to participate 
(2) Withdrawal events 
These are events leading to withdrawal from the trial although participants were 
followed up with the same schedule of clinic visits (with the participants consent). 
The following events were grounds for withdrawal from the study: 
• Acute myocardial infarction, angina pectoris, or other serious medical 
condition 
• A major psychiatric disorder which impedes compliance with trial protocol 
• Pregnancy 
• A serious adverse drug event (defined as any untoward medical occurrence 
that at any dose results in death, in significant or permanent disability or 
incapacity, is life-threatening, requires hospitalisation or prolongs 
hospitalisation)  
 
Data Collection and Follow up for Withdrawn Subjects  
If a participant was withdrawn from the study or withdrew consent to participate in 
the study part way through, attempts were made to obtain permission to record at least 
adverse events and other data up to the end of the last visit. This was done via phone 
calls to the participant and contact with the participant’s general practitioner. 
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Confidentiality and data protection 
Participants were asked to complete the standard clinic questionnaire and the 
additional questionnaires required for this study. Medical information about 
participants was not requested from their other doctors (hospital or general 
practitioner). All information was kept confidential, just as is normal for smokers 
attending the NHS-SSS. Participants GPs were informed, with the participants 
consent, of their participation in the study.  
 
Only study staff had access to the study data, which were stored securely at the 
TDRU. CRFs were anonymised and kept separate to any personal information, 
baseline questionnaires and consent forms. Participants were allocated a participant 
number, which was used as the main identifier throughout the study. The Microsoft 
access, excel and SPSS (version 18) databases were also anonymised and contained 
no individual identifiers other than the participant and randomisation number. 
 
Treatment setting 
In cases where participants found the group setting unsuitable, individual sessions 
were offered.  
 
Complaints 
Participants were made aware that if they had any complaints or concerns about the 
study that they could contact Barts and the London Trust for advice and guidance. All 
relevant details for making a complaint were included in the patient information sheet. 
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Adverse Event (AE)  
An AE is any untoward medical occurrence in a subject to whom a medicinal product 
has been administered, including occurrences which are not necessarily caused by or 
related to that product.  An AE can therefore be any unfavourable and unintended sign 
(including an abnormal laboratory finding), symptom or disease temporarily 
associated with the use of an Investigational Medicinal Product (IMP), whether or not 
considered related to the IMP. 
 
Serious Adverse Event (SAE)  
An SAE fulfils at least one of the following criteria: 
• Is fatal – results in death (NOTE: death is an outcome, not an event) 
• Is life-threatening 
• Requires inpatient hospitalisation or prolongation of existing hospitalisation 
• Results in persistent or significant disability/incapacity 
• Is a congenital anomaly/birth defect 
 
Suspected Unexpected Serious Adverse Reaction (SUSAR)  
The definition of a SUSAR is any serious adverse event related to an IMP that is both 
suspected to be related to the IMP and unexpected. In this case the event is not 
outlined in the Summary of Product Characteristics (SPC) for that product.  
 
Trained study clinicians were responsible for documenting these events including the 
timescale of the event and assessing the severity of the event and whether it was 
linked to the study medications. As per usual protocol participants experiencing 
medication related to adverse events were advised to reduced dose or stop medication 
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where appropriate. All adverse events were judged on a case-by-case basis and in full 
discussion with the participant. Any adverse events, which warranted contacted with 
the study doctor for advice, were documented in the trial master file. 
 
Notification and Reporting of Serious Adverse Events/SUSAR  
In cases where an SAE or SUSAR were reported, the following procedures were 
followed; 
All Serious Adverse Event (SAEs) were recorded in the subjects’ notes, the CRF, the 
sponsor SAE form and reported to the Joint Research and Development Office (JRO)/ 
IMP provider within 24 hours of the CI or PI or co-investigators becoming aware of 
the event.  A nominated co-investigator was authorised to sign the SAE forms in the 
absence of the CI.  
 
Any SUSARs that occur during the trial were reported to the Joint Research Office 
(JRO)/ main REC/IMP provider within 24 hours of the CI or co-investigator 
becoming aware of the event. SUSARs were to be reported to the sponsor within 24 
hours as the sponsor has a legal obligation to report this to the MHRA within 7 days 
(for fatal or life-threatening SUSARs) or 15 days for all other SUSARs. In the case of 
multicentre studies, the PI or the co-investigators at the participating site must inform 
the CI within 24 hours of the event. The CI or co-investigators at the co-ordinating 
site must inform the sponsor (JRO) immediately to allow reporting to the MHRA 
within the allocated timelines.  
 
The original and any subsequent follow up of SAE Forms together with the fax 
confirmation sheet were kept with the TMF at the study site. 
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Annal Safety Reporting  
The Annual Safety Reports (ASR) was sent to the sponsor, the ethics committee and 
MHRA on 3rd January 2012.  
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Statistical considerations 
 
Primary Endpoint Efficacy Analysis  
The primary endpoint was MPSS ratings of urges to smoke during the first week of 
abstinence. The difference between groups was assessed using analysis of variance 
(ANOVA). 
 
Secondary Endpoint Efficacy Analysis  
Differences in validated abstinence rates over 12 weeks of abstinence were assessed 
using chi-square tests. 
 
Safety Endpoints  
Type and frequency of adverse events will be reported. Frequency of adverse events 
between groups will be assessed using chi-square tests. 
 
Sample Size 
MPSS is a rating scale sensitive to tobacco withdrawal and to both pharmacological  
(West 1990) and behavioural (McRobbie 2007) treatment effects. Effective treatments 
typically generate a difference in ratings over the first week of abstinence of at least 
0.7 compared to control procedures, e.g. 1.8 (SD=1) compared to 2.5 (SD=1). As in 
this case the advantage of the combination over the first week of abstinence may be 
subtle and even a difference of 0.6 would be worth detecting, 45 participants would be 
needed in each group (p<0.05, 2-tailed test, power=0.80). Patient attrition between the 
TQD and Week 1 session is usually between 10% and 20%. The study aimed to 
randomise upto 120 participants. 
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Anticipated participant attrition 
It is usual to expect a number of people to not complete all study procedures. Patient 
attrition between the Week 1 and TQD session is usually between 10% and 20% in 
the standard smoking cessation clinics that are run at the smokers clinic. The study 
aimed to randomise at least 120 participants in total to allow for a 25% rate of 
participant attrition (allowing 45 participants minimum in each condition).  
 
Statistical Analysis  
Differences between the study arms were assessed by analysis of variance for 
continuous variables and chi-square for categorical variables. The relationship 
between pre-quit variables and post-quit endpoints were assessed using regression 
modelling. Differences in urges to smoke at 24 hours and one week were compared 
using one way ANOVA. Changes in withdrawal symptom ratings from TQD to 24h 
and one week were assessed using repeated measures ANOVA. Differences were 
adjusted for all baseline characteristics related to outcome that differed between the 
two groups. As the direction of the results could not be predicted (due to this being 
the first study of its kind), the study statistician deemed that the use of two-tailed tests 
for all analysis was reported. 
 
The results were un-blinded only after the data analysis was completed.  
 
Estimating missing data 
In cases were there were missing data, no data computation (e.g. maximum score) was 
undertaken. If a scale measure has one or more values missing, then SPSS will 
include this as a missing value if computing an overall composite score, e.g. if 
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someone had only rated irritability and depression then when a composite score was 
calculated across all 5 MPSS then this participants compsite MPSS score would be 0. 
There were several participants who, like in the example, had not completed all of the 
MPSS ratings. The decision was made to manually calcualte the composite score 
based on the numbers completed but only in the case were over 50% of the ratings 
remained. 
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Quality Control and Quality Assurance 
 
Self monitoring form  
A self-monitoring report was completed on 6th October 2011, which was sent to JRO 
to check for accuracy in recruitment, data collection and safety reporting. 
 
Study database 
In order to comply with MHRA regulations a Microsoft Access database was 
designed with a full audit trail and limiters, where appropriate. SOPs were developed 
for data entry, auditing and data export.  
 
A non-study member of staff independently audited the database. The final database 
was exported first to a Microsoft Excel spreadsheet, then to SPSS (version 18) for 
final analysis. 
 
Outliers 
The data set was checked for inconsistencies in the data. Variables were examined to 
see if there were any outliers in the results that needed to be checked. As part of the 
data entry process, limiters had been placed on variables where there were only 
certain answers that could be included. For example, yes/no answers had only an 
option of 0 = yes, 1 = no, or the variable was left blank if there was missing data.  
 
 
 
 
 170 
Record Retention and Archiving 
During the study, all records were the responsibility of the CI and were kept in a 
secure location. Records from this study will be kept for 20 years as per standard 
university regulations.  
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Final approvals 
EudraCT 
All trials involving IMPs are registered with a European database of all clinical trials 
called EudraCT. This project was registered and assigned the EudraCT number 2010-
022334-92. 
 
Ethics 
Ethical approval was given by the North London Research Ethics Committee (REC). 
A provisional opinion was given at first with the suggestion of changing the patient 
information sheet to include more detail on the differences between taking part in the 
study and normal clinic care and to also include an updated inclusion criteria for 
women; requiring them to be using contraception during the study period. All changes 
were included in an updated version of the protocol (version 1.1) (see Appendix 10). 
These documents were updated and a favourable opinion was given on 17 December 
2010. The REC number was 10/H0703/85 (see Appendix 11). 
 
Medical Health Regulatory Authority (MHRA) 
After submission of an initial application, MHRA requested further details about the 
placebo patches and the manufacturer’s authorizations certificates for Bilcare (the 
company labelling the study medications) and McNeil (the company providing the 
patches). This information was provided to them and a notice of acceptance was 
received on 7 January 2011 (see Appendix 12).  
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Sponsorship 
The study was sponsored by QMUL JRO. After final approval was given by MHRA 
and Ethics the study was granted final research and development (R&D) approval on 
2 February 2011 (Appendix 13). 
 
Local SSI 
Local ethics (East London and the City Research Ethics Committee) were informed 
about this study and following a site-specific assessment by the local assessor the 
study site was approved. Official confirmation of this was received on 28 January  
2011 (Appendix 14). 
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Results 
Sample characteristics 
A total of 280 people were screened as eligible over the phone and booked an 
appointment to attend the screening/baseline session.  Of the 280 booked, 144 
particpants (51%) attended, 136 (49%) were screened as eligible by the clinic doctor 
and consented to take part in the study. Ten (4%) were ineligible for the following 
reasons; unable to commit to weekly sessions, not registered with a GP and current 
use of medications for depression. Figure 7 shows the flow of participants through the 
trial. 
 
Figure 7: Flow of participants  
 
One hundred and seventeen participants (87%) started on varenicline at week 2. All 
participants returned to attend the quit day session and were randomised to receive 
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either nicotine or placebo patches (N=117).  Table 9 shows the baseline 
characteristics of the participants. 
 
 Table 9: Baseline characteristics of participants  
 Placebo patch 
(N=59) 
Nicotine patch 
(N= 58) 
Statistical 
significance of 
difference 
between groups 
Age in years; mean (SD) 43.8 (11.0) 45.3 (10.8) f (115, 1) = 0.54; 
p = 0.47 
Cigarette consumption (per 
day); mean (SD) 
18 (11) 22 (26) f (115, 1) = 0.83; 
p = 0.36 
Baseline CO ppm; mean 
(SD) 
21 (10.4) 21 (8.5) f (115, 1) = 0.00; 
p = 0.99 
FTND; mean (SD) 5 (2.6) 5 (2.2) f = (115, 1) 0.83; 
p = 0.36 
Age when started smoking; 
mean (SD) 
17 (6.8) 18 (5.5) f (115, 1) = 0.70; 
p = 0.40 
Male N (%)  40 (68)  38 (66) x# =0.07; p = 
0.80 
White British N (%)  36 (61) 37 (64) x# =0.10; p = 
0.76 
Married N (%) 16 (27) 15 (26) x# =0.02; p = 
0.88 
Partner smokes N (%) 15 (25) 15 (26) x# =0.10; p = 
1.00 
In paid employment N (%)* 491 (85) 41 (71) x# =3.20; p = 
0.08 
Body Mass Index; mean 
(SD)* 
262 (4.6)  273 (4.8)  f (107, 1) = 0.76; 
p = 0.39 
*N s differ due to missing data       SD= standard deviation      
1N=58; 2N=53; 3N=56 
 
 
A total of 78 males were randomised into the study (38 in the nicotine patch group 
and 40 in the placebo patch group). The age range for the sample was 18-67 years, 
with a mean age of 45 years (45 years in the nicotine patch group and 44 years in the 
placebo patch group). Over 60% of the participants were white-British (n=73). Only 
one participant did not wish to answer the question on ethnicity. 
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The majority of the smokers who took part in the study were in paid employment 
(71% in the nicotine patch group versus 85% in the placebo patch group). Thirty one 
participants were married (15 versus 16 in the nicotine and placebo group, 
respectively). Twenty nine (25%) of the participants received free prescriptions (17 in 
the nicotine patch group and 12 in the placebo patch group). The average alcohol 
consumption per week among the participants was 11 units (SD=14).  
 
Smoking history  
Baseline average cigarette consumption was similar between the participants in the 
nicotine patch and the placebo groups (22 vs. 18 cigarettes per day, respectively). The 
groups reported a similar age of starting smoking (18 years in the active patch group 
versus 17 years in the placebo group) and 15 participants in each group had a partner 
who currently smoked. 
 
The average CO reading that was taken at baseline was 21 ppm in both groups. Both 
groups had FTND scores of 5. Only 5 participants (4%) reported current use of 
cannabis in combination with tobacco. 
 
Smoking cessation 
Only 8 (12%) participants in the nicotine patch and 7 (14%) in the placebo patch 
group had never tried to stop smoking before. Regarding the longest period of time 
that they had managed to stop for 27 participants (23%) reported managing to stop 
smoking for over 3 months, with 12 (10%) managing less that 24 hours.  
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Twenty two (19%) of the participants had never used any form of smoking cessation 
medications. Only 6 (4%) participants reported using varenilcine in a previous quit 
attempt.  The majority of participants had used a patch in previous quit attempts 
(n=78, 66%). 
 
Overall the randomised groups were well matched with no significant differences 
seen across any of the baseline measures. The study sample profile was typical of 
smokers attending the East London Specialist stop smoking clinic for treatment. 
 
Non-randomised participants 
Of the 134 participants who consented to take part, 17 did not attend session 3 and 
were not randomised. The population who were not randomised were compared to 
those who were to see if there were any baseline differences between the two groups.  
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Table 10 - Baseline characteristics of all participants that consented 
 Randomised 
(N=117) 
Not randomised 
(N= 17) 
Statistical 
significance of 
difference 
between groups 
Age in years; mean (SD) 45 (11) 48 (9) f (132,1) = 1.55; 
p = 0.22 
Cigarette consumption (per 
day); mean (SD) 
20 (20) 19 (6) f (132,1) = 0.05; 
p = 0.82 
Baseline CO ppm; mean 
(SD) 
21 (9.5) 20 (6.4) f = (131,1) 0.10; 
p = 0.80 
Male N (%) 78 (67) 12 (71) x# =0.00; p = 
1.00 
Married N (%) 31 (26) 5 (29) x# =0.01; exact p 
= 1.00* 
In paid employment N (%) 89 (76) 12 (71) x# =0.10; p = 
0.32 
Ethnicity – White-British N 
(%) 
72 (62) 12 (65) x# =0.43; p = 
0.51 
FTND; mean (SD) 4.8 (2.4) 5.3 (2.0) f (131,1)= 0.81; 
p = 0.37 
*In cases where cells had an expected count of less than 5, a Fisher’s exact 
significance test was used 
 
 
There were no significant differences  between those who attended the TQD session 
and those who did not on any baseline variable.  
 
Effect of varenicline and nicotine patch combination on cigarette withdrawal 
symptoms 
A total of 85 participants (43 in placebo patch and 42 nicotine patch group) of 105 (52 
in the placebo and 53 in the nicotine arm) who were successfully contacted by 
telephone at 24 hours after their TQD reported abstinence from smoking and provided 
MPSS data. The two groups did not differ in urge scores (2.8 vs 2.9, F=0.18, P=0.67) 
or in change in withdrawal discomfort composite ratings (0.14 vs 0.07, F=0.31, 
p=0.58). One week after the TQD, 33 (placebo patch) and 40 (nicotine patch) 
participants who were abstinent at that time provided MPSS ratings. There was no 
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difference between the study arms in urge score (2.7 vs 3.0, F= 2.14, P=0.15) or in the 
change in the composite score of withdrawal discomfort (0.42 vs 0.42, F=.001, 
P=0.98).  
 
At four weeks after TQD, 35 (placebo patch) and 35 (nicotine patch) of participants 
who achieved sustained abstinence provided MPSS data and 34 (placebo patch) and 
35 (nicotine patch) provided urge ratings. There were no differences in urge score (2.1 
vs 2.2, F=0.08, P=0.78) or in withdrawal discomfort (0.05 vs 0.01, F=0.08, P=0.78).  
 
Looking at each withdrawal symptom at each time point separately, there was a 
significant group difference in the change in depression ratings between TQD and 24 
hours post TQD in 43 participants on the placebo patch (-0.14) and 42 on nicotine 
patch (-0.38) (F=4.10, P=0.05). This however was due to the difference between the 
two groups at TQD (1.21 vs 1.43 in the placebo patch and nicotine patch group, 
respectively) i.e. prior to the initiation of the patch treatment. At 24 hours after TQD 
the ratings of the two groups were similar (1.07 vs 1.05). There were no other 
differences or trends emerging for any single withdrawal symptom or any time-point. 
 
Effect of varenicline and nicotine patch combination on abstinence rates  
Table 11 shows the rates of continuous abstinence (not a puff since the TQD) at 4 and 
12 weeks and the Russel Standard sustained validated abstinence at 4 and 12 weeks 
(up to 5 cigarettes allowed). There were no differences between the two study arms at 
any time point. 
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Table 11: Effect of varenicline + NRT combination on abstinence rates 
Period after TQD Placebo patch Nicotine patch Pearson Chi-
square; p value 
 N=59 N=58  
24 hour abstinence N (%) 47 (80) 46 (79) x# =.00; p = 0.96 
1 week continuous 
abstinence N (%) 
35 (59) 40 (69) x# =1.18; p = 0.28 
4 weeks continuous 
abstinence N (%) 
24 (41) 29 (50) x# =1.03; p = 0.31 
4 weeks sustained abstinence 
N (%) 
35 (59) 35 (60) x# =0.01; p = 0.91 
12 weeks continuous 
abstinence N (%) 
7 (12) 8 (14) x# =.10; p = 0.76 
12 weeks sustained 
abstinence N (%) 
11 (19) 14 (24) x# = .53; p = 0.47 
      
The effect of nicotine patches on participants who did not have a strong reaction to 
varenicline during the pre-quit week was evaluated seperately. These participants 
were defined as those who did not reduce their CO reading by 50% or more between 
initiation of varenicline and the TQD session, based on the previous findings by Hajek 
et al. (2011). The study found that when varenicline was given to participants for upto 
4 weeks before quitting their cigarette consumption, CO and cotinine levels all 
reduced. All 3 measures of reduction were moderately correlated. As the current study 
did not take cotinie measures, CO levels were taken into account to see if a similar 
population of participants could be seen.  
 
There were 18 participants who were classified as varenicline reactors, as per the 
definition of Hajek et al. (2011). Their sustained abstinence rate at 4 weeks was 78%, 
compared to 57% in non-reactors (x2 = 2.85;p=0.09). Their continuous abstinence rate 
at 12 weeks was 28%, compared to 10% in non-reactors (p=0.054).  
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Looking at the subsample of non-reactors only (49 in the placebo and 50 in the 
nicotine patch group), the abstinence rates at 1 and 4 weeks after TQD were 55% and 
66% (x# = 1.23; p = 0.27) and 53% and 60% (x# = 0.49; p = 0.49) in the placebo patch 
arm and nicotine patch arm, respectively. The non-reactors in the two study arms did 
not differ in urges to smoke or other withdrawal symptoms at 24 hours, 1 or 4 weeks 
after TQD.  
 
Adherence to study medication 
Table 12 shows adherence to medication use at different time points. There was no 
difference between the two study arms at any time point. The adherence to 
medications at the crucial Session 4 (1 week post-TQD) was high, with only one 
participant not using the patches at all and all using varenicline.    
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Table 12: Adherence to medication 
 Placebo patch 
group 
Nicotine 
patch group 
Statistical 
significance of 
difference 
between 
groups** 
Not using patch at 24 h 6/52 5/53 x# = 0.12; p = 
0.73 
No use of patch in the past week 
at 1W post-TQD                
0/53 1/56 x# = 1.00; exact 
p = 1.00** 
No use of patch in the past week 
at 4W post-TQD                        
11/53 13/51 x# = 0.33; p = 
0.57 
Not taken varenicline at 24h               0/52 3/53 x# = 3.03; exact 
p = 0.24** 
Not taken varenicline in the past 
week at 1W post-TQD         
0/53 0/57 NS 
Not taken varenicline in the past 
week at 4W post-TQD         
6/53 6/53 x# =0.00; p = 
1.00 
Not taken varenicline in the past 
week at 3M post-TQD      
23/31 24/33 x# =0.18; p = 
0.89 
*N varies dues to missing data 
**In cases where cells had an expected count less than 5, a Fisher’s exact significance 
test was used 
 
Adverse events 
A total of 257 AEs were reported by 104 participants in the study. Table 13 shows the 
summary of all adverse events which were reported by more than 5% of participants. 
The most frequently reported AE was nausea. 
 
Participants were also asked weekly to rate if they had experienced nausea since the 
last visit. There were no differences in ratings of nausea on the MPSS scale between 
the two groups at any time points (1.6 vs 1.5, 1.7 vs 1.8 and 1.5 vs 1.4 at 24h, 1 week 
and 4 weeks after TQD in the placebo patch and nicotine patch group, respectively, all 
NS).  
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Table 13: Adverse events reported by over 5% of participants 
AE reported Number of participants experiencing 
the problem 
Statistical 
significance of 
difference 
between groups** 
 Placebo Patch 
group N=59 
Nicotine patch 
group N=58 
 
Abnormal dreams 5 12 x# = 3.51; p = 0.06 
Headache 4 6 x# = 0.48; exact p 
= 0.53* 
Insomnia 11 11 x# = 0.00; p = 0.97 
Nausea 26 33 x# = 1.93; p = 0.17 
Pruritis 1 5 x# = 2.90; exact p 
= 0.11* 
Somnolence 2 3 x# = 0.23; exact p 
= 0.70* 
*In cases where cells had an expected count of less than 5, a Fisher’s exact 
significance test was used 
 
Serious adverse events 
One serious adverse event (SAE) was reported during the trial. The SAE was a 
hospital admission for surgery owing to a crush fracture. This SAE was unrelated to 
the study medication. 
  
 183 
Discussion 
Adding nicotine patches to varenicline had no beneficial or detrimental effect on 
urges to smoke, withdrawal discomfort or abstinence rates at 24 hours and 1 week 
after quitting. There were no differences seen in adverse effects profile between the 
two groups.  
 
Overall the randomised groups were well matched with no significant differences 
seen across any of the baseline measures. There were no difference seen between the 
participants who were randomised and those who consented but did not attend the 
randomisation session. Baseline demographics were similar to those seen in the 
population of smokers who attend the East London Specialist stop smoking clinic for 
treatment.  
 
Limitations  
Several issues need to be considered when interpreting these results. 
 
The study was originally powered as a proof in principle trial to answer some key 
questions about the effectiveness of combining varenicline and a nicotine patch. The 
sample size was sufficient to detect clinically meaningful differences in withdrawal 
ratings and craving, but the trial was not powered to detect small differences in 
abstinence. We cannot rule out a possibility of a subtle effect detectable on a large 
sample. However, it is likely that the active ingredient of any effect would be 
lowering of withdrawal discomfort, which is more likely to be seen in the first few 
weeks of quitting. As this did not happen, we can probably rule out any robust effect 
on abstinence. 
 184 
The study was not powered for long-term follow up and did not provide data for 
abstinence rates beyond 3 months. The short-term follow-up of the study would limit 
the generalisability of the results only if the results were positive. It is unlikely that a 
lack of effect during the patch use period and up to 2 months after the patch has been 
discontinued could change into a significant effect later on.  
 
The majority of the participants included in the study were assumed to be daily 
smokers, however, we did not ask specifically if this was the case. The current study 
was aimed at an increased dose of medication for use with dependent smokers. 
Participants who do not smoke daily would normally be advised to use oral 
medications in their quit attempt. This is so their medication use can be tailored 
around the situations they would normally smoke (e.g. use of the fast acting nicotine 
nasal spray when socialising). Giving these types of smokers a patch when they do 
not smoke every day is not usually something that is recommended. Giving non-daily 
smokers varenciline and a patch in combination, in the context of this study, may not 
be the best treatment option for them. There is no safety aspect of using NRT on days 
where the person would not normally smoke. However, using varenicline every day 
may result in nausea. Social/non-daily smokers should be screened out in any future 
studies looking at high dose medications. 
 
Adding a qualitative component to this study would have been useful. Understanding 
how participants perceived the use of a combination and whether they felt it was of 
benefit might have clinical relevance. For example, smokers may find use of an oral 
NRT product a useful distraction whilst using varenicline rather than using the 
product to get added nicotine.  
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Despite these constraints the study findings are novel and potentially important for 
future practice and guidance. 
 
The negative results found in this study cannot be attributed to low compliance with 
medication use, as almost all participants used both medications during the first week 
after TQD when any beneficial effects would be expected to be the strongest. We 
used 16h/15mg patch, which has extensive evidence of its efficacy (Fiore, Smith, 
Jorenby & Baker 1994). The 24-hour patch has been shown to have stronger effects 
on early urges to smoke (Shiffman & Ferguson 2008), but both types of patches have 
the same effect on smoking cessation outcome (Stead et al. 2008). 
 
It could be argued that other short-acting NRT formulations, which can be used 
opportunistically, could be more effective (i.e. nicotine inhaler). This is possible, but 
any gains in better efficacy of short-acting NRT products are usually undermined by 
the fact that they are less user-friendly and generate much lower adherence than 
patches. Good sustained adherence to oral NRT products and nasal spray usually 
requires a period of supervised frequent and regular use (Hajek et al. 1999). Where 
the expectation is that the product will be used only sporadically, the adherence is 
likely to be low. Nevertheless, our results should be generalised to alternative NRT 
products with caution.  
 
Varenicline was provided to participants as per standard dosing instructions for 12 
weeks in total (Pfizer limited 2011). Nicotine patches were provided to participants on 
the TQD and for a total of 4 weeks. Standard practice would see use of patches for 9-
12 weeks from the TQD when using the product as part of a cessation attempt 
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(McNeil Limited 2009). In this study the use of patches for 4 weeks was primarily to 
give the “extra” pharmacotherapy support during the 4-weeks when the symptoms of 
tobacco withdrawal are at their most acute. It may be argued that the duration of 
patches should be extended, however, our results on withdrawal and urges reflect that 
the inclusion of a nicotine patch to varenicline was not beneficial in the first few 
weeks of quitting which would logically be the time where any useful benefit of the 
combination is likely to be seen. 
 
Adding nicotine patches to varenicline did not increase the incidence of nausea. This 
suggests that the nausea producing effect of varenicline may be unrelated to its effects 
on nicotinic receptors involved in the dopamine pathway. The finding tallies with the 
fact that nausea caused by varenicline is not related to the drug’s effects on smoking 
behaviour, which has been noted by other previous studies (Hajek et al. 2011).   
 
The one pre-marketing study conducted by Pfizer Ltd (2011) showed that smokers 
using varenicline and a transdermal patch for 12 days reported a higher incidence of 
nausea, headache, vomiting, dizziness, dyspepsia, and fatigue than smokers who used 
NRT alone. This study found no differences in the adverse events reported between 
the 2 groups. It is highly probable that the symptoms that were reported in this study 
may have been due to common medication specific reactions (i.e. varenicline (nausea) 
or patch use (itching)), as opposed to any combination use of varenicline and patches. 
 
The quit rates at 4 weeks are in line with the UK standard success rate of 
approximately 38% (The NHS Information Centre for Health and Social Care 2012). 
It could be argued that you would expect a much higher quit rate just from individuals 
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being part of a study, acting almost as a ‘placebo’ effect. It is important to remember 
that this data was rigorous in its collection and participants had to report complete 
cessation over the final 2 weeks of treatment (session 6 and 7) and CO verified in 
order to be classed as sustained quitters. If we look at the continuous rates, a much 
stricter measurement with no lapses allowed throughout treatment, the results show 
that less than 30% at 4-weeks were abstinent. However, this is in line with previous 
research in this area of research (Hajek et al. 2011). Typically, high abstinence rates 
in practice and research are often due to a less stringent measure of abstinence, for 
example, using point prevalence as an outcome. Point prevalence is asking the 
participant whether they smoked in the last week and does not take into account any 
lapses before this time point. 
 
There are two obvious interpretations of the negative finding found by this study. One 
is that NRT and varenicline are achieving their effects via similar target mechanisms, 
which overlap to a large or even full extent. Varenicline may act on a more limited 
range of nicotinic receptors than nicotine itself, but these seem to include those 
involved crucially in the rewarding effects of smoking. By blocking such receptors, 
varenicline may be limiting any potentially beneficial effects of NRT as well. For 
example, nicotine patches normally alleviate weight gain in continuous abstainers 
(Farley et al. 2012) but they had no such effect here. 
 
The other explanation, which seems more likely, is that by blocking the relevant 
nicotinic receptors, varenicline blocks any potentially beneficial effects of NRT as 
well.  
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Patients who have a weak reaction to varenicline during an extended pre-quit period 
have been shown to have low success rates (Hajek et al. 2011). In theory, the addition 
of nicotine replacement could be of particular benefit to such patients. To test this 
hypothesis, we evaluated separately the effect of nicotine patches on participants who 
did not reduce their CO reading by 50% or more during their pre-TQD varenicline 
dosing. This definition was based on the work by Hajek et al. (2011), who looked at 
the effect of using varenicline upto 4 weeks pre-quitting. The study found that when 
varenicline was given to participants for upto 4 weeks before quitting their cigarette 
consumption per day (cpd), CO and cotinine levels all reduced, these were identified 
as “Reactors”. Those who did not change their cpd, CO or cotinine were defined as 
“Non-Reactors”. All 3 measures of reduction were found to be modertaly correlated. 
As the current study did not take cotinine measures, changes in CO level in the first 
week of varenicline use were taken into account to identify the number of “Reactors” 
in the current study. 
 
Nicotine patches were of little additional benefit even to smokers who did not have a 
strong response to varenicline early on. When looking at this specific population the 
findings of the study are somewhat more tentative than the main result, as a trend was 
seen in favour of nicotine patches in this sub-analysis for abstinence rate at 4 and 12 
weeks in the participants identified as “Reactors”. If patch effects are blocked by 
varenicline in varenicline reactors and non-reactors alike, an interesting question 
arises as to whether varenicline non-reactors may benefit from NRT in the absence of 
varenicline. If this were the case, treatment efficacy could be improved by switching 
smokers who show no reaction to varenicline during the pre-quit period over to NRT. 
Future studies should evaluate this notion further.    
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It should be noted that the 50% cut off mark for varenicline “Reactors” and “Non-
reactors” is arbitrary and was replicated, for the purposes of this study, based on the 
recent varenicline pre-loading study definitions outlined by Hajek et al. (2011). There 
is a possibility that this could be looked at differently i.e. a reduction in cpd, cotinine 
and CO levels of 20% may still be clinically relevant. 
 
Apart from generating information relevant for considering the mechanisms of the 
two medications, the trial results have an important practical implication. Finding a 
positive effect would not provide a definitive proof of efficacy, but it would indicate 
that a large scale study with a long-term follow-up is warranted. A negative result on 
the other hand provides a strong indication that such a trial is unlikely to provide 
positive results and that combining the two treatments is not helpful. There is 
widespread interest in giving both medications at the same time to highly dependent 
smokers in the hope of providing more powerful medication. The results of this study 
suggest that such practice is unlikely to be productive or economical. 
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Next steps 
This proof in principle trial has shown that a large-scale study on the use of 
combination varenicline and NRT is not currently warranted. However, the need for 
new options for the treatment of dependent smokers is needed. One study that is 
currently running at the TDRU is looking at the efficacy of using a tailored dose of 
varenicline. 
 
The standard varenicline dosing has been formulated to avoid adverse reactions 
(primarily nausea) in sensitive clients. The downside of this cautious approach is that 
a substantial proportion of clients may be under-dosed. A blanket dose increase would 
inevitably increase the incidence of side effects, but it is likely that tailoring 
varenicline dosing to clients’ needs would be safe and may further increase 
varenicline’s efficacy. 
 
Tailoring the dose to client need is likely to receive positive endorsement from clients 
who appreciate individualised care, as well as from doctors. The study will provide an 
indication on whether this approach is likely to increase the efficacy of varenicline 
and if the results are positive, the trial will also provide data essential for planning any 
future outcome study. The results of this study will be available in 2013. 
 
  
 191 
Conclusions  
The efficacy of varenicline is not enhanced by the addition of nicotine patches. The 
finding has theoretical implications for interpreting the effects of the two medications. 
It has also an important practical corollary. There is widespread interest in combining 
the two medications. Our results suggest that this is unlikely to be a productive or 
economical approach.   
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PART 2: A SYSTEMATIC REVIEW OF SMOKING 
CESSATION INTERVENTION: A REPORT TO THE 
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL 
EXCELLENCE (NICE) 
 
Abstract  
 
Introduction 
In 2010/11, approximately 460,000 NHS secondary care admissions in the UK were 
estimated to be attributed to smoking tobacco (Office of National Statistics 2012). 
Hospitalisation provides a good opportunity to stop smoking.  Such patients are often 
highly motivated to quit, and the hospital admission brings people into direct contact 
with healthcare professionals who can advise on giving up smoking and offer 
evidence-based treatment.  
 
Objective 
This piece of work was commissioned by the National Institute of Health and Clinical 
Excellence (NICE) to review the available evidence concerning the efficacy of 
different types of smoking cessation interventions for hospital patients and their 
relatives to help guide clinical recommendations for smoking cessation in acute 
services. The guidelines are due to be published in November 2013. 
 
Methods 
A systematic search for reviews and randomised controlled trials published between 
1990 and December 2011 in the English language was undertaken. Electronic 
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databases were searched including ASSIA, MEDLINE, Cochrane Central Register of 
Controlled Trials, CINAHL and PsychINFO. A total of 29,083 records were found of 
which 141 papers were identified for full text retrieval. Seventy-five trials evaluating 
smoking cessation interventions delivered in acute care settings were found.  
 
Results 
Hospitalised smokers – For interventions with hospital patients to be effective, an 
extended period of support and stop smoking medication provided for over 4 weeks 
after discharge is recommended. Interventions that are provided face-to-face after 
discharge may provide better results than support provided over the telephone. 
Relatives – There is limited research for this population, however, brief stop smoking 
interventions with parents of hospitalised children did not show any efficacy in long 
term abstinence rates.  
Hospital staff – There is evidence that providing the stop smoking medication 
bupropion (Zyban) with regular face-to-face support is an effective treatment for 
hospital staff.  
 
Conclusion 
The NHS practice for hospitalised smokers currently involves interventions at bedside 
accompanied by medications and/or referrals to specialist stop-smoking services for 
treatment after discharge, which combines extended face-to-face support with 
smoking cessation medications. The reviewed evidence confirms that this is likely to 
be the optimal approach. 
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Background to the systematic review 
In September 2011 a tender was advertised for applications to conduct a series of 
systematic reviews for NICE. The reviews were to be part of a new smoking guideline 
for acute and maternity services across the UK, which is due for release in 2013. My 
clinical background has been primarily working with inpatient smokers in acute care 
settings, which made my expertise very relevant to the tender call and application. 
Applications to write 3 of the 6 reviews were submitted by Professor Hajek, Dr 
McRobbie and myself. We were successful in our application for all 3 of the reviews; 
I present one of the 2 papers I led, which looks at the effectiveness of smoking 
cessation interventions in acute care settings. 
 
This guideline will not be released until 2013. The contents of the review remain 
confidential until its publication. 
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Introduction 
 
Why help smokers during hospitalisation? 
In 2010/11, of the 10 million NHS secondary care admissions in the United Kingdom 
(UK), it was estimated that 460,000 were attributed to smoking tobacco (Office of 
National Statistics 2012). Nearly 35% of admissions attributable to smoking were 
cancer related (Office of National Statistics 2012). With such a high number of 
smokers being admitted into hospital and with a high percentage of those attributed to 
serious illnesses, the provision of education and treatment for smokers during their 
hospital stay is seen as a priority for the UK DoH (Croghan 2011).  
 
Helping smokers during hospitalisation provides a unique opportunity for people to 
stop smoking. Smokers who are admitted to hospital are often more receptive to 
information being provided about improvements to their health, are often more highly 
motivated to quit and the hospital setting provides a potentially supportive 
environment to do so (Rigotti, Munafo, Lindsay 2007). Patients report that hospitals 
are an appropriate and preferred place for health education (Haynes 2008). 
 
During a hospital stay patients are often in a situation where they feel vulnerable and 
are more focused on the health problem they have been admitted to hospital with, and 
so as a result of this distraction, they may find they are able to cope with tobacco 
abstinence during their hospital stay better than they would under normal 
circumstances (Mackenzie, Pereira & Mehler 2004).  
 
 216 
Anecdotally dependent smokers who have been unsuccessful at stopping smoking in 
the past, report that when they are hospitalised they do not think about cigarettes 
during their stay and feel comfortable without smoking (Myers & Hajek 2009).  
 
UK hospitals have been smoke-free since 2007 (Bauld 2011), which means that 
smokers who are admitted undergo a period of abstinence from smoking, without 
being exposed to the usual environmental cues and prompts to smoke.  For most 
hospitals smoking is forbidden in the grounds of the hospital as well as on the wards, 
which for many sick patients adds a further barrier to accessing an area where they 
can smoke.   
 
Interestingly, previous research has noted that smokers have reported that they can 
“put up” with being unable to smoke and report little or no smoking withdrawal 
symptoms in other situations such as religious occasions, meetings and long-haul 
flights (Dar, Stronguin, Marouani, Krupsky & Frenk 2005). Limiting cues and 
prompts to smoke and restricting access to smoke appears to dampen the effects of 
tobacco withdrawal symptoms in these situations.  
 
Smoking–related illness and hospitalisation are important windows of opportunity for 
smoking cessation interventions. Helping such smokers should be an important 
priority for health care staff, because in many cases stopping smoking facilitates 
recovery from illness and reduces the need for further demands on health service 
resources (Croghan 2011). The role of the inpatient smoking cessation service has 
been given further importance as the evidence continues to emerge, supporting the 
positive health impacts for those undergoing surgical procedures, even short term 
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abstinence can have for the individual (Kuri, Nakagawa, Tanaka, Hasuo & Kishi 
2005; Lindstrom, Sadr Azodi, Wladis, Tonnesen, Linder, Nasell, Ponzer & Adami 
2008). The close involvement with health care systems should make provision of such 
interventions relatively easy, however, in practice this is not always the case.  
 
What is happening in the UK? 
 
Department of Health Recommendations 
Provision of stop smoking interventions in secondary care is a priority for the UK 
DoH and current guidelines for local stop smoking services include detailed service 
delivery recommendations (Croghan 2011). Recommendations include that all 
frontline healthcare professionals (HCPs) should be trained to provide very brief 
advice to all smokers admitted to hospital, assessment of dependency and to provide 
pharmacotherapy for patients who would like to quit smoking or to temporarily 
abstain during their stay in hospital.  
 
The UK health service is much more conducive to a successful adoption of this best 
practice by HCPs than is the case in any other country. This is because the NHS 
established the stop smoking service (SSS) in 1999, and stop smoking treatment by 
specialists are now available throughout the UK (Croghan 2011). This makes the task 
of the front line NHS staff much simpler than that of their counterparts in other 
countries. Staff are only required to advise smokers to quit and refer those who need 
and want help to the NHS-SSS. The NHS-SSS is then ideally placed to support 
patients after discharge in the community and to continue the treatment provided in 
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hospital (Croghan 2011). Even in such a simplified scenario however, there are a 
number of practical considerations, which influence practice. 
 
 
UK hospital smoking cessation in practice 
In practice, the opportunity for HCPs to provide routine encouragement and advice to 
smokers is often missed. There are many HCPs trained to screen for tobacco use and 
give brief advice to quit (nurses (Haddock & Burrows 1997); doctors (Campbell, 
Prescott & Tjeder-Burton 1996); and dedicated in-hospital smoking cessation 
advisors (Prathiba, Tjeder, Phillips & Campbell 1998), however, they are much less 
likely to provide further assistance, such as referring on to the local SSS (Schofield, 
Hill, Johnston & Streeton 1995; Vaughn, Ward, Doebbling, Uden-Holman, Clarke & 
Woolson 2002; Vokes, Bailey & Rhodes 2006; Von Garnier, Kochuparackal, 
Miedinger, Leuppi, Tamm, Battegay & Zeller 2008, Warner 2009; Whyte, Watson & 
McIntosh 2006; Wilber, Sullivan, Gaeta, Walters, Camargo & Boudreaux 2011).  
 
One study analysed audiotapes from doctor-patient interactions in an emergency 
department to see what advice, if any, was given to smokers (Vokes et al. 2006). Just 
over half were screened for smoking, with 56% of smokers given advice to quit, and 
13% offered further help. Similarly in a survey of outpatients (Von Garnier et al. 
2008) contacted by phone within 24 hours after their hospital appointment, 81% were 
asked about smoking, 28% received advice on risks, 10% received advice to quit and 
9% were offered help to quit.  
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A consistent finding in the literature is that the more HCPs are asked to do, the less 
likely they are to do it (Myers, McRobbie, West & Hajek 2012).  Lack of time, 
knowledge and skills are among the most commonly cited barriers for intervening at 
any level with a smoker (Thy, Boker, Gallefoss & Bakke 2007; Warner, Sarr, Offord 
& Dale 2004, Warner, Klesges, Dale, Offord, Schroeder, Vickers & Hathaway 2008). 
It is strongly recommended that in the UK, training for HCPs should focus 
exclusively on motivating and simply referring smokers to NHS-SSS (Myers et al. 
2012). There is evidence that brief training (40 minutes) is effective in increasing 
referrals from UK GPs (McRobbie, Hajek, Feder & Eldridge 2008).  There is no 
reason to expect that the same approach would not work in secondary care. 
 
Other barriers include short hospital stays and patients leaving wards for 
investigations and interventions, which make on-ward stop-smoking sessions by 
HCPs difficult to deliver (Thompson, Caslin, Murray, Zissimos, Newhouse & Yung 
2006; Vaughn et al. 2002; Goldstein 1999; Rigotti, Arnsten, McKool, Wood-Reid, 
Pasternak & Singer 1997). An obvious solution is to have dedicated staff providing 
smoking cessation treatment.  
 
Many NHS-SSS in the UK now employ staff to provide specialist help and initiate 
stop-smoking interventions at the patient’s bedside. There is good evidence that 
smoking cessation treatment that begins during a hospital stay and includes follow-up 
support for at least one month after discharge is effective (Rigotti et al. 2007). 
However, despite the evidence of the effectiveness of intensive interventions and the 
availability of NHS- SSS funded to provide them, such interventions are far from 
universal.  
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There are limited data describing smoking cessation support within NHS hospitals. In 
2003, a survey of 260 UK Hospitals (with a 91% response rate) suggested only 
around 50% had a dedicated smoking cessation service on-site (Campbell, Lewis, 
Preston & Comm 2003). A recent e-survey in 2011 (cited in Lewis 2012) confirmed a 
slight overall increase in hospital provision compared with 2003 data but due to 
financial cuts many UK hospitals have lost their in-house smoking cessation services 
and there remains widespread disparity between the availability, location and content 
across hospitals. Another recent survey (Proctor, Myers-Smith, McRobbie & Hajek 
2013) found that in a survey of hospitals employing staff to provide an inpatient 
smoking cessation service that most had first contact with the patient during their 
hospital stay. However, some services did not employ smoking cessation advisors to 
start treatment at bedside, but instead focused on training staff in providing 
interventions and/or referral to local services. 
 
Provision of pharmacotherapy during hospitalisation 
Abstaining from smoking often results in a tobacco withdrawal syndrome (TWS) that 
comprises of a number of changes such as mood alterations, physical symptoms and 
signs, as well as biochemical and physiological changes (Hughes, Stead & Lancaster 
2007).  Not all smokers who are hospitalised will experience TWS (Myers et al. 2009) 
but for those who do these symptoms can be managed.  Current pharmacotherapies 
for smoking cessation, in particular fast acting nicotine replacement therapy (NRT) 
products, can be effective in alleviating tobacco withdrawal symptoms (West & 
Shiffman 2001) and should be offered to assist patients to abstain during their hospital 
stay. 
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A 2005 NHS Health Development Agency (HDA) survey (Health Development 
Agency 2004) found that although 40% of hospitals had NRT on the hospital 
formulary, that it was only available to the patients in 10% of hospitals.  The same 
survey also reported that only 8% of hospitals were able to provide NRT, and pro-
actively offered it to smokers.  
 
Thirty-nine UK inpatient hospital services were surveyed in the recent report by 
Proctor et al. (2013). All reported being able to provide NRT, while fewer services 
were able to provide varenicline (57%) and buproprion (35%). After discharge, only 
54% of services were able to supply patients with medication to take home. Only 23% 
of services provided patients with the option of hospital appointments after discharge.  
 
May, Stocks & Barton (2008) interviewed 13 members of staff from an acute cardiac 
care unit in Australia where NRT was not used at all. The key barriers included the 
fact that NRT was not on the formulary and staff lacked relevant knowledge. Related 
to the latter, there were some concerns about NRT cost and its safety.  
 
What evidence is there on hospital intervention effectiveness? 
Smoking cessation counselling delivered in an acute hospital setting, combined with 
at least 1 month follow-up support post discharge, is associated with an increase in 
smoking cessation rates at both 6 and 12 months (Rigotti et al. 2007). There are also 
data from systematic reviews to show that intensive smoking cessation interventions 
delivered to people awaiting surgery can be effective in increasing long-term 
cessation rates (Moller & Villebro 2005; Theadom & Cropley 2006).  
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The aim of this piece of work was to review the available evidence concerning the 
efficacy of different types of smoking cessation interventions for hospital patients and 
their relatives and hospital staff to help guide clinical recommendations for smoking 
cessation in acute services. Reviewing this extensive body of literature will provide 
some useful pointers, which will contribute to guidelines on how best to support such 
smokers and to provide some direction for future implementation of such 
interventions.  
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Methods 
Aim 
The aim of this review was to examine the efficacy of smoking cessation delivered in 
acute services (including patients, partners, parents, visitors, and staff). 
  
Research questions 
This review’s aim was to answer the following question posed by NICE: 
Question 1: How effective are smoking cessation interventions in helping people from 
the populations of interest? 
 
Populations of interest 
Smoking cessation interventions delivered in acute secondary care services to: 
1. Inpatients  
2. Partners/parents/visitors of inpatients 
3. Hospital staff 
 
Structure of the review 
The review is divided into 5 sections that address the populations of interest: (1) users 
of acute secondary care services and (2) staff and visitors of these services.  
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Section 1 covers the efficacy of interventions delivered to non-surgical patients. This 
section concerns trials comparing interventions of different intensity with minimal 
support or usual care;   
Section 2 covers the efficacy of interventions delivered to patients undergoing 
surgery;  
Section 3 covers the efficacy of pharmacotherapies to aid smoking cessation in acute 
secondary care service users. This section concerns trials where comparison groups 
differed in the provision of medications but not in the level of behavioural support; 
Section 4 covers the efficacy of interventions delivered to hospital employees;  
Section 5 covers the efficacy of interventions delivered to parents of hospitalised 
children. 
 
Each section includes meta-analyses and an interpretative evaluation is outlined. 
 
Types of studies considered in this review 
All randomised controlled trials with the populations of interest were included.  
 
Types of interventions considered in this review 
Any intervention that was initiated during hospitalisation and that aimed to assist 
clients in stopping or reducing smoking or in remaining abstinent were included. 
Studies were also included where interventions started before and after 
hospitalisation, e.g. those commenced during pre-operative assessment or initiated 
after discharge, where such practice could be initiated by the secondary care teams. 
Studies of smoking interventions delivered as part of broader rehabilitation 
programmes were included if it was possible to extract data on the outcome of the 
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smoking cessation component. Interventions that were delivered to staff and visitors 
of acute services were also included.  
 
Inclusion criteria 
The following were included in the review:  
! Systematic reviews 
! Randomised controlled studies published from 1990 to the most recent 
available at the time of the search 
 
Exclusion criteria 
The following were excluded in the review: 
! Animal studies 
! Studies that do not primarily address the review questions; and 
! Studies not published in English 
 
Categorising interventions by intensity 
A number of different types of behavioural interventions have been proposed to help 
smokers quit. They can be categorised according to their theoretical underpinning, use 
of treatment aids such as booklets, videos and biological feedback, background of the 
person delivering the intervention, etc. The Cochrane review of interventions with 
hospital patients (Rigotti et al. 2007) categorised the interventions according to the 
length of time over which support was provided. Length of support is generally 
related to the cost of the intervention and also to its efficacy. Such approach seems 
practical for informing clinical recommendations and we used it throughout this 
review.  
 226 
The studies have been categorised by the length of time over which support was 
provided into the following levels of intensity: 
 
Intensity 1: Single contact with or without take-away written and other materials, 
no follow-up support 
 
Intensity 2: One or more contacts with or without take-away written and other  
  materials up to but not beyond the TQD 
 
Intensity 3: Any contact plus follow-up for up to but not beyond 4 weeks after 
TQD 
 
Intensity 4: Any contact plus telephone/correspondence/e-mail etc. based follow-
up for> 1 month 
 
Intensity 5: Any contact plus follow-up for > 1 month including at least one face-
to-face contact 
 
We also considered whether combination with or without pharmacological treatments 
influenced treatment outcomes. 
 
Issues not covered in this review 
We excluded trials of interventions delivered entirely outside the secondary care and 
maternity care settings, and trials with psychiatric patients. This review did not 
consider evidence relating to the health benefits of stopping smoking.  
 
Outcomes and data extraction 
The principal outcome measure was abstinence from smoking at least six months after 
the start of the intervention.  
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Regarding data extraction, we followed the approach used in the Cochrane report 
(Rigotti et al. 2007) and extracted data indicating the most conservative measure of 
quitting at the longest follow up. Biochemically validated quit rate was preferred to 
self-reported abstinence, continuous or sustained abstinence was preferred to point 
prevalence abstinence, and abstinence at later time-points was preferred to abstinence 
at shorter time points. Participants lost to follow up were counted as continuing 
smokers. 
 
Evaluation of trial quality 
In smoking cessation studies where study arms differ in patient contact, one of the 
main potential sources of bias is lack of validation of self-reported abstinence. This is 
because participants who receive more attention and resources can feel under greater 
pressure to report benefit. Another factor, which has a potential to bias smoking 
cessation studies, is the use of short-term 7-day ‘point prevalence’ abstinence reported 
long after the intervention finished, as opposed to sustained abstinence that traces the 
effects of the initial intervention. Not using intention to treat (ITT) is the third major 
potential source of bias as patients failing in their quit attempt are more likely to drop 
out than those who are successful. We were able to largely remove this bias as most 
studies reported the original sample sizes and so we were able to re-calculate ITT 
results where needed. We also assessed randomization procedures and allocation 
concealment, but these features can be expected to have only limited impact on trials 
of smoking cessation interventions where there exist no strong predictors of outcome 
exists.  
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Each of the included studies was rated ++, + or - to indicate its quality. The quality of 
the included reviews was assessed using criteria outlined in NICE guidance (see Table 
1). The quality of included trials was assessed as follows. 
 
Table 1: Quality assessment ratings 
 
++ Self-reported abstinence was verified biochemically, sustained or 
continuous abstinence reported, no other risks of bias  
+ Self-reported abstinence was verified biochemically, only point 
prevalence abstinence reported, no major risks of bias 
–  Self-reported abstinence not validated and/or other major risks of bias 
(e.g. incomplete randomisation, unclear N, unclear calculation of 
success rates) 
 
We rated the quality of reviews as ++ for systematic reviews showing awareness of 
key methodological features of stop-smoking studies, + for reviews which were less 
systematic and/or did not take into account the key quality aspects of included studies, 
and – for reviews which were selective and/or posed methodological problems.  
 
Data analysis  
Where it was appropriate to pool studies, data were entered into RevMan (version 5). 
We pooled data using Mantel-Haenszel fixed-effect method, with 95% confidence 
intervals. To investigate statistical heterogeneity we used the I2 statistic. Where there 
was substantial heterogeneity between studies we explored possible reasons for this 
using subgroup analyses. We express results as odds ratios (intervention odds/control 
odds) for achieving abstinence from smoking together with the 95% confidence 
interval for this estimate. 
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Applicability statements 
The degree of applicability of the main conclusions to the UK setting is assessed in 
the narrative summary at the end of the Chapter.  
 
Search methodology 
We systematically searched reviews and trials published between 1990 and December 
2011 in the English language, but we also included literature published in early 2012 
while we were working on the review. The search date was restricted to studies 
published after 1990 with agreement from NICE, as the literature in this area does not 
emerge until after this date when the implementation of hospital smoking cessation 
services was first established. The electronic resources and websites searched are 
included in Appendix 1. 
 
A systematic search of the grey literature was not undertaken but hand searching of 
bibliographies of systematic reviews that met the inclusion criteria was carried out to 
ensure that relevant data was included in this review. The search terms included for 
this review are included in Appendix 2. 
 
Search results 
Searches of the databases returned 29,083 records. After duplicates were removed a 
total of 19,520 titles and abstracts were screened. Full papers were also obtained 
where there was no abstract and the relevance could not be assessed by the title alone. 
One member of the project team screened all titles and abstracts and a second member 
of the team re-screened 30% to check accuracy, as agreed with NICE. Ideally 100% 
would have been double-checked but with the high number of hits returned from the 
search this was not feasible in the time frame available. Of the total number of 
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abstracts 267 (1.4%) required review from a third member of the project team as to 
whether they should be included in the review. These were papers where the details of 
the study were not clear from the abstract alone, so agreement was sought from the 3rd 
reviewer to check if the full paper should be reviewed. There were also 5 papers that 
the first 2 reviewers did not agree on so the 3rd reviewer made the final decision over 
its inclusion. A total of 141 papers were identified for full text retrieval. A flow 
diagram illustrating the screening procedure is included in figure 1 below. Studies 
excluded at the full-paper screening stage are listed in Appendix 3, along with a brief 
reason for exclusion. Papers that were unavailable for full paper retrieval are detailed 
in Appendix 4. 
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Figure 1: Flow diagram for papers  
          
Database Searches (n=29083)       
      Duplicates removed (n=9563) 
      
Abstracts screened (n=19520)       
      Excluded at abstract screening 
(n=19241)       
Included for full-paper screening 
(n=141) 
      
      Papers not found in time (n=19) 
      
          
      Papers excluded (n=41)  
      
          
Full-text papers (n=81)       
      Website resources included (n=0) 
      
          
      Papers sourced from bibliographies of 
included papers (n=4)  
Paper found after database search (n=1) 
      
Total papers included (n= 86) 
Hospital review = 75  
 
Systematic reviews included (N=11) 
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Structure of the review  
We found 75 studies evaluating smoking cessation interventions with users of acute 
services, which had follow-up periods of at least 6 months. The studies are 
summarised in Table 2.  
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Table 2 - Summary of studies included  
 Summary 
Bolman et al 
2002 
Netherlands 
Participants: 789 inpatients recruited from cardiac wards across 11 
hospitals 
Intervention: Advice from a cardiologist and 15-30 min nurse 
counselling on ward. Advice again in the outpatient clinic at 4-6 weeks 
post discharge. (Intensity 5) 
Control procedure: Usual care 
Outcomes: 12 months sustained abstinence 
Validation: None 
Quality: - 
Notes: Data from 25 deaths, 38 refusals, and 64 people with missing 
baseline data were excluded from analysis.  
Borglykke et 
al 2008 
Denmark 
Participants: 223 patients hospitalised with COPD 
Interventions: Standard information offered in hospital and group 
counselling over 5 weeks, NRT offered (Intensity 5) 
Control procedure: Standard information only 
Outcomes:  7 day PP at 12m 
Validation: Blood COHb  
Quality: + 
Notes: Blood samples assessed in 84% of patients 
Brandt 1997, 
Denmark 
Participants: 56 hospitalised COPD patients  
Interventions: Smokers informed they have an illness called ‘smokers 
lung’ (Intensity 1) 
Control procedure:  Smokers informed they have an illness called 
chronic bronchitis 
Outcomes: 12 months (not clear if PP or cont) 
Validation:  CO 
Quality:  + 
British 
Thoracic 
Society A 
Participants: 1462 chest outpatients 
Interventions: advice + TQD discussed, 5 letters and 2 HV contacts 
(Intensity 5) 
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1990, UK Control procedure: Advice only 
Outcomes: 9 months continuous abstinence 
Validation: Blood COHb 
Quality: ++ 
British 
Thoracic 
Society B 
1990, UK 
Participants: 1392 chest outpatients 
Interventions: (1) advice only; (2) advice + agreement to quit; (3) 
advice + 6 letters; and (4) advice + agreement + letters 
Outcomes: 6 months continuous abstinence 
Validation: Blood COHb 
Quality: ++ 
Notes: We merged 1+2 (one-off intervention, Control) and 3+4 
(extended contact; Intensity 4) for analysis 
Campbell et 
al 1991, 
UK 
Participants: 212 in-patients with smoking-related diseases 
Intervention: Physician advice plus a single session of inpatient 
counselling and nicotine gum for 3 months. Followed up at 2, 3, 5 
weeks, 3 months, and 6 months by counsellor (Intensity 4) 
Control procedure: Same as intervention but with placebo gum 
Outcomes: 12 month sustained abstinence 
Validation: CO 
Quality: ++ 
Campbell et 
al 1996, UK 
Participants: 62 Inpatients with respiratory or cardiovascular disease 
Intervention: Physician advice plus a single session of inpatient 
counselling and nicotine patch for 3 months. Outpatient follow-up by 
counsellor at 2, 4, 8, and 12 weeks (Intensity 4) 
Control procedure: Same as intervention but with placebo patch 
Outcomes: 12 months sustained abstinence 
Validation: CO 
Quality: ++ 
Carlsson 
1997, 
Sweden 
 
Participants: 168 MI patients, intervention after discharge 
Interventions: CVD prevention programme with exercise, diet and 
stop-smoking advice (Intensity 5) 
Control procedure:  Usual care via GP 
Outcomes: Abstinence from smoking at 1 year (not clear if PP or cont) 
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Validation: none 
Quality:  -  
Caruthers 
2005, USA 
 
Participants: 80 smokers after discharge from hospital 
Interventions: 8 phone calls, some used medications (Intensity 4) 
Control procedure: Usual care 
Outcomes: 7 day PP at 6 months  
Validation: CO validated 
Quality: + 
Notes: Unpublished PhD thesis. Controls for baseline differences not 
clear. 
Chan et al 
2005, 
Hong Kong 
Participants: 80 smoking parents of sick children brought to hospital  
Interventions: Motivational interviewing and telephone reminders 1 
week after intervention (Intensity 3) 
Control procedure: Healthy diet counselling 
Outcomes: 7 day PP at 1 months  
Validation: None 
Quality: - 
Note: Intervention with parents of patients 
Chouinard et 
al 2005, 
Canada 
Participants: 168 inpatients with CVD or PVD 
Interventions: (1) Single session of inpatient nurse counselling plus 
pharmacotherapy (nicotine patches, gum and bupropion). (Intensity 2); 
(2) Same as intervention (1), but with 6 follow-up telephone calls over 
2 months post discharge (Intensity 4) 
Control procedure: Cessation advice 
Outcomes: 6 months sustained abstinence 
Validation: Urine cotinine or CO 
Quality: ++ 
Notes: 23% used pharmacotherapy.  
Croghan et al 
2005, USA 
Participants: 30 smokers undergoing surgical resection of lung or 
oesophageal cancers 
Intervention: Advice from surgeons and study nurses and a single 
session of inpatient counselling (Intensity 2) 
Control procedure: Physician advice only 
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Outcomes: 6 months 7-day PP 
Validation: CO or saliva tobacco alkaloid 
Quality: + 
Dalsgaro et 
al 2004, 
Denmark 
 
Participants: 336 hospital employees 
Interventions: 5 counselling sessions, 2 phone calls over 6 months, and 
7 weeks Bupropion. (Intensity 5) 
Control procedure: Identical support + 7 weeks placebo 
Outcomes: 6 months continuous abstinence 
Validation: CO validated 
Quality: ++ 
Notes: Hospital employees, not patients 
De Busk et al 
1994, USA 
Participants: 252 inpatients with acute MI 
Intervention: Physician advice plus single session of counselling and 
NRT. Self help materials and relaxation tapes were also provided. 
Follow-up at 48hrs, 1 weeks and then monthly for 6-months via 
telephone (Intensity 4) 
Control procedure: Advice only 
Outcomes: 12 months continuous abstinence 
Validation: CO and plasma cotinine. 
Quality: ++ 
Notes: NRT was provided to only the ‘highly-addicted’ patients. 
Intervention post-discharge.  
Dornelas et 
al 2000, 
USA 
Participants: 100 smokers. Inpatients with acute MI. 
Intervention: Single inpatient counselling session followed by 
telephone calls at weeks 1, 4, 8, 12, 16, 20, and 26 (Intensity 4) 
Control procedure: Advice only 
Outcomes: 7 day PP at 12 months 
Validation: Significant other  
Quality: - 
Note: Validation available for only 70% of cases 
Feeney et al 
2001, 
Australia, 
Participants: 198 inpatients with acute MI  
Intervention: Physician advice to quit plus single session of nurse 
counselling. Outpatient telephone follow up at 1,2,3,4 weeks and 
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2,3,6,12 months (Intensity 4) 
Control procedure: Same as above but no proactive follow-up contact  
Outcomes: 12 months continuous abstinence 
Validation: Urinary cotinine 
Quality: ++ 
Froelicher et 
al 2004 
USA 
Participants: 277 inpatients with CVD or PVD from across 10 
hospitals 
Intervention: Physician advice plus single session of nurse counselling. 
Then outpatient telephone follow-up at 2,7,21,28,90 days (Intensity 4) 
Control procedure: Physician advice + booklet 
Outcomes: 7-day PP at 12 months  
Validation: Saliva cotinine OR verification by significant other 
Quality: + 
Hajek et al  
2002,  
UK 
Participants: 540 inpatients with acute MI. 
Intervention: Nurse advice and single session of inpatient counselling 
with self-help materials (Intensity 2) 
Control procedure: Brief advice and booklet 
Outcomes: 12 months continuous abstinence 
Validation: CO and salivary cotinine. 
Quality: ++ 
Hand et al 
2002,  
UK 
Participants: 245 hospital in-patients and outpatients with smoking 
related diseases 
Interventions: Advice and support + 3 weeks use of nicotine patch and 
nicotine inhalator (Intensity 5) 
Control procedure: Advice and support only 
Outcomes: 1 year continuous abstinence 
Validation: CO validated 
Quality: ++ 
Hanssen et al 
2009, 
Norway 
 
Participants: 288 MI patients 
Interventions: pro-active telephone follow-up included smoking 
cessation advice (8 calls in 6 months + access to reactive line) 
(Intensity 4) 
Control procedure: No intervention 
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Outcomes: 18 months (not clear if PP or cont) 
Validation: None 
Quality: - 
Notes: 7 died in each group. Intervention was provided post-discharge 
Hasuo et al  
2004, 
Japan 
Participants: 120 inpatients with any diagnosis 
Intervention: 3 sessions of inpatient nurse counselling and then 
telephone follow up at 7, 21, 42 days (Intensity 4) 
Control procedure:  Same as above, but no follow-up calls  
Outcomes: 12 months (not clear if PP or cont) 
Validation: urinary cotinine (not clear if results are self-report or 
cotinine validated) 
Quality: - 
Haug et al  
2011, 
Germany 
Participants: 477 patients in a rehabilitation centre (following acute 
medical illnesses) 
Interventions: Internet based smoking cessation intervention + 6 post 
discharge email invites to log on (Intensity 4) 
Control procedure: Baseline smoking assessment only 
Outcomes: 7 day PP at 6 months  
Validation: None 
Quality: - 
Hennrikus et 
al 2005, 
USA 
Participants: 2095 inpatients (all diagnoses) from across 4 hospitals 
Interventions: (1) Physician advice and smoking cessation booklet with 
an additional booklet mailed after discharge (Intensity 1); (2) Physician 
advice plus single session of inpatient nurse counselling followed by 3-
6 telephone calls over 6 months (Intensity 4) 
Control procedure: Smoking cessation booklet in hospital 
Outcomes:  7-day PP at 12 months  
Validation: Saliva cotinine 
Quality: + 
Notes: 43% of counselling sessions in intervention 2 were conducted 
after discharge by telephone rather than at bedside 
Hennrikus et 
al 2010,  
Participants: 124 outpatients with peripheral arterial disease 
Interventions: minimum of 6 counselling sessions over 5 months + 
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USA pharmacotherapy (a choice of NRT, bupropion or varenicline) 
(Intensity 5) 
Control procedure: Brief advice and information about smoking 
cessation services 
Outcomes: 7 day PP at 6 months  
Validation: CO validated or salivary cotinine 
Quality: + 
Hilleman et 
al 2004, 
USA 
Participants: 39 smokers who had recently undergone CABG 
Interventions: referred immediately to smoking cessation service for 8 
week course + NRT (Intensity 5) 
Control procedure: Called monthly and if reported smoking then 
referred onto 8 week course 
Outcomes: 12 months continuous abstinence 
Validation: CO validated 
Quality: ++ 
Horn et al 
2008,  
USA 
Participants: 75 teenage smokers 
Interventions: In-hospital counselling, audio workbook, personalised 
postcard sent after discharge and 3 FU calls (1, 3 and 6 months) 
(Intensity 4) 
Control procedure: Basic advice  
Outcomes: 6 months – asked, “did you smoke in the last month?” 
Validation: None 
Quality:  - 
Kim 2005, 
South Korea 
Participants: 401 general outpatients 
Interventions: Nurse advice, stage matching, setting TQD, booklets, 
mailed reminders, phone calls at 1 week and 1 month (Intensity 3) 
Control procedure:  Usual care  
Outcomes: Abstinence from smoking at 5 months (‘since the last quit 
attempt’)  
Validation: CO 
Quality:  + 
Lacasse et al 
2008, 
Participants: 196 patients on cardio-pulmonary wards 
Interventions: Psychological support and NRT + up to 4 phone calls 
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Canada within 6 weeks post discharge (Intensity 4) 
Control procedure: Usual care 
Outcomes: 7 day PP at 1 year  
Validation:  Urine cotinine, but not taken into account 
Quality: - 
Lewis  
2009,  
UK 
Participants: 450 hospitalised smoker 
Interventions: (1) counselling + 4 weekly out-patients appointments 
and information about stop smoking services (Intensity 4); (2) as above 
but given an appointment at the stop smoking service (Intensity 5). 
Patients were recommended to use NRT or bupropion. 
Control procedure: brief intervention 
Outcomes: 7 day PP at 1 year  
Validation: CO validated 
Quality:  + 
Lewis et al  
1998,  
USA 
Participants: 185 inpatients with any diagnosis except certain cardiac 
conditions 
Interventions: (1) Physician advice, a single session of counselling, 
nicotine patch for 6 weeks and self-help materials. Follow-up 
telephone calls at 1,3,6 weeks and 6 months. [Intensity 4];  (2) As 
above but with placebo patch (Intensity 4) 
Control procedure: Advice only 
Outcomes: 7 day PP at 6 months  
Validation: CO 
Quality: + 
Li et al  
2008 
USA 
Participants: 277 female smokers hospitalized with CVD 
Interventions: Inpatient counselling + 5 follow up phone calls over 3 
months (Intensity 4) 
Control procedure: Usual care 
Outcomes: 7 day PP at 30 months  
Validation: None 
Quality: - 
Lindström et 
al 2008, 
Participants: 117 smokers undergoing elective surgery 
Interventions: Weekly sessions, face-to-face or by telephone and NRT, 
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Sweden 
 
4 week pre and post surgery (Intensity 5) 
Control procedure: Usual care 
Outcomes: Abstinence from 3 weeks pre to 4 weeks post surgery 
Validation: CO validation 
Quality: ++ 
Mahabee-
Gittens et al 
2008, 
USA 
 
Participants: 365 smoking parents of paediatric patients admitted to 
the emergency department. 
Interventions: Brief advice + fax referral to a quitline (Intensity 1) 
Control procedure: Usual care 
Outcomes: 7 day PP at 3 months  
Validation: None 
Quality: - 
Notes: Parents of patients 
Martucci et 
al 2010 
Italy 
Participants: 233 smokers undergoing bronchoscopy 
Interventions: 15 minutes advice before and after surgery. 
Pharmacotherapy suggested but only prescribed on demand (Intensity 
2) 
Control procedure: Usual care 
Outcomes: 7 day PP at 12 months 
Validation: CO validation 
Quality: + 
Metz et al  
2007, 
Germany 
Participants: 307 smokers at a rehabilitation centre for acute and 
chronic disorders 
Interventions: CBT or Motivational Treatment in hospital + 5 
telephone booster sessions (Intensity 4) 
Control procedure: CBT or Motivational Treatment in hospital + usual 
care 
Outcomes: 7 day PP at 12 months  
Validation: None 
Quality: - 
Miller et al  
1997, 
USA 
Participants: 1942 general hospital inpatients 
Interventions: (1) Physician advice, single inpatient counselling 
session and self help materials. Telephone follow-up at 48 hours, 1, 3, 
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and 12 weeks (Intensity 4); (2) As above by only one follow-up call (at 
48 hours) (Intensity 3). 
Control procedure: Advice only 
Outcomes: 12 months continuous abstinence  
Validation: Plasma cotinine or family member corroboration 
Quality: + 
Mohiuddin et 
al 2007, 
USA 
Participants: 209 in-patients with acute coronary syndrome or 
decompensated CHF 
Intervention: Single session of inpatient counselling, self-help booklet, 
and NRT and/or bupropion. Outpatient follow-up consisted of weekly 
group meetings for up to 3m. (Intensity 5) 
Control procedure: Same as intervention but without any follow up 
(Intensity 2) 
Outcomes: 12 months continuous abstinence 
Validation: CO 
Quality: ++ 
Notes: NRT or bupropion offered on individualized basis to both 
groups 
Moller et al 
2002, 
Denmark 
Participants: 120 smokers undergoing surgery 
Intervention: Weekly counselling initiated 6-8 week pre-operatively 
with NRT (type not specified). Abstinence or reduction option. 
(Intensity 5) 
Control procedure: Usual care 
Outcomes: 12 months continuous abstinence 
Validation: CO validation 
Quality: ++  
Molyneux et 
al 2003, 
UK 
Participants: 274 medical and surgical inpatients  
Interventions: (1) brief counselling plus a self-help booklet, no NRT 
and no follow up (Intensity 2), (2) brief counselling plus a self-help 
booklet and an offer of 6-week supply of NRT. No follow up (Intensity 
2) 
Control procedure: Usual care 
Outcomes: 12 months sustained abstinence 
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Validation: CO 
Quality: ++ 
Notes: NRT offered= gum, patch, inhalator, lozenge, nasal spray; 96% 
used NRT 
Mosca et al 
2010, 
USA 
Participants: 304 admitted to hospital with CHD 
Interventions: Counselling during hospital + 3 FU calls (2, 4, 12 
weeks) and a final visit/call at 6 weeks post discharge (Intensity 4) 
Control procedure: Usual care 
Outcomes: 6 months (not clear if PP or cont) 
Validation: CO validated 
Quality: + 
Nagle et al 
2005, 
Australia 
Participants: 1422 inpatients (all diagnoses, but those in ICU were 
excluded)  
Intervention: Two sessions of inpatient nurse counselling plus a 
booklet and offer of NRT in hospital and for 5 days post-discharge. 
There was no follow-up (Intensity 2) 
Control procedure: Physician advice and booklet 
Outcomes: 7-day PP at 12 months  
Validation: Saliva cotinine 
Quality: + 
Neuner et al 
2009, 
Germany 
Participants: 1044 smokers at an emergency department 
Interventions: in-hospital counselling + telephone booster sessions 
(nicotine gum given to those who set a TQD) (Intensity 3) 
Control procedure:  Usual care 
Outcomes: 7 day PP at 12 months  
Validation: None 
Quality:  - 
Ortigosa et al 
2000, 
Spain 
Participants: 90 Inpatients with acute MI 
Intervention: Physician advice with telephone follow up at 2,3 and 4 
weeks (Intensity 3) 
Control procedure: Usual care 
Outcomes: 7 day PP at 12 months 
Validation: CO 
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Quality: + 
Papadakis et 
al 2011, 
Canada 
Participants: 28 patients at stroke prevention clinic 
Interventions: 4 weeks supply of free smoking cessation medication (a 
choice of NRT, bupropion or varenicline) + a prescription for further 
supply (Intensity 1) 
Control procedure: Prescription only 
Outcomes: 7 day PP at 6 months  
Validation: CO validated 
Quality: + 
Pedersen et 
al 2005, 
Denmark 
Participants: 105 inpatients with CHD 
Intervention: Advice to quit plus information about NRT (NRT was 
available). Patients attended 5 outpatient visits post discharge 
(Intensity 5) 
Control procedure: As above, but without follow-up 
Outcomes: 7 day PP at 12 months  
Validation: None 
Quality: - 
Pederson et 
al 1991, 
USA 
Participants: 74 inpatients with COPD. 
Intervention: Physician advice (prior to admission), followed by 3-9 
sessions of inpatient counselling and self help materials, but no 
outpatient follow-up (Intensity 2) 
Control procedure: Advice only 
Outcomes: 7 day PP at 6 months 
Validation: Serum COHb  
Quality: + 
Notes: Only a subset validated 
Pelletier et al 
1998, 
Canada 
Participants: 504 inpatients with acute MI. 
Intervention: Physician advice and self-help materials (Intensity 2) 
Control procedure: Usual care 
Outcomes: 7 day PP at 12 months  
Validation: None 
Quality: - 
Note: Not fully randomised  
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Quist-
Paulsen et al 
2003, 
Norway 
Participants: 240 inpatients admitted to a cardiac ward 
Intervention: 1-2 sessions of inpatient nurse counselling and advice on 
using NRT. Telephone follow up at 2,7 and 21 days and 3 and 5 
months, with a clinic visit with a cardiac nurse at 6 weeks (Intensity 4) 
Control procedure: Advice to quit and self-help booklet 
Outcomes: 7 day PP at 12 months  
Validation: Urine cotinine 
Quality: + 
Notes: Nicotine gum or patch encouraged for patients with strong 
urges to smoke in hospital 
Ralston et al 
2008, 
USA 
 
Participants: 42 smoking caregivers of children admitted to hospital 
for respiratory illness 
Interventions: Counselling >30 minutes and offered NRT (Intensity 2) 
Control procedure: Brief counselling 
Outcomes: 6 months (not clear if PP or cont) 
Validation: None 
Quality: - 
Ratner et al 
2004, 
Canada 
Participants: 237 patients awaiting surgery 
Interventions: Face-to-face counselling 1-3 weeks pre surgery and 
written materials, nicotine gum and smoking cessation hotline number. 
Post surgery counselling in hospital and via telephone (Intensity 4) 
Control procedure: Usual care 
Outcomes: Abstinence at 12 months (not clear if PP or cont) 
Validation: CO validation or urine cotinine 
Quality: + 
Reid et al   
2003 
Canada 
Participants: 254 inpatients admitted with CVD 
Intervention: A single session of brief nurse counselling followed by 
telephone call at 4 weeks. If patients were smoking at this time they 
were offered 3 counselling sessions (weeks 4, 8 and 12) and nicotine 
patch for 8 weeks (Intensity 4) 
Control procedure:  Same as above, but without outpatient follow-up. 
Outcomes:  7-day PP at 12 months 
Validation: CO validation in a random sample of 25 self-reported 
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abstainers 
Quality: + 
Reid et al   
2007 
Canada 
Participants: 99 hospitalised smokers with CAD 
Interventions: Counselling in hospital and offer of NRT + interactive 
voice response follow up (contact patients at 3,14 and 30 days post 
discharge) (Intensity 4) 
Control procedure: Counselling in hospital and offer of NRT + usual 
care 
Outcomes: 7 day PP at 12 months  
Validation: None 
Quality: - 
Rigotti et al  
1997 
USA 
Participants: 615 inpatients in medical or surgical services. 
Intervention: Physician advice and a single session of inpatient 
counselling plus self-help materials. Telephone follow-up was 
provided weekly for 3 weeks post discharge (Intensity 3) 
Control procedure: Usual care 
Outcomes: 7 day PP at 6 months 
Validation: Salivary cotinine. 
Quality: + 
Rigotti et al 
1994 
USA 
Participants: 87 inpatients scheduled for CABG surgery 
Intervention: 3 inpatient counselling sessions, plus self-help material, 
followed by one telephone call 1 week post discharge (Intensity 3) 
Control procedure: Advice only 
Outcomes:  12 months continuous abstinence 
Validation: Salivary cotinine. 
Quality: ++ 
Rigotti et al 
2006 
USA 
Participants: 254 inpatients with CVD or PVD from across 5 hospitals 
Intervention: Bupropion 150 mg b.d. for 12 weeks plus a single session 
of nurse counselling in hospital. Patients were also given a self-help 
booklet and received 5 follow up phone calls at 2,7,21 days, and 2 and 
3 months (Intensity 4) 
Control procedure: Same as above but with placebo 
Outcomes: 12 months continuous abstinence 
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Validation: Saliva cotinine 
Quality: ++ 
Rodriguez et 
al 2007 
USA 
Participants: 111 smokers undergoing deep sedation (for incision and 
drainage of abscess, or orthopaedic reduction or relocation) 
Interventions: 30 minutes of music played during sedation + scripted 
smoking-cessation message (Intensity NA) 
Control procedure: Music only  
Outcomes: 2 week sustained abstinence 
Validation: Self report 
Quality: - 
Notes: Study was stopped due to lack of effect 
Rosal et al  
1992,  
USA 
Participants: 267 inpatients (smokers or recent quitters) with coronary 
artery stenosis. 
Intervention: 2 sessions of inpatient counselling, plus self help 
materials and relaxation tapes. Telephone follow up at 1, 3 weeks and 
3 months if quit, or 2 and 4 months if did not quit (Intensity 4) 
Control procedure: Advice only 
Outcomes: 12 months continuous abstinence 
Validation: CO 
Quality: ++ 
Schiebel et al 
2007 
USA 
Participants: 39 smokers at an emergency department 
Interventions: Advice to quit + proactive quitline intervention (baseline 
session + 4 FU calls around TQD) (Intensity 3) 
Control procedure: Advice to quit + self help manual 
Outcomes: 7 day PP at 6 months  
Validation: None 
Quality:  - 
Schofield et 
al 1999, 
Australia 
 
Participants: 4158 hospitalised smokers 
Interventions: Personalised letter urging them to quit from physician, 
sent 1-2 weeks post discharge (Intensity 1) 
Control procedure: Usual care 
Outcomes: 7 day PP at 12 months 
Validation: Urine cotinine or CO validated 
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Quality: + 
Simon et al   
2003, 
USA 
Participants: 223 inpatients (all diagnoses)  
Intervention: A single session of nurse or health educator counselling 
and booklet, plus nicotine patch treatment for 8 weeks. Telephone 
follow-up conducted at 1 and 3 weeks and 1, 2, and 3 months 
(Intensity 4) 
Control procedure: A single session of nurse or health educator 
counselling and booklet, plus nicotine patch treatment for 8 weeks but 
no telephone contact 
Outcomes: 7-day PP at 12 months  
Validation: Saliva cotinine OR report by spouse  
Quality: + 
Simon et al  
2009, 
USA 
Participants: 85 smokers admitted to hospital for at least 24 hours 
Interventions: counselling and 5 FU calls +7 weeks Bupropion 
(Intensity 4) 
Control procedure:  counselling and 5 FU calls + 7 weeks placebo 
Outcomes: 7 day PP at 6 months 
Validation: Salivary cotinine 
Quality: + 
Simon et al 
1997, USA 
Participants: 229 smokers undergoing non-cardiac surgery 
Intervention: Inpatient counselling (30-60 mins), self-help materials, 
video and nicotine gum (3mg) if no contraindications. Telephone FU 5 
times in 1-3 weeks post discharge, 2m and 3m (Intensity 4) 
Control procedure: Advice only 
Outcomes: 7 day PP at 12 months  
Validation: CO or corroboration by significant other 
Quality: - 
Sivarajan et 
al 2004,  
USA 
Participants: 277 women hospitalized with CVD 
Interventions: Counselling at bedside, tapes and booklets + 5 FU calls 
(Intensity 4) 
Control procedure: Usual care 
Outcomes: 7 day PP at 30 months  
Validation: None 
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Quality:  - 
Smith et al  
2009, 
Canada 
Participants: 276 patients admitted with MI or for a CABG 
Interventions: Counselling, take home materials + 7 FU calls over 2 
months post discharge (Intensity 4) 
Control procedure: Advice from doctor/nurse + 2 pamphlets 
Outcomes: 7 day PP at 12 months  
Validation: None 
Quality:  - 
Smith et al  
2011, 
Canada 
Participants: 643 inpatients 
Interventions: In-hospital education + multiple FU calls (up to 60 days 
post discharge) (Intensity 4) 
Control procedure: Brief in-hospital advice + pamphlets 
Outcomes: 7 day PP at 12 months 
Validation: Salivary cotinine 
Quality:  + 
Steinberg et 
al 2011, 
USA 
Participants: 79 hospitalised smokers 
Interventions: Brief behavioural support (5-10 mins) + varenicline. 
Data collection visits at 4, 12 and 24 weeks (Intensity 5) 
Control procedure: Support + placebo 
Outcomes: 7 day PP at all time points (4, 12 and 24 weeks)  
Validation: CO validated 
Quality:  + 
Stevens et al 
1993, 
USA 
Participants: 1119 general hospital inpatients admitted for >36 hours 
Intervention: Single session of inpatient counselling supplemented by 
self-help materials. 1-2 telephone contacts were provided in the first 3 
weeks of discharge (Intensity 3) 
Control procedure: Usual care 
Outcomes: 12 month sustained abstinence 
Validation: None 
Quality: - 
Stevens et al 
2000, 
USA 
Participants: 1173 general hospital inpatients admitted for >36 hours 
Intervention: Single session of counselling supplemented by self-help 
materials, video. Follow up consisted of 1 telephone call at 1-week 
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post discharge (Intensity 3) 
Control procedure: Usual care 
Outcomes: 12 months sustained abstinence 
Validation: None 
Quality: - 
Taylor et al   
1990, 
USA 
Participants: 173 inpatients with acute MI. 
Intervention: A single session of inpatient counselling supplemented 
by self-help materials and relaxation tapes. Nicotine gum was 
available. 6-7 telephone follow-up calls were undertaken over 4 
months post discharge (Intensity 4) 
Control procedure: Usual care 
Outcomes: 12 months sustained abstinence 
Validation: Serum thiocyanate and CO 
Quality: + 
Taylor et al  
1996, 
USA 
Participants: 328 hospitalised smokers 
Interventions: 1 hour in-hospital counselling session + 4 FU calls after 
discharge (Intensity 4) 
Control procedure: Brief advice 
Outcomes: 7 day PP at 1 year  
Validation: plasma cotinine or family confirmation 
Quality:  + 
Thomsen et 
al 2010a, 
Denmark 
Participants: 130 female smokers undergoing breast cancer surgery 
Interventions: Single smoking cessation counselling session and NRT, 
3-7 days pre surgery (Intensity 3) 
Control procedure: Usual care 
Outcomes: 12 month continuous abstinence 
Validation: None 
Quality: + 
Tonnesen et 
al 2000, 
Denmark 
Participants: 446 smokers referred to a lung clinic 
Interventions: 1) 15mg patch 2) nicotine inhaler 3) 15mg patch + 
inhaler for 3 months (Intensity 4) 
Control procedure: 5mg patch “placebo” for 3 months 
Outcomes: 12 month continuous abstinence 
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Validation: Salivary cotinine 
Quality:  ++ 
Tonnesen et 
al 2006, 
Denmark 
Participants: 370 COPD patients 
Interventions: 12 week course of nicotine sublingual tablets with low 
(4 visits + 6 phone calls) or high (7 visits + 5 phone calls) intensity 
support (Intensity 5 for both) 
Control procedure: 12 week course of placebo sublingual tablets with 
low (4 visits + 6 phone calls) or high (7 visits + 5 phone calls) intensity 
support 
Outcomes: 1 year continuous abstinence 
Validation: CO validated 
Quality:  ++ 
Vial et al 
2002, 
Australia 
Participants: 102 inpatients from medical and surgical wards 
Interventions: (1) Pharmacist consultation about NRT use, 
supplemented by a booklet and up to 16 weeks of subsidized nicotine 
patches that could be obtained at weekly visits to the hospital 
pharmacist; (2) As above, but patches were obtained from a 
community pharmacists (Intensity 5) 
Control procedure: advice to quit plus a booklet 
Outcomes: 12 months continuous abstinence 
Validation: CO test ’whenever possible’ 
Quality: - 
Wakefield et 
al 2004, 
Australia 
Participants: 137 cancer patients 
Interventions: Motivational intervention and a FU call (Intensity 4) 
Control procedure: Usual care 
Outcomes: 6 months continuous abstinence 
Validation: Urine cotinine or CO validated 
Quality:  ++ 
Wiggers et al 
2006, 
Netherlands 
 
Participants: 385 smokers at outpatient departments (vascular surgery, 
cardiology and vascular medicine) 
Interventions: counselling, 8 weeks nicotine patches + a FU call 
(Intensity 3) 
Control procedure: Usual care 
 252 
Outcomes: 7 day PP at 12 months  
Validation: Urine or Salivary cotinine;          
Quality:  + 
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1) Efficacy of interventions delivered to non-surgical patients 
 
Intervention intensity 
Below we analyse all studies where more intensive support was compared with less 
intensive or no support. Drug trials where both study arms received the same intensity 
of behavioural support are analysed in Section 3.  
 
Figure 2 – Efficacy of intervention to non-surgical patients - Intensity 1 (Single 
contact in hospital lasting up to 15 minutes, no follow-up support) 
 
 
 
Three studies (Brandt et al 1997 [RCT +]; Hennrikus, et al 2005 [RCT +]; Papadakis 
et al 2011 [RCT +]) reported on the effects of one-off brief interventions (short advice 
and booklets) with no follow-up. The results were homogenous and show no 
additional effect of such interventions compared to usual care (OR=1.26; 95% 
CI:0.89-1.78).  
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Figure 3 - Efficacy of intervention to non-surgical patients - Intensity 2 (One or 
more contacts in hospital lasting in total > 15 minutes, no follow-up support)  
 
 
 
The results from six studies (Chouinard et al 2005 [RCT ++]; Hajek et al 2002 [RCT 
++]; Molyneux et al 2003 [RCT ++]; Nagle et al 2005 [RCT +]; Pederson et al 1991 
[RCT +]; Pelletier et al 1998 [RCT -]) which reported slightly more intensive 
interventions in hospital (a longer counselling session or two plus booklets) with no 
further follow up were similar, showing no effect of such interventions (OR=1.04; 
95%CI: 0.83-1.31). The results were again homogenous.  
 
Figure 4 - Efficacy of intervention to non-surgical patients - Intensity 3 (Any 
hospital contact plus follow-up <=1 month) 
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Ten studies (Kim et al 2005 [RCT +]; Miller et al 1997 [RCT +]; Neuner et al 2009 
[RCT -]; Ortigosa et al 2000 [RCT +]; Rigotti et al 1994 [RCT ++]; Rigotti et al 1997 
[RCT +]; Schiebel et al 2007 [RCT -]; Stevens et al 1993 [RCT -]; Stevens et al 2000 
[RCT -]; Wiggers et al 2006 [RCT +]) provided telephone support post-discharge for 
up to 4 weeks. This generated a marginally significant effect overall (OR=1.17; 95% 
CI: 1.01-1.36), but there was no effect when only studies which validated self-
reported abstinence were included (see below). The studies were homogenous. Only 
one study (Stevens et al 1993, [RCT -]) yielded a significant result. If there is an 
effect, it is likely to be small. 
 
Figure 5 - Efficacy of intervention to non-surgical patients - Intensity 4  
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The largest number of trials (26) included telephone follow-ups for over 4 weeks 
(British Thoracic Society B 1990 [RCT ++]; Chouinard et al 2005 [RCT ++]; De 
Busk et al 1994 [RCT ++]; Dornelas et al 2000 [RCT +]; Feeney et al 2001 [RCT 
++]; Froelicher et al 2004 [RCT +]; Haug et al 2011 [RCT -]; Hasuo et al 2004 [RCT 
+]; Hennrikus et al 2005 [RCT +]; Horn et al 2008 [RCT -]; Lacasse et al 2007 [RCT 
-]; Li et al 2008 [RCT -]; Metz et al 2007 [RCT -]; Miller et al 1997 [RCT +]; Mosca 
et al 2010 [RCT +]; Quist-Paulsen et al 2003 [RCT +]; Reid et al 2003 [RCT +]; Reid 
et al 2007 [RCT -]; Rosal 1992 [RCT ++]; Simon et al 2003 [RCT +]; Sivarajan et al 
2004 [RCT -]; Smith et al 2009 [RCT -];  Smith et al 2011 [RCT +]; Taylor et al 1990 
[RCT +]; Taylor et al 1996 [RCT +]; Wakefield et al 2004 [RCT ++]). Such 
interventions were effective (OR=1.54; 95%CI: 1.39-1.70). The studies were 
heterogeneous, with two outliers (Feeney et al 2001, [RCT ++]; Taylor et al 1996, 
[RCT +]). Removing them reduced the heterogeneity (p=0.06) with the result 
remaining significant (OR=1.48, 1.33-1.64). 
 
Figure 6 - Efficacy of intervention to non-surgical patients - Intensity 5 (Any 
hospital contact plus follow-up >1 month including at least one face-to-face session)  
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Ten studies included at least one post-discharge face-to-face contact (Bolman et al 
2002 [RCT -]; Borglykke et al 2008 [RCT +]; British Thoracic Society A 1990 [RCT 
++]; Carlsson et al 1997 [RCT -]; Hennrikus et al 2010 [RCT +]; Hilleman et al 2004 
[RCT ++]; Lewis et al 2009 [RCT +]; Mohiuddin et al 2007 [RCT ++]; Pedersen et al 
2005 [RCT -]; Vial et al 2002 [RCT-]). They differed widely in the number of 
sessions and the nature of support provided. There were also substantial differences in 
the nature of the control interventions, which ranged from minimal to Intensity 5. 
There was an overall significant effect (OR=1.66; 95%CI: 1.38-2.00), but the studies 
were heterogeneous. Removing the two outliers, which both provided intensive face-
to-face treatment over extended periods of time (Hilleman et al 2004, [RCT ++]; 
Mohiuddin et al 2007, [RCT ++]) reduced heterogeneity (p=0.19). The overall effect 
was reduced as well but it remained significant (OR=1.45, 1.19-1.76). 
 
Overall we found that only interventions of Intensity 4 and 5, which provide support 
to smokers over a period longer than 4 weeks showed efficacy.  
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Validated studies by intensity of intervention 
We next re-ran the five analyses including only studies, which validated self-reported 
abstinence.  
 
Figure 7 – Validated by intensity of intervention in non-surgical patients - 
Intensity 1 
 
 
Figure 8 – Validated by intensity of intervention in non-surgical patients - 
Intensity 2 
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Figure 9 – Validated by intensity of intervention in non-surgical patients - 
Intensity 3 
 
 
Figure 10 – Validated by intensity of intervention in non-surgical patients - 
Intensity 4 
 
 
Figure 11 – Validated by intensity of intervention in non-surgical patients - 
Intensity 5 
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The results remain unaltered, showing a lack of efficacy for low intensity 
interventions, and significant effects of interventions providing follow-up support for 
the duration longer than four-weeks.  They thus agree with the finding of Rigotti et al. 
(2007 [Systematic Review ++]).  
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Use of medications 
The next key question, not addressed in the previous meta-analyses, concerns the role 
of stop smoking medications. Some of the interventions examined in these studies 
included medications and some did not. The analyses presented above do not clarify 
whether significant effects can be achieved without medications, and whether the 
finding of differential effectiveness of interventions of different intensity is 
confounded by more intensive interventions being more likely to include 
pharmacotherapy. Clarifying this issue has obvious implications for recommended 
practice and for intervention costs. 
 
We divided studies of each intensity into those, which included medications and those 
that did not. The relevant meta-analyses are presented below. Medication was mostly 
NRT. 
 
Figure 12 - Intensity 1 – behavioural support only 
 
 
Two studies (Brandt et al 1997 [RCT +]; Hennrikus et al 2005 [RCT +]) included 
behavioural support only and this showed no effect on abstinence (OR=1.24; 95%CI: 
0.87-1.76). 
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Figure 13 - Intensity 1 – behavioural support plus medications 
 
 
One study (Hennrikus, et al 2005 [RCT +]) included medications. The study allowed 
a choice of NRT, bupropion or varenicline. At this level of support, such interventions 
were not effective (OR=2.00; 95%CI: 0.30-13.26).  
 
Intensity 1 interventions are ineffective with or without medications.   
 
Figure 14 - Intensity 2 – behavioural support only 
 
 
Three studies (Hajek et al 2002 [RCT ++]; Pederson et al 1991 [RCT +]; Pelletier et 
al 1998 [RCT -]) included behavioural support only and pooled data show that this 
was not effective (OR=1.07; 95%CI: 0.79-1.45). 
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Figure 15 - Intensity 2 – behavioural support plus medications 
 
 
Three studies (Chouinard et al 2005 [RCT ++]; Molyneux et al 2003 [RCT ++]; Nagle 
et al 2005 [RCT +]) included NRT. At this level of support, such interventions were 
not effective (OR=1.01; 95%CI: 0.71-1.42).  
 
Intensity 2 interventions are ineffective with or without medications.   
 
Figure 16 - Intensity 3 – behavioural support only 
 
 
Seven studies (Kim et al 2005 [RCT +]; Miller et al 1997 [RCT +]; Ortigosa et al 
2000 [RCT +]; Rigotti et al 1997 [RCT +]; Schiebel et al 2007 [RCT -]; Stevens et al 
1993 [RCT -]; Stevens et al 2000 [RCT -]) included behavioural support only and 
pooled data show that this was not effective (OR=1.17; 95%CI: 0.98-1.40). 
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Figure 17 - Intensity 3 – behavioural support plus medications 
 
 
Three studies (Neuner et al 2009 [RCT -]; Rigotti et al 1997 [RCT +]; Wiggers et al 
2006 [RCT +]) used NRT. At this level of support, such interventions were not 
effective (OR=1.19; 95%CI: 0.91-1.55). Intensity 3 interventions are ineffective with 
or without medications.  The results are homogenous. 
 
Figure 18 - Intensity 4 – behavioural support only  
 
 
Eighteen studies (British Thoracic Society B 1990 [RCT ++]; Dornelas et al 2000 
[RCT +]; Feeney et al 2001 [RCT ++]; Froelicher et al 2004 [RCT +]; Hasuo et al 
2004 [RCT +]; Haug et al 2011 [RCT -]; Hennrikus et al 2005 [RCT +]; Horn et al 
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2008 [RCT -]; Li et al 2008 [RCT -]; Metz et al 2007 [RCT -]; Miller et al 1997 [RCT 
+]; Mosca et al 2010 [RCT +]; Rosal et al 1992 [RCT ++]; Sivarajan et al 2004 [RCT 
-]; Smith et al 2009 [RCT -; Smith et al 2011 [RCT +]; Taylor et al 1996 [RCT +]; 
Wakefield et al 2004 [RCT ++])) included behavioural support only and pooled data 
show this level of support was effective (OR=1.51; 95%CI: 1.35-1.69). 
 
The results of the pooled behaviour support only studies were heterogeneous. 
Removing the outlier (Feeny et al. 2001) reduces heterogeneity (0.10) and remained 
significant (OR=1.43, 1.26-1.61). 
 
Figure 19 - Intensity 4 – behavioural support plus medications  
 
 
Eight studies (Chouinard et al 2005b [RCT ++]; De Busk et al 1994 [RCT ++]; 
Lacasse et al 2008 [RCT -]; Quist-Paulsen et al 2003 [RCT +]; Reid et al 2003 [RCT 
+]; Reid et al 2007 [RCT -]; Simon et al 2003 [RCT +]; Taylor et al 1990 [RCT +]) 
included medications. All studies used NRT, but Chouinard et al 2005 included 
bupropion as well. At this level of support, such interventions were effective 
(OR=1.66; 95%CI: 1.33-2.08).  
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Intensity 4 interventions are effective without medications and their efficacy further 
increases when medications are added.   
 
Figure 20 - Intensity 5 – behavioural support only 
 
 
Three studies (Bolman et al 2002 [RCT +]; British Thoracic Society A 1990 [RCT 
++]; Carlsson et al 1997 [RCT -]) included behavioural support only and pooled data 
showed borderline efficacy (OR=1.28; 95%CI: 1.01-1.63).  
 
Figure 21 - Intensity 5 – behavioural support plus medications  
 
 
Eight studies (Borglykke et al 2008 [RCT +]; Hennrikus et al 2010 [RCT +]; 
Hilleman et al 2004 [RCT ++]; Lewis et al 2009 [RCT +]; Mohiuddin et al 2007 
[RCT ++]; Pedersen et al 2005 [RCT -]; Tonnesen et al 2006 [RCT ++]; Vial et al 
2002 [RCT -]) included medications. At this level of support, such interventions were 
effective (OR=2.26; 95%CI: 1.71-2.98). All studies used NRT, Mohiuddin et al 2007 
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[RCT ++] included bupropion as well and Hennrikus et al 2010 [RCT +] provided a 
choice of NRT, bupropion or varenicline. 
 
Intensity 5 interventions without medications showed borderline effects, but with 
medications included, such interventions have good efficacy.    
 
We next re-ran intensity 4 & 5 analyses including only studies which validated self-
reported abstinence.  
 
Figure 22 - Intensity 4 – behavioural support only – validated 
 
 
The results of the pooled validated behaviour support only studies were 
heterogeneous. Removing the outlier (Feeny et al. 2001 [RCT ++]) reduces 
heterogeneity (p=0.28) with the result remaining significant (OR=1.35, 1.15-1.57). 
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Figure 23 - Intensity 4 –behavioural support plus medications – validated 
 
 
Figure 24 - Intensity 5 – behavioural support only – validated 
 
 
Figure 25 - Intensity 5 – behavioural support plus medications – validated 
 
 
The results of the pooled validated behaviour support plus medications studies were 
heterogeneous. Removing the outlier (Tonnesen et al. 2006 [RCT ++]) reduces 
heterogeneity (p=0.13) with the result remaining significant (OR=4.39, 2.81-6.84). 
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The analyses including validated studies only show good efficacy of intensive 
interventions accompanied by medications, especially when support is provided face-
to-face.  
 
Low intensity interventions were ineffective with or without medications. 
Interventions of Intensity 4 and 5 showed uncertain or modest efficacy without 
medications and good efficacy when medications were included. The analysis of 
studies, which validated self-reported abstinence, replicated these findings. 
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2) Patient groups  
There is little reason to expect that stop-smoking interventions targeting dependent 
smokers motivated to quit will differ in efficacy depending on smokers’ physical 
illness. However, we analysed separately the interventions for the main groups of 
hospital patients. 
 
Patients with cardiovascular disease 
 
Intensity 1:  There were no such studies 
 
Figure 26 – Patients with cardiovascular disease - Intensity 2 
 
 
Pooled results from 3 studies (Chouinard et al 2005 [RCT ++]; Hajek et al 2002 [RCT 
++]; Pelletier et al 1998 [RCT -]) showed no effect of this intensity (OR=1.11; 
95%CI: 0.82-1.51). 
 
Figure 27 – Patients with cardiovascular disease - Intensity 3
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Pooled results from 4 studies (Miller et al 1997 [RCT +]; Ortigosa et al 2000 [RCT 
+]; Rigotti et al 1997 [RCT +]; Wiggers et al 2006 [RCT +]) showed no effect of this 
intensity (OR=1.12; 95%CI: 0.83-1.52). 
 
Figure 28 – Patients with cardiovascular disease - Intensity 4  
 
 
Pooled results from 16 studies (Chouinard et al 2005 [RCT ++]; De Busk et al 1994 
[RCT ++]; Dornelas et al 2000 [RCT +]; Feeney et al 2001 [RCT ++]; Froelicher et al 
2004 [RCT +]; Lacasse et al 2007 [RCT -]; Li et al 2008 [RCT -]; Miller et al 1997 
[RCT +]; Mosca et al 2010 [RCT +]; Quist-Paulsen et al 2003 [RCT +]; Reid et al 
2003 [RCT +]; Reid et al 2007 [RCT -]; Rosal et al 1992 [RCT ++]; Sivarajan et al 
2004 [RCT -]; Smith et al 2011 [RCT +]; Taylor et al 1990 [RCT +]) showed that this 
level of intensity is effective in patients with CVD (OR=1.54; 95%CI: 1.34-1.79).  
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Figure 29 – Patients with cardiovascular disease - Intensity 5 
 
 
Pooled results from 6 studies (Bolman et al 2002 [RCT -]; Carlsson et al 1997 [RCT -
]; Hennrikus et al 2010 [RCT +]; Hilleman et al 2004 [RCT ++]; Mohiuddin et al 
2007 [RCT ++]; Pedersen et al 2005 [RCT -]) showed that this level of intensity is 
effective in patients with CVD (OR=1.81; 95%CI: 1.42-2.32). 
 
The results are the same as for all patient groups together, showing lack of efficacy 
for low intensity interventions, and significant effects of interventions providing 
support over periods longer than four weeks.   
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Patients with respiratory disease 
 
Figure 30 – Patients with respiratory disease - Intensity 1 
 
 
There was only one study offering this intensity of treatment (Brandt et al 1997 [RCT 
+]) that showed no significant effect (OR=2.83; 95%CI: 0.77-10.47). 
 
Figure 31 – Patients with respiratory disease - Intensity 2 
 
 
Similarly one study offering this intensity of treatment (Pederson et al 1991 [RCT +]) 
showed no significant effect (OR=1.22; 95%CI: 0.55-2.70). 
 
Intensity 3: No studies were available 
 
Figure 32 – Patients with respiratory disease - Intensity 4 
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Pooled results from 1 study (British Thoracic Society B 1990 [RCT ++]) showed no 
effect of this intensity in patients with respiratory illness (OR=1.78; 95%CI: 1.16-
2.74). 
 
Figure 33 – Patients with respiratory disease - Intensity 5 
 
 
Pooled results from 3 studies (Borglykke et al 2008 [RCT +]; British Thoracic Society 
A 1990 [RCT ++]; Tonnesen et al 2006 [RCT ++]; showed that this level of intensity 
is effective in patients with respiratory illness (OR=1.50; 95%CI: 1.11-2.02).  
 
The results are similar to those from other patient groups, showing lack of efficacy for 
low intensity interventions, and better effects of more intensive interventions, 
although in this group of studies, only interventions with extended face-to-face 
support achieved a significant effect.   
 
 
 
Patients with cancer 
There was only one study focusing on cancer patients. This was Intensity 4 with no 
medications and showed no intervention effect (Wakefield et al 2004, [RCT ++]).   
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Unselected/other hospital patients 
 
Figure 34 – Patients with cancer - Intensity 1 
 
 
Pooled results from 2 studies (Hennrikus, et al 2005 [RCT +]; Papadakis et al 2011 
[RCT +]) showed no effect (OR=1.18; 95%CI: 0.83-1.70). 
 
Figure 35 – Patients with cancer - Intensity 2 
 
 
Results from two studies (Molyneux et al 2003 [RCT ++]; Nagle et al 2005 [RCT +]) 
showed no effect (OR=0.90; 95%CI: 0.62-1.30). 
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Figure 36 – Patients with cancer - Intensity 3 
 
 
Pooled results from 7 studies (Kim et al 2005 [RCT +]; Miller et al 1997 [RCT +]; 
Neuner et al 2009 [RCT -]; Rigotti et al 1997 [RCT +]; Schiebel et al 2007 [RCT -]; 
Stevens et al 1993 [RCT -]; Stevens et al 2000 [RCT -]) showed a modest 
improvement in abstinence rates (OR=1.19; 95%CI: 1.02-1.40).   
 
Figure 37 – Patients with cancer - Intensity 4 
 
 
Pooled results from 10 studies (Feeney et al 2001 [RCT ++]; Hasuo et al 2004 [RCT 
+]; Haug et al 2011 [RCT -]; Hennrikus et al 2005 [RCT +]; Horn et al 2008 [RCT -]; 
Metz et al 2007 [RCT -]; Miller et al 1997 [RCT +]; Simon et al 2003 [RCT +]; Smith 
et al 2011 [RCT +]; Taylor et al 1996 [RCT +]) showed a positive effect (OR=1.60; 
95%CI: 1.38-1.84).   
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Figure 38 – Patients with cancer - Intensity 5 
 
 
Pooled results from 2 studies (Lewis et al 2009 [RCT +]; Vial et al 2002 [RCT-]) 
failed to show a significant effect (OR=1.43; 95%CI: 0.85-2.42).  
 
The results show lack of efficacy for low intensity interventions and significant 
effects of Intensity 4 interventions, though the results of the two Intensity 5 
interventions did not reach significance (Lewis et al 2009 [RCT +]; Vial et al 2002 
[RCT -]).  
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3) Patients receiving intervention after hospital discharge 
Three trials evaluated interventions delivered after hospital discharge (i.e. patients did 
not receive any intervention whilst in hospital). We are including them because they 
target hospital patients and hospitals could in theory refer patients to such 
programmes. One trial (Carruthers et al 2005 [RCT +]) included NRT.  
 
Figure 39 – Intervention received after hospital discharge - Intensity 1  
 
 
Figure 40 – Intervention received after hospital discharge - Intensity 4  
 
 
Only one study evaluating the efficacy of extended support accompanied by NRT 
showed a significant effect (Carruthers et al 2005 [RCT +]). 
 
Conclusions 
The overall picture emerges showing that brief interventions with users of acute care 
are not effective, even if they include medications. Regarding interventions providing 
support for over 4 weeks, interventions with face-to-face support seem to achieve 
better results than interventions relying on phone calls, but without the addition of 
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medications, any effects are modest. The inclusion of medications strongly enhances 
efficacy of these treatments. 
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4) Efficacy of interventions delivered to surgery patients 
Six trials evaluated interventions initiated prior to surgery. With one exception 
(Croghan et al 2005 [RCT +]), all trials included NRT.  
 
Intensity 1: There were no such trials 
 
Figure 41 – Interventions delivered to surgery patients - Intensity 2 
 
 
Two trials (Croghan et al 2005 [RCT +]; Martucci et al 2010 [RCT +]) found mixed 
effects but the pooled result reached statistical significance (OR=1.97; 95% CI:1.04-
3.75). 
 
Figure 42 – Interventions delivered to surgery patients - Intensity 3 
 
 
One study (Thomsen et al 2010a [RCT +]) showed no effect (OR=1.42; 95% CI: 
0.43-4.74). 
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Figure 43 – Interventions delivered to surgery patients - Intensity 4 
 
 
Two studies (Ratner et al 2004 [RCT +]; Simon et al. 1997 [RCT +]) showed no 
effect (OR=1.37; 95% CI:0.83-2.27). 
 
Figure 44 – Interventions delivered to surgery patients - Intensity 5 
 
 
Two studies (Lindstrom et al 2008 [RCT ++]; Moller et al 2002 [RCT ++]) showed a 
significant effect (OR=3.99; 95%CI: 1.83-8.70). 
 
Of the two studies examining level 2 intensity interventions, one was positive 
(Croghan et al 2005 [RCT +]) and one was negative (Martucci et al 2010 [RCT +]). 
As the larger study was positive, the pooled results reach statistical significance. Both 
studies of Intensity 5 interventions provided face-to-face contact and NRT. Both 
showed good efficacy. 
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One trial [Rodriquez et al 2007 [RCT -]) evaluated effects of one session of stop-
smoking messages delivered under deep sedation.  
 
Figure 45 – Intervention delivered under deep sedation 
 
 
The intervention had no effect. 
 
Conclusions 
 
Brief interventions initiated prior to surgery lack efficacy even if accompanied by 
NRT. Face-to-face support lasting for over 4 weeks accompanied by NRT is effective. 
Stop-smoking messages delivered under sedation are not effective. 
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5) Efficacy of pharmacological interventions with hospital patients  
In this section, we cover trials which evaluated medications by comparing study arms 
with the same intensity of behavioural support which only differed in whether they 
received active medications or not.  
 
Six trials compared NRT treatment accompanied by behavioural support with the 
same support delivered with placebo or with no medication. The intensity of 
behavioural support was 4 or 5 in all trials.  
 
Figure 46 – NRT intervention - Intensity 4 or 5 
 
 
Six trials (Campbell et al 1991 [RCT ++]; Campbell et al 1996 [RCT ++]; Hand et al 
2002 [RCT ++]; Lewis et al 1998 [RCT +]; Tonnesen et al 2000 [RCT ++]; Tonnesen 
et al 2006 [RCT ++]) compared NRT accompanied by behavioural support (intensity 
4 or 5 in all studies) with the same support delivered with placebo or with no 
medication. NRT was effective (OR=1.52; 95%CI: 1.07-2.17). 
 
In this group of studies, NRT was effective. 
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Figure 47 – NRT and inhalator - Intensity 4  
 
 
One trial (Tonnesen et al 2000 [RCT ++]) compared patch and inhaler alone with the 
two medications combined. The results showed that single NRTs were as effective as 
their combination (OR=0.50; 95% CI: 0.16-1.53).  
 
Figure 48 – Bupropion - Intensity 4  
 
 
Two trials (Rigotti et al 2006 [RCT ++]; Simon et al 2009 [RCT +]) compared 
bupropion and placebo. Both trials relied on telephone calls and neither offered any 
post-quit face-to-face support. The trials did not show the intervention to be effective 
(OR=1.17; 95%CI:0.67-2.07). 
 
Figure 49 – Varenicline - Intensity 5  
 
 285 
One small placebo controlled trial (Steinberg et al 2011 [RCT +]) evaluated 
varenicline accompanied by brief counselling session/sessions (it is not clear if there 
was one or more, but it was attended by 16 participants only). The trial did not find 
the treatment effective (OR=0.64; 95%CI: 0.22-1.80).  
 
Conclusions 
NRT accompanied by behavioural support extended over four weeks is effective. A 
combination of patches and inhaler was not more effective than each medication on 
its own. Bupropion and varenicline provided without on-going face-to-face support 
lack efficacy.  
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6) Efficacy of intervention with patients’ relatives 
Three trials evaluated interventions with parents of children hospitalised on paediatric 
wards. Two used one-off advice with a phone reminder (Chan et al 2005 [RCT -]) or 
fax referral to Quitline (Mahabee-Gittens et al 2008 [RCT -]) and one used >30 
minutes of counselling and access to NRT for some participants (Ralston et al 2008 
[RCT -], Intensity 2). This group of studies had shorter follow-ups (Chan 2005 - one 
month, Mahabee-Gittens 2008 - 3 months, Ralston 2008 - 6 months).  
 
Figure 50 – Interventions with patients relatives - Intensity 1 or 2  
 
 
The interventions overall lacked efficacy despite a short follow-up. This is relevant 
because intervention effects often dissipate over time. 
 
Conclusions 
Brief interventions (Intensity 1 and 2) with parents of hospitalised children lack 
efficacy. 
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7) Efficacy of intervention with hospital staff  
We found only one study evaluating an intervention with hospital employees. It was a 
high-quality placebo controlled trial of bupropion with Intensity 5 support. 
 
Figure 51 – Interventions with hospital staff - Intensity 5 
 
 
The trial showed bupropion with regular face-to-face support to be an effective 
treatment for hospital employees.  
 
Conclusions 
Bupropion accompanied by intensive support is an effective treatment for hospital 
employees.  
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Systematic reviews 
We found two relevant Cochrane reviews. We discussed the Rigotti (2007 [systematic 
review, ++]) review earlier. Our conclusions in the areas covered by Rigotti (2007) 
are similar. The same applies to the review by Thomsen (2010b [systematic review, 
++]) concerning surgery patients. 
 
We identified 11 other reviews, listed below. We rated their quality as ++ for 
systematic reviews showing awareness of key methodological features of stop-
smoking studies, + for reviews which were less systematic and/or did not take into 
account the key quality aspects of included studies, and – for reviews which were 
selective and/or posed methodological problems. All relevant and eligible studies 
included in these reviews are also included in our review. 
 
Table 3 – Summary of systematic reviews 
Author Aim No of 
studies 
Findings Quality 
Aziz et al. 
2009 
Effectiveness of 
smoking cessation 
intervention in 
hospitalised patients 
with cardiovascular 
disease 
11 Significantly higher 
abstinence rates in patients 
receiving intervention in 
hospital continued post 
discharge for at least 3 
months alongside NRT 
compared to usual care 
+ 
Barth et 
al. 2008 
Effectiveness of 
behavioural 
interventions, 
telephone support 
and self-help 
16 Positive effects of 
interventions on abstinence 
after 6 to 12 months 
+ 
 289 
interventions in 
people with coronary 
heart disease (CHD) 
Mistiaen 
et al. 2006 
Effectiveness of 
follow –up telephone 
calls in the first 
month after discharge 
(not smoking 
specific) 
33 Inconclusive evidence 
about the effectiveness of 
telephone FU 
++ 
Munafo et 
al. 2001 
Effectiveness of 
interventions for 
hospitalised patients 
15 High intensity behavioral 
support of at least 1 month of 
follow up contact is effective 
++ 
Nayan et 
al. 2011 
Smoking cessation 
interventions and 
rates of smoking in 
cancer patients 
8 No significant difference 
between interventions and 
usual care 
++ 
Rice et al. 
2008 
Effectiveness of 
nurse-delivered 
smoking cessation 
intervention 
42 Slightly increased rate of 
quitting 
++ 
Rice et al. 
2009 
Effectiveness of 
nurse-delivered 
smoking cessation 
intervention – 
updated from Rice 
2008 
34 Interventions of high and low 
intensity provided by a nurse 
generated an increased rate of 
quitting 
++ 
Rigotti et 
al. 2008 
Effectiveness of 
hospital interventions 
initiated during 
hospital stay 
 
 
 
33 Counselling initiated during 
hospitalization with follow up 
of at least 1 month increased 
long term smoking cessation 
++ 
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Van der 
Meer 
2001 
Effectiveness of 
smoking cessation 
interventions in 
people with COPD 
5 Interventions including 
medications were effective 
++ 
Wagena 
2004 
 
Effectiveness of 
behavioural 
interventions for 
people with COPD 
 
 
5 Intensive behavioral support 
+ NRT increased abstinence 
rates. Bupropion did not 
increase abstinence rates. 
++ 
Wiggers 
2003 
Effectiveness of 
smoking cessation 
interventions in 
cardiovascular 
patients 
12 No evidence of effectiveness 
for pharmacotherapy, self 
help materials, group, 
individual or telephone 
counselling. Limited 
evidence for doctor or nurse 
delivered advice 
+ 
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Discussion 
A large number of studies have been included in this review, which evaluated a range 
of stop-smoking interventions trying to use the window of opportunity that a hospital 
admission provides. It is worth noting at this stage, that there are some problems in 
generalising the results of the majority of these studies to the UK setting.  
 
The NHS is now far ahead in terms of the care available for smokers compared to 
most other countries, in that stop smoking medications are provided free of charge 
and there is also free access to the NHS-SSS who provide specialist multi session 
face-to-face counselling (Croghan 2011). Most of the existing trials were conducted in 
environments and with methods, which were much less favourable to successful 
smoking cessation than the current UK routine practice. Nevertheless, the existing 
literature is extensive and it does provide some useful pointers, which can contribute 
to guidelines on how best to support such smokers. We now discuss our findings in 
the context of the intensity of the intervention, patient groups, pharmacotherapy, 
patient relatives, and hospital staff. 
 
Intervention intensity 
We defined the intensity of an intervention based on the description provided in the 
Rigotti (2007) hospital review. We further expanded their single definition of follow 
up, to include 2 levels of intervention intensity that looked at the impact of face-to-
face and no face-to-face contact post discharge. We initially considered whether using 
a definition based on the intensity levels described in Rigotti’s (2007) paper was 
adequate for the purpose of looking at this extensive body of literature. Using 
intensity based on length of contact is a useful and practical way of analysing this 
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data, particularly when the focus of nationwide recommendations is often cost 
effectiveness of the services being implemented. Being able to show that an 
intervention is successful in the long term by providing a post discharge follow-up 
service via telephone calls weekly would be more cost effective, for example, than 
using HCPs in the community to schedule appointments and see patients in practice.  
 
However, there are things worth considering that are not covered by this definition. 
One of the main criticisms of our current definition is that we use the term ‘brief 
advice’ to describe a contact but this is not fully defined. What do we mean by ‘brief 
advice’? In one study this could be simply identifying a smoker and asking if they 
would like to quit whereas in another study this could be smoking status checked, 
asked if they want to quit, medication dispensed and advice given, and include more 
tailored individual support and advice. Within this body of research there are many 
different methods used to provide smoking cessation advice; interactive voice follow 
up systems (e.g. Reid 2007); self- help booklets (e.g. Molyneux et al. 2003); cognitive 
Behavioural treatment (CBT) (e.g. Metz et al. 2007); motivational treatment (MT) 
(e.g. Metz et al. 2007); audio workbooks (e.g. Horn et al. 2008). There would be clear 
justification for using methodology and different behaviour change techniques as a 
definition to look at the effectiveness of smoking cessation interventions across the 
studies rather than our current definition of frequency and duration of support.  
 
However, as the focus of this review was to look at recommendations for the 
provision of smoking cessation services in UK services, where the delivery of support 
is defined by NICE guidelines (NICE 2008), the use of looking at the intensity of the 
service provision rather than the content was deemed as the best definition for the 
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purpose of looking at results across this large body of global research. To consider the 
evidence in terms of the content of the service provided (e.g. CBT, MT) would also be 
of interest for future research in this area. 
 
The results of the systematic review by definition of the intensity of the smoking 
cessation intervention are presented in the following passages. 
 
Intensity 1 – 3 
Advice by doctors and nurses during hospitalisation, possibly repeated and reinforced 
during the hospital stay and accompanied by leaflets, is by far the simplest and least 
expensive option, which could be provided routinely on a large scale. Unfortunately, 
we found no evidence that such interventions work. Dealing with a population of 
hospital smokers who may have received strong encouragement to stop smoking on a 
number of previous occasions but continue to smoke despite high motivation to stop 
as a result of illness suggests a high level of dependence and a need for more intensive 
treatment. The provision of a single contact from a HCP in hospital (with or without 
take-home materials) is not effective with this population. 
 
Intensity 4 
The next level of intervention, which still requires modest resources, is to reinforce 
the in-hospital intervention by telephone calls over the first few weeks after discharge. 
This too was not shown to be effective. 
 
Intensity 5 
The next level of intervention, which requires more extensive resources, is to 
reinforce in-hospital intervention with face-to-face contact post discharge. This 
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approach was also found to be effective and is in-line with the findings by Rigotti 
(2007), who concluded that for interventions with hospital patients to be effective, an 
extended support and stop smoking medication should provided for at least 4 weeks.  
 
The results compared studies that gave at least one post discharge face-to-face follow 
up visit (Intensity 5) was similar to the effect of support provided over telephone with 
no face-to-face contact (Intensity 4) in non-surgical patients. It appears that it in this 
case it is the duration of the follow-ups that is important rather than the mode in 
which it is delivered. However, one thing that was not assessed was who provided the 
follow up sessions. We were unable to assess systematically assess any effects of the 
background of the person providing the advice in hospital and after discharge. This 
was due mostly to the limited description provided in the methods section of these 
studies. In practice, the provision of post-discharge support would be more cost 
efficient if provided via telephone. 
 
Our results also found that support alone without medications has only uncertain 
effects but it has good efficacy when provided in combination with smoking cessation 
medications. This finding could be explained simply as the result of use of a 
medication during a quit attempt and would put into question whether the provision of 
behavioural support, above that of providing information on the use of the medication, 
is effective in this situation. The difficulty we have with this large data set, which was 
commented on earlier, is that the content of the behavioural support is not always 
outlined in sufficient detail. This is an important consideration for future reviews, to 
untangle whether there is any difference seen in different behavioural support 
approaches when provision of medication is included.  
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In summary, based on our definition of intensity, for smoking cessation interventions 
with hospital patients to be effective, an extended support and stop smoking 
medication provided for over 4 weeks seem necessary.  
 
Patient groups 
There is no a-priori reason to expect that smokers with different diagnoses would 
react differently to different interventions. However, it could be argued that those 
admitted with generic reasons compared with those admitted for reasons attributed to 
smoking (e.g. coronary heart disease (CHD), chronic obstructive pulmonary disease 
(COPD)), may differ in their dependence and therefore require different levels of 
input in order to successfully quit. In order to look at this more closely we extracted 
the studies that provided data on patients with cardiovascular disease, respiratory 
disease, and general patient samples separately.  
 
Our results broadly confirm the main findings; that the more intensive the follow up 
the more effective the intervention for smoking cessation was longer term.  
 
We further looked at the intensity of interventions in a population of patients 
undergoing surgery. The results showed that only Intensity 5 interventions (extended 
face-to-face support post discharge) accompanied by medications were effective with 
these patients. No effect was seen in this population when solely using telephone 
follow-up only post-discharge. There were only 2 studies for both intensity 4 and 5 
analyses so both results need to be evaluated with some caution. However, it may be 
the case that those undergoing surgery respond better if they are seen face-to-face to 
discuss smoking cessation. This could be for a number of reasons including: they may 
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be visiting the hospital/GP after discharge and may expect the same level of 
interaction for smoking cessation treatment. Additionally, those who have not quit 
pre-operatively, even with the advice of their surgeon, may have a higher level of 
dependence, which requires more intense support. Post-operative patients may need 
more support than general admissions, although this is unlikely but due to the limited 
data available this is an area that needs to be investigated further when more research 
is available. 
 
Pharmacotherapy 
 
Single NRT products 
We next looked at trials, which evaluated medications by comparing study arms with 
the same intensity of behavioural support, which only differed in whether they 
received active or placebo medications. We found that NRT accompanied by 
intensive behavioural support extended over a period of four weeks was effective. 
Provision of NRT without behavioural support was not effective.  
 
Combination NRT products 
One trial looked at the effectiveness of a combination of patches and the inhaler 
compared with each medication on its own (Tonnesen et al 2000 [RCT ++]). There 
was no significant difference found between using a combination or a single product. 
Previous research has shown an advantage of combination treatment over single NRT 
product use (RR 1.35, 95% CI: 1.11-1.63) (Stead et al. 2008). The explanation as to 
why combination use was not superior to single use may be due to the particular 
products used for this study. Oral nicotine products are popular among smokers but 
compared with the nicotine patch, they take a lot of effort from the user to get 
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adequate nicotine delivery and to avoid under dosing (Killen, Fortmann, Newman & 
Varady 1990). As a result many smokers only use the inhalator sporadically when in 
combination with a patch. As there was only one study looking at combination 
therapy use in this setting then more data is required before concluding that 
combination is no more effective than single NRT products in hospital patients. We 
know from previous research that in general population’s combination therapy is 
more successful (Stead et al. 2008). We see no reason why this would not also be the 
case in hospitalised patients. 
 
Bupropion and varenicline 
When looking at bupropion and varenicline, we found that without on-going face-to-
face support that the medications lacked efficacy. This would support the current 
protocol in clinical practice where this medication is only available on prescription 
and usually only provided in combination with support from GPs or the NHS-SSS. 
Previous research into NRT has shown it to be ineffective without support (Stead et 
al. 2008). It is likely that this is also the case with both bupropion and varenicline. 
 
To summarise, NRT accompanied by extended multi-session support lasting over 4 
weeks is effective in the acute services setting. A few small trials evaluated bupropion 
and varenicline accompanied by minimal support and did not find such treatments 
effective. NRT is known to be ineffective without support and follow-up and this is 
probably true for other stop-smoking medications as well. 
 
Patient relatives  
Only 3 trials were available to evaluate the effect of smoking cessation interventions 
with parents of hospitalised children on paediatric wards. We found that brief 
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interventions with parents of hospitalised children did not show efficacy. 
Approaching parents at a time when they are likely distracted and distressed at their 
child being hospitalised does not appear to be the optimal time to provide them with 
smoking cessation support. This does not mean it is not a time to discuss it with 
parents but it may be more effective if the offer of treatment is provided at discharge 
rather than during the child’s hospital stay.  
 
Hospital staff  
Only one study was found that evaluated an intervention with hospital employees. 
The results found that using bupropion alongside regular face-to-face support was an 
effective treatment for hospital staff. This study is extremely important, as one issue 
that is debated frequently is the rights of hospital staff who smoke and how they do 
that when they work at a smoke-free hospital. Provision of treatment has been 
proposed whether for temporary abstinence during work hours or for cessation, like 
the above example. Setting up pathways for smoking staff is an important issue that 
needs to be addressed, evidence that medication and support with this population can 
work would offer some assurance to employers that this would be a worthwhile 
initiative to implement. 
 
Grey literature 
Unfortunately due to the large number of papers found in this review it was not 
possible to cover the grey literature in this expansive field of research. However, this 
would be an important thing to do next as the current review only focused on RCTs. 
Further exploration of the grey literature would lead to more understanding on the 
content needed for the provision of behavioural support, the importance of the 
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background of the provider and highlight some of the more practical barriers and 
facilitators for implementing smoking cessation interventions in the populations of 
interest 
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Next steps 
Current practice 
The NHS practice currently involves interventions at bedside accompanied by 
medications and/or referrals to the NHS-SSS for treatment after discharge, which 
combines extended face-to-face support with smoking cessation medications. The 
reviewed evidence confirms that this is likely to be the optimal approach. The high 
cost of such approach is mitigated by the fact that the NHS provides centrally funded 
stop-smoking services, which are proactively recruiting smokers and have ample 
capacity to accept such referrals and to treat them without further costs and without 
any delays.    
 
The UK is now well ahead of the existing research in this area, compared to most 
countries where front line staff cannot refer smokers to specialists and so are trained 
to provide treatment themselves. Referral for smoking cessation treatment post-
discharge is essential. This review demonstrates that hospital based smoking cessation 
interventions of any kind are ineffective unless they include multi-session follow-up 
of 4 weeks or more post-discharge. Routine front line staff cannot take on the role of 
specialist advisors and organise extended support over a number of consultations set 
up just for this purpose. Even if they did, and such activities were given priority over 
their primary purpose, training tens of thousands of doctors and nurses in specialist 
interventions and supervising and monitoring them would be impractical.  
 
Since the establishment of the NHS-SSS, the task of front line staff in the UK is to 
motivate smokers to quit and refer them on, rather than to take on the role of stop-
smoking advisors. Training in the UK for HCPs or implementing automated prompts 
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can thus focus exclusively on motivating and referring smokers. There is evidence 
that a brief training (40 minutes) is effective in increasing referrals from UK GPs 
(McRobbie et al. 2008).  There is no reason to expect that the same approach would 
not work in secondary care.  
 
Apart from organisational, financial, and time constraints, we are aware of two other 
barriers to a routine implementation of training within acute care, which are not 
captured in the current literature. The notes below are only anecdotal, but they may be 
informative.  
 
As a legacy from past initiatives, many PCTs continue to try to train front line staff in 
smoking cessation interventions they are asked to provide themselves. Some others 
try to focus on the core tasks of motivating smokers and referring them on, but cannot 
resist including a host of marginal topics and making the training events unnecessarily 
long and demanding (e.g. half-day long). This makes such events expensive and 
poorly attended, without improving the chance that they will increase referrals more 
than a simple straightforward instruction. We estimate that less than 40 minutes of 
training should be sufficient as per the findings from McRobbie et al. (2008), 
especially if the hospital organisation is willing to include this as a part of compulsory 
induction of all new staff, and monitor the rates of referrals for smoking cessation 
treatment and provide feedback to staff who under-perform.  
 
Another barrier to implementing such a brief and practicable approach is that there 
exists no clear template for what such training should involve. Perhaps the UK Centre 
for Tobacco Control Studies (UKCTCS), which includes specialists with direct 
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experience of smoking cessation interventions in acute care can be commissioned to 
develop a simple and straightforward training content which would be easy to 
disseminate. One possible hurdle to such a plan is the lack of consistency in the way 
different SSS operate.  
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Conclusion 
The NHS practice for hospitalised smokers currently involves interventions at bedside 
accompanied by medications and/or referrals to specialist stop-smoking services for 
treatment after discharge, which combines extended face-to-face support with 
smoking cessation medications. The reviewed evidence confirms that this is likely to 
be the optimal approach. 
 
There seems to be a number of barriers to providing help to smokers in secondary 
care.  For instance there is a widespread concern that stopping smoking shortly before 
surgery may have negative effects on surgery outcomes, hospital electronic records 
are often inflexible and make recording of patient smoking status difficult and staff do 
not see addressing smoking as a part of their core duties. There is a need to 
systematically review not just the efficacy of stop smoking interventions, which are 
usually evaluated in a somewhat rarefied research setting but also the barriers and 
facilitators of stop smoking activities in acute and maternity settings.  There is a scope 
to systematically increase referrals and access to smoking cessation services in acute 
hospital settings, which such a review could facilitate. The authors of this review are 
currently undertaking such a review to look at the facilitators and barriers to 
implementing stop smoking interventions in acute and maternity settings. This review 
will be part of the guidance published along with this review in 2013 by NICE. 
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Table 4 – Glossary for part 4 
Abstinence Throughout this review we refer to abstinence from smoking as 
abstinence. Rates of abstinence are also presented. See point prevalence 
abstinence, continuous abstinence, sustained abstinence and CO-
validated abstinence. 
Biochemically 
validated 
Self-reported abstinence rates are often validated, or confirmed, by 
biochemical tests. These tests include measurement of CO in expired 
breath and cotinine in saliva, blood, and urine. 
Bupropion Bupropion or Zyban ™ is an atypical antidepressant that is also 
effective in helping people to stop smoking. In the UK it is only 
licensed as a smoking cessation aid 
CO-validated 
abstinence 
Measurement of carbon monoxide in expired breath is commonly used 
to validate self-reported abstinence. A cut-off of 10 ppm is routinely 
used, so if someone reports they have not smoked and have a CO 
reading of less than 10ppm then they would be considered to be a CO-
validated abstainer. 
Continuous 
abstinence 
This measures continuous abstinence from smoking, either not a single 
puff or a small number of slips allowed (e.g. less than 5 cigarettes in 
total), from a pre-determined time point (e.g. Quit Date) to all follow-
up points. Continuous abstinence rates are typically lower than point 
prevalence abstinence rates, but more likely to give a more accurate 
assessment of the effect of an intervention. 
Nicotine 
replacement 
therapy 
Nicotine replacement therapy is a licensed medicinal product to aid 
smoking cessation, smoking reduction and temporary abstinence. There 
are seven different formats: patch, gum, lozenge, sublingual tablet, 
nasal spray, mouth spray and inhalator. 
Point 
prevalence 
abstinence 
This measures abstinence from smoking at a particular time. 7-day 
point prevalence (i.e. not smoking at all over the past 7 days) is a 
commonly used measure. 
Varenicline Varenicline or Champix ™ is a nicotine analogue that was developed 
specifically to help people stop smoking. It acts primarily to reduce the 
severity of tobacco withdrawal symptoms thus making quitting easier. 
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PART 3 – PROFESSIONAL PRACTICE 
In part 3 of the portfolio, 2 case studies are presented; which reflect on my 
professional practice whilst on the Doctorate in Health Psychology (post-chartered 
“Top-up”) degree. 
 
Summary of Part 3 
Case study 1 (2 sections) 
The first case study follows the theme of treatments for smoking cessation and 
provides a clinician and patient perspective on current practices. 
 
There are two sections to the first case study. Section 1 of the professional practice 
chapter highlights the clinician view of current practices in combining smoking 
cessation medications; the section reviews the experience of clinician use of 
combination nicotine replacement therapy (NRT), which is a licensed and evidence-
based medication option. The clinician views were taken after a lecture I presented at 
the “Stop Smoking Live” conference in London in December 2010. The case study 
highlights the extent to which combination NRT is recommended in current practice, 
barriers to use for the clinician and client and provides a reflection on my own 
experience of presenting at an educational symposium. 
 
For the second patient perspective case study for this chapter (section 2), clients 
attending the Tobacco Dependence Research Unit (TDRU) smokers’ clinic in East 
London, who were using a combination of varenicline and NRT during their quit 
attempt, were approached and asked if they were willing to discuss why they had 
chosen these mediations and what benefit (if any) it gave them. The National Institute 
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for Health and Clinical Excellence (NICE 2008) guidelines currently do not advocate 
the combination of varenicline and NRT as there is a lack of evidence on its efficacy. 
Anecdotally, however, we are aware that clients will take it upon themselves to use 
the medications in combination and report that this is useful in helping them to stop. 
This piece of work gives some background into how clients attending an NHS-SSS 
clinic find the experience of using a combination treatment of varenicline and NRT. 
 
Case study 2 
The second case study is a reflection on my current clinical practice, giving some 
insight into my day-to-day role at the TDRU. I reflect on some of the key issues when 
conducting research and some of the things I have learnt over the last few years 
during my involvement in research. An example of a trial I have been involved in is 
also discussed. 
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Chapter 1 - Case study 1 – using combination treatment in 
practice 
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Section 1 - Health Professional views on combination NRT  
Introduction 
It is standard practice in the UK to offer pharmaceutical treatments to help smokers 
who are trying to quit. Use of stop smoking medications is offered at the initiation of 
a quit attempt in order to help alleviate withdrawal symptoms that are experienced 
post cessation. In the UK patients have access to NRT, bupropion (Zyban) and 
varenicline (Champix) (NICE 2008). All are proven methods for increasing successful 
quitting (Cahill, Stead & Lancaster 2012, Hughes, Stead & Lancaster 2007, Stead, 
Perera, Bullen, Mant & Lancaster 2008).  
 
There are extensive data showing the efficacy of NRT (Stead et al. 2008). The use of 
NRT products during a quit attempt approximately double the chances of long-term 
abstinence compared with placebo (Stead et al. 2008). There is evidence to show that 
use of combination NRT (e.g. using a nicotine patch in combination with another 
nicotine product such as the nicotine gum) is more beneficial during a quit attempt 
than using a single product alone (Stead et al. 2008).  
 
The advice to routinely prescribe NRT products in combination is included in the 
NICE (2008) guidelines for treating nicotine dependence. However, despite evidence-
based recommendations for this treatment option there are still clinical issues arising 
within local NHS stop smoking services (NHS-SSS), which limit and often prevent 
clients receiving combination NRT.  
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The following case study is a reflection on a presentation given on combination 
treatment at a London conference to health care professionals (HCPs) involved in 
treating smokers in the UK. The case study discusses some of the issues raised by UK 
HCPs treating smokers. 
 
 “Stop Smoking Live” conference 2010 
In 2010 I was invited by GlaxoSmithKline (GSK) to be the key speaker at an 
educational symposium on the use of combination NRT products at a national 
conference called “Stop Smoking Live”. This was a London-based conference at the 
Islington Business Design Centre, which was held on 10 December 2010. GSK are a 
worldwide leading company who manufacture NRT products.  
 
My supervisor, Dr Hayden McRobbie had suggested that, given my experience in 
working with smokers and my extensive knowledge of NRT, I would be an 
appropriate presenter for this session. The presentation’s focus was on the 
effectiveness, use and practical issues of using combination NRT. As part of my on-
going role as a Health Psychologist working within the NHS-SSS, it was an excellent 
opportunity to discuss current medication options for smokers with other clinicians in 
the field.   
 
The brief given by GSK was to present and discuss the issues around the use of 
combination NRT in NHS-SSS and to increase knowledge around the evidence on 
combination NRT. The intention was to increase confidence among HCPs when using 
combination NRT in clinical practice.  
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In preparation for the presentation I reviewed all the current literature on combination 
treatment and also reflected on my current clinical practice in order to inform the 
sessions content. 
 
Background 
Personal perspective – current clinical practice 
I have worked as a Research Health Psychologist at the TDRU, Queen Mary’s School 
of Medicine and Dentistry (QMUL), University of London for the last 7 years. The 
TDRU delivers smoking cessation support (provided by specialist advisors) alongside 
stop smoking medications, across 2 boroughs in London (City & Hackney and Tower 
Hamlets). The service provides intense withdrawal-oriented therapy (Hajek 1989) 
over seven weeks to patients that indicate they would like to stop smoking. In order to 
successfully help people to stop smoking, the aim of the sessions are to enhance 
motivation to quit, increase self-efficacy, to understand the role of habits, to discuss 
coping skills, cue sensitivity, individual patterns of smoking and to ultimately endorse 
behaviour change. Objective measures of self-reported smoking status are routinely 
measured by carbon monoxide (CO) monitors.  
 
Pharmaceutical treatments are also discussed, NRT and non-nicotine medications 
(bupropion and varenicline) are offered as part of standard treatment. As per current 
NICE guidelines (2008), patients who choose to use NRT are offered the option of 
using more than one NRT product to use in combination during their quit attempt. 
However, since January 2013, due to recent changes to the structure of the Primary 
Care Trusts (PCTs), financial cuts to the service have been implemented. This has 
resulted in combination treatment no longer being offered to patients accessing the 
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TDRU. At the time of the presentation development for the “Stop Smoking Live” 
conference, the TDRU offered combination treatment to every smoker using NRT. 
 
What do we know about combination NRT? 
In a 2008 Cochrane review on the effectiveness of combination NRT (Stead et al. 
2008), six studies were identified that compared combination NRT versus single NRT 
use (see Table 1 for study summaries). Pooling of the six trials comparing 
combination treatment with single NRT showed an advantage of combination use at 6 
month follow up (RR 1.35, 95% CI: 1.11-1.63). Only one of the trials (Blondal, 
Olafsdottir, Gustavsson & Westin 1999), comparing nasal spray and patch with patch 
alone, showed a significantly higher rate of sustained abstinence at one year with 
combined NRT. 
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Table 1 – Summary of studies included in Stead et al (2008) Cochrane review on 
NRT 
Study Products RR 95% CI 
Kornitzer, Boutsen, 
Dramaix, Thijs, & 
Gustavsson 1995 
Patch + gum vs. 
patch 
1.43 0.83-2.46 
Puska, Korhonen, 
Vartiainen, 
Urjanheimo, 
Gustavsson & 
Westin 1995 
Patch + gum vs. 
gum 
1.38 0.88-2.17 
Blondal et al. 1999 Nasal spray + patch 
vs. patch 
2.48 1.37-4.49 
Bohadana, 
Rasmussen & 
Martinet 2000 
Patch + inhalator 
vs. inhalator 
1.39 0.89-2.17 
Tonnesen & 
Mikkelsen 2000 
Patch + inhalator 
vs. either product 
0.51 0.17-1.52 
Croghan, Sloan, 
Croghan, Novotny, 
Hurt & Dekrey 
2003 
Patch + nasal spray 
vs. nasal spray vs 
patch   
1.23 0.85-1.78 
 
Since the release of the Cochrane review two further studies have been published. 
 
Piper, Smith, Schlam, Fiore, Jorenby, Fraser & Baker (2009) conducted a study using 
monotherapy (single product), combination NRT (patch and lozenge) and bupropion 
versus placebo. The results found that all treatments showed a significant effect 
compared to placebo. Only patch and lozenge combination was found to be better 
than monotherapy (OR, 1.35, 95% CI: 1.01-1.79).  
 328 
A 2009 study (Cooney, Cooney, Perry, Carbone, Cohen, Steinberg, Pilkey, Sevarino, 
Onken & Litt 2009) used combination nicotine patch plus either active or placebo 
nicotine gum in alcohol dependent smokers in an outpatient setting. At 1 year follow 
up the patch plus active gum group had higher rates of validated prolonged smoking 
cessation rates compared to the placebo gum group (13% versus 0%). As the results 
of this study cannot easily be generalised due to the specific population of dependent 
drinkers that it included, only the Cochrane review (Stead 2008) and study by Piper et 
al. (2009) were used in the development of the slides for the “Stop Smoking Live” 
presentation (see Appendix 1). 
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Presentation preparation 
 
Conference calls with GSK 
As part of the preparation for the presentation I was contacted by GSK on 2 
occasions. They arranged conference calls several weeks before the stop smoking live 
event in order to discuss the content and development of the presentation and the 
logistics for the day. This was the first time I had been involved in this process before 
a presentation; it was very useful to confirm that the ideas I wanted to present were in 
line with the aims GSK had for the session.  
 
Feedback questionnaire 
A feedback questionnaire had been designed by GSK to be given to delegates to 
complete after the presentation. The feedback questionnaires were placed on each seat 
by the GSK team at the beginning of the lecture. At the end of the session a request 
was made at the end for people to complete the questionnaire and to hand in on their 
way out of the lecture theatre (for details of questions see Appendix 2). The main 
purpose of the feedback questionnaire was to see how useful the topic of combination 
treatment was for the audience and also to gauge what is currently happening across 
services in the UK.  
 
Participants 
A total of 462 delegates attended the “Stop Smoking Live” conference and of those, 
300 (64%) attended the educational symposium on combination therapy for smoking 
cessation. Forty of those who attended (13%), completed the feedback questionnaire 
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and returned them at the end of the session. The summary of the feedback provided by 
the delegates is discussed below. 
 
Background of delegates 
The majority of those who attended the session and completed the feedback 
questionnaire were smoking cessation advisors (N=27, 68%), with a small number of 
pharmacists (N=2, 5%), practice nurses (N=3, 8%) and a further 8 attendees (20%) 
were health care professionals such as health psychologists, PCT public health 
consultants, healthcare assistants and those from a commercial background.  
 
The knowledge of the audience varied with 28% (N=11) of the delegates rating their 
knowledge of combination NRT before the presentation as very good, while 50% 
(N=20) said that their knowledge was good. 
 
Knowledge improvement 
Nearly all of the delegates (N= 39, 97%) found the session useful/very useful. Thirty-
two (80%) delegates felt that they had learnt something new from the presentation.  
 
Applying combination treatment in practice 
Nearly 70% (N=28) of the delegates said they would increase their use of 
combination therapy after the presentation, with 30% (N=12) saying they would stay 
as they were.  Over 80% (N=32) of the delegates said they would be discussing the 
information from the presentation with colleagues and would use the information 
from the presentation at work. 
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Speaker evaluation 
Thirty-four (85%) delegates found the speaker to be very knowledgeable on the 
subject of combination treatment and 93% (N=37) felt that the speaker encouraged 
participation. The following comments were included in the open text section of the 
questionnaire. 
 
‘Very interesting talk.’ 
 
‘I found this session very good. I learnt a few things that I didn’t know.’ 
 
‘Very good session.’ 
 
Over 80% (N=33) of the delegates agreed that there was a good mix of theory and 
real-life experience included in the presentation.  
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Reflection on the presentation  
 
Accepting the offer of presenting at “Stop Smoking Live” 
This was the first time I have ever been asked to be present at an educational 
symposium. Before agreeing to do the presentation I discussed the presentation with 
my supervisor, who is a very experienced presenter. He was able to advise me about 
what I should expect with regards to the work that would be involved in the 
development of the presentation and we also discussed the amount of input GSK 
would have. After the discussion with my supervisor I accepted the invitation to 
present, as it was a good opportunity for my professional development; presenting in 
front of a large audience, knowledge development on combination treatment as well 
as understanding from the audience what the current UK situation is with regards to 
combination NRT prescribing. 
 
Feedback 
Only forty delegates (13%) completed the feedback questionnaire after the 
presentation. This seemed like a disappointingly low return rate which I discussed this 
with the GSK team after the session. The number appeared to be consistent with 
previous events they had had experience of running. On reflection, I should have 
spoken about the feedback questionnaire at both the beginning and end of the 
presentation in order to re-iterate the importance of getting their feedback for the 
development of future presentations on the topic rather than just mentioning at the end 
of the discussion, when everyone was ready to leave.  
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As the sponsors provided lunch at the session, it may help to increase the number of 
people completing the feedback questionnaires by handing out a lunch box on 
condition that the questionnaire is completed and handed in.  
 
It would be good practice to aim to have at least half of the delegates providing 
feedback and to use different methods to see how this rate can be increased rather 
than accepting that low numbers will return the questionnaires.  
 
The feedback questionnaire that was given to the delegates was developed by GSK. I 
had no input into the development of the feedback questionnaire, which on reflection 
would have been an interesting exercise. I could have included more clinician focused 
questions for the purposes of my own professional development, for example, details 
on how they treat smokers (groups, one to one sessions) and how they prescribe 
combination treatment. For future presentations I will take more time to consider the 
content of the feedback, which on reflection is as important as the presentation itself. 
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Discussion and feedback from the presentation 
 
There were several discussions that took place after the presentation which were very 
informative about the current practices and issues facing UK clinicians working with 
smokers. 
 
Financial constraints on prescribing 
During the presentation several discussions were raised. One of the key topics was the 
financial barrier of providing combination treatment. 
 
Financial cuts are affecting the NHS-SSS and unfortunately this affects if and what 
stop smoking medications are provided. The current NICE guidelines (2008) ask that 
anyone treating smokers to ‘consider offering a combination of nicotine patches and 
another form of NRT (such as gum, inhalator, lozenge or nasal spray) to people who 
show a high level of dependence on nicotine or who have found single forms of NRT 
inadequate in the past’. However, in practice it appears this is not the case in some 
NHS-SSS, as many delegates after the presentation raised the issue of not being able 
to provide both combination NRT or varenicline due to financial constraints. 
 
One of the reported reasons some NHS-SSS do not provide varenicline, is because the 
course of treatment is more expensive than using a single NRT product (e.g. 12 week 
course; varenicline £327.60, 4mg gum £218.88). Currently, it is the decision of each 
NHS-SSS and individual GP prescribers to adjust their prescribing based on their 
budget and they decide if and who can receive smoking cessation medications. 
Although this practice is seen as standard I think there is scope here for discussion 
with NICE and the NHS-SSS about the current prescribing practice across the 
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country, in order to improve the provision of medications for smokers in the UK. The 
most effective medications should be offered to all smokers attending the NHS-SSS 
as per NICE guidelines (2008). It should not be as a result of a postcode lottery.  
 
As a result of financial restrictions, many NHS-SSS now only prescribe one form of 
NRT, while advising patients to purchase a second form of NRT themselves. This can 
be met with a negative response. Cost of NRT has been mentioned in the literature, as 
one of the main barriers to patients not being able to access and use stop smoking 
medications (Foulds, Hughes, Hyland, Le Houezec, McNeill, Melvin, Okuyemi, 
Shiffman, Wassum, Williams & Zeller 2009). In my own clinical experience, asking 
people to pay for their own medications usually means they will fail to get the 
medications you recommend or only use them for a short period of time. Offering 
stop smoking medications on prescription is important in order to increase access to 
effective medications, especially to those on a low income. 
 
In preparation for this presentation I had been thinking about my own experience as a 
clinician and the protocols that are in place at my place of work. Whereby I am able to 
provide treatment to anyone interested in using combination NRT, as part of a quit 
attempt. I had not experienced any restrictions on what pharmacotherapy I could offer 
patients, so in hindsight I had not considered this issue fully. On reflection I should 
have researched thoroughly what practice is common in other NHS-SSS as it appears 
for a large majority due to financial saints they can be very restricted not just in 
prescribing combination treatment but also how long they are able to provide the 
medication. Since the presentation was delivered this is also the same scenario as we 
now have at the TDRU. 
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This hot topic aroused some debate among delegates but was not something included 
in the feedback questionnaire. Asking the delegates why combination treatment was 
not offered as standard would have been extremely informative to clearer picture of 
what is happening across the UK.  
 
High-dose NRT 
Another issue that was discussed regards protocols for the use of combination and 
high doses of nicotine. Multiple NRT products i.e. two or three patches are being used 
in practice and some delegates felt there was a need for guidance on this approach. In 
addition, some delegates would have liked to have more discussion about using dual 
oral NRT. This was not something I had prepared for and could only give anecdotal 
information from my experience of prescribing multiple products i.e. 2 patches. The 
most typical smoker that would be given this form of treatment at the TDRU are 
highly dependent smokers, often those who also have mental health illnesses and who 
find it particularly challenging to quit. My colleague commonly prescribes in this way 
and after the presentation I discussed with her some plans to write up a protocol for 
use of high dose NRT alongside some of our findings. 
 
Despite only 40 of the 300 delegates providing feedback, the discussion during the 
session provided some good insight into the varied experience across the country 
when using combination NRT. 
 
The delegates agreed on the feedback form that there was a good mix of theory and 
real-life experience in the presentation. I think this reflects the relevance of the 
presentation to UK clinicians. The briefing sessions that were held by GSK before the 
presentation helped me to focus on the content and enabled me to facilitate the 
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practical discussion. The contact GSK had with me regarding the development of the 
presentation also conveyed how important the presentation was to GSK and that I had 
a key role to play. This was the first time I had been involved in an educational 
symposium and so the importance of being prepared and confident in my knowledge 
on the subject was incredibly important. I found that taking time to review all the 
literature as well as discussion among colleagues helped me to prepare for the 
presentation and I will use this approach for future presentations. 
 
It was encouraging to learn that as a result of the presentation, a large number of the 
delegates would increase their practice of combination NRT. I think this reflects the 
importance of my role as a practicing Health Psychologist, being able to communicate 
both evidence and practical clinical experience, which can lead to a change and/or 
improvement in clinical practice. 
 
The experience improved my confidence in speaking to large numbers of clinicians. I 
felt that talking about my own experience alongside the evidence behind combination 
treatment really helped me to feel more at ease when presenting. 
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Summary and next steps 
 
UK combination therapy use 
The majority of those attending on the day had a good knowledge of using 
combination treatment in practice so it was positive to see that 80% (N=33) of the 
participants had learnt something new from the session. It was also encouraging to 
hear that a high percentage of those who attended would increase practice of 
combination treatment.  
 
This case study highlights that there is currently a high proportion of people advising 
the use of combination treatment NRT. However, routine practice of combination 
treatment has been reduced due to financial barriers. Limited knowledge was also 
seen as a barrier in recommending combination treatment. This highlights the 
importance of clinicians attending practice-based lectures and conferences. I know 
from previous experience that it is often very useful to discuss barriers and facilitators 
in the provision of NHS-SSS among colleagues, as it often is the way to find solutions 
to these issues. Conferences can act as a forum for aiding discussion among clinicians 
in the field.  
 
On reflection, acknowledging the importance of being involved in the development of 
any feedback questionnaire was a useful lesson to learn. Consideration for how best to 
get the majority of the delegates to complete them is as important as the development 
of the presentation content. As a health professional my presenting skills will not be 
improved without feedback from other HCPs. Feedback is also important in order to 
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understand what issues are affecting NHS-SSS and to use this to also guide future 
presentations on the topic of combination NRT treatment.  
 
I enjoyed the experience of presenting at the “Stop Smoking Live” conference. If the 
opportunity arises to be involved in any future conferences I shall strive to make 
presentations both practical as well as evidence based. 
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Section 2 - Patient perspective of combination varenicline 
and NRT use 
 
Introduction 
Nicotine replacement therapy (NRT) is the most widely used medicine for smoking 
cessation (Stead et al. 2008). There are extensive data showing the efficacy of NRT 
(Stead et al. 2008). Using more than one NRT product as part of a stop smoking 
attempt is something that is commonly used in practice and is recommended by UK 
national guidelines (NICE 2008) as an effective treatment option.  
 
In the UK, smokers also have the option of using non-nicotine treatment options when 
attempting to stop smoking, these include bupropion and varenicline. Varenicline is a 
popular medication choice due to its limited contraindications (Pfizer Limited 2011), 
which means the majority of smokers, even those with other illnesses and medication 
use, can be recommended the product. Varenicline also has very few side effects that 
are associated with its use (Pfizer Limited 2011). The adverse event most commonly 
reported is nausea (28.6%) (Pfizer Limited 2011). In the majority of cases nausea 
occurs early in the treatment period, is mild to moderate in severity and seldom 
resulted in discontinuation (Pfizer Limited 2011).  
 
Varenicline is a partial nicotinic agonist which acts on !4"2 nicotinic receptors 
(Cahill et al. 2012). It is presumed to alleviate withdrawal discomfort, but also 
diminishes rewarding effects of cigarettes (Cahill et al. 2012). Varenicline has been 
shown to increase the success of quitting and some evidence shows a slightly higher 
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success rate when compared to bupropion but the results are slightly less clear for its 
increased efficacy compared to NRT (Cahill et al. 2012).  
 
Unlike NRT research, which shows an increased effectiveness when using more than 
one nicotine product (Stead et al. 2008), the use of a combination of varenicline and 
NRT treatment have not yet been experimentally evaluated. An increasing number of 
clients request and are using a combination of varenicline and NRT products, despite 
there being no evidence to show that this combination has any benefit above and 
beyond using either product on its own. At the TDRU, our approach is that we do not 
put people off combining products but we are clear that we do not know if it is better 
than using only varenicline or NRT on its own. However, from clinical experience it 
is common for people to self medicate and “top up” their varenicline use with other 
NRT products (which can easily be obtained over the counter and without a 
prescription) and report feeling a benefit from doing so.  
 
The other reported reason for using an NRT product when using varenicline, is that 
smokers miss the sensory and behavioural cues associated with smoking (e.g., the 
sensory effects of smoke in the mouth and throat and the action of puffing on a 
cigarette). Sensory and behavioural cues appear to provide additional reinforcement 
of smoking behaviour (Rose 2008), which is often missed when attempting to stop 
smoking. So for someone using varenicline, use of an oral NRT product may help to 
compensate for the reduced sensory cues associated with stopping smoking and 
should in theory improve cessation rates. 
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Part 1 of this portfolio outlines the first randomised trial on the effectiveness of using 
a combination of a nicotine patch and varenicline, which found no increased efficacy 
when using the products in combination. This case study aims to give a qualitative 
reflection on smokers attending the TDRU Smokers’ Clinic, who were using a 
combination of both varenicilne and NRT, without given instruction to do so. The 
case studies aim was to explore the reasons why they chose to use both products, 
despite not being advised to do so and whether they found any benefit from it. Clients 
were also asked to discuss if they had any concerns whilst using the combination of 
medications. 
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Method 
The researcher developed a structured questionnaire. The questions included were 
guided from experience of working with smokers using combination treatment (see 
Appendix 3). Questions were written in order to allow participants to expand on the 
topic rather than eliciting a yes/no response. The questions aimed to establish the 
reasons for using combination treatment, where they got the medications from, 
frequency and duration of use and their thoughts on how useful combination treatment 
was. 
 
Participants 
Participants were recruited opportunistically and approached if they were using 
combination treatment and would consent to answering some questions. Two clients 
who were attending treatment sessions at the TDRU Smokers’ Clinic, who were 
highlighted as using combination varenicline and NRT, consented to take part. All 
data was collected anonymously, no demographic details were collected other than 
specific questions on their use of combination treatment and their smoking history. 
Both participants were using varenicline (1mg BID as per standard protocol) but with 
an added oral product. Neither of the participants had ever used a varenicline and 
NRT combination in previous quit attempts. 
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1) Case study  – Mr Inhalator 
Mr Inhalator reported smoking 15 hand rolled cigarettes per day and had been 
smoking since the age of 11.  His FTND score was 4 (low tobacco dependence rating) 
and it was his first visit to the NHS-SSS. Mr Inhalator had used nicotine patch and 
inhalator in a previous quit attempt. He had tried to quit smoking 2-3 times in the last 
5 years and his last quit attempt was in the last 3 months. He reported stress as the 
main thing that led to relapse on the previous quit attempt. 
 
Mr Inhalator had reported a slip back to smoking, 4 weeks into the quit attempt. The 
inhalator had been bought to avoid full relapse back to smoking. He reported hearing 
another member in the smokers group discussing use of a combination of varenicline 
and an inhalator, which is why he felt it was ok for him to use the same combination. 
Using both the varenicline and inhalator was discussed with his clinician who said it 
was fine to use. 
 
Mr Inhalator reported that the inhalator would only work if he had a slip and saw the 
inhalator more of a last option before smoking. The inhalator was being used 2-4 
times per day, mainly after meals. Mr Inhalator reported that he would complete the 
12-week course of varenicline and that the inhalator would be used during this time if 
needed. 
 
Mr Inhalator reported no side effects from using combination varenicline and 
inhalator and had no concerns about using the medication combination. 
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2) Case study – Mr Lozenge  
Mr Lozenge reported smoking 20 cigarettes per day and had been smoking since the 
age of 16.  His FTND score could not be calculated due to missing data. It was his 
first visit to the NHS-SSS.  
 
Mr Lozenge had used nicotine lozenges in the past and had some at home (left over 
from a previous quit attempt). He had found the TQD hard and so used the lozenges 
to “get through the day”. He started using the lozenges from day 7 of the quit attempt 
and its use was situation dependent (the participant reported increased use when 
drinking). He reported that the benefit of using the lozenges was that it was 
“something to do”. 
 
Mr Lozenge was asked how long he would use the medications for; he said he would 
use the lozenges for the foreseeable future (at least a further 3 months if not longer) 
and was going to use varenicline for the full course of treatment (12 weeks). 
 
His clinician had agreed to it being used and the general message seemed to be 
“whatever works for you”.  
 
Mr Lozenge reported no side effects from using combination varenicline and lozenge 
and had no concerns about using the medication combination. 
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Summary and reflection on the findings of the case studies  
Part 1 of this portfolio, was the first randomised study of using a combination of both 
varenicline and nicotine patches versus varenicline alone in smokers seeking help to 
stop smoking. The results found no difference in efficacy between the two treatment 
options. The aim of these brief case studies was to look at patients’ perspectives and 
to reflect on the current thinking about combination of varenicline and NRT, in 
attendees at the TDRU Smokers’ Clinic.  
 
The 2 participants that were interviewed for this case study were both using an oral 
NRT product (inhalator and lozenge) alongside varenicline. The medication choice 
described by the two participants was one made by them without the guidance of a 
clinician, who in practice is not currently able to recommend and prescribe NRT and 
varenicline in combination. Both participants gave different reasons for using the 
product they chose; hearing about another smokers experience with the product and 
having the product at home after a previous quit attempt.   
 
Both smokers reported that they found the combination beneficial which contradicts 
the main findings in part 1, which reported no difference in efficacy when using 
combination NRT and varenicline. It could be argued that use of the short-acting oral 
NRT formulations such as the ones used by the two participants interviewed, which 
can be used opportunistically, could be more effective than a nicotine patch.  This is 
possible, but any gains in better efficacy of short-acting NRT products are usually 
undermined by the fact that they are less user-friendly and generate much lower 
adherence than patches. Nevertheless, this is something that should be considered. 
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Anecdotally, it is unusual for someone to report use of a nicotine patch in 
combination with varenicline. So from a patient perspective using a patch “top-up” 
product does not typically have the same appeal as an oral product. There could be 
several reasons for this. 
 
There are other underlying mechanisms of smoking that are not addressed when using 
varenicline on its own (i.e. sensory and environmental cues) which may be something 
that needs to be addressed for some smokers to be able to succeed in stopping 
smoking (Rose 2008). 
 
Most smokers report that the first few weeks of a quit attempt are the hardest to get 
through. Cravings to smoke are typically more frequent and intense in the early stages 
of quitting, so risk of relapse is high (Hughes, Kelly & Naud 2004). Use of NRT 
whilst using varenicline may in theory act as a distraction when cravings are difficult 
to control, as was the case with Mr Lozenge.  
 
It would be interesting to see if those who choose to use a combination of NRT and 
varenicline would be identified as more sensitive to sensory and environmental cues 
than those who use varenicline on its own.  
 
For some patients, having a ‘back up’ treatment option when experiencing increased 
urges and cravings early into a quit attempt is important. This is supported by the 
views of the participants about their use of combination varenicline and NRT. It is 
interesting to hear that Mr Inhalator viewed the NRT as important in case of having a 
slip. It seems having the products does not indicate then need for regular use, for these 
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participants it was having the product there in case they experience an increase in 
cravings to smoke that they have something to use. This appears to help the smoker to 
feel more in control when cravings do occur and is a way then can delay relapsing to 
smoking. 
 
It was interesting that in this case study, both participants chose an oral NRT as 
opposed to a patch. I think that practically, the oral products seem more useful to the 
patients as they can be used as and when desired. 
 
Regarding the safety of combination use of NRT and varenicline, a single pre-
marketing study has previously shown that smokers using varenicline and a 
transdermal patch for 12 days reported a higher incidence of nausea, headache, 
vomiting, dizziness, dyspepsia, and fatigue than smokers who used NRT alone (Pfizer 
Limited 2011). However, these symptoms may have been due to varenicline use, as 
opposed to combined use of varenicline and NRT. Post-marketing data suggests that 
combined use of varenicline and NRT is well tolerated (Ebbert 2009).  
 
It was encouraging to see that no negative effects from combining the two treatment 
options were reported by the 2 participants that were interviewed; this is also 
supported by the results found from section 1.  
 
  
 349 
Conclusion 
Combination varenicline and NRT is currently being used by smokers during attempts 
to stop smoking, despite there being no current guidelines to implement this treatment 
regimen. The results of Part 1 of this portfolio found no efficacy for using nicotine 
patches and varenicline above using varenicline alone. Once these results are 
published and are available for clinicians to guide patient treatment, it is thought that 
patients will continue to use this combination treatment option as for many it is used 
to compensate for the reduce sensory aspects associated with being a smoker that 
some smokers find harder than others to deal with when initially trying to stop 
smoking.  
 
Adopting a qualitative approach to this topic could be very interesting, especially in 
the light that combination treatment may not be more effective than using a single 
product. The current case studies targeted people who were regularly using a 
combination, so it would be presumed that these people would be the people reporting 
a benefit. It would be important to interview people who had started using a 
combination but stopped and to find out the reasons why they stopped. 
 
To conclude, it is thought that the occasional practice of combining varenicline and 
NRT will continue for the few smokers that find it useful. As there are no safety 
implications of using combination varenicline and NRT, smokers may continue its use 
if they find it of benefit.  
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Chapter 2 - Case study 2 – Reflection on clinical practice 
 
Summary of clinical practice 
Working for an NHS-SSS has been a great experience for developing my clinical and 
academic skills. As I came into my job straight from university I had no experience of 
providing behaviour change interventions, which was initially extremely daunting. 
However, I was encouraged by my supervisor to attend training days and courses and 
I soon found my confidence improving both when dealing with other HCPs and also 
with my patients.  
 
Having a role, which sees me as part of QMUL, the NHS and the PCT has led me to 
meet a variety of HCPs and students and has enabled me to have many different 
opportunities within all these service providers.  
 
I have worked at the TDRU as the clinic administrator, hospital inpatient stop 
smoking advisor, as a research health psychologist and now my role is as a research 
fellow; managing several trials within the unit. I am regularly involved in teaching 
and have examiner experience involving the medical students of QMUL.  
 
After nearly 7 years in the unit, my role is now primarily in research which has been a 
very steep learning curve for me. I am involved in grant applications for funding 
studies (details can be found in the preface), study protocol development, in addition 
to the day-to-day running of research conducted in the unit. We currently have 5 
studies running in both smoking cessation and weight management; in which I 
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supervise the research leads for each project. This role is extremely demanding and 
requires regular reflection and knowledge development.  
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Reflection on research practice 
Over the last 2 years, my supervised practice on the DPsych course has really helped 
me to focus on my role and to develop systems for ensuring all my work is kept to a 
high professional standard. 
 
In order to reflect on my practice during the supervised period of my DPsych, I will 
discuss some of the practical considerations and issues that are faced on a daily basis 
when involved in clinical research and how protocols have been implemented to 
ensure Good Clinical Practice (GCP) is followed. This case study also highlights key 
skills my job entails and a discussion of some of the practicalities that are involved in 
research in an academic setting. These issues are also discussed in the context of a 
study I have been involved in to reflect my current and on-going practice. 
 
Background to GCP regulations 
GCP is a term used to identify the components of Schedules 1 and 2 of the Medicines 
for Human Use (Clinical Trials) Regulations 2004. Table 2 describes 13 principles 
and 3 conditions, which define lawful conduct when carrying out research into 
medicinal products. GCP is a major part of the overall Research Governance 
Framework for Health and Social Care. 
  
 353 
Table 2 – GCP guidelines 
• Clinical trials shall be conducted in accordance with the ethical principles that 
have their origin in the Declaration of Helsinki, and that are consistent with 
good clinical practice and the requirements of these regulations.  
• Before the trial is initiated, foreseeable risks and inconveniences have been 
weighed against the anticipated benefit for the individual trial subject and 
other present and future patients. A trial should be initiated and continued only 
if the anticipated benefits justify the risks.  
• The rights, safety and well-being of the trial subjects are the most important 
considerations and shall prevail over interests of science and society.  
• The available non-clinical and clinical information on an investigational 
medicinal product shall be adequate to support the clinical trial.  
• Clinical trials shall be scientifically sound, and described in a clear, detailed 
protocol.  
• A trial shall be conducted in compliance with the protocol and has a 
favourable opinion from an ethics committee.   
• The medical care given to, and medical decisions made on behalf of, subjects 
shall always be the responsibility of an appropriately qualified doctor or, when 
appropriate, of an qualified dentist.   
• Each individual involved in conducting a trial shall be qualified by education, 
training, and experience to perform his or her respective task(s).  
• Subject to the other provisions of this schedule relating to consent, freely 
given informed consent shall be obtained from every subject prior to clinical 
trial participation.  
• All clinical trial information shall be recorded, handled, and stored in a way 
that allows its accurate reporting, interpretation and verification.   
• The confidentiality of records that could identify subjects shall be protected, 
respecting the privacy and confidentiality rules in accordance with the 
requirements of the Data Protection Act 1998 and the law relating to 
confidentiality.  
• Investigational medicinal products used in the trial shall be 
a)  manufactured or imported, and handled and stored, in accordance with the 
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principles and guidelines of good manufacturing practice, and 
b)  used in accordance with the approved protocol.  
• Systems with procedures that assure the quality of every aspect of the trial 
shall be implemented.  
 
The importance of these guidelines is crucial to the successful running of a clinical 
research project. Below is a discussion of some of the steps and issues to consider 
when conducting clinical trials in an academic setting. 
 
Associated requirements 
One of the key things to understand in research is who does what in the process of 
gaining approval. This can often be very challenging, especially with regular 
document and process change within departments. The first experience I had with this 
process was when I went on the GCP training course, run by Barts and the London 
and QMUL’s Research and Development (R&D) department. The complexities of all 
the processes can be quite overwhelming, with several different research bodies being 
involved in the process of gaining approval to do research; National Research Ethics 
Service (NRES), local ethics, Medicines and Healthcare Products Regulatory Agency 
(MHRA) and R&D. 
 
Over the last few years I have found that the most important relationship is with the 
local R&D department. Having good working relationships with the team means that 
queries can be answered quickly and it also is reassuring to know that there are people 
on hand to help with queries throughout the process of gaining approval for research. 
It is important to keep up to date with any changes in documentation and legislation. I 
have found that regularly visiting the websites for all the key bodies involved keeps 
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me up to date with the information we need to know to run our studies in line with 
UK standards. 
 
Approval from all the relevant research bodies is needed before commencing a 
research project, although giving approval to start a project is not their only role. They 
maintain contact throughout the trial and it is important to know at what stage they 
need to be involved. If any substantial changes (e.g. a change to the statistical plan of 
the project) happen to the project whilst it is being conducted then this will need to be 
approved by R&D and NRES. For example, we recently had to send a substantial 
amendment document to relevant bodies in order to change the number of participants 
we were going to recruit, in the first instance R&D will approve this.  
 
The MHRA require an annual report, this includes the number of adverse events that 
have occurred as well as the number of participants recruited and a summary of the 
project. All of the study bodies will be informed when the study is closed by the site 
and once all the data is analysed, a summary of the results will be sent to all involved 
to officially close the project. 
 
To summarise, there is regular contact needed with many research bodies throughout 
the running of a research project, which requires planning. It is key to be aware of 
what needs to be sent and when, as this is a legal obligation of the Principal 
Investigator on behalf of the project sponsor. 
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Protocol development 
Protocol development is one of the most importance aspects of research, which can 
sometimes be underestimated. Having a research protocol that is detailed and 
methodical ensures good working practice and really can act as the researcher’s 
‘bible’ should any issues come up. Getting as much feedback and review from 
different parties is important to ensure you have a robust protocol that covers all the 
key aspects of the research proposed. One important issue to consider is when there 
are multiple researchers simultaneously working on the same protocol, as it very easy 
to lose track of new amendments. In my experience the key is to have someone 
overseeing the process to ensure version control. 
 
Trial Master file (TMF) 
In order to keep all documentation mentioned above in order, a Trial Master File 
(TMF) is maintained for the duration of the study. The TMF should tell the ‘story’ of 
the research project from start to finish. The TMF contains all approved documents 
and the most current versions of all the study documents e.g. study questionnaires, 
informed consent form and protocol. It should reflect any changes made to the study 
and it should be clearly documented if there are any deviations from the protocol. One 
of the most important things is to keep it current, which means reviewing it regularly. 
All communication (email, faxes, letters) should be included in the TMF from study 
staff, funders and the sponsor alongside any communication with the main approval 
bodies (R&D, NRES and MHRA). 
 
Standard Operating Procedures (SOPs) 
Within the TMF, Standard Operating Procedures (SOPs) are outlined at the start of 
the study, which work simply as the working protocol for the study. The SOPs give 
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details, for example, about deviation protocols, managing data, regular auditing of 
clinic practice and data collection. The SOPs that are used within the department are a 
mixture of QMUL wide guidelines along with some that have been developed at the 
unit for our specific studies. These documents are essential for the running of a 
successful study as they provide clear guidelines for any major challenges that the 
team may face in the process of running the study. 
 
Database management 
Having come into the post from my masters I had very little knowledge of legal, 
ethical and professional standards. As part of my role as the inpatient advisor I was 
required to manage an SPSS database. As I had used SPSS during my time at 
university, I was familiar with how it worked but I had not been involved in 
implementing any SOPs for entering and analysing data.  
 
The importance of database management and audit is essential when conducting 
research. It is important to know that once the database is finally shut down ready for 
analysis that the data entry is accurate. Over the last few studies I have implemented 
SOPs to help deal with errors, for example, applying limiters to questions which 
prevent any outliers being entered. We have also put in place SOPs for auditing the 
data throughout the data entry period. We usually work from a Microsoft Access 
database, which gets exported to a Microsoft Excel to then finally be exported to 
SPSS (version 18) for analysis. At the excel stage an independent member of staff not 
involved in the study will pick 10% of the CRFs to input. This is then compared to the 
original data entry and errors are highlighted. Data will only be exported once the 
team is confident that the data is accurate. 
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Data protection 
The Data Protection Act (1998) was developed to protect the confidentiality of 
personal data stored on living individuals.  Personal data is defined as data, which 
relates to a living individual who can be identified from those data. It is a legal duty to 
abide by the Data Protection Act. Its eight defining principles are that data should be; 
- Fairly and Lawfully processed  
- Processed for specified purposes  
- Adequate, relevant and not excessive  
- Accurate  
- Not kept for longer that necessary   
- Processed in accordance with the data subjects rights  
- Secure from unauthorised access or alteration  
- Not transferred to countries without adequate data protection controls 
 
The security of the database at the TDRU is one of our main priorities. Data is stored 
in a locked room, on a stand-alone computer with 2 password-protected screens. 
Having no internet link on the computer increases the security of the database. Many 
of the changes I have implemented were as a result of extensive conversations with 
QMUL IT services, as well as with R&D. All databases and study computers within 
the unit are now in-line with both QMUL and MHRA regulations. 
 
Auditing 
I have learnt that the safety and interests of patient information and confidentiality of 
data is one of the most important issues to consider. Systems need to be regularly 
monitored so that clinic procedures can be audited without any problems. This is an 
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issue I had not even considered until attending the GCP training course in which they 
discussed the regularity with which the university is audited. In October 2008 a trial 
in which I was involved was audited and the procedures we had in place passed all the 
auditors criteria. On reflection, this was as a result of on-going efforts to keep the 
TMF up to date. 
 
The trials I have been involved in have opened my eyes to the amount of paperwork 
that is involved in research and its importance in conducting clinical trails correctly. It 
is important to be up-to-date with all documents including staff CVs and training 
courses such as the GCP training.. I have learnt that for legal reasons documentation 
for a trial must be up-to-date and be easily accessible for review.  
 
Dealing with clinical issues 
Reflecting on when issues have arisen concerning the service, I have tried to use 
opportunities such as appraisals to address these matters. As I have progressed in my 
career, the importance of immediate action when issues or concerns are raised about 
the service has become very evident. I feel my confidence when approaching senior 
colleagues has risen since starting my training. I now enjoy discussing patient and 
service issues with my manager and other colleagues rather than shying away from 
concerns, which I think is a reflection of my confidence as a practicing Health 
Psychologist. 
 
Care Quality Commission (CQC) 
After several years of being involved in the processes of conducting research, I was 
asked by the head of R&D at QMUL to apply and represent our unit as a Care Quality 
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Commission (CQC) manager. CQC is the government body that regulates, inspects 
and reviews the quality of patient care across clinical care settings. There are a total of 
5 CQC managers within QMUL. Having research experience has helped me to focus 
on the important organizational aspects involved in running the smokers’ clinic. 
Implementing SOPs to deal with patient care at the smokers’ clinic is very similar to 
the process of SOP development for research. This is an extremely important role that 
I now have and it comes with some responsibility. However, I believe my training and 
organisational skills with regards to research has increased my confidence in being 
able to implement clear pathways for ensuring patient care is our priority in a clinical 
care setting as well as a research unit. 
 
In order to reflect on some of the above points in practice, I have outlined a recent 
study I was involved in and some of the issues that occurred and how they were dealt 
with. 
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Example of a recent study - Varenicline treatment for four weeks 
prior to quitting smoking reduces ad-lib smoking and increases 
smoking cessation rates  
 
In 2009 I was asked to co-ordinate and manage a Randomised Control Trial (RCT) 
using a new treatment regime for the stop smoking medication, varenicline. The 
current treatment schedule is to commence the medication one week before the patient 
stops smoking. Participants who were involved in the study were asked to instead, 
take the medication for 4 weeks before quitting to see if the increased period of 
medication reduced cigarette satisfaction and improved chances of quitting.  
 
Recruitment for the trial began in July 2009. We aimed to recruit and randomise 100 
participants. The study consisted of telephone screening, followed by a first visit to 
the clinic to be screened for eligibility and consented. If a participant was eligible then 
they were asked to start taking varenicline in anticipation of quitting 4 weeks later. 
Participants were asked to smoke ad-lib until the quit day. All participants recruited 
for the study attended the smokers’ clinic on a weekly basis for a total of 7 weeks as 
per usual NHS-SSS protocol. 
 
This was not the first time I had managed a clinical trial but it was the first time I had 
full control over the protocol and procedural logistics for the trial. Previously, the 
studies I had been involved in were supervised by data monitoring companies that 
were recruited to oversee the running of the trial on behalf of the funder. 
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Several members of staff were recruited for the study; it was important that the staff 
involved understood their responsibilities and I ensured that all members of staff were 
properly trained. This involved role-plays of sessions and printed protocols of 
responsibility for each person. It was key to ensure people were doing appropriate 
jobs that worked with their strengths. For example, I used several members of staff 
that had previous trial experience in more complex areas of the study. More junior 
members of the team were involved in telephone screening and day-to-day 
management of the trial paperwork. 
 
Another important aspect that needed to be considered was to ensure all participants 
were up to date with training courses required to take part in the study. The university 
was contacted and everyone involved attended a GCP training course before the trial 
began. 
 
Recruitment 
Participants were recruited via an advertisement in 2 London wide papers; The Metro 
and Evening Standard. Participants were screened over the phone for eligibility to be 
invited to the screening/baseline session. I then developed a telephone-screening 
questionnaire, which was to be completed by the delegated clinicians for each 
participant that called.  In order to unify the procedures for this a simplified script 
covering the main points of the protocol was developed for their use during the calls. I 
also trained everyone involved on the simplified protocol for the screening. I found 
conducting role-plays was a very useful way of highlighting any areas that needed 
improvement and we were then able to discuss these as a team.  
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Auditing 
The JRO at QMUL audited the clinic site, which included my storing of confidential 
information. This allowed us the opportunity to review our procedure. The auditor had 
very few criticisms with regard to the running of the study, which was extremely 
positive. All documents were up to date, including the temperature logs and staff 
documentation.  
 
General Issues 
We had several participants who experienced a Serious Adverse Events (SAEs), this 
is defined as any unknown medical occurrence that at any dose results in: 
1. Death 
2. is life-threatening 
3. requires hospitalisation or prolongation of existing hospitalisation 
4. results in persistent or significant disability/incapability, or 
5. is a congenital anomaly/birth defect 
 
It was important that I knew how to identify these but also how to report them and to 
who. It highlighted the importance of knowing who to contact when experiencing 
these problems. I felt it was part of GCP to email for confirmation of my actions and 
also to keep a concise log of all communications regarding the trial.  
 
One of the major issues we had concerned the labelling of the commercial supply of 
the medications. We had to contract a company to do this for us but we had to spend a 
lot of time researching the options available to us. We also needed to go through 
several layers of approval before we could contract the company, which again added 
delays.  The start of the project was substantially delayed as a result of this process.  
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With the next project I was involved in, this process was started months before it was 
needed to ensure that we started recruitment on time. 
 
Learning 
I have learnt several things as a result of this experience that I hope to address in any 
future study management. 
 
I have learnt that it is important to delegate work and not to put too much pressure on 
myself. At the start of the study I wanted to do everything because I wanted to be 
involved and also because I knew that I had to check that things were being done 
correctly. However, this is not a practical way to manage a study. I am now confident 
that mistakes can be minimised if staff are well trained and that they know you are 
available to discuss any issues/problems. 
 
Continued reflection and discussion with all members of the team is essential to the 
smooth running of any trial. Initially meetings would be arranged ad hoc but the 
importance of discussing project progress is crucial. I now book regular weekly 
meetings with key members of staff. I find this is useful to keep me up to speed with 
the project but also ensures that the researchers are able to discuss any problems they 
are experiencing with me and also to share good practice. 
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SUMMARY 
 
To summarise I have had several years of experience working in an academic 
research setting. This case study was presented to discuss some of the many obstacles 
that are faced by researchers when conducting research. My role as a practicing health 
psychologist is to continue to use my training and research experience to conduct new 
and important pieces of research within my areas of expertise in order to help inform 
and try to improve smoking cessation services and treatment outcome. I hope to 
continue to further develop my skills in both research and clinical practice. 
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Appendix 1 – Advertisements 
Advertisements version 1.0 25 May 2010 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SMOKERS 
WANTED 
A new approach to stopping 
smoking is being tested at Barts 
and The London Medical School. 
For information please call: 
 
 
 
Barts and The London School of Medicine is testing a new 
approach to help smokers quit. 
 
If you would like to take part call: 
 
for more information 
Smokers Wanted 
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Appendix 2 – Telephone Screening Questions 
We need to ask a few questions about you and your health to 
make sure that this study is suitable for you. Is this ok? 
Y 
N 
If no, excluded 
Are you 18 years or older? Y       
N 
If no, excluded 
Do you have severe kidney disease? Y       
N 
If yes, excluded 
Have you ever had an allergic reaction to champix? Y       
N 
If yes, exclude 
Have you ever had an allergic reaction to Nicotine Patches? Y       
N 
If yes, exclude 
Are you currently receiving treatment for any psychiatric illness 
such as depression or schizophrenia? 
Y       
N 
If yes, exclude 
If female, are you breast-feeding, pregnant or planning to 
become pregnant within the next 3 months? 
Y    N   
N/A 
If yes, exclude 
Have you taken part in any clinical trials within the last 3 
months or do you intend to participate in another clinical trial at 
the same time as this trial? 
Y       
N 
If less than 3 
months, 
exclude 
 
Eligible:  Yes  No 
If eligible: 
Name: 
Address: 
Phone number home/work 
Mobile number 
Email:  
Where did you see this advertised? 
Date of appointment for Baseline visit: 
Time of Baseline visit: 
Appointment letter sent:  Yes  No 
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Appendix 3 – Telephone screening script 
Hello, Tobacco Dependence Research Unit. 
Thank you for calling us. Let me explain what this is about. There are two main medications proven to 
help smokers quit. Varenicline (Champix) and nicotine replacement treatments such as patch and gum.  
Smokers normally have to choose one or the other.  However, some people  found it most effective to 
use both and we are now trying to find out if using Champix and patch together is better than using 
Champix alone. 
If you are eligible and willing to take part, you will receive our standard state-of-the art treatment at our 
research clinic with specialist support and Champix, taken for up to 12 weeks. In addition, you will be 
allocated by a computer to use a nicotine patch or a placebo (dummy) patch from your quit day for 4 
weeks.  
All treatment will be free of charge and will be provided at the clinic so you will not have to go to a 
chemist.  
If interested, you will be invited to a screening session on Saturday 7th or Sunday 8th May to be seen 
by the study doctor. This will take some 20 minutes and takes place at the Royal London Hospital 
opposite the tube station in Whitechapel. You will then attend 7 weekly sessions at the smoker’s clinic. 
Each participant will be given an option of coming to the smokers on either a Tuesday or Wednesday 
evening (5.30-6.30 and 6.30-7.30 will be available). The clinics will start on 10th and 11th May (the 
Tuesday and Wednesday after the weekend screening). 
 
If this is of interest, can I ask you a few question to see if you are eligible to take part in the trial  
 
Ask questions and fill in the telephone screening form. 
If not suitable at any point: Unfortunately this means that you cannot take part in this study. 
However, you are still able to attend our clinic and take part in the standard treatment programme. If 
you would like to do this, I will get someone to call you and make an appointment for you later today 
or tomorrow.  
 
Write NOT ELIGIBLE on the form, and if interest in the local Clinics, write address and telephone 
contact, and pass on to XXXX. If out of area give them the national number, they can direct them to 
their local service  
If eligible: Great, thank you, you are eligible for the initial visit.  Before I give you a slot for the 
screening session, let me warn you that on the weekend of 7-8 May, the underground service will be 
suspended, Is this OK? We will send you detailed information in the post about how you can get to us. 
 
If OK, allocate a slot and note this on the form. 
 
If you give me your address and phone number I will send you the confirmation and study details. (The 
phone number is needed if there are any last minute changes). We will also be including some 
questionnaires, if you could fill these in before your visit it will save time during your visit. 
 
Put contact details on the form, fill in the appointment letter, write address on the envelope and seal 
it. 
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Appendix 4 – Patient information sheet 
 
 
INVITATION TO PARTICIPATE IN A RESEARCH PROJECT 
Effects of a combination of varenicline and transdermal nicotine patch on post-quitting urges to 
smoke 
 
We invite you to take part in a research study which we think may be important. The information that 
follows tells you what will happen if you take part and what the risks might be. Whether or not you do 
take part is entirely your choice. Please ask any questions you want to about the research and we will try 
our best to answer them. 
 
The Study 
Varenicline (Champix) and Nicotine Replacement Therapy (NRT) are effective treatments for helping 
people to quit smoking. Smokers will usually choose to use either Varenicline or NRT alone, but some 
people have reported finding it beneficial to use both medications. We are trying to find out if using 
Varenicline and a Nicotine Patch is better than using Varenicline alone. 
This study has been developed by researchers at Barts and The London, Queen Mary’s School of 
Medicine and Dentistry. It is funded  by Pfizer (who make Champix) and has been approved by the 
local ethical committee.   
 
What will happen to you if you take part? 
If you are eligible and willing to take part in the study there will be only small differences from the 
normal treatment that smokers receive at our clinic.  
The main difference is that whilst using Varenicline you will be randomly allocated (by chance) to use 
a 15mg/16hr nicotine patch or a placebo patch (dummy patch) from your quit day for a total of 4 
weeks. Neither your advisor nor yourself will know which patch you have received. Varenicline will be 
continued for a total of 12 weeks after the quit day (this is standard treatment). 
The visits and phone calls that need to be made are outlined in the table below. 
If you are included in the study there will be a couple of things that you will be asked to do that is not 
usually required with the standard stop smoking clinic. For this study we will ask you to attend one 
extra visit to the clinic 12 weeks after the target quit day (8 visits compared to the usual 7) and we will 
call you once, 24 hours after the target quit day. You will be asked to fill in a brief questionnaire on 
both of these occasions. 
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Study outline 
 
Session 1 2 weeks 
before quit 
day 
At this first visit to the Smokers’ Clinic we will describe the study and go 
through this information sheet. You will then have the opportunity to ask 
any questions. We will then ask you to sign a consent form to show that you 
have agreed to take part. You will then complete a short questionnaire to tell 
us about your smoking and mood. We will also measure the amount of 
carbon monoxide (CO) in your breath. You will be given an appointment 
time to attend the clinic the following week. 
 
Session 2  1 week before 
quit day 
At this second visit to the Smokers’ Clinic we will ask you to complete a 
short questionnaire. We will also record the number of cigarettes that you 
are smoking per day and measure the amount of CO in your breath.  
You will be given a week’s supply of Varenicline to start using. 
We will also help you prepare for your Quit Day the next week. 
Session 3 QUIT DAY You will visit the Smokers’ Clinic and we will ask you to complete some 
short questionnaires to measure any withdrawal symptoms. We will also 
record the number of cigarettes that you are smoking per day and we will 
measure the amount of CO in your breath. You will be given another supply 
of Varenicline and you will be given a nicotine patch to start using.  
  
We will provide you with some counselling to help you get through the first 
week. 
Session 4 24 hours after 
quit day 
We will call you 24 hours after your quit day to see how you are getting on. 
We will provide you with some support and assess your level of craving for 
cigarettes and other withdrawal symptoms. 
 
Sessions 5-7 1-3 weeks 
after the quit 
day 
At each of these sessions you will visit the Smokers’ Clinic and we will ask 
if you have smoked or not, measure the amount of CO in your breath and 
ask whether you are experiencing withdrawal symptoms. Medication will be 
given to you at each session.  
 
We will provide you with support on a weekly basis to assist you in your 
quit attempt. 
Session 8 4 weeks after 
the quit day 
At this session we will ask you to stop using the Nicotine patches but will 
ask you to continue using Varenicline. 
 
After this session we will not formally contact you again until you have 
finished the course of treatment (8 weeks later). Of course you should feel 
able to contact us during this time if you have any questions or concerns. 
Session 9 12 weeks after 
quit day 
We will ask you to attend one final visit to see how you are after finishing 
the medication and how you are managing with not smoking. We will ask if 
you have smoked or not, measure the amount of CO in your breath and ask 
whether you are experiencing withdrawal symptoms. Advice will be given 
on how to stay stopped or try to quit again if you have not been able to stop. 
 
Who Can Take Part 
Like all medicines, the ones approved for use to stop smoking can have side effects and people with 
certain medical conditions are more likely to experience these than others. As in our routine care, we 
will check your medical history and only allow you to take part in the study if it is safe for you to use 
varenicline. 
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You will not be able to take part if you 
• You are under 18 years of age 
• Are pregnant or breastfeeding 
• Have severe kidney disease 
• Have a current psychiatric illness 
• Are unable to fill in questionnaires in English 
• You have an allergy to varenicline 
• You have an allergy to Nicotine Patches 
• Are planning to conceive during the study period 
• Are currently involved in another clinical trial 
 
Data Protection 
If you agree to take part, we will ask you to complete the standard clinic questionnaire and some short 
additional questionnaires required for this study. We will not request any medical information about 
you from your doctor. All information will be kept confidential, just as is normal for smokers attending 
the clinic. We will inform your GP, with your consent, that you are taking part in this study.  
Only the study staff will have access to this data.  The results of the study will be presented to the 
smoking cessation experts and may be printed in medical journals. However this will not include any 
information which could identify you. 
 
Risks/Side Effects 
Varenicline is used in routine clinical treatment.  It can have a number of side effects; the most 
common of these is nausea. Mostly this is mild/moderate and usually gets less over time. Other side 
effect may include abdominal pain, abnormal dreams, constipation, dry mouth, indigestion, flatulence 
(gas), flu syndrome, headache, increased appetite, insomnia (sleeplessness), irritability, drowsiness, 
altered taste, trouble concentrating, and vomiting.    
More recently there have been reports of depression and suicidal thoughts in people taking varenicline. 
However this may not be due to the medicine. Advice from agencies that monitor medicines 
recommend that people taking varenicline should be informed about this possible adverse effect and 
monitored. We will be seeing you on a weekly basis and you will be asked to report any low mood. 
Nicotine patches are also used commonly in routine clinical treatment. The most common side effect is 
for the patches to irritate the skin. Other side effects such as nausea, dizziness and headaches have been 
reported. 
Your study doctor will check you carefully before you start treatment and during the study to make 
sure that you are able to take these medications.  
 
Medication 
Varenicline and Nicotine/Placebo Patches will be supplied at the smokers’ clinic free of charge.  Pfizer 
is donating the Varenicline and Johnson & Johnson will be providing the patches.  
 
Your Rights 
Participation in this study is entirely voluntary.  You are free to decide not to be in this trial or to drop 
out at any time.  If you decide not to be in the study, or drop out, this will not put at risk you ordinary 
medical care.  All records relating to the study will be kept strictly confidential. 
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What happens if you are worried or if there is an emergency? 
 
You will be able to contact Katie Myers at the Smokers’ Clinic to discuss your concerns and/or get 
help.  The phone number is  or email .  Outside office hours you 
can call . 
 
The chief investigator in this study is  
 
 
 
We believe that this study is safe and do not expect you to suffer any harm or injury because of your 
participation in it. However, Queen Mary and Westfield College, University of London has agreed that if your 
health does suffer as a result of your being in the study then you will be compensated. In such a situation, you 
will not have to prove that the harm or injury which affects you is anyone’s fault. If you are not happy with 
any proposed compensation, you may have to pursue your claim through legal action. 
 
If you have a complaint please contact  
Email:  
 
If you wish to ask any further questions, or you have entered the study and are unsure about something, 
then please do not hesitate to contact Katie Myers, telephone    
 
We would like to thank you for your interest in this study, even if you decide not to take part. 
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Appendix 5 – Invitation to participate 
 
 
Dear  
 
Re: “Effects of a combination of varenicline and transdermal nicotine patch on 
post-quitting urges to smoke” 
 
Thank you very much for your interest in taking part in this study.  
Please find enclosed some information about it (see Participant Information Sheet). 
We will go through this with you in more detail when you come to see us at your first 
appointment on: 
 
 ________________________at _______________at the Royal London Hospital 
Smokers’ Clinic. We have enclosed a map to help you find us. 
We would also be most grateful if you could complete the short questionnaire 
enclosed. This is our standard Smokers’ Clinic Questionnaire that gives us 
information about you, your current health and your smoking. 
In case you decide not to take part or cannot come for your appointment, please do let 
us know so we can allocate your slot to someone else (the phone number and e-mail 
address are below) 
If you have any questions or concerns regarding taking part in this study please do not 
hesitate to contact me on 020 7882 8230 or by e-mail on k.myers@qmul.ac.uk 
 
Yours sincerely, 
Miss Katie Myers 
Study Manager 
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Appendix 6 – Smokers clinic questionnaire 
CLIENT TREAT NO:   201 _  :  _  _  _  _ 
                Smokers Clinic Questionnaire 
Please complete this form and bring it to your first appointment. If you have any problems with the 
questions, please don’t worry or be put off coming. We will help you if necessary. The information 
collected is strictly confidential, for use by Trust staff. Some items, e.g. age, sex, ethnicity, are required 
by the Department of Health to monitor the service we provide. Other items, including those obtained 
from all sessions and follow-ups, will be used by the clinic to guide your treatment, and may be used in 
research on smoking. No names or information that might identify you will be used in any reports, only 
figures from many smokers together. The information will be stored in accordance with the Data 
Protection Act and you have the right to review it, or withdraw your permission for us to use it. Your 
participation in this work is voluntary and your treatment at the clinic will not be affected if you refuse. 
Please discuss any concerns you may have regarding this information with the clinic staff.  Signing 
below indicates that you have read this notice and agree to your information being used in this way. 
Signature ____________________________________            Date ___________________ 
 
Please write where you see the lines. Circle the word which applies to you
Your name: _____________________________________________      Are you?     1 Male   2 Female   (circle ONE 
only) 
Your date of Birth: ______________     Your age?  _____   years 
Your  address: ______________________________________________________________________________ 
_______________________________________________________________     Post Code: _______________ 
Home tel no: _______________________________  Work tel no: ____________________________________ 
Mobile tel no: ______________________________   Email: _________________________________________ 
Person to contact if we cannot reach you: ________________________________  Tel No: ___________________ 
Name/Address of your GP: _____________________________________________________________________ 
________________________________________   Post Code: ___________   Tel No: ______________________ 
1.  Are you?          1 Married      2  Divorced     3  Separated    4  Widowed     5  Single (never married)                  (circle 
ONE ) 
2. Do you live?   1 With your spouse/partner  2 Family/friends   3 On your own   4 Hostel/residential home   (circle 
ONE ) 
3.  Are you? ( circle ONE ) 
1 Working in a routine or manual occupation                                           5 Full time student 
2 Working in an intermediate occupation                                                  6  Retired 
3 Working in a managerial or professional occupation                            7 Sick / Disabled / Unable to return to work 
4 Unemployed / not working for a year or more                                      8 Home carer (unpaid) 
9 None of these 
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4. What is your most recent or current occupation? 
______________________________________________________ 
5. Which qualifications do you have?   1 None     2 GCSE/CSE    3 A-Level    4 Diploma/HND    5 Degree     6 
Other______ 
6.  Are you entitled to free prescriptions?                               1 Yes         2 No                (circle one ) 
7.  Which of these best describes your ethnic origin?    ( circle ONE category below ) 
1 WHITE - British                                         2 WHITE - Irish                                        3 WHITE - other background 
4 MIXED - White and Black Caribbean      5 MIXED - White and Black African       6  MIXED - White and Black 
Asian 
7 MIXED - other background                      8 ASIAN / Asian British - Indian           9 ASIAN / Asian British - 
Pakistani 
10 ASIAN / Asian British - Bangladeshi     11 ASIAN or Asian British - other           12 BLACK or Black British - 
Caribbean 
13 BLACK or Black British - Africa              14 BLACK or Black British - other           15 CHINESE 
16 TURKISH or KURDISH                            17 Another ethnic group: __________________         18 Don’t wish to 
answer 
 
Questions about your smoking 
8.  How many cigarettes do you usually smoke each day?    ________     (write a SINGLE average number ) 
9. How many of these are hand-rolled cigarettes?    _________      (write a single average number ) 
10.  How soon after waking up do you usually smoke?                                                                                               
(circle one ) 
3 Within 5 mins          2 6 to 30 mins         1 31 to  60 mins         0 After 1 hour 
11.  Do you find it difficult not to smoke in places where smoking is not allowed?         1 Yes         0 No                (circle 
one ) 
12.  Do you smoke more in the first hours after waking up than during the rest of the day?   1 Yes    0 No             
(circle one ) 
13. Which cigarette would you hate most to give up?      1 The first of the morning       0 Another one               (circle 
one ) 
14.  Do you smoke if you are so ill that you are in bed most of the day?           1 Yes           0 No                              
(circle one ) 
15.  How often do you wake up at night and smoke?  (circle one ) 
1 Never       2 Less than once a month       3 1 or 2 times a month      4 1 or 2 times a week       5 Most nights 
16.  How old were you when you first started smoking regularly?  _________ years old 
17.  Do you smoke mainly to cope or because you enjoy it?                                                                                       (circle 
one ) 
1  Mainly to cope              2  Mainly because I enjoy it              3  About the same 
18.  Does your spouse or partner smoke?             1 Yes         2  No         3  No spouse/partner                                   (circle 
one ) 
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19.  How many times have you tried to stop smoking in the last 5 years?                                                   ****    (circle 
one ) 
1  Not at all               2  Once               3  2 or 3 times              4  4 or 5 times            5  More than 5 times 
20.  What is the longest time you’ve succeeded in giving up smoking in the last 5 years?                      ****    (circle 
one ) 
1 Few hours     2 1  day      3 2 -3 days     4  4 -7 days     5 1-3 weeks     6 1-3 months    7  More than 3 months     8 Not 
tried 
21.  How long ago was your last serious attempt to stop?                                                                                    (circle 
one ) 
1 1 - 3 weeks       2 1 - 6 months        3  More than 6 months          4 More than a year       5  Never tried before 
22. What was the ONE MAIN THING that led you back to smoking last time?                      (circle JUST ONE 
reason below ) 
1 Never stopped before    2 Got too miserable    3 Craved too much     4  Put on too much weight      5 Got too bad-
tempered 
6 Got too stressed     7 Thought I could smoke and stop easily    8 Cannabis smoking    9 Getting drunk    10  
Something else 
23.  If you have tried to stop smoking before, which of these was more difficult to cope with?                   (circle one ) 
1 That something was constantly missing and that I could not function normally without smoking 
2 That I could not smoke at those special moments when smoking was really enjoyable and made me feel good 
3 Both were equally difficult 
24. If you try stopping smoking now with clinic help, how confident are you of succeeding?     (circle one number 
below) 
Not at all confident     1         2          3          4          5          6          7          8          9         10     Totally confident 
25. How determined are you to stop for good in the next few weeks?                                                                    (circle 
one ) 
1  Not sure            2  Fairly determined           3  Very determined          4  Totally determined 
26. How recently has your GP advised you to stop?   1 In the last year    2 More than a year ago     3 Never          
(circle one ) 
27. What is your ONE MAIN REASON for wanting to stop now?                             (circle JUST the most important 
ONE ) 
1 To save money   2 To stop being addicted   3 To protect my health   4 To please others   5 It’s anti-social   6 Another 
reason 
28. Which of these medicines have you tried before to help you stop?               (circle ALL THE ONES you have ever 
tried ) 
(a) None 0     (b) Nicotine Gum 1      (c) Nicotine Inhalator 2      (d) Nicotine Patch 3     (e) Nicotine Microtab 4 
(f) Zyban 5    (g) Nicotine Lozenge 6    (h) Nicotine Nasal Spray 7     (i)  Champix (Varenicline) 8 (j) (j) Nicotine Minis 9 
29.  Have you ever suffered any unpleasant reactions to any of the above medications?          (a)   1 Yes    2 No 
If yes, 
(b)  Which medication? ______________________________________________________ 
(c)  What reaction? _________________________________________________________ 
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30. Which of these methods have you tried before to help you stop?  (circle all the ones you have tried ) 
(a) None 0     (b) Hypnosis 1       (c) Help-lines 2        (d) Books/videos 3      (e) Counselling 4      (f) Herbal cigarettes 5 
(g) Acupuncture 6     (h) Alan Carr 7       (i) NicoBloc 8        (j) Nicobrevin 9    (k) Stoppers 10      (x) Other 11  
______________ 
31.  How did you hear about this smokers’ clinic?  (circle one ) 
1 Told about it by a GP   2 Hospital doctor    3 Nurse   4 Friend or family member   5  Telephone Help-line   6  Advert         
7 
Newspaper/magazine    8 A leaflet or poster ( 8a where? ____________________ )   9 Street recruitment   10 Another 
way 
32.  Have you been to this Smokers’ Clinic before?    (a)   1 Yes    2 No      (b)   If Yes,  which year was it?  
____________ 
 
Questions about your health 
What is your weight _________kg      What is your height __________cm 
 
33. How many times have you been to your GP about your health in the last year? 
1  Not at all         2 1  or  2 times         3 3  or  4 times          4  5  to 10 times       5 More than 10 times           (circle one ) 
34. Do you regularly use cannabis?     1 No        2 Yes, with tobacco      3 Yes, but not with tobacco                 (circle 
one ) 
35. How many units of alcohol do you drink during a typical WEEK?    ________________ units                                         
* 
(one unit = glass of wine / half pint of beer / single spirit) 
36. If you are female, are you?     1 Pregnant            2 Trying to conceive         3 Breast Feeding         4 None of these              
* 
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Please turn over and complete the last page 
If join the clinic programme, you may be prescribed a medicine to help. Some medicines can be 
harmful for some people, so we ask everyone to complete the medical checklist below. If you 
don’t understand some of the questions, a therapist at the clinic will help you. 
Have you EVER suffered from these illnesses? & Do you take any medicines for these 
illnesses? 
(circle one )  (circle one)      Name of any medicine you are 
taking 
37. Heart disease or condition? 1 YES 2 NO A       B 1 YES 2 NO  
38. Cancer? 1 YES 2 NO A       B 1 YES 2 NO  
39. Bronchitis? 1 YES 2 NO A       B 1 YES 2 NO  
40. High blood pressure? 1 YES 2 NO A       B 1 YES 2 NO  
41. Emphysema or lung disease 1 YES 2 NO A       B 1 YES 2 NO  
42. Asthma? 1 YES 2 NO A       B 1 YES 2 NO  
43. Alcohol problems? 1 YES 2 NO A       B 1 YES 2 NO  
44. Drug problems? 1 YES 2 NO A       B 1 YES 2 NO  
45. Depression? 1 YES 2 NO A       B 1 YES 2 NO  
46. Any form of psychosis? 1 YES 2 NO A       B 1 YES 2 NO  
47. Skin allergies or eczema? 1 YES 2 NO A       B 1 YES 2 NO  
48. Nasal problems or nose bleeds? 1 YES 2 NO A       B 1 YES 2 NO  
49. Bi-polar (high-low) depression? 1 YES 2 NO A       B 1 YES 2 NO * 
50. A stroke? 1 YES 2 NO A       B 1 YES 2 NO * 
51. An eating disorder? 1 YES 2 NO A       B 1 YES 2 NO * 
52. Liver or kidney disease? 1 YES 2 NO A       B 1 YES 2 NO * 
53. A brain tumour? 1 YES 2 NO A       B 1 YES 2 NO * 
54. A head injury? 1 YES 2 NO A       B 1 YES 2 NO * 
55. Fits or seizures or epilepsy? 1 YES 2 NO A       B 1 YES 2 NO * 
56. Diabetes? 1 YES 2 NO A       B 1 YES 2 NO * 
Other CURRENT illness not listed above : Name of other medicines / tablets / injections not listed above: 
57.  
58.  
59.  
Please check that you have included ALL the medicines you are currently taking somewhere 
above 
 
60. To my knowledge the information I have given above is correct.   
Signed:________________________________ 
 
 
Thank you very much.  Please remember to bring this form with you to the clinic 
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Appendix 7 – Consent form                                                                       
       
Effects of a combination of varenicline and transdermal nicotine patch on post-
quitting urges to smoke -   Informed Consent Form 
Investigator: Dr Al-Rehan Abdul Aziz Dhanji 
Participant Name:                                     Participant Number: 
 Please initial each line 
I confirm that I have read (or someone else has read to 
me) and I understand the Participant Information Sheet 
(Version 1.1) dated 14 Dec 2010 for the above study. 
 
I have had the opportunity to consider the information, 
ask questions and have had these answered 
satisfactorily. 
 
I understand that my participation is voluntary (my 
choice) and that I am free to withdraw at any time 
without giving reason, without my medical care or legal 
rights being affected. 
 
I understand that all information collected will be in 
accordance to the Data Protection Act of 1998. 
 
I agree to my GP being informed of my participation in 
the study 
 
I agree to take part in the above study  
 
I understand that the research data collected during the study may be looked at by 
other individuals from the research team, sponsor, from regulatory authorities or from 
the NHS Trust, where it is relevant to my taking part in this research. I give 
permission for these individuals to have access to my data.  
____________________________ ___________________ ________ 
Participant Name (please print) Signature of Participant Date 
____________________________ __________________ _______ 
Name of person taking consent Signature   Date 
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Appendix 8 – GP letter 
 
 
 
[Insert Date] 
[Insert GP Name and Address] 
 
Dear Dr [GP Name], 
Re: Patient participation in a smoking cessation study “Effects of a combination of varenicline and 
transdermal nicotine patch on post-quitting urges to smoke” 
 
This is to inform you that your patient 
[insert patient details] 
has volunteered to take part in the above-mentioned study. We have included a brief summary of the 
study on the reverse of this letter. 
If you have any questions or concerns regarding your patient taking part in this study please do not 
hesitate to contact me. 
 
Kind regards 
 
Yours sincerely, 
Miss Katie Myers 
Research Health Psychologist 
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Study Summary 
 
Varenicline and nicotine replacement therapy (NRT) are both effective smoking cessation treatment. 
Anecdotally smokers who are finding their quit attempt difficult have reported benefit from adding 
NRT to varenicline. Using varenicline in combination with NRT may reduce craving and increase 
quitting.   
 
This study will recruit 120 smokers and randomly allocate them to take varenicline + 15mg/16hr patch 
or varenicline + 15mg/16hr placebo patch. All participants will receive standard NHS Stop Smoking 
Service support. Urges to smoke, and other withdrawal symptoms, experienced during the study period 
will be compared between groups to see if this combination therapy may be useful. 
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Appendix 9 – Clinical record form (CRF) 
 
PARTICIPANT Treatment 
Number: 
   
PARTICIPANT INITIALS:    
 
 
CLINICAL RECORD FORM 
 
CONVICT STUDY 
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__________________________________________________________________ 
STUDY STAFF USE ONLY:  
Session 1 (Screening session) 
Date:   /   / 2 0 1  
Group 
Clinic/Number 
 
 
Inclusion/Exclusion Criteria 
Excluded if answers YES to any of the below questions: 
        No   Yes 
 
Aged < 18  
Pregnant or breastfeeding 
End-stage renal disease 
Current psychiatric illness 
Previous allergic reaction to varenicline or patch 
Females only:  
Not using contraception/planning pregnancy 
 
 
Eligible to take part                                      Yes                            No  
  
 
Documents completed (please tick when completed) 
 
Consent form 
Assigned to group clinic (please add detail above) 
 
Study staff initials   
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Please help us monitor your progress by completing this page 
 
 
                        
About how many cigarettes did you smoke per day in the last week? 
___________     (write one number)                                                                         
 
Please show for each of the items how you have been feeling over the past week  
(circle the ONE which best applies to you on each line) 
 
Depressed 
 
Not at all Slightly Somewhat Very Extremely 
Irritable 
 
Not at all Slightly Somewhat Very Extremely 
Restless 
 
Not at all Slightly Somewhat Very Extremely 
Hungry 
 
Not at all Slightly Somewhat Very Extremely 
Poor concentration 
 
Not at all Slightly Somewhat Very Extremely 
Slept worse than usual 
 
Not at all Slightly Somewhat Very Extremely 
 
 
 
 
Carbon monoxide 
reading 
  ppm 
 
 
 
Weight ________ kg    Scale Number   
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Session 2 (Preparation session) 
 
Please help us monitor your progress by completing this page 
 
Date: _____________________________ 
                          
About how many cigarettes did you smoke per day in the last week? 
___________     (write one number)                                                                         
 
Please show for each of the items how you have been feeling over the past week  
(circle the ONE which best applies to you on each line) 
 
Depressed 
 
Not at all Slightly Somewhat Very Extremely 
Irritable 
 
Not at all Slightly Somewhat Very Extremely 
Restless 
 
Not at all Slightly Somewhat Very Extremely 
Hungry 
 
Not at all Slightly Somewhat Very Extremely 
Poor concentration 
 
Not at all Slightly Somewhat Very Extremely 
Slept worse than usual 
 
Not at all Slightly Somewhat Very Extremely 
 
 
Carbon monoxide 
reading 
 
 
 ppm 
 
___________________________________________________________________ 
STUDY STAFF USE ONLY:  
 
Champix starter pack dispensed   
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Session 3 (Target Quit Date - TQD)  
Please help us monitor your progress by completing this page 
Date: _____________________________ 
 
About how many cigarettes did you smoke per day in the last week? 
___________     (write one number)                                                                         
Please show for each of the items how you have been feeling over the past week  
(circle the ONE which best applies to you on each line) 
 
Depressed 
 
Not at all Slightly Somewhat Very Extremely 
Irritable 
 
Not at all Slightly Somewhat Very Extremely 
Restless 
 
Not at all Slightly Somewhat Very Extremely 
Hungry 
 
Not at all Slightly Somewhat Very Extremely 
Poor concentration 
 
Not at all Slightly Somewhat Very Extremely 
Slept worse than usual 
 
Not at all Slightly Somewhat Very Extremely 
Nausea 
 
Not at all Slightly Somewhat Very Extremely 
 
Have you found your urges to smoke stronger or weaker than usual in the last 
week? (circle one below) 
Much stronger Slightly stronger Same as before Slightly weaker Much weaker 
 
Have you found cigarettes more or less enjoyable than usual in the last week? 
(circle one below) 
Much more 
enjoyable 
Slightly more 
enjoyable 
Same as before Slightly less 
enjoyable 
Much less 
enjoyable 
 
On how many days did you use your tablets over the past week? ______________ 
If you didn’t take your tablets what was the one main reason for not taking it? 
Forgot  Too unpleasant Didn’t need it It wasn’t helping 
Other (please specify) 
 
______________________ 
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Have you experienced any unpleasant effects from the tablets in the last 
week?  
! No 
! Yes - please list these on the ADVERSE EVENTS PAGE 
 
___________________________________________________________________ 
STUDY STAFF USE ONLY:  
 
 
Carbon monoxide 
reading 
  ppm 
 
  
Randomisation code 
              
 
Patches dispensed                     
 
 
GP letter sent and copy in file 
 
 
Study staff initials    
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__________________________________________________________________ 
STUDY STAFF USE ONLY:  
     Phone call 1 (24 hour phone call)  
Date: _____________________________ 
                           
Have you smoked any cigarettes in the last 24 hours?   YES NO
 (circle one) 
 
If YES, how many cigarettes did you smoke? 
Just a few puffs Between 1 and 5 
cigarettes 
More than 5 cigarettes 
 Please show for each of the items how you have been feeling over the past 24 
hours  
(circle the ONE which best applies to you on each line) 
Depressed 
 
Not at all Slightly Somewhat Very Extremely 
Irritable 
 
Not at all Slightly Somewhat Very Extremely 
Restless 
 
Not at all Slightly Somewhat Very Extremely 
Hungry 
 
Not at all Slightly Somewhat Very Extremely 
Poor concentration 
 
Not at all Slightly Somewhat Very Extremely 
Slept worse than usual 
 
Not at all Slightly Somewhat Very Extremely 
Nausea 
 
Not at all Slightly Somewhat Very Extremely 
 
How much of the time have you felt the urge to smoke in the past 24 hours?  
(circle one below) 
Not at all A little of the time Some of the time A lot of the time 
Almost all the 
time All the time 
 
How strong have these urges been?  (circle one below) 
No urges Slight Moderate Strong Very strong Extremely 
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Champix Use 
 
Did you take your tablet this morning? 
! Yes 
! No 
 
If you didn’t take your tablet what was the one main reason for not taking it? 
 
Forgot  Too unpleasant Didn’t need it It wasn’t helping 
Other (please specify) 
 
______________________ 
 
Nicotine Patch Use 
 
Did you put on the patch this morning? 
! Yes 
! No 
 
If you didn’t use the patch what was the one main reason for this? 
 
Forgot  Too unpleasant Didn’t need it It wasn’t helping 
Other (please specify) 
 
______________________ 
 
Have you experienced any unpleasant effects from the tablets or patches in 
the last 24 hours?  
 
! No 
! Yes - please ask participants for details and list these on the ADVERSE 
EVENTS PAGE 
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Session    4    5    6    7 
Please help us monitor your progress by completing this page 
 
 
Date: _____________________________ 
                         
Have you smoked any cigarettes since your last visit?   YES NO
 (circle one) 
If YES, how many cigarettes did you smoke? 
Just a few puffs Between 1 and 5 
cigarettes 
More than 5 cigarettes 
 Please show for each of the items how you have been feeling over the past 
week  
(circle the ONE which best applies to you on each line) 
Depressed 
 
Not at all Slightly Somewhat Very Extremely 
Irritable 
 
Not at all Slightly Somewhat Very Extremely 
Restless 
 
Not at all Slightly Somewhat Very Extremely 
Hungry 
 
Not at all Slightly Somewhat Very Extremely 
Poor concentration 
 
Not at all Slightly Somewhat Very Extremely 
Slept worse than usual 
 
Not at all Slightly Somewhat Very Extremely 
Nausea 
 
Not at all Slightly Somewhat Very Extremely 
 
How much of the time have you felt the urge to smoke in the last week?  (circle 
one below) 
Not at all A little of the time Some of the time A lot of the time 
Almost all the 
time All the time 
 
How strong have these urges been?  (circle one below) 
No urges Slight Moderate Strong Very strong Extremely strong 
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Champix Use 
 
On how many days did you use the tablets over the past week? 
_______________ 
How many tablets did you use, on average per day? (please circle)  1    2 
If you didn’t take your tablet every day what was the one main reason for not 
taking it? 
 
Forgot  Too unpleasant Didn’t need it It wasn’t helping 
Other (please specify) 
 
______________________ 
 
Nictone Patch Use 
On how many days did you use patches over the past week?  ________ 
If you didn’t use your patches every day what was the one main reason for not 
using them? 
 
Forgot  Too unpleasant Didn’t need it It wasn’t helping 
Other (please specify) 
 
______________________ 
 
Have you experienced any unpleasant effects from the tablets or patches since 
your last visit?  
! No 
! Yes - please list these on the ADVERSE EVENTS PAGE 
 
__________________________________________________________________ 
STUDY STAFF USE ONLY:  
 
Carbon monoxide 
reading 
  ppm 
 
Champix dispensed   
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Session 8 (12 week follow up)  
 
Please help us monitor your progress by completing this form 
 
Date: _____________________________ 
                           
Have you smoked any cigarettes since your last visit?   YES NO
 (circle one) 
If YES, how many cigarettes did you smoke? 
Just a few puffs Between 1 and 5 
cigarettes 
More than 5 cigarettes 
 Please show for each of the items how you have been feeling over the past 
week  
(circle the ONE which best applies to you on each line) 
Depressed 
 
Not at all Slightly Somewhat Very Extremely 
Irritable 
 
Not at all Slightly Somewhat Very Extremely 
Restless 
 
Not at all Slightly Somewhat Very Extremely 
Hungry 
 
Not at all Slightly Somewhat Very Extremely 
Poor concentration 
 
Not at all Slightly Somewhat Very Extremely 
Slept worse than usual 
 
Not at all Slightly Somewhat Very Extremely 
Nausea 
 
Not at all Slightly Somewhat Very Extremely 
 
How much of the time have you felt the urge to smoke in the last week?  (circle 
one below) 
Not at all A little of the time Some of the time A lot of the time 
Almost all the 
time All the time 
 
How strong have these urges been?  (circle one below) 
No urges Slight Moderate Strong Very strong Extremely strong 
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Champix Use 
On how many days did you use the tablets over the past week? 
_______________ 
How many tablets did you use, on average per day? (please circle)  1    2 
If you didn’t take your the tablets every day what was the one main reason for 
not taking them? 
Forgot  Too unpleasant Didn’t need it It wasn’t helping 
Other (please specify) 
 
______________________ 
 
Nictone Patch Use 
On how many days did you use patches over the past week_______________ 
If you didn’t use your patches every day what was the one main reason for not 
taking it? 
Forgot  Too unpleasant Didn’t need it It wasn’t helping 
Other (please specify) 
 
______________________ 
 
Have you experienced any unpleasant effects from the tablets or patches since 
your last visit?  
! No 
! Yes - please list these on the ADVERSE EVENTS PAGE 
 
__________________________________________________________________ 
STUDY STAFF USE ONLY:  
 
 
Carbon monoxide 
reading 
 
 
 ppm 
 
 
 
Date of last Champix dose: ____________________ 
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Adverse Events Page 
 
List each effect below 
Date side 
effect started 
Date side effect 
finished (leave 
blank if still 
ongoing) 
Study staff use only 
   Severity: ! Mild ! Moderate 
! Severe 
Related to study medication? 
! Yes ! No ! Unknown 
If yes, which IMP?  
Patch ! Champix ! 
Serious? ! Yes  ! No  
Action taken:  
! None  
! Dose reduction! Stopped 
medication 
! Withdrawn from study 
   Severity: ! Mild ! Moderate 
! Severe 
Related to study medication? 
! Yes ! No ! Unknown 
If yes, which IMP?  
Patch ! Champix ! 
Serious? ! Yes  ! No  
Action taken:  
! None  
! Dose reduction! Stopped 
medication 
! Withdrawn from study 
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Final /Early termination 
Subject Summary 
Subject completed study            YES !  NO ! 
Subject withdrawn before randomisation              YES !  NO ! 
Subject was withdrawn during active treatment period         YES ! NO ! 
 
Date subject withdrawn (dd-mm-yyyy)    ________________________ 
Date of last dose (dd-mm-yyyy)             _________________________ 
 
Reason for withdrawal 
Adverse event      YES !  NO ! 
Subject died       YES !  NO ! 
Protocol violation      YES !  NO ! 
Lost to follow-up      YES !  NO ! 
Did not meet entrance criteria    YES !  NO ! 
Subject no longer willing to participate   YES !  NO ! 
Withdraw due to pregnancy    YES !  NO ! 
Study terminated by sponsor    YES !  NO ! 
Other       YES !  NO ! 
Specify ______________________________ 
 
Investigator’s declaration 
_____________________________________________________________________ 
 
I have reviewed this subject’s data and confirm that, to the best of my knowledge, it 
accurately reflects the study information obtained from the subject. 
 
Investigator Signature:        
 
Date (dd-mm-yyyy)     _______________________________________ 
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Appendix 10 – Protocol for CONVICT study 
 
 
It is a requirement of Good Clinical Practice (GCP) and the Research Governance Framework 
for Health & Social Care 2005, that all research projects have a scientifically sound and ethically 
valid protocol.  
The protocol is the starting point of any high quality research and all research studies must be 
conducted according to the protocol. A protocol provides written evidence for the necessity and 
feasibility of a study, as well as giving a detailed plan of investigation.  
This document is to be submitted for approval to a Research Ethics Committee and the 
Competent Authority (MHRA). This allows the regulatory, ethical and peer review processes to 
validate the scientific and ethical considerations of the study. The guidance detailed below is for 
Clinical Trials of Investigational Medicinal Products (CTIMPs). 
Red border or text – Mandatory text – not be changed or removed 
Blue border or text – further details to be inserted in line with the comments attached  
Yellow border or text – if applicable to this study, further details to be inserted 
Purple border or text – further information to be inserted by the statistician 
 
The front page of the Protocol requires the full study title along with the EudraCT number for 
that protocol.  
 
The protocol must be versioned and dated with the date of finalisation of the version.  
 
(If there are any subsequent changes made to the protocol, both the version number and 
finalisation date should be updated accordingly.) 
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TITLE OF THE PROTOCOL: 
 
Effects of a combination of varenicline and transdermal nicotine patch on post-quitting urges to 
smoke 
Short title/Acronym: Combination of NRT and varenicline to increase cessation of tobacco 
(CONVICT Study) 
Sponsor: Queen Mary University of London 
 Representative of the Sponsor: 
  
  
 
  
  
  
  
  
 
REC reference: 10/H0709/85 
EudraCT reference: 2010-022334-92 
Clinical Trial Registration No: NCT01184664 
 
Version control 
Version Date Comments 
Version 1.0 25 May 2010  
Version 1.1 14 Dec 2010 Updated and approved by Ethics Committee 
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STUDY SUMMARY/SYNOPSIS  
TITLE Effects of a combination of varenicline and transdermal nicotine patch 
on post-quitting urges to smoke 
SHORT TITLE Combination of NRT and varenicline to increase cessation of tobacco 
(CONVICT study) 
Protocol Version Number 
and Date 
Version 1.1 (14 Dec 2010) 
 
Methodology 
 
Randomised double blind placebo controlled trial 
Study Duration 
 
1-year 
Study Centre 
 
Single centre: Tobacco Dependence Research and Treatment Unit 
Objectives 
 
Primary objective: To determine if combining NRT and varenicline 
provides better withdrawal and craving relief in the first week of 
abstinence than varenicline alone. 
Secondary objective: To determine the effect of combination NRT 
and varenicline use on ratings of urges in the first  24 hours of 
abstinence, short-term abstinence rates and withdrawal symptoms 
during the first 4-weeks of abstinence; client ratings of treatments; and 
adverse effects of combined NRT and varenicline use. 
Phase of the Trial 
 
Phase IV 
Number of 
Subjects/Patients 120 smokers who want to quit 
Main Inclusion Criteria 
 
Smokers seeking treatment, aged 18 and over, consenting to take part 
in the trial 
Statistical Methodology and 
Analysis 
 
Differences between the varenicline with NRT and varenicline with 
placebo arms will be assessed using analysis of variance for 
continuously distributed endpoints and using chi-square tests for 
categorical endpoints. The relationship between pre-quit variables and 
post-quit endpoints will be assessed using regression modelling. 
The primary analysis will include only those who attended the first 
weekly treatment session and provided an MPPS score. Randomised 
patients lost to follow-up will be classified as non-abstainers in all 
analyses.  
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Glossary of Terms and Abbreviations  
 
AE   Adverse Event    
AR   Adverse Reaction 
ASR   Annual Safety Report 
CA   Competent Authority 
CI   Chief Investigator 
CRF   Case Report Form 
CRO   Contract Research Organisation 
CTA   Clinical Trial Authorisation 
CTIMP   Clinical Trial of Investigational Medicinal Product 
DMC   Data Monitoring Committee 
EC   European Commission 
EMEA   European Medicines Agency 
EU   European Union 
EUCTD  European Clinical Trials Directive 
EudraCT  European Union Drug Regulating Authorities Clinical Trials  
EudraVIGILANCE European Union Drug Regulating Authorities Pharmacovigilance 
GAfREC Governance Arrangements for NHS Research Ethics Committees 
GCP   Good Clinical Practice 
GMP   Good Manufacturing Practice  
IB   Investigator Brochure 
ICF   Informed Consent Form 
IMP   Investigational Medicinal Product 
IMPD   Investigational Medicinal Product Dossier 
ISRCTN International Standard Randomised Controlled Trial Number 
JRO   Joint Research and Development Office 
MA   Marketing Authorisation 
MHRA   Medicines and Healthcare products Regulatory Agency 
MS   Member State 
Main REC  Main Research Ethics Committee 
NHS R&D  National Health Service Research & Development   
PI   Principle Investigator 
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QA   Quality Assurance 
QC   Quality Control 
QP   Qualified Person for release of trial drug 
Participant  An individual who takes part in a clinical trial 
RCT   Randomised Controlled Trial 
REC   Research Ethics Committee 
SAE   Serious Adverse Event 
SAR   Serious Adverse Reaction 
SDV   Source Document Verification 
SmPC   Summary of Product Characteristics 
SOP   Standard Operating Procedure  
SSA   Site Specific Assessment 
SUSAR  Suspected Unexpected Serious Adverse Reaction  
TMG   Trial Management Group 
TSC   Trial Steering Committee 
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 Introduction  
 
1.1 Background  
Nicotine replacement therapy (NRT) is the most widely used medicine for smoking cessation. Almost 
70% of NHS-SSS patients used NRT last year in 2009 (The Health and Social Care Information 
Centre, 2009). There are extensive data showing the efficacy of NRT (Stead et al., 2008a) however 
despite its good track record people who use NRT still have a less than 20% chance of quitting for a 
year or more. 
 
Varenicline is a partial nicotinic agonist which acts on alpha4 beta2 nicotinic receptors. It is presumed 
to alleviate withdrawal discomort, but also to diminish rewarding effects of cigarettes. In studies 
evaluating its efficacy, patients who lapsed and smoked after the target quit date were asked to rate 
their experience. Compared to patients on placebo, bupropion and nicotine patch, those on varenicline 
derived less satisfaction from their cigarettes (West et al., 2008, Jorenby et al., 2006, Gonzales et al., 
2006, Aubin et al., 2008). 
 
Combining varenicline and NRT may in theory improve withdrawal relief; help to extinguish smoking 
rewards and lower the risk of lapses translating into relapse, and/or NRT may reduce some withdrawal 
symptoms which are less sensitive to varenicline and vice versa. There are smokers who report no 
reaction to one of the treatments who may be sensitive to the other and the combination may be of 
particular benefit to this group. 
 
Such hypotheses have not been experimentally evaluated. One cohort report from an in-patient 
smoking cessation facility found no difference between NRT plus varenicline combination and NRT 
plus bupropion (Ebbert et al., 2009). As there was no ‘NRT only’ or ‘varenicline only’ group, the 
results are difficult to interpret, but the report reinforces the need to conduct a randomised ‘proof-of-
concept’ study before launching into a large outcome trial. 
 
Regarding the safety of combination use of NRT and varenicline a single pre-marketing study showed 
that smokers using varenicline and transdermal patch for 12 days reported a higher incidence of nausea, 
headache, vomiting, dizziness, dyspepsia, and fatigue than smokers who used NRT alone (Pfizer 
Limited, 2009). However these symptoms may have been due to varenicline use, as opposed to 
combined use of varenincline and NRT. Post-marketing data suggests that combined use of varenicline 
and NRT is well tolerated (Ebbert et al., 2009). 
 
This is a proposal to examine whether combining NRT and varenicline provides better withdrawal and 
craving relief than varenicline alone, in a sample of 120 smokers who want to quit, short-term post-
quitting urges to smoke and withdrawal severity.  
 
1.2 Investigational Medicinal Product - VARENICLINE 
Sections 1.2 – 1.5 are taken from the Summary of Product Characteristics for varenicline. 
Varenicline binds with high affinity and selectivity at the !4"2 neuronal nicotinic acetylcholine 
receptors, where it acts as a partial agonist - a compound that has both agonist activity, with lower 
intrinsic efficacy than nicotine, and antagonist activities in the presence of nicotine. 
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1.2.1 Preclinical Data  
Non-clinical data reveal no special hazard for humans based on conventional studies of safety 
pharmacology, repeated dose toxicity, genotoxicity, fertility and embryo-foetal development. In male 
rats dosed for 2 years with varenicline, there was a dose-related increase in the incidence of hibernoma 
(tumour of the brown fat). In the offspring of pregnant rats treated with varenicline there were 
decreases in fertility and increases in the auditory startle response. These effects were observed only at 
exposures considered sufficiently in excess of the maximum human exposure indicating little relevance 
to clinical use. Nonclinical data indicate varenicline has reinforcing properties albeit with lower 
potency than nicotine. In clinical studies in humans, varenicline showed low abuse potential. 
 
1.2.2 Clinical Data  
The efficacy of CHAMPIX in smoking cessation is a result of varenicline's partial agonist activity at 
the !4"2 nicotinic receptor where its binding produces an effect sufficient to alleviate symptoms of 
craving and withdrawal (agonist activity), while simultaneously resulting in a reduction of the 
rewarding and reinforcing effects of smoking by preventing nicotine binding to !4"2 receptors 
(antagonist activity). 
 
1.2.3 Rationale and Risks/Benefits  
Smoking cessation with or without treatment is associated with various symptoms. For example, 
dysphoric or depressed mood; insomnia, irritability, frustration or anger; anxiety; difficulty 
concentrating; restlessness; decreased heart rate; increased appetite or weight gain have been reported 
in patients attempting to stop smoking. No attempt has been made in either the design or the analysis of 
the CHAMPIX studies to distinguish between adverse events associated with study drug treatment or 
those possibly associated with nicotine withdrawal. 
Clinical trials included approximately 4,000 patients treated with CHAMPIX for up to 1 year (average 
exposure 84 days). In general, when adverse reactions occurred, onset was in the first week of therapy; 
severity was generally mild to moderate and there were no differences by age, race or gender with 
regard to the incidence of adverse reactions. 
In patients treated with the recommended dose of 1mg BID following an initial titration period the 
adverse event most commonly reported was nausea (28.6%). In the majority of cases nausea occurred 
early in the treatment period, was mild to moderate in severity and seldom resulted in discontinuation. 
The treatment discontinuation rate due to adverse events was 11.4% for varenicline compared with 
9.7% for placebo. In this group, the discontinuation rates for the most common adverse events in 
varenicline treated patients were as follows: nausea (2.7% vs. 0.6% for placebo), headache (0.6% vs. 
1.0% for placebo), insomnia (1.3% vs. 1.2% for placebo), and abnormal dreams (0.2% vs. 0.2% for 
placebo). 
 
1.3 Investigational Medicinal Product – NICOTINE TRANSDERMAL PATCH 
Sections 1.2 – 1.5 are taken from the Summary of Product Characteristics for Nicorette® 15mg 
transdermal patch 
Nicotine has no therapeutic uses except as replacement therapy for the relief of abstinence symptoms in 
nicotine-dependent smokers. Owing to its many actions, the overall effects of nicotine are complex. A 
wide variety of stimulant and depressant effects are observed that involve the central and peripheral 
nervous, cardiovascular, endocrine, gastro-intestinal and skeletal motor systems. Nicotine acts on 
specific binding sites or receptors throughout the nervous system. 
1.3.1 Preclinical Data  
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Preclinical data indicate that nicotine is neither mutagenic nor genotoxic. 
 
1.3.2 Clinical Data  
Nicorette Patch is indicated for the relief of nicotine withdrawal symptoms as an aid to smoking 
cessation in adults and children over 12 years of age. It is also indicated in pregnant and lactating 
women. 
 
No clinically relevant interactions between nicotine replacement therapy and other drugs has definitely 
been established. However nicotine may possibly enhance the haemodynamic effects of adenosine i.e. 
increase in blood pressure and heart rate and also increase pain response (angina-pectoris type chest 
pain) provoked by adenosine administration. 
1.3.3 Rationale and Risks/Benefits  
There are no risks in using nicotine replacement therapy in people who smoke as it provide only 
nicotine that smokers would have other received from tobacco. Nicorette Patch may cause adverse 
reactions similar to those associated with nicotine given by other means, including smoking, and these 
are mainly dose-dependent. At recommended doses Nicorette Patch has not been found to cause any 
serious adverse effects. Excessive use of Nicorette Patch by those who have not been in the habit of 
inhaling tobacco smoke could possibly lead to nausea, faintness or headaches. About 20% of Nicorette 
patch users experience mild local skin reactions, during the first weeks of treatment. In some patients 
the skin reactions may become more severe eg skin blistering or a burning sensation or may be more 
generalized. 
 
2. Trial Objectives and Design 
2.1 Trial Objectives  
Primary Objective 
The principal question this project plans to answer is does using a combination of varenicline and NRT 
reduce post-quitting urges to smoke more than varenicline alone. 
 
Secondary Objectives 
In addition to change in urges to smoke this study will determine if combined use of varenicline and 
NRT: 
Affects severity of withdrawal symptoms over 4-weeks after quitting 
Affects 4-week and 12-week abstinence rates 
Is associated with an increase in adverse effects 
 
Primary Endpoint 
Ratings of urges to smoke one week after the target quit date assessed by Mood and Physical 
Symptoms Scale [MPSS] (West and Hajek, 2004). 
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Secondary Endpoints 
Ratings of urges to smoke 24 hours after target quit date, change in MPSS scores of urges to smoke and 
tobacco withdrawal symptoms throughout the first four weeks of abstinence; client ratings of 
treatments; adverse events profile; abstinence rates at 4-weeks and 3-months. 
 
2.2 Trial Design  
This is a randomised double blind placebo-controlled trial. Participants will be randomised to using 
varenicline plus nicotine 15mg/16hr transdermal patch or varenicline plus placebo 15mg/16hr patch. 
Varenicline will be used in the standard way (commenced 1-week prior to quitting and continued for 
12 weeks). The patches will be started on the quit day and be used for 4-weeks.  
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2.3 Study Scheme Diagram  
 
  Study information provided and eligible smokers invited to attend a 
baseline session 
  ! 
Day 0  Session 1: Baseline Visit 
(consent and baseline data collected) 
  ! 
Day 7  Session 2: Preparation Session 
(commence varenicline) 
  ! 
Day 14  Session 3: Target Quit Day 
(randomization) 
  !  ! 
  Varenicline + 15mg patch  Varenicline + 0mg patch 
  !  ! 
Day 15  Session 4: 24 hour telephone 
call 
 Session 4: 24 hour telephone 
call 
  !  ! 
Days 21-
35 
 Sessions 5-7: Treatment 
sessions 
 Sessions 5-7: Treatment 
sessions 
  !  ! 
Day 42  Session 8: Last treatments 
session (patches discontinued, 
varenicline continued) 
 Session 8: Last treatments 
session (patches discontinued, 
varenicline continued) 
  !  ! 
Day 98  Session 9: 12-week follow-up 
(varenicline discontinued) 
 Session 9: 12-week follow-up 
(varenicline discontinued) 
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3. Subject Selection 
 
3.1    Number of Subjects and Subject Selection  
A total of 120 smokers who want to quit will be recuited for this study 
 
Participants would be recruited by advertising in London Newspapers including the Evening Standard, 
Metro, and local papers. Callers would be mailed study information and baseline questionnaire and 
invited to attend a baseline session several days later. 
Prior to randomisation all particpants will provide written informed consent.  
The expected duration of participation in this study is 14 weeks (2 weeks prior to and 12 weeks after 
the target quit date). 
 
3.2    Inclusion Criteria  
Smokers seeking treatment, aged 18 and over, consenting to take part in the trial. 
 
3.3 Exclusion Criteria  
Current psychiatric illness, pregnant or breastfeeding, end-stage renal disease, previous allergic 
reaction to varenicline or patch, females planning to conceive during the study period, unable to fill in 
the questionnaire in English, currently involved or intends to be involved in another research project. 
 
3.4 Criteria for Premature Withdrawal  
(1) The participant withdraws his/her consent to participate 
 
(2) Withdrawal events 
These are events leading to withdrawal from the trial although participants will continue to be followed 
with the same schedule of clinic visits. The following events are grounds for withdrawal from the 
study: 
Acute myocardial infarction, angina pectoris, or other serious medical condition 
A major psychiatric disorder which impedes compliance with trial protocol 
Pregnancy 
A serious adverse drug event (defined as any untoward medical occurrence that at any dose results in 
death, in significant or permanent disability or incapacity, is life-threatening, requires hospitalisation or 
prolongs hospitalisation). In the event of a serious adverse drug event the investigator will notify the 
appropriate ethical committee and sponsor within 48 hours of becoming aware of the event 
 
4. Investigational Medicinal Product  
4.1 List and definition of each IMP, including placebos   
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Test condition 
Standard dose of varenicline (Champix™) 1 mg bid combined with Nicorette® 15mg patch 
 
Reference condition 
Standard dose of varenicline (Champix™) 1 mg bid combined with Nicorette® 0mg (placebo) patch 
 
4.2 Formulation of IMP 
 
Varenicline (Champix™) Film-coated tablet 
0.5 mg film-coated tablets (commercial supply): White, capsular-shaped, biconvex tablets debossed 
with “Pfizer” on one side and “CHX 0.5” on the other side. Each film-coated tablet contains 0.5 mg of 
varenicline (as tartrate). 
 
1 mg film-coated tablets (commercial supply): Light blue, capsular-shaped, biconvex tablets debossed 
with “Pfizer” on one side and “CHX 1.0” on the other side. Each film-coated tablet contains 1 mg of 
varenicline (as tartrate). 
 
Excipients: Core Tablet, Cellulose, Microcrystalline, Calcium Hydrogen Phosphate Anhydrous, 
Croscarmellose Sodium, Silica, Colloidal Anhydrous, Magnesium Stearate, Film Coating, 
Hypromellose, Titanium Dioxide (E171), Macrogols, Triacetin 
 
Nicorette® 15mg/16 hour transdermal patch 
Nicotine, 15mg released over 16 hours use. Each patch is 30 sq.cm, containing nicotine 0.83mg/sq.cm. 
Excipients: Medium molecular weight polyisobutylene, Low molecular weight polyisobutylene, 
Polybutylene, Polyester non-woven backing film, Siliconised polyester release liner 
 
Placebo 0mg/16 hour transdermal patch 
The placebo patch is identical to the standard patch except that it contains no nicotine. 
 
4.3 IMP Supply  
 
Dispatch of study medications:  
A commercial supply of varenicline, supplied by Pfizer, will come from the EU (residing in a 
warehouse in the UK).  
Patches will be supplied by McNeil Products Limited within the EU. 
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Name and address of manufacturer of varenicline: Pfizer GmbH Werk Godecke, Mooswaldallee 1, 
Freiburg, D-79090, Germany 
 
Manufacturer authorisation number: 25-5482/2-FR 
 
Name and address of manufacturer of nicotine 15mg/16hr patches 
McNeil Products Limited 
Foundation Park  
Roxborough Way  
Maidenhead  
Berkshire  
SL6 3UG  
UK  
 
Manufacturer authorisation number: PL 15513/0177  
 
 
Name and address company packaging study medication: Bilcare GCS (Europe) Ltd, Waller 
House, Elvicta Business Park, Crickhowell Powys, NP8 1DF 
 
Manufacturer authorisation number: MA IMP 10284 
 
4.4 Prescription of IMP  
IMP will be supplied by study staff under the supervision of the study physician.  
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4.5 Preparation and Administration of IMP  
 
The table below shows the study treatment regimen. 
Day(s) 7-13 14-42 43-98 
Session(s) 2 3 - 8 9 
Varenicline dose Days 1-3: 0.5mg o.d. 
Days 4-7: 0.5mg b.d. 
1mg b.d 1mg b.d 
Patch dose Nil 15mg/16hr or 
0mg/16hr o.d. 
Nil 
 
4.6 Packaging and Labelling of IMPs  
A 4-week supply of patches (active or placebo) will be packaged into a single box. Computer generated 
randomisation codes will be affixed to each box. The medication boxes will be sorted in numerical 
order and will be dispensed sequentially at the study site. 
 
4.7 Accountability/Receipt /Storage and Handling of IMP  
All packaged medications will be shipped to the Pharmacy (The Royal London) where they will be 
securely stored until required for dispensing in the study.  Medications will not be dispensed to 
participants by the pharmacy, as study visits will be after hours. Instead, the study manager will be 
responsible for collecting study medications from the pharmacy when required and transferred to 
storage on the study site (Tobacco Dependence Research and Treatment Unit) in a locked cabinet in a 
locked room. Room temperature will be monitored on a daily basis. Only the study manager will have 
access to study medicines. 
 
4.8 Dispensing of IMP  
 
All participants will receive a commercial starter pack of varenicline at session 2. They will receive a 
commercial continuation pack (56 1mg tablets) at session 4, and a further two continuation packs at 
session 8. Participants will be randomised to either active patch or placebo by randomisation codes that 
will be prepared by computer in advance. On arrival on session 3 participants will be sequentially 
allocated to a randomisation code. The study staff will retrieve the product corresponding to the 
relevant randomisation code.  
 
IMP will be dispensed by the study manager at the clinic site under supervision of the study doctor. A 
dispensing log will be kept. Participants will be asked to return any unused medication each week. 
Quantities of returned medication will be counted to assess compliance with treatment.  
 
4.9 IMP Stability  
The IMPs are stable at room temperature. 
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4.10 Prior and Concomitant Therapies  
Information on whether the participants are currently taking concomitant therapy will be gathered 
during the first session prior to randomisation. There are no known drug interactions with varenicline 
or nicotine replacement therapy. 
 
4.11 Dose modification/reduction/ delay  
Not applicable 
 
4.12  Return/Recall or Destruction of IMP   
Unused study medication will be returned to the Bilcare for destruction. Return of study drugs will be 
documented in the study files. 
 
5. Study Procedures  
5.1 Informed Consent Procedures 
All participants for this study will be provided with a consent form describing this study and providing 
sufficient information for participants to make an informed decision about their participation in this 
study. This consent form will be submitted with the protocol for review and approval by the ethics 
committee.  The formal consent of a participant, using the approved consent form, will be obtained 
before that participant is submitted to any study procedure.  This consent form will be signed by the 
participant, and the investigator-designated research professional (in this case the study physician) 
obtaining the consent.  
 
Before obtaining his/her consent, the investigator will inform each participant of the objectives, 
benefits, risks and requirements of the study, as well as the nature of the test medication.  An 
information sheet drafted in simple language will be given to each participant. All participants will 
have at least 24 hours to consider if they wish to take part. 
 
All participants will give their written informed consent before entering the study. The consent form 
will be dated and co-signed by the investigator-designated research professional and the patient. A 
copy of the consent form will be provided to the participant. 
 
5.2 Screening Procedures  
At the baseline session, study details will be discussed and informed consent collected. Participants 
will be screened for inclusion and exclusion criteria. 
 
5.3 Randomisation Procedures  
Participants will be randomised to either active patch or placebo patch by randomisation codes that will 
be prepared by computer in advance. On arrival on the quit day session (session 3) participants will be 
sequentially allocated to a randomisation code. The study staff will retrieve the product corresponding 
to the relevant randomisation code.  
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5.4 Schedule of Treatment for each visit  
Session 1: Baseline Session 
At baseline session study details would be discussed and informed consent collected. Participants 
would be screened for inclusion and exclusion criteria. They would have CO measured in expired 
breath (this will be measured at every session) and receive information on the preparation session to be 
held on the following week. All participants would be asked to smoke ad-lib until the target quit day 
(TQD) when they will be asked to stop smoking.  
 
Session 2: Preparation session 
This session would be one week prior to participant’s TQD. They would receive advice and support 
regarding their quit attempt and start their preparation. All participants would be provided with a 
standard varenicline starter pack, which they will start on the next day. 
 
Session 3: Target Quit Date Session 
Participants would be randomised to receive a four-week supply of active (15mg/16hr) or placebo 
patches on this day. They would be instructed to start using these at this session. Standard behavioural 
support will be provided. 
 
Session 4: 24-hour telephone call 
Participants will be called 24 hours after their TQD. Occurrence and severity of urges to smoke and 
tobacco withdrawal symptoms will be measured. Information on any adverse events will also be 
collected. Brief behavioural support will also be provided. 
 
Sessions 5-8: Weekly treatment sessions 
Participants will be provided with behavioural support and medication. Patches will be provided until 
session 8. An 8-week supply of varenicline will be provided at session 8. The occurrence and severity 
of tobacco withdrawal symptoms and adverse events will be measured at each session. Information on 
any adverse events will also be collected. Satisfaction with the treatment will also be assessed via self-
completed questionnaire at session 8. 
 
Most treatment sessions will take place between the hours of 5 and 7 pm during weekdays. 
 
Session 9: 12-week follow-up 
Participants will be asked to attend a 12-week follow up visit to measure abstinence. The occurrence 
and severity of tobacco withdrawal symptoms and adverse events will be measured   
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5.5 Schedule of Assessment  
 
Table 2: Study sessions 
DAY 0 7 14 15 21 28 35 42 98 
Session number 1 2 3 Phone 
call 1 
5 6 7 8 9 
Measures/ 
procedures 
Base-
line 
visit 
Wk 1 
visit 
Wk 0 
TQD 
24h 
call 
Wk 1 
visit 
Wk 2 
visit 
Wk 3 
visit 
Wk 4 
visit 
Wk 12 
visit 
Informed consent X         
Baseline 
questionnaire 
X         
FTND X         
CO X X X  X X X X X 
MPSS X X X X X X X X X 
Medication 
dispensed 
 X X  X   X  
Weight X X X  X X X X X 
Smoking 
status/rate 
X X X X X X X X X 
Adverse events   X X X X X X X 
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5.6 Measures 
All proposed questionnaire measures are contained in the Baseline Smokers Clinic Questionnaire and 
Clinical Record Forms. These include the following: 
 
Baseline questionnaire: Demographic details, health status, and smoking history. 
Fagerstrom Test of Nicotine Dependence (FTND): Measure of dependence (Heatherton et al., 1991). 
End-expired carbon monoxide reading: Collected using a Bedfont CO monitor  
Mood and Physical Symptoms Scale (MPSS): Measure of severity of tobacco withdrawal symptoms 
(West and Hajek, 2004). 
Smoking rate: Estimate of the average number of cigarettes smoked per day since the last visit 
Smoking status: Any cigarettes smoked since last visit 
Adverse events: Participants will be asked about the occurrence of any adverse events (AE’s) at each 
contact. 
Weight: Participants will have their weight taken at each session 
 
5.7 End of Study Definition  
The last participant completes 3-month (post TQD) follow-up. 
 
5.8 Procedures for unblinding  
In the event of an SAE the principal investigator will agree to the unblinding. The Principal 
Investigator is responsible for following the unblinding procedures when unblinding subjects from a 
trial and/or during study closeout.  In instances when the PI needs to remain blinded, another member 
of the research team will be responsible for following these procedures. 
The study statistician will hold the randomisation codes. A second responsible person, who is not a 
member of the study team, but located at the study site will hold the randomisation codes in a sealed 
envelope. 
In the event of unblinding the standard operating procedure for unblinding will be followed. The 
unblinding will be recorded as a protocol violation. 
All SAEs reported to the MHRA by the R&D office will be unblinded reports. 
 
5.9 Subject Withdrawal  
(1) The participant withdraws his/her consent to participate 
 
(2) Withdrawal events 
These are events leading to withdrawal from the trial although participants will continue to be followed 
with the same schedule of clinic visits. The following events are grounds for withdrawal from the 
study: 
Acute myocardial infarction, angina pectoris, or other serious medical condition 
418 
 
A major psychiatric disorder which impedes compliance with trial protocol 
Pregnancy 
A serious adverse drug event (defined as any untoward medical occurrence that at any dose results in 
death, in significant or permanent disability or incapacity, is life-threatening, requires hospitalisation or 
prolongs hospitalisation). In the event of a serious adverse drug event the investigator will notify the 
appropriate ethical committee and sponsor within 48 hours of becoming aware of the event 
 
5.10 Data Collection and Follow up for Withdrawn Subjects  
If a participant is withdrawn from the study or withdraws consent to participate in the study part way 
through, attempts will be made to obtain permission to record at least adverse events and other data up 
to the end of the last visit. This will be done via phone calls to the participant and contact with the 
participant’s general practitioner. 
 
6. Laboratories 
No laboratory services will be used in this study. 
 
7. Pharmacovigilance  
 
7.1 General Definitions 
 
7.1.1 Adverse Event (AE) 
An AE is any untoward medical occurrence in a subject to whom a medicinal product has been 
administered, including occurrences which are not necessarily caused by or related to that product.  An 
AE can therefore be any unfavourable and unintended sign (including an abnormal laboratory finding), 
symptom or disease temporarily associated with the use of an Investigational Medicinal Product (IMP), 
whether or not considered related to the IMP. 
 
7.1.2 Adverse Reaction (AR)  
An AR is any untoward and unintended response in a subject to an Investigational Medicinal Product 
(IMP), which is related to any dose administered to that subject.  All adverse events judged by either 
the reporting investigator or the Sponsor as having a reasonable causal relationship to a medicinal 
product qualify as adverse reactions. The expression reasonable causal relationship means to convey in 
general that there is evidence or argument to suggest a causal relationship. 
 
7.1.3       Serious Adverse Event (SAE) or Serious Adverse Reaction (SAR)  
An SAE fulfils at least one of the following criteria: 
Is fatal – results in death (NOTE: death is an outcome, not an event) 
Is life-threatening 
Requires inpatient hospitalisation or prolongation of existing hospitalisation 
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Results in persistent or significant disability/incapacity 
Is a congenital anomaly/birth defect 
 
Serious Adverse Reaction (SAR) 
An SAR is an adverse reaction that is classed as serious and which is consistent with the information 
about the medicinal product as set out in the Summary of Product Characteristics (SmPC) or 
Investigator’s Brochure (IB) for that product.   
 
7.1.4 Suspected Unexpected Serious Adverse Reaction (SUSAR)  
The definition of a SUSAR is any serious adverse event related to an IMP that is both suspected to be 
related to the IMP and unexpected. In this case the event is not outlined in the Summary of Product 
Characteristics (SmPC) or Investigator’s Brochure (IB) for that product.  
 
7.2 Investigators Assessment  
 
7.2.1 Seriousness 
The Chief/Principal Investigator responsible for the care of the patient, or in his absence an authorised 
medic within the research team, is responsible for assessing whether the event is serious according to 
the definitions given in section 7.1. 
 
7.2.2 Causality 
The Investigator must assess the causality of all serious adverse events/reactions in relation to the trial 
treatment according to the definition given. If the SAE is assessed as having a reasonable causal 
relationship, then it is defined as a SAR. 
 
7.2.3 Expectedness 
The investigator must assess the expectedness of all SARs according to the definition given.  If the 
SAR is unexpected, then it is a SUSAR. 
 
7.2.4 Severity 
The Investigator must assess the severity of the event according to the following terms and 
assessments. The intensity of an event should not be confused with the term “serious” which is a 
regulatory definition based on patient/event outcome criteria. 
 
Mild: Some discomfort noted but without disruption of daily life 
Moderate: Discomfort enough to affect/reduce normal activity 
Severe: Complete inability to perform daily activities and lead a normal life 
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7.3 Notification and reporting Adverse Events or Reactions 
If the AE is not defined as SERIOUS, the AE is recorded in the study file and the participant is 
followed up by the research team. The AE is documented in the participants’ medical notes (where 
appropriate) and the CRF. 
 
7.4 Notification and Reporting of Serious Adverse Events/SUSAR  
 
7.4.1 All Serious Adverse Event (SAEs) will be recorded in the subjects’ notes, the CRF, the sponsor 
SAE form and reported to the Joint Research and Development Office (JRO)/ IMP provider (if 
applicable) within 24 hours of the CI or PI or co-investigators becoming aware of the event.  
Nominated co-investigators will be authorised to sign the SAE forms in the absence of the CI at the co-
ordinating site or the PI at the participating sites. Please ensure that the sponsor has been informed of 
these nominated co-investigators. 
 
7.4.2 Suspected Unexpected Serious Adverse Reactions (SUSARs) that occur during the trial will be 
reported to the JRO/ main REC/IMP provider (if applicable) within 24 hours of the CI or co-
investigator becoming aware of the event. SUSARs should be reported to the sponsor (JRO Office) 
within 24 hours as the sponsor has a legal obligation to report this to the MHRA within 7 days (for fatal 
or life-threatening SUSARs) or 15 days for all other SUSARs. In the case of multicentre studies, the PI 
or the co-investigators at the participating site must inform the CI within 24 hours of the event. The CI 
or co-investigators at the co-ordinating site must inform the sponsor (JRO) immediately to allow 
reporting to the MHRA within the allocated timelines.  The CI will need to complete the CIOMS form 
in conjunction with the sponsor SAE form to be sent to the MHRA by the sponsor. If warranted, an 
investigator alert may be issued, to inform all investigators involved in any study with the same drug 
(or therapy) that this serious adverse event has been reported. 
 
The original and any subsequent follow up of Serious Adverse Event Forms and CIOMS forms (where 
applicable), together with the fax confirmation sheet must be kept with the TMF at the study site. 
 
7.5 Urgent Safety Measures 
The CI may take urgent safety measures to ensure the safety and protection of the clinical trial subjects 
from any immediate hazard to their health and safety, in accordance with Regulation 30. The measures 
should be taken immediately. In this instance, the approval of the Licensing Authority Approval prior 
to implementing these safety measures is not required. However, it is the responsibility of the CI to 
inform the sponsor, Main Research Ethics Committee (via telephone) and the MHRA (via telephone 
for discussion with the medical assessor at the clinical trials unit) of this event immediately.  
 
The CI has an obligation to inform both the MHRA and Main Ethics Committee in writing within 3 
days, in the form of a substantial amendment. The sponsor (JRO) must be sent a copy of the 
correspondence with regards to this matter. 
 
7.6 Annual Safety Reporting  
The Annual Safety Reports (ASR) will be sent by the CI to the sponsor, the MREC and MHRA (the 
date of the anniversary is the date on the “notice of acceptance letter” from the MHRA) using the ASR 
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form. The CI will carry out a risk benefit analysis of the IMPs encompassing all events having arisen 
on the trial.  
 
The CI will send the Annual Progress Report to the main REC using the NRES template (the 
anniversary date is the date on the MREC “favourable opinion” letter from the MREC) and to the 
sponsor. 
 
7.7 Procedures for reporting blinded SUSARs 
In the case of a blinded study, it is recommended the treatment code for the patient is broken in the 
reporting of a SUSAR. However, the blind should be maintained, where possible and appropriate, for 
staff that are involved in data analysis and interpretation. It is the allocated responsibility of the CI by 
the sponsor for pharmacoviligance management and reporting. In this instance, an allocated unblinded 
individual (s), with no involvement in data management of the study should be responsible for the 
unblinding event. The unblinding of single cases by the PI/CI in the course of a clinical trial should 
only be performed if necessary for the safety of the trial subject. 
 
It is recommended that in the case of a blinded study, the case is assessed for seriousness, expectedness 
and causal relationship as if it was the tested IMP that caused the reaction. If the case appears to be a 
SUSAR then it should be unblinded and the following considered: 
 
If the administered product is the tested IMP, the case would be reported as a SUSAR to the MHRA/ 
appropriate Main Research Ethics Committee/IMP provider (if applicable) within the timelines 
outlined in section 7.4.2. 
 
If the administered product is a comparator with a marketing authorisation, the adverse reaction should 
be reassessed for expectedness according to the study protocol. If the adverse reaction is unexpected 
then the SUSAR should be reported; otherwise it is an expected serious adverse reaction which still 
requires reporting to the sponsor/IMP provider (if applicable) within 24 hours. 
 
7.8 Overview of the Safety Reporting Process/Pharmacoviligance responsibilities 
The CI/PI has the overall pharmacovigilance oversight responsibility. The CI/PI has a duty to ensure 
that pharmacovigilance monitoring and reporting is conducted in accordance with the sponsor’s 
requirements.  
 
Please outline the process/organisation within the study team to ensure that all SAE/SUSAR reporting 
is conducted in accordance with the sponsor’s timelines. Display this information within an 
organogram to be located in the appendices in section 15 to ensure that there is a clear and distinct 
reporting process outlined with the study members detailed within this process. 
 
7.9 Pregnancy  
If a patient becomes pregnant whilst involved in a CTIMP, it is not considered to be an SAE or an AE. 
However, it is an event that requires monitoring and follow up. If a patient, or his partner, becomes 
pregnant whilst enrolled in a CTIMP in which the foetus has been exposed to an investigational 
medicinal product, immediate reporting to the sponsor is required (within one working day of the PI/CI 
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becoming aware of the event) using a JRO pregnancy template form. The CI/PI has the responsibility 
to ensure that the pregnancy form is completed and sent to the sponsor within the agreed timelines. 
Please state whether the patient can continue on the study or whether the patient has to be prematurely 
withdrawn from the study here. 
 
The PI/CI also must follow up the pregnancy until delivery as well as monitoring the development of 
the newborn for the appropriate time (please indicate for this IMP) after birth. Any events that occur 
during this time that could be considered to be a SAE must be reported to the sponsor in line with 
section 7.4.1, utilising the sponsor SAE reporting form. 
 
8. Statistical Considerations 
 
8.1 Primary Endpoint Efficacy Analysis  
The primary endpoint is MPSS ratings of urges to smoke during the first week of abstinence. The 
difference between groups will be assessed using analysis of variance. 
 
8.2 Secondary Endpoint Efficacy Analysis  
Differences in validated abstinence rates over 12 weeks of abstinence will be assessed using chi-square 
tests. 
 
8.3 Safety Endpoints  
Type and frequency of adverse events will be reported. Frequency of adverse events between groups 
will be assessed using chi-square tests. 
 
8.4 Sample Size  
MPSS is a rating scale sensitive to tobacco withdrawal and to both pharmacological (West et al., 1990) 
and behavioural (McRobbie and Hajek, 2007) treatment effects. Effective treatments typically generate 
a difference in ratings over the first week of abstinence of at least 0.7 compared to control procedures, 
e.g. 1.8 (SD=1) compared to 2.5 (SD=1). As in this case the advantage of the combination over the first 
week of abstinence may be subtle and even a difference of 0.6 would be worth detecting, 45 
participants would be needed in each group (p<0.05, 2-tailed test, power=0.80). Patient attrition 
between the TQD and Week 1 session is usually between 10% and 20%. The study would aim to 
randomise 120 participants. 
 
8.5 Statistical Analysis  
Differences between the varenicline with NRT and varenicline with placebo arms will be assessed 
using analysis of variance for continuously distributed endpoints and using chi-square tests for 
categorical endpoints. The relationship between pre-quit variables and post-quit endpoints will be 
assessed using regression modelling. 
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The primary analysis will include only those who attended the first weekly treatment session and 
provided an MPPS score. Randomised patients lost to follow-up will be classified as non-abstainers in 
all analyses.  
 
9. Data Handling & Record Keeping 
 
9.1 Confidentiality  
Participants will be asked to complete the standard clinic questionnaire and the additional 
questionnaires required for this study. We will not request any medical information about participants 
from their other doctors (hospital or general practitioner). All information will be kept confidential, just 
as is normal for smokers attending the Stop Smoking clinic. We will inform participants’ GPs, with 
their consent, of their participation in the study. Copies of all documents sent regarding the current 
study will be kept in the study master file.  
 
Only study staff will have access to study data. All records relating to the study will be kept strictly 
confidential. 
 
9.2 Study Documents  
A signed protocol and any subsequent amendments 
Current Summary of Product Characteristics/ Investigator’s Brochure 
Sponsor Self-Monitoring template for the trial team to complete on a regular    basis as detailed by the 
Monitoring section 
Current/Superseded Patient Information Sheets (as applicable) 
Current/Superseded Consent Forms (as applicable) 
Indemnity documentation from sponsor 
Conditions of Sponsorship from sponsor 
Conditional/Final R&D Approval  
Signed site agreement 
Ethics/MHRA submissions/approvals/correspondence 
CVs of CI and site staff 
UK regulations (GCP) course certificate of each of trial team 
Laboratory accreditation letter, certification and normal ranges for all laboratories to be utilised in the 
study 
Sample IMP labels  
IMP accountability logs 
Delegation log 
Staff training log 
424 
 
Site signature log 
Patient identification log 
Screening log 
Enrolment log  
Monitoring visit log 
Protocol training log 
Correspondence relating to the trial 
Communication Plan between the CI/PI and members of the study team 
SAE reporting plan for the study 
 
9.3 Case Report Form  
The CRF was developed by Profesor Peter Hajek, Katie Myers and Dr Hayden McRobbie. 
The elements of the CRF include: 
Registration form (Standard Smokers Clinic Questionnaire) 
Eligibility/exclusion criteria checklist 
Visit details 
Drug/dose, any dose reductions/delays 
AEs page 
End of study form 
 
9.4 Record Retention and Archiving 
During the course of research, all records are the responsibility of the Chief Investigator and must be 
kept in secure conditions. When the research trial is complete, it is a requirement of the Research 
Governance Framework and Trust Policy that the records are kept for a further 20 years. For trials 
involving BLT Trust patients, undertaken by Trust staff, or sponsored by BLT or QMUL, the approved 
repository for long-term storage of local records is the Trust Modern Records Centre which is based at 
9 Prescot Street. Site files from other sites must be archived at that external site and cannot be stored at 
the Modern Records Centre. 
 
9.5 Compliance 
The CI will ensure that the trial is conducted in compliance with the principles of the Declaration of 
Helsinki (1996), the principles of GCP and in accordance with all applicable regulatory requirements 
including but not limited to the Research Governance Framework and the Medicines for Human Use 
(Clinical Trial) Regulations 2004, as amended in 2006 and 2008, Trust and Research Office policies 
and procedures and any subsequent amendments. 
 
9.6 Clinical Governance Issues 
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9.6.1 Ethical Considerations 
This protocol and any subsequent amendments, along with any accompanying material provided to the 
patient in addition to any advertising material will be submitted by the Investigator to an Independent 
Research Ethics Committee. Written Approval from the Committee must be obtained and subsequently 
submitted to the JRO to obtain Final R&D approval. 
 
9.7 Quality Control and Quality Assurance 
 
9.7.1 Summary Monitoring Plan 
This study will be subject to the Quality Control (QC)/Quality Assurance (QA) system of the Joint 
BLT/QMUL R&D Office (JRO).  
 
The monitoring process is based on the Principal Investigator (PI) ensuring that the Study Manager 
completes a “Monitoring report” and sends it to the JRO for review. In addition, a routine check of the 
content, accuracy, and the completeness of data supplied by the PI to the JRO will be performed. This 
report will be reviewed by the JRO. Some of the data provided in the report will be entered into the 
R&D database. Any corrective/preventive actions will be followed up by the R&D Department. A 
number of reports will be selected; a staff member of the JRO will visit the trial team and verify the 
accuracy of the information entered.  
 
9.7.2 Audit and Inspection 
Auditing: Definition “A systematic and independent examination of trial related activities and 
documents to determine whether the evaluated trial related activities were conducted, and the data were 
recorded, analysed and accurately reported according to the protocol, sponsor's standard operating 
procedures (SOPs), Good Clinical Practice (GCP), and the applicable regulatory requirement(s).” 
 
A study may be identified for audit by any method listed below:  
1. A project may be identified via the risk assessment process. 
2. An individual investigator or department may request an audit. 
3. A project may be identified via an allegation of research misconduct or fraud or a suspected breach 
of regulations. 
4. Projects may be selected at random. The Department of Health states that Trusts should be auditing a 
minimum of 10% of all research projects. 
5. Projects may be randomly selected for audit by an external organisation (e.g. MHRA). 
 
Internal audits will be conducted by a sponsor’s representative 
 
9.8 Serious Breaches in GCP or the Trial Protocol 
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The sponsor of the Clinical Trial is responsible for notifying the licensing authority in writing of any 
serious breach of: 
 
The conditions and principles of GCP in connection with that trial; or 
The protocol relating to the trial, as amended from time to time in accordance with regulations 22 to 
25, within 7 days of becoming aware of that breach. 
 
For the purposes of this regulation, a ‘serious breach’, is a breach which is likely to effect to a 
significant degree: 
The safety or physical or mental integrity of the subjects of the trials; or 
The scientific value of the trial. 
 
The CI is responsible for reporting any serious breaches to the sponsor (JRO) within 24 hours. The 
sponsor will notify and report to the MHRA within 7 working days of becoming aware of the serious 
breach.     
 
9.9 Non-Compliance        
(A noted systematic lack of both the CI and the study staff adhering to SOPs/protocol/ICH-GCP and 
UK regulations, which leads to prolonged collection of deviations, breaches or suspected fraud.) 
 
These non-compliances may be captured from a variety of different sources including monitoring 
visits, CRFs, communications and updates. The sponsor will maintain a log of the non-compliances to 
ascertain if there are any trends developing which to be escalated. The sponsor will assess the non-
compliances and action a timeframe in which they need to be dealt with. Each action will be given a 
different timeframe dependant on the severity. If the actions are not dealt with accordingly, the JRO 
will agree an appropriate action, including an on-site audit. 
 
10. Trial Committees  
There will not be any data monitoring/steering/safety committees set up for this study 
 
11. Publication Policy  
Study data will be collected and held by the study investigators. Data analyses will be undertaken 
independently of the study funders. 
 
A paper will be written for publication in a peer reviewed journal. 
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Appendix 1 - Databases used for the review 
Electronic resources 
• AMED (Allied and Complementary Medicine) 
• ASSIA (Applied Social Science Index and Abstracts) 
• British Nursing Index 
• CINAHL (Cumulative Index of Nursing and Allied Health Literature) 
• Cochrane Central Register of Controlled Trials 
• Cochrane Database of Systematic Reviews 
• Database of Abstracts of Reviews of Effectiveness (DARE; ‘other reviews’ and Health 
Technology Assesment (HTA) database in CRD database) 
• Current Contents 
• EMBASE 
• EPPI Centre TRoPHI 
• HMIC (or King’s Fund catalogue and DH data) 
• Medline 
• UK Clinical Research Network Portfolio Database 
• PsycINFO 
• Sociological Abstracts 
• Social Policy and Practice 
• Web of Knowledge (Science and Social Science Citation Indexes) 
• CDC Smoking & Health Resource Library database  
• Specialist (public health) systematic review registers 
o EPPI Centre DoPHER 
o Health Evidence ca 
 
Websites 
• Smoke free http://smokefree.nhs.uk  
• NHS Centre for Smoking Cessation and Training http://www.ncsct.co.uk/,  
• Action on Smoking and Health (ASH) http://www.ash.org.uk    
• Treat tobacco.net  http://www.treatobacco.net/en/index.php  
• Society for Research on Nicotine and Tobacco  http://www.srnt.org   
• International Union against Cancer  http://www.uicc.org  
• WHO Tobacco Free Initiative (TIF)  http://www.who.int/tobacco/en  
• International Tobacco Control Policy Evaluation Project  http://www.itcproject.org  
• Tobacco Harm Reduction  http://www.tobaccoharmreduction.org/index.htm  
• Current controlled trials www.controlled-trials.com  
• Association for the treatment of tobacco use and dependence (ATTUD) www.attud.org  
• National Institute on drug abuse- the science of drug abuse and addiction 
http://www.nida.nih.gov/nidahome.html  
• NICE  
• Public health observatories 
• Scottish Government 
• Welsh Assembly Government 
• NHS Evidence 
• Joseph Rowntree Foundation 
• The Centre for Tobacco Control Research (University of Stirling) 
• UK Centre for Tobacco Control Studies 
• Tobacco Control Research Group (University of Bath) 
• http://www.controlled–trials.com 
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Appendix 2 - Search terms 
 
Example search strategy for Medline 
Platform: EBSCO 
Results: 6634 
# Query Results 
S1  MH ("TOBACCO USE CESSATION+")  18854 
S2  (MH "Smoking Cessation")  16197  
S3  (MH "Smoking/PC")  13139  
S4  
TI ("hand-roll" OR handroll* OR "hand-rolls" OR "hand-rolled" OR bidi OR bidis OR 
beedi OR beedis OR rolie OR rolies OR paan OR gutkha OR snuff OR betel OR cigar 
OR cigars)  
1331  
S5  
AB ("hand-roll" OR handroll* OR "hand-rolls" OR "hand-rolled" OR bidi OR bidis OR 
beedi OR beedis OR rolie OR rolies OR paan OR gutkha OR snuff OR betel OR cigar 
OR cigars)  
2629  
S6  TI (quit* OR abstain* OR abstinence OR reduction OR restrict* OR reduce OR cessation)  119903  
S7  AB (quit* OR abstain* OR abstinence OR reduction OR restrict* OR reduce OR cessation)  1167034  
S8  TI ((stop N2 smoking) OR (stopping N2 smoking) OR (stopped N2 smoking) OR (stoppage N2 smoking))  526  
S9  TI ((stop N2 cigarette) OR (stopping N2 cigarette) OR (stopped N2 cigarette) OR (stoppage N2 cigarette))  6  
S10  AB ((stop N2 cigarette) OR (stopping N2 cigarette) OR (stopped N2 cigarette) OR (stoppage N2 cigarette))  63  
S11 TI ((stop N2 cigarettes) OR (stopping N2 cigarettes) OR (stopped N2 cigarettes) OR (stoppage N2 cigarettes))  4  
S12  AB ((stop N2 cigarettes) OR (stopping N2 cigarettes) OR (stopped N2 cigarettes) OR (stoppage N2 cigarettes))  39  
S13 AB ((stop N2 tobacco) OR (stopping N2 tobacco) OR (stopped N2 tobacco) OR (stoppage N2 tobacco))  106  
S14  TI ((stop N2 tobacco) OR (stopping N2 tobacco) OR (stopped N2 tobacco) OR (stoppage N2 tobacco))  28  
S15  TI ((smoking N3 services) OR (smoking N3 service) OR (anti N1 smoking) OR (anti N1 tobacco))  531  
S16 AB ((smoking N3 services) OR (smoking N3 service) OR (anti N1 smoking) OR (anti N1 tobacco))  1348  
S17  
AB ((smoking N2 prevent) OR (smoking N2 prevention) OR (smoking N2 preventing) 
OR (smoking N2 prevents) OR (tobacco N2 prevent) OR (tobacco N2 prevention) OR 
(tobacco N2 preventing) OR (tobacco N2 prevents) OR (cigarette# N2 prevent) OR 
(cigarette# N2 prevention) OR (cigarette# N2 preventing) OR (cigarette# N2 prevents) 
OR (smoker# N2 restrict#) OR (smoker# N2 restriction) OR (smoker# N2 restricted) 
3480 
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OR (cigarette# N2 restrict) OR (cigarette# N2 restricted) OR (cigarette# N2 restricts) 
OR (cigarette# N2 restricting) OR (cigarette# N2 restriction) OR (tobacco N2 restrict) 
OR (tobacco N2 restricted) OR (tobacco N2 restricts) OR (tobacco N2 restricting) OR 
(tobacco N2 restriction) OR (smoking N2 restrict) OR (smoking N2 restricted) OR 
(smoking N2 restricts) OR (smoking N2 restricting) OR (smoking N2 restriction)) OR 
TI ((smoking N2 prevent) OR (smoking N2 prevention) OR (smoking N2 preventing) 
OR (smoking N2 prevents) OR (tobacco N2 prevent) OR (tobacco N2 prevention) OR 
(tobacco N2 preventing) OR (tobacco N2 prevents) OR (cigarette# N2 prevent) OR 
(cigarette# N2 prevention) OR (cigarette# N2 preventing) OR (cigarette# N2 prevents) 
OR (smoker# N2 restrict#) OR (smoker# N2 restriction) OR (smoker# N2 restricted) 
OR (cigarette# N2 restrict) OR (cigarette# N2 restricted) OR (cigarette# N2 restricts) 
OR (cigarette# N2 restricting) OR (cigarette# N2 restriction) OR (tobacco N2 restrict) 
OR (tobacco N2 restricted) OR (tobacco N2 restricts) OR (tobacco N2 restricting) OR 
(tobacco N2 restriction) OR (smoking N2 restrict) OR (smoking N2 restricted) OR 
(smoking N2 restricts) OR (smoking N2 restricting) OR (smoking N2 restriction)) 
S18  AB (temporary abstinence) OR TI (temporary abstinence)   34  
S19  
TI ((tobacco N2 quit) OR (tobacco N2 quitting) OR (tobacco N2 quitted) OR (tobacco 
N2 abstain) OR (tobacco N2 abstinence) OR (tobacco N2 reduction) OR (tobacco N2 
reduces) OR (tobacco N2 reduce) OR (tobacco N2 abstaining))  
269  
S20  
AB ((tobacco N2 quit) OR (tobacco N2 quitting) OR (tobacco N2 quitted) OR (tobacco 
N2 abstain) OR (tobacco N2 abstinence) OR (tobacco N2 reduction) OR (tobacco N2 
reduces) OR (tobacco N2 reduce) OR (tobacco N2 abstaining))  
1157  
S21  
TI ((smoking N2 quit) OR (smoking N2 quitting) OR (smoking N2 quitted) OR 
(smoking N2 abstain) OR (smoking N2 abstinence) OR (smoking N2 reduction) OR 
(smoking N2 reduces) OR (smoking N2 reduce) OR (smoking N2 abstaining))  
1154  
S22 
AB ((smoking N2 quit) OR (smoking N2 quitting) OR (smoking N2 quitted) OR 
(smoking N2 abstain) OR (smoking N2 abstinence) OR (smoking N2 reduction) OR 
(smoking N2 reduces) OR (smoking N2 reduce) OR (smoking N2 abstaining))  
6788  
S23  
TI ((cigarette N2 quit) OR (cigarette N2 quitting) OR (cigarette N2 quitted) OR 
(cigarette N2 abstain) OR (cigarette N2 abstinence) OR (cigarette N2 reduction) OR 
(cigarette N2 reduces) OR (cigarette N2 reduce) OR (cigarette N2 abstaining))  
154  
S24  
AB ((cigarette N2 quit) OR (cigarette N2 quitting) OR (cigarette N2 quitted) OR 
(cigarette N2 abstain) OR (cigarette N2 abstinence) OR (cigarette N2 reduction) OR 
(cigarette N2 reduces) OR (cigarette N2 reduce) OR (cigarette N2 abstaining))  
586  
S25  
TI ((cigarettes N2 quit) OR (cigarettes N2 quitting) OR (cigarettes N2 quitted) OR 
(cigarettes N2 abstain) OR (cigarettes N2 abstinence) OR (cigarettes N2 reduction) OR 
(cigarettes N2 reduces) OR (cigarettes N2 reduce) OR (cigarettes N2 abstaining))  
30  
S26  
AB ((cigarettes N2 quit) OR (cigarettes N2 quitting) OR (cigarettes N2 quitted) OR 
(cigarettes N2 abstain) OR (cigarettes N2 abstinence) OR (cigarettes N2 reduction) OR 
(cigarettes N2 reduces) OR (cigarettes N2 reduce) OR (cigarettes N2 abstaining))  
282  
S27  TI ((smoking N2 cessation) OR (tobacco N2 cessation) OR (cigarettes N2 cessation) OR (cigarette N2 cessation))  6240  
S28  AB ((smoking N2 cessation) OR (tobacco N2 cessation) OR (cigarettes N2 cessation) OR (cigarette N2 cessation))  12419  
S29  
TI ((smoker# N2 quit) OR (smoker# N2 quitting) OR (smoker# N2 quitted) OR 
(smoker# N2 abstain) OR (smoker# N2 abstaining) OR (smoker# N2 abstinence) OR 
(smoker# N2 reduction) OR (smoker# N2 reduce#) OR (smoker# N2 abstaining))  
231  
S30  
AB ((smoker# N2 quit) OR (smoker# N2 quitting) OR (smoker# N2 quitted) OR 
(smoker# N2 abstain) OR (smoker# N2 abstaining) OR (smoker# N2 abstinence) OR 
(smoker# N2 reduction) OR (smoker# N2 reduce#) OR (smoker# N2 abstaining))  
2118  
S31  (S4 OR S5) AND (S6 OR S7)  530  
S32  S1 or S2 or S3 or S8 or S9 or S10 or S11 or S12 or S13 or S14 or S15 or S16 or S17 or 36889 
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S18 or S19 or S20 or S21 or S22 or S23 or S24 or S25 or S26 or S27 or S28 or S29 or 
S30 or S31  
S33  (MH "Patient Admission")  16145  
S34  (MH "Hospitalization+")  133618  
S35  (MH "Outpatients")  6928  
S36  (MH "Inpatients")  10026  
S37  (MH "Child, Hospitalized")  5455  
S38  (MH "Adolescent, Hospitalized")  376  
S39  (MH "Pregnant Women")  4529  
S40  (MH "Patients")  14318  
S41  TI (patient#)  1076780  
S42  TI ((pregnant N3 teens) OR (pregnant N3 teenage#) OR (pregnant N3 teenager#) OR (pregnant N3 adolescent#) OR (pregnant N3 women) OR (pregnant N3 mothers))  13792  
S43  AB ((pregnant N3 teens) OR (pregnant N3 teenage#) OR (pregnant N3 teenager#) OR (pregnant N3 adolescent#) OR (pregnant N3 women) OR (pregnant N3 mothers))  45618  
S44  TI (inpatient# OR outpatient# OR "out patient" OR "out patients" OR "inhospital" OR (day N2 patient#) OR "ill patients" OR "acutely ill" OR primip* OR primigravid*)  40738  
S45  AB (inpatient# OR outpatient# OR "out patient" OR "out patients" OR "inhospital" OR (day N2 patient#) OR "ill patients" OR "acutely ill" OR primip* OR primigravid*)  169326  
S46  
TI ((patient# N2 surgery) OR (patient# N2 operation) OR (patient# N2 discharge#) OR 
(patient# N2 readmission#) OR (patient# N2 postdischarge#) OR (patient# N2 
emergency) OR (patient# N2 emergencies))  
14963  
S47  
AB ((patient# N2 surgery) OR (patient# N2 operation) OR (patient# N2 discharge#) 
OR (patient# N2 readmission#) OR (patient# N2 postdischarge#) OR (patient# N2 
emergency) OR (patient# N2 emergencies))  
119288  
S48  
TI ((patient# N2 referral#) OR (patient# N2 referring) OR (patient# N2 admittance#) 
OR (patient# N2 admitting) OR (patient# N2 admission#) OR (patient# N2 
readmittance) OR (patient# N2 readmitting) OR (patient# N2 readmission#) OR 
(patient# N2 postoperable) OR (patient# N2 postoperative) OR (patient# N2 refer) OR 
(patient# N2 refers) OR (patient# N2 admit) OR (patient# N2 admits))  
4715  
S49  
AB ((patient# N2 referral#) OR (patient# N2 referring) OR (patient# N2 admittance#) 
OR (patient# N2 admitting) OR (patient# N2 admission#) OR (patient# N2 
readmittance) OR (patient# N2 readmitting) OR (patient# N2 readmission#) OR 
(patient# N2 postoperable) OR (patient# N2 postoperative) OR (patient# N2 refer) OR 
(patient# N2 refers) OR (patient# N2 admit) OR (patient# N2 admits))  
46690  
S50  
TI (maternity OR "maternal health" OR obstetrics OR "prenatal care" OR "prenatal 
services" OR "antenatal care" OR "antenatal services" OR "obstetric care" OR 
"obstetric services" OR "perinatal care" OR "prenatal clinic" OR "prenatal clinics" OR 
"prenatal health" OR "prenatal service" OR "antenatal clinic" OR "antenatal clinics" 
OR "antenatal service" OR "antenatal health" OR "obstetric clinic" OR "obstetric 
clinics" OR "obstetric service" OR "obstetric health" OR "perinatal clinic" OR 
"perinatal clinics" OR "perinatal service" OR "perinatal services" OR "perinatal health" 
OR pregnancy OR "maternity healthcare" OR "obstetric healthcare" OR "prenatal 
healthcare" OR "antenatal healthcare" OR "perinatal healthcare" OR "maternal care" 
OR "maternal service" OR "maternal services" OR hospitalised OR hospitalized OR 
"secondary care" OR "acute care" OR "secondary health service" OR "secondary health 
services" OR "acute health service" OR "acute health services" OR "acute setting" OR 
"acute settings" OR "acute service" OR "acute services")  
157954  
S51  AB (maternity OR "maternal health" OR obstetrics OR "prenatal care" OR "prenatal services" OR "antenatal care" OR "antenatal services" OR "obstetric care" OR 255290  
436 
 
"obstetric services" OR "perinatal care" OR "prenatal clinic" OR "prenatal clinics" OR 
"prenatal health" OR "prenatal service" OR "antenatal clinic" OR "antenatal clinics" 
OR "antenatal service" OR "antenatel health" OR "obstetric clinic" OR "obstetric 
clinics" OR "obstetric service" OR "obstetric health" OR "perinatal clinic" OR 
"perinatal clinics" OR "perinatal service" OR "perinatal services" OR "perinatal health" 
OR pregnancy OR "maternity healthcare" OR "obstetric healthcare" OR "prenatal 
healthcare" OR "antenatal healthcare" OR "perinatal healthcare" OR "maternal care" 
OR "maternal service" OR "maternal services" OR hospitalised OR hospitalized OR 
"secondary care" OR "acute care" OR "secondary health service" OR "secondary health 
services" OR "acute health service" OR "acute health services" OR "acute setting" OR 
"acute settings" OR "acute service" OR "acute services")  
S52  
TI ((acute W2 ward) OR (acute W2 wards) OR (general W2 ward) OR (general W2 
wards) OR (stay W2 ward) OR (staying W2 ward) OR (stay W2 wards) OR (staying 
W2 wards))  
677  
S53  
AB ((acute W2 ward) OR (acute W2 wards) OR (general W2 ward) OR (general W2 
wards) OR (stay W2 ward) OR (staying W2 ward) OR (stay W2 wards) OR (staying 
W2 wards))  
2962  
S54  
TI ((accident W3 unit) OR (accident W3 department) OR (emergency W1 unit) OR 
(emergency W1 department) OR (surgical W1 ward) OR (patient# N2 surgery) OR 
(surgery W2 unit) OR (surgery W2 department) OR (acute W2 unit) OR (acute W2 
department))  
23092  
S55  
AB ((accident W3 unit) OR (accident W3 department) OR (emergency W1 unit) OR 
(emergency W1 department) OR (patient# N2 surgery) OR (surgical W1 ward#) OR 
(surgery W2 unit) OR (surgery W2 department) OR (acute W2 unit) OR (acute W2 
department))  
108278  
S56  TI (hospitals OR hospital OR (patient# N2 "post discharge"))  181415  
S57 AB (hospitals OR hospital OR (patient# N2 "post discharge"))  493665  
S58  (MH "Maternal Health Services+")  28351  
S59  (MH "Obstetrics and Gynecology Department, Hospital")  2214  
S60  (MH "Obstetrics")  14150  
S61  (MH "Hospitals+")  180568  
S62  (MH "Hospital Units+")  66597  
S63  (MH "Outpatient Clinics, Hospital+")  14543  
S64  (MH "Emergency Service, Hospital+")  40071  
S65  (MH "Emergency Medical Services")  27584  
S66  TI (("hospital staff") OR ("hospital personnel") OR (hospital W1 worker#) OR surgeon# OR gyne#cologist# OR obstetrician# OR midwiv* OR midwife)  25287  
S67  AB (("hospital staff") OR ("hospital personnel") OR (hospital W1 worker#) OR surgeon# OR gyne#cologist# OR obstetrician# OR midwiv* OR midwife)  103541  
S68  TI (hospital) OR AB (hospital)  533136  
S69  TI (doctor# OR nurse# OR physician# OR clinician# OR pharmacist# OR health W1 worker# OR consultant# OR (medical W1 specialist#) OR (medical W1 officer#))  191646  
S70  AB (doctor# OR nurse# OR physician# OR clinician# OR pharmacist# OR health W1 worker# OR consultant# OR (medical W1 specialist#) OR (medical W1 officer#))  412247  
S71  S69 or S70  543647  
S72  (S68 and S71)  67181  
S73  AB (partnership# or "team work" or "teamwork" OR teamworking OR "team working" or cooperation or (cooperative W1 behavio#r) or "integration" or "integrative approach" 261508  
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OR "integrative approaches" or collaborat* or interagenc* or multiagenc* or "inter-
institutional" or "inter-institutionally" or "inter-professional" or "inter-departmental" or 
"inter-departmentally" or interinstitutional* or interprofessional or interdepartmental* 
or "interprofessional relations" or "interprofessional relationships" or (multidisciplin*) 
or "cross discipline" OR "cross disciplinary" or (interagency) OR linkage# OR "cross-
discipline" OR "cross-disciplinary")  
S74  
TI (partnership# or "team work" or "teamwork" OR teamworking OR "team working" 
or cooperation or (cooperative W1 behavio#r) or "integration" or "integrative approach" 
OR "integrative approaches" or collaborat* or interagenc* or multiagenc* or "inter-
institutional" or "inter-institutionally" or "inter-professional" or "inter-departmental" or 
"inter-departmentally" or interinstitutional* or interprofessional or interdepartmental* 
or "interprofessional relations" or "interprofessional relationships" or (multidisciplin*) 
or "cross discipline" OR "cross disciplinary" or (interagency) OR linkage# OR "cross-
discipline" OR "cross-disciplinary")  
71666  
S75  
(S33 or S34 or S35 or S36 or S37 or S38 or S39 or S40 or S41 or S42 or S43 or S44 or 
S45 or S46 or S47 OR S48 OR S49 OR S50 OR S51 OR S52 OR S53 or S54 or S55 or 
S56 or S57 or S58 or S59 or S60 or S61 or S62 or S63 or S64 or S65 or S66 or S67 or 
S68 or S72 or S73 or S74)  
2614599  
S76  S75 AND S32 7304 
S77 MH ("Humans") AND MH ("Animals")  1253188  
S78  MH ("Animals")  4777882  
S79  S78 NOT S77  3524694  
S80  S76 NOT S79  6634  
 
Notes: 
# = wildcard of 1 or 0 characters 
* = truncation 
N2 = words within 2 places of each other in any order 
W2 = words within 2 places of each other in the order written in the text  
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Appendix 3 – Papers excluded from the hospital section (n=41) 
 
(2007). "Inpatient smoking-cessation programs get 
the job done."  Article not relevant 
(2008). "Treating patients who use tobacco."  Article not relevant 
(2009). "Stop smoking hospitals pilots."  Newspaper article 
(2010). "Thoracic surgeons can help patients stop 
smoking with a brief smoking cessation program."  Link to another paper - Kozower 2010  
(2011). "Motivate patients to stop smoking."  Not RCT 
Allen (1998)  Excluded by Rigotti 
An (2008) Not RCT 
Bernstein (2011) Only 3 month FU 
Canga (2000) Not included as not in right setting 
Carson (2010)  Conference paper preliminary data only 
Choo (2004)  Only 1 month FU data available 
Dalton (1991)  Psychiatric setting 
Fonteyn (2004)  Commentary on Quist-Paulsen 2003, exclude 
Gies (2008)  Not RCT 
Gritz (1991)  Describes trial and SS but no results 
Hanssen (2007) 2008 paper includes longest time FU - 18 months 
Holmes-Rovner(2008) Cannot extract data 
Jha (2005)  Review of Taylor 
Joseph (1996) Study methods - get full paper 
Lacasse (2005)  Conference report on Lacasse 2007 study 
Lisspers (1999)  Cannot extract data 
Moller (2003) Different question but related to Moller 2002 
Mackay (2010)  Poster - not RCT 
Maud-Christine (2005)  Chouinard paper - already included in Rigotti 
Mohjuddin (2006)  Summary of Mohiuddin (2007) 
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Murray (2002)  Commentary on 2002 paper 
Park (2011) Non-randomised 
Peterson (2004) Not relevant setting 
Reid (2011)  Conference report 
Richman (2000)  3 month FU only 
Stainislaw (1994) Only 5 week FU 
Tan (2011) Not RCT 
1994) "Nicotine replacement therapy for patients 
with coronary artery disease. Working Group for 
the Study of Transdermal Nicotine in Patients with 
Coronary artery disease." 
Not acute services setting 
Thorndike (2008) Secondary analysis of Rigotti paper 
Uzuner (2008) Review 3 
van Elderen-van Kemenade (1994) No detail on number of baseline smokers 
Vander Weg (2008)  Not relevant setting 
Volpp (2006) Not relevant setting 
Wolfenden (2005) No data - include in review 3 
Wolfenden (2008) Less than 12 month follow up, results not clear 
Wong (2005) No data/focus on smoking cessation 
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Appendix 4 – Papers unavailable for the hospital section (n=19) 
 
(1994) "Nicotine replacement therapy for patients with coronary artery disease. Working Group for the Study of 
Transdermal Nicotine in Patients with Coronary artery disease."  
(2010) "How one facility helps patients stop smoking."  
(2011) "How one facility helps patients stop smoking."  
Anders (2011)  
Bock (2008) 
Eisenberg (2011) 
Glavas (2003) 
Grandi (2011)  
Kapur (2004) 
Meysman (2010) 
Murphy (1994)  
Nett (1992)  
Rigotti (1996)  
Spencer (2004)  
Strayer (2004)   
Todd (1998) 
Weissfeld (1991) 
Wewers (1992)  
Wewers (1993)  
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Appendix 1 – “Stop smoking live” presentation  
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Appendix 2 – Feedback form 
 
Question 1 
What is your profession? 
% 
Question 2 
Prior to attending this session please rate your knowledge of using 
NRT in combination 
% 
Question 3 
After attending this session please rate your knowledge of using NRT 
in combination 
% 
Question 4 
As a result of attending this session please indicate if you will now 
increase or decrease your recommendations of using NRT in 
combination for suitable patients? 
% 
Question 5 
Following attendance at this session please indicate how useful you 
found it 
% 
Question 6 
Please rate the following elements of the session from disagree (-) to 
agree (+) 
The speaker was knowledgeable on the subject 
% 
There was a good balance of theory combined with real-life 
experience 
% 
The speaker engaged with the audience and encouraged 
participation 
% 
I learned something new by attending this session 
% 
I will use the information from this session in my work 
% 
I plan to discuss this information with my colleagues 
% 
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Appendix 3 - Case study questions 
 
• What products are you currently using? 
• What made you combine NRT and Champix? 
• At what point in your treatment did you begin to use a combination? E.g. from 
the beginning, from QD etc. 
• Where did you get the NRT from? E.g. already had some, tesco, chemist etc. 
• How often are using the NRT product? 
• Do you feel any benefit from using a combination of products? If yes, what 
benefit do you get?  
• Have you spoken to a HP/LSSS about combining the products?  
• Have you had any side effects using a combination of champix and NRT? 
• Did using a combination of NRT and champix ever concern you at any point?  
• When do you think is the most important time to combine products 
• How long do you feel you will need to use both medications for?/How long do 
you intend to use both products for? 
• Have you ever combined NRT products before in previous quit attempts? 
 
 
 
